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Summary 
Emerging bacterial resistance to antibiotics has led to increased interest in 
development of new, improved antimicrobials. In these studies we have used a number of 
biochemical assays in order to investigate the mechanism of action of several antibiotics 
inhibiting protein synthesis. We show that using biosynthetic intermediates of parental 
compounds we are able to evaluate the functionality of structural features of the drug 
(hygromycin A, thiopeptides). We revisited the mechanism of action of three classes of 
antibiotics (macrolides, thiopeptides and orthosomycins) and demonstrated that cryo-electron 
microscopy can be successfully applied to localize and visualize small molecules, such as 
drugs (fusidic acid). To overcome cross-resistance with clinically used antibiotics, new 
antimicrobial targets are needed. Bacterial virulence and pathogenicity factors have been 
suggested as such future targets. One such factor is elongation factor P (EF-P), a post-
translationally modified protein that regulates expression of virulence determinants. Here we 
have investigated the discrepancies between the 144 Da and 128 Da modification states 
reported for EF-P in vivo and in vitro, respectively. This led us to identify a third enzyme in 
the EF-P modification pathway. In addition to providing fundamental insight into the role of 
EF-P in the cell, these studies may provide additional targets for development of novel 
“antivirulence“ agents. 
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1 Introduction 
Since their discovery in 1928 (Fleming, 1929), penicillins remain the most 
frequently prescribed antibiotics (ECDC, 2010). However, as shown in the “Annual 
epidemiological report on communicable diseases in Europe” published by the European 
Center for Disease Prevention and Control (ECDC), Escherichia coli, the most common 
Gram-negative bacteria responsible for bloodstream and urinary tract infections, showed a 
Europe-wide increase of resistance to all antibiotic classes under surveillance (ECDC, 2010). 
At this level of resistance, it eliminates aminopenicillins as a therapeutical strategy for these 
common infections (ECDC, 2010). Moreover, multidrug resistance among Gram-negative 
bacteria such as E. coli, Klebsiella pneumoniae and Pseudomonas aeruginosa, further 
increases, which limits the possibility of the antimicrobial treatment (ECDC, 2010) and raises 
the problem of bacterial infection to a level never seen before. 
Although antibiotics have been available for the treatment of bacterial infections for 
over 70 years, analyses of a 30,000 years old sample show that genes encoding resistance to 
β-lactams, tetracycline and glycopeptides antibiotics are indeed much more ancient (D'Costa 
et al., 2011). This underlines the fact that bacteria are years ahead of researchers in the 
process of learning how to neutralize antibiotics. Furthermore, the time from the discovery of 
a new compound until its introduction into the market takes an average of 10-15 years 
(DrugDiscovery), while, as shown in experiments with E. coli treated with ciprofloxacin, 
bacteria can develop resistance within as little as 10 hours (Zhang et al., 2011). This finding, 
as well as recent bacterial outbreaks, emphasizes the scale of the problem of emerging 
antibiotic resistance among bacteria. 
Cholera outbreak 
Roughly 20,000 clinical cases of cholera and 1100 deaths were officially reported 
since the outbreak was first detected on the 21st October 2010 in the Artibonite region of Haiti 
(Butler, 2010). Toxigenic Vibrio cholerae O1, serotype Ogawa, biotype El Tor, was identified 
by the National Laboratory of Public Health of the Ministry of Public Health and Population 
in Haiti (NLPH). Identification of the isolate was confirmed by the Center for Disease 
Prevention and Control (CDC) in Atlanta (US). Antimicrobial susceptibility testing of 
selected V. cholerae O1 isolates conducted at the NLPH and at the CDC demonstrated 
susceptibility to tetracyclines, ciprofloxacin, and kanamycin; and resistance to trimethoprim, 
sulfamethoxazole, furazolidone, nalidixic acid, sulfisoxazole, and streptomycin (CDC, 2010). 
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NDM-1 
The NDM-1 strain was discovered in 2008 in a Swedish patient of Indian origin 
who traveled to New Delhi, India, and acquired a urinary tract infection. The infection caused 
by a carbapenem-resistant K. pneumoniae strain that typed to the sequence type 14 complex. 
The isolate, K. pneumoniae 05-506, was shown to possess a metallo-β-lactamase (MBL), but 
was negative for previously known MBL genes (Yong et al., 2009). Gene libraries and 
amplification of class 1 integrons revealed three resistance-conferring regions which are (i) 
easily transferable to recipient strains and (ii) that confer resistance to all antibiotics, except 
fluoroquinolones and colistin. NDM-1 (New Delhi metallo-β-lactamase) has a molecular 
mass of 28 kDa, is monomeric and can hydrolyze all β-lactams, except aztreonam (Yong et 
al., 2009). Further investigations revealed cases of NDM-1 bacterial strains in Pakistan, India 
and the United Kingdom. Isolated strains were highly resistant to many antibiotics (including 
β-lactams, fluoroquinolones and aminoglycosides), but not to tigecycline and colistin 
(Kumarasamy et al., 2010). 
An Escherichia coli O104:H4 outbreak 
The E. coli bacteria outbreak begun in May 2011 in Germany. Since then, nearly 
4000 cases and more than 40 deaths were reported (ECDC, 2011). A virulent E. coli strain 
O104:H4 causes haemolytic uraemic syndrome and bloody diarrhea (also known as 
enterohemorrhagic E. coli, EHEC) (Bielaszewska et al., 2011). The strain produces Shiga 
toxin 2 and aggregative adherences to epithelial cells (Bielaszewska et al., 2011). A Shiga-
like toxin (verocytotoxin) may cause direct renal and endothelial cell damage and may adhere 
to the intestinal epithelium resulting in bloody diarrhea (Bae et al., 2006). Moreover, the 
bacteria produces extended-spectrum β-lactamases (Bielaszewska et al., 2011). According to 
the German Society for Infectious Diseases (DGI), the EHEC strain is susceptible to 
carbapenem, new generation macrolides and rifampicin, while being resistant, or not 
responding to fluoroquinolones, aminoglycosides, and fosfomycin (DGI, 2011). 
1.1 Traditional antibiotics 
1.1.1 Introduction to antibiotics 
Traditional antibiotics, depending on their ability to either kill, or inhibit the growth 
of bacteria, can be classified as bactericidal, or bacteriostatic, respectively. They act by 
inhibiting processes essential for exponential growth, namely (i) cell wall synthesis, (ii) DNA 
replication, (iii) RNA transcription, and (iv) protein synthesis (Clatworthy et al., 2007). The 
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history of antibiotics begun in 1929 when Sir Alexander Fleming discovered penicillin 
(Fleming, 1929). Since that time a significant number of new antimicrobials have been 
discovered. Development and availability of biochemical tools have provided an 
understanding into the mechanism of action of new compounds, and provide a basis for 
development of new derivatives through the chemical modification of already existing 
molecules (Kohanski et al., 2010b). The dynamics of discovery of new classes of antibiotics 
lapsed in the 1960’s following the introduction of quinolones. Nearly 40 years passed before a 
new class of antimicrobials was introduced, namely, the oxazolidinones with linezolid 
(Zyvox) as the lead compound (Walsh, 2003). However, the clinically significant resistance to 
each of the known classes of antimicrobials has emerged within a few years following their 
introduction into medical usage (Figure 1) (Clatworthy et al., 2007).  
 
Figure 1. Timeline of antibiotic deployment and the evolution of antibiotic resistance (Fischbach and 
Walsh, 2009) (Clatworthy et al., 2007). 
1.1.2 Targets for antibiotic action  
Most commonly used classes of antibiotics target four processes essential for 
bacterial life: (i) cell wall biosynthesis, (ii) DNA and RNA replication, (iii) protein 
biosynthesis, and (iv) folate coenzyme biosynthesis, which leads to DNA biosynthesis arrest 
(Figure 2) (Walsh, 2003).  
1.1.2.1 Inhibition of cell wall synthesis 
The bacterial cell is surrounded by murein (also called peptydoglycan), a structure 
built with a number of layers assembled with N-acetylglucosamine (GlcNAc) and N-acetyl-
muramic acid (MurNAc) crosslinked with β-(1-4)-glycosidic bonds (Bugg and Walsh, 1992). 
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The cell wall provides bacteria with the mechanical strength to allow microorganisms to 
survive under varying environmental conditions. Various processes allow bacteria to maintain 
the fitness of the cell wall. The enzymes, transglycosylases and penicillin-binding proteins 
(PBSs, also called transpeptidases), add disaccharide pentapeptides to extend the glycan 
filaments of existing peptidoglycan molecules and cross-link neighboring peptide filaments of 
immature peptidoglycan subunits (Park and Uehara, 2008).  
Application of antibiotics inhibiting cell wall synthesis can induce changes in 
bacterial morphology, cell elongation, filamentation, and trigger cell stress response leading 
to cell lysis (Tomasz, 1979). Nearly every step of cell wall synthesis can be inhibited. β-
lactams (penicillins, carbapenems and cephalosporins) penicilloylate the catalytic center of 
PBSs (Waxman et al., 1980), which abolishes crosslinking of peptidoglycan moieties (Figure 
2a) 
Figure 2. Major targets for antibiotics within the bacterial cell. (a) Cell-wall synthesis: Peptydoglycan is
composed of two hexoses (filled hexagons) - GlcNac and MurNAc. Cytoplasmatic steps of peptydoglycan
synthesis are catalyzed by the enzymes MurA-F and MurG (steps 1-4). In following step, a carrier lipid –
bactoprenol phosphate (orange circle) transferrs peptidoglycan blocks across the membrane. In the next steps
sugars and phosphates are added by transglycosylation and pyrophosphorylation (steps 5 and 6). Eventually,
peptide chains are linked together (step 7). Inhibitors of cell-wall synthesis are marked. (b) Translation:
bacterial ribosomes consist of two subunits (30S and 50S) which are targets for a number of antibiotics (c) DNA
synthesis and RNA replication: rifampin binds to RNA polymerase preventing polymerase-DNA interaction,
thereby inhibiting transcription. Ciprofloxacin and novobiocin inhibit DNA gyrase (d) Folate metabolism: folate
is necessary for the synthesis of thymine, one of nucleotides building DNA. Antibiotics arresting thymine
synthesis are depicted. Adapted from (Walsh, 2003). (e) Membranes: lipopeptides antibiotics insert into lipid
bilayer inducing depolarization of membrane potential (Clatworthy et al., 2007). 
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(Wise and Park, 1965). Glycopeptide antibiotics (vancomycin) (Figure 2a) bind 
peptidoglycan subunits and are steric inhibitors of transglycosylases and transpeptidases 
(Kahne et al., 2005). Fosfomycin inhibits synthesis (Kahan et al., 1974), while bacitracin 
inhibits transport (Storm, 1974) of single peptidoglycan units (Figure 2a). Lipopeptides 
(daptomycin) modulate the structural integrity of bacterial cell by inserting themselves into 
the cell membrane and triggering membrane depolarization (Figure 2e) (Jung et al., 2004). 
Polymyxins are cyclic, positively charged peptide antibiotics, which have high affinity for 
lipid moiety of lipopolysaccharides. These cationic agents bind to the anionic bacterial outer 
membrane and disrupt their integrity (Landman et al., 2008). 
1.1.2.2 Inhibition of DNA replication 
DNA synthesis, messenger RNA (mRNA) transcription and cell division involve 
topoisomerase reactions to maintain these essential processes. Topoisomerases control the 
DNA winding by breaking strands, untangling the nucleic acid and then rejoining the DNA 
strands (Drlica and Zhao, 1997). Quinolones stall both the topoisomerase II and IV at the 
DNA cutting phase and prevent DNA strand ligation (Figure 2b) (Chen et al., 1996). Arrested 
DNA synthesis induces bacteriostasis leading to cell death (Kohanski et al., 2007). Sublethal 
dosage of quinolones, as well as β-lactams, can lead to hydroxyradical formation. This 
induces mutagenesis, which together with SOS-related mutagenesis and RecA-mediated 
processes, can stimulate evolution of mutations conferring antibiotic resistance (Kohanski et 
al., 2010a).  
1.1.2.3 Inhibition of RNA synthesis 
Rifampicin is a semi-synthetic bactericidal antibiotic, which like quinolones, can 
induce cell death (Kohanski et al., 2007). It binds to the β-subunit of DNA-dependent RNA 
polymerase leading to arrest of mRNA transcription (Figure 2b) (Campbell et al., 2001). 
1.1.2.4 Inhibition of protein synthesis 
The complexity of the structure and function of the ribosome makes it an important 
target for antimicrobial therapies. High-resolution crystal structures of ribosomes and 
ribosome-antibiotic complexes have provided detailed understanding into the mechanism of 
action of many classes of antibiotics (Figure 2c). Inhibitors of translation can bind to the 
functional centers on either of the subunits and inhibit nearly every step of translation (Figure 
3). Four major binding sites for ribosomal inhibitors can be distinguished: (i) the decoding 
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center on the small subunit, (ii) the peptidyl-transferase center (PTC), (iii) exit tunnel and (iv) 
GTPase-associated center (GAC) on the large subunit. 
1.1.3 Protein synthesis 
Protein synthesis is an essential process in every living cell. Ribosomes are complex 
macromolecules which translate genetic information encoded in mRNA into the polypeptide 
sequence using transfer tRNAs (tRNAs) as amino acid carriers. Ribosomes consist of two 
distinct subunits composed of RNA and proteins, which assemble together and create three 
unique binding sites for tRNAs (Figure 3). E. coli small 30S ribosomal subunit (SSU) is 
composed of a single 16S ribosomal RNA (rRNA) and 21 ribosomal proteins, while the 
50S large subunit (LSU), is composed of 5S rRNA, 23S rRNA and 33 ribosomal proteins. 
Both subunits join together to form a 70S ribosome (Schmeing and Ramakrishnan, 2009). 
mRNA is encoded by triplets of nucleotides called codons, which determine the amino acids 
sequence of proteins. The SSU’s role is decoding of the information carried by the mRNA. 
Figure 3. Four phases of translation: initiation, elongation, termination and recycling. Protein synthesis starts
with 30S initiation complex formation where mRNA and initiator-tRNA positions on small ribosomal subunit,
which is followed by subunit joining. 70S initiation complex can now allow EF-Tu to deliver aa-tRNA to A-site.
GTP hydrolysis triggers EF-Tu to dissociate from ribosome and allows aa-tRNA to accommodate on the large
subunit, which leads to peptide bond formation between peptidyl-tRNA in the P-site and aminoacyl moiety of A-
tRNA. In the next step EF-G, catalyses the reaction of translocation. The cycle is repeated until a stop codon
reaches the A-site. The ribosome enters into termination and recycling phases, where, with the help of release
factors, RF1 and RF2, the polypeptide is released from ribosome. RRF splits ribosome into subunits which allows
it to start a new cycle of translation. Almost every step is targeted by antibiotics (according to (Wilson, 2009)). 
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The LSU has the transferase activity and catalyses peptide bond formation between the tRNA 
carrying the nascent polypeptide chain, the peptidyl-tRNA, and an aminoacyl-tRNA (aa-
tRNA), which carries an amino acid. Newly delivered aa-tRNAs accommodate into the A-
site, peptidyl-tRNA binds in the P-site, while deacylated tRNA exits the ribosome via the E-
site. 
Translation is a cyclic reaction, which can be divided into four sequential steps: 
initiation, elongation, termination and recycling (Figure 3). In each step, additional factors 
facilitate the reaction. Translation starts with 30S initiation complex (30SIC) formation. 
Initiation factor 3 (IF3) binds to the SSU and prevents premature subunit joining (Karimi et 
al., 1999). The SSU-IF3 complex then assembles with mRNA, IF1, IF2 and initiator fMet-
tRNA. The ribosomal protein S1 binds to the A/U rich 5’ untranslated region (UTR) of 
mRNAs (Ringquist et al., 1993) and helps to position the mRNA on the SSU. The GGAGG 
Shine-Dalgarno (SD) sequence (Shine and Dalgarno, 1974) of canonical mRNA interacts with 
3’-end of 16S rRNA (anti-SD) (Demeshkina et al., 2010; Jenner et al., 2010b; Kaminishi et 
al., 2007) and the start codon (AUG) is positioned in P-site. IF1 binds at a site overlapping the 
A-site (Carter et al., 2001; Dahlquist and Puglisi, 2000) and, together with IF2 and IF3, 
cooperatively promotes fMet-tRNA binding to the SSU and its positioning in a P/I site 
(peptidyl/initiation site) (Antoun et al., 2006; Julian et al., 2011). IF3 discriminates fMet-
tRNA from other aa-tRNAs in a P-site by recognition of three unique G:C pairs in the initiator 
tRNA, and probably the guanosine at third position of the initiation codon (Hartz et al., 1990; 
Hartz et al., 1989; O'Connor et al., 2001; Risuleo et al., 1976; Sussman et al., 1996). IF 
binding induces head swiveling of the SSU (Julian et al., 2011). During the formation of the 
70S initiation complex (70SIC), subunits join in rotated orientation and upon IF2-driven GTP 
hydrolysis, fMet-tRNAfMet accommodates into the P-site, while subunits unratchet (Marshall 
et al., 2009). IFs are released from the ribosome, which then enters into the elongation cycle. 
Ribosomes entering the elongation cycle have an fMet-tRNAfMet bound to P-site and 
vacant A-site. The aa-tRNA is delivered as a ternary complex with EF-Tu and GTP 
(Schmeing et al., 2009; Schuette et al., 2009). tRNA within the ternary complex binds to 
ribosomes in a bent conformation (Blanchard et al., 2004; Schmeing et al., 2009; Voorhees et 
al., 2010) in an A/T position, where anticodon stem loop is bound to the A-site on the SSU 
and the acceptor stem carrying the amino acid is still bound to EF-Tu. Such a conformation 
enables direct contact with the decoding site on the SSU and discrimination of a cognate 
codon-anticodon interaction while remaining bound to EF-Tu. Rearrangements in the 
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decoding site trigger conformational changes in the ribosome, namely shoulder movement 
towards EF-Tu (domain closure) that increases the rate of GTPase activation of EF-Tu (Ogle 
et al., 2002). EF-Tu undergoes conformational changes which positions the catalytic histidine 
84 (His84) in proximity with the phosphate of the nucleotide A2662 (E. coli numbering) of 
the sarcin-ricin loop (SRL) located in helix 95 (H95) of 23S rRNA (Voorhees et al., 2010). 
His84 places a water molecule in a position to nucleophilically attack the γ-phosphate of GTP, 
which leads to GTP hydrolysis (Daviter et al., 2003) and EF-Tu-GDP dissociation from the 
ribosome. The aa-tRNA accommodates from A/T position to A/A position, where aa-tRNA is 
bound to A-site on both the SSU and LSU (Blanchard et al., 2004; Douthwaite et al., 1983; 
Schmeing et al., 2009; Voorhees et al., 2010). Three nucleotides of the 16S rRNA, namely 
G530, A1492 and A1493, were shown to be crucial for tRNA binding in the decoding center 
(Moazed and Noller, 1990). Nucleotides A1492 and A1493 flip-out from helix 44 (h44) and 
together with G530 monitor Watson-Crick base-pairing geometry of the minor groove of the 
first two base pairs between codon and anticodon (Ogle et al., 2001). Both, rearrangements in 
the proteins and 23S rRNA in the LSU, accelerate interactions with the anticodon stem loop 
and elbow region of the tRNA, leading to positioning of the acceptor end at the PTC (Jenner 
et al., 2010a).  
Accommodation of the aa-tRNA at the A site is followed by peptide bond formation 
at the PTC. The PTC is composed of nucleotides of domain V of 23S rRNA and is an active 
site of the ribosome. The PTC binds the CCA ends of peptidyl- and aminoacyl-tRNAs and 
catalyzes the nucleophilic attack of the α-amino group of the aa-tRNA on the ester carbonyl 
carbon of the peptidyl-tRNA, which leads to a new peptide bond (Green and Lorsch, 2002).  
Crystal structures of the CCA end analogues showed that the A-site CCA end is 
coordinated by nucleobases G2553, U2555, U2556 of an A-loop and G2583, while the P-site 
CCA stacks onto nucleobases from the P-loop, including G2251, G2252, and additionally 
A2451 (Hansen et al., 2002b; Nissen et al., 2000), which is consistent with the CCA end 
positions found for entire tRNA substrates bound to ribosome (Selmer et al., 2006) and is in 
agreement with biochemical data (Moazed and Noller, 1991). The A-tRNA induces 
conformational changes in the PTC (Schmeing et al., 2005a; Schmeing et al., 2005b), which 
orients reactive nucleotides in the position for peptide bond formation. The 2’-OH group of 
A2451 positions the A76 of the P-tRNA to promote peptide bond formation (Lang et al., 
2008). The 2’-OH group of the A76 of the P-tRNA mediates proton passage from attacking α-
amino group of the A-tRNA to the leaving 3’-OH group (Weinger et al., 2004), while the 
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water molecule, coordinated by U2584 and A2602 (Schmeing et al., 2005a), acts as a proton 
shuttle and stabilizes the (eight-membered) transition state (Kuhlenkoetter et al., 2011). In this 
model, the ribosome positions substrates, but does not contribute to the catalysis of the 
reaction. However, recent works show that the ribosome can modulate the catalysis by 
changing the transition state rates (Hiller et al., 2011). Post-peptide bond formation the 
ribosome carries a peptidyl-tRNA at A-site and a deacylated tRNA at the P-site. 
Once the peptide bond is formed, the mRNA-tRNA2 complex must be moved across 
the ribosome in a process called translocation. In the pre-translocation state (PRE), P- and A-
tRNAs move in respect to the LSU forming P/E and A/P hybrid states, where the anticodon 
stem loops interact with P- and A-sites on the SSU and at the same time, the acceptor arms of 
respective tRNAs interact with E- and P-sites on the LSU (Munro et al., 2007). The tRNA 
hybrid state formation is coupled with a subunit rotation (Agirrezabala et al., 2008). EF-G 
interacts with the ribosome (Clementi et al., 2010; Datta et al., 2005; Moazed et al., 1988; 
Stark et al., 2000) and stabilizes the ratcheted state of the ribosome (Munro et al., 2010a). 
GTP hydrolysis triggers conformational changes in EF-G (Rodnina et al., 1997). The 
translocation reaction, i.e. the movement of mRNA and anticodon stem-loops of P- and A-
tRNAs across the SSU, is catalyzed by domain IV of EF-G (Savelsbergh et al., 2000) and is 
coupled with inorganic phosphate (Pi) release (Rodnina et al., 1999). In the post-translocation 
state (POST), the A-site becomes vacant and is ready to accept the next incoming aa-tRNA. 
The elongation cycle ends when a stop codon reaches the A-site, which is then recognized by 
release factors (RFs) (Caskey et al., 1968). Two release factors, RF1 and RF2, recognize 
UAA/UAG and UAA/UGA stop codons, respectively (Scolnick et al., 1968). RFs bind in the 
A-site spanning both subunits (Jin et al., 2010; Korostelev et al., 2008; Korostelev et al., 
2010; Laurberg et al., 2008; Petry et al., 2005; Weixlbaumer et al., 2008). RFs recognize stop 
codons directly, and conserved nucleotides G530, A1492, A1493 of 16S rRNA do not 
participate in stop codon recognition (Korostelev et al., 2008). Instead, these nucleotides 
stabilize the open form of the RFs. Amino acids GxxE from helix 5 of both RF1 and RF2 
recognize the first nucleobase, uridine in all stop codons. The second position is recognized 
by PVT motif of RF1 and SPF motif in RF2 located in the recognition loop of RFs, while the 
third position is monitored by threonine (T194), and additionally by glutamine (Q181) in the 
RF1 (Korostelev et al., 2008; Korostelev et al., 2010; Laurberg et al., 2008; Weixlbaumer et 
al., 2008). Upon recognition of the stop codon, RFs induce conformational changes in H69 of 
23S rRNA. Nucleobase A1913 (H69) stacks onto A1493 (h44) and, together with A1492, 
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forms a pocket into which RFs accommodate (Korostelev et al., 2010; Weixlbaumer et al., 
2008). Structural findings are in accordance with biochemical data showing defects in the 
termination of the ribosomes lacking H69 (Ali et al., 2006; Korostelev et al., 2010). 
Moreover, interactions between RFs and H69 help to position GGQ motif in a PTC 
(Korostelev et al., 2008; Laurberg et al., 2008). It should be noted that the structures of free 
RFs compared with RFs bound to the ribosome can differ significantly. The crystal structures 
of free RF1/2 showed they adopt closed conformations where GGQ and PTV/SPF motifs are 
approximately 23Å from each other, which is not sufficient to establish interactions with the 
PTC and the decoding center (Shin et al., 2004; Vestergaard et al., 2001; Zoldak et al., 2007). 
However, small-angle X-ray scattering (SAXS) studies showed that in the solution, RFs are 
present in equilibrium between open and closed forms (Vestergaard et al., 2005; Zoldak et al., 
2007). Upon recognition of the stop codon, RFs undergo conformational changes from closed 
to active, open form where GGQ motif residing in the PTC and PTV/SPF motifs interacting 
with decoding center are 73 Å apart from each other (Klaholz et al., 2003; Korostelev et al., 
2008; Korostelev et al., 2010; Laurberg et al., 2008; Rawat et al., 2006; Rawat et al., 2003; 
Weixlbaumer et al., 2008). A universally conserved GGQ motif is critical for the function of 
RFs, (Frolova et al., 1999; Shaw and Green, 2007). The glycines from the GGQ motif 
position the catalytically active glutamine (Q230) in the PTC between 23S rRNA nucleotides 
U2584, U2585, A2602, and A2451 (Jin et al., 2010; Korostelev et al., 2008; Korostelev et al., 
2010; Weixlbaumer et al., 2008). Mutational analysis of Q230 showed that the glutamine side 
chain is not critical for the release reaction of the nascent polypeptide (Seit-Nebi et al., 2001; 
Shaw and Green, 2007), however the Q230 side chain discriminates the RF’s specificity for a 
water molecule as the nucleophile (Shaw and Green, 2007). The amide group of Q230 
backbone interacts with leaving 3’-OH group of A76 of the peptidyl-tRNA, which accounts 
for the catalytic activity of glutamine (Laurberg et al., 2008). The crystal structure of RF2 
bound to the ribosome in a presence of non-hydrolysable analogues of Phe-tRNAPhe where the 
ester bond was replaced by an amide bond gives inside into structural basis of catalysis of 
peptide release (Jin et al., 2010). Consistent with biochemical data (Brunelle et al., 2008; 
Zaher et al., 2011), it was suggested that 2’-OH group of A76 of the peptidyl-tRNA 
coordinates a water molecule for nucleophilic attack onto the ester bond, leading to hydrolysis 
of the newly synthesized nascent polypeptide (Jin et al., 2010). RF3 is a GTPase that 
destabilizes the RF1 and RF2 interaction with the ribosome (Freistroffer et al., 1997; Gao et 
al., 2007) by stabilization of the ratcheted form of the ribosome with tRNAs in hybrid states 
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(Jin et al., 2011). Moreover recent data suggest that RF3 plays a role in the fidelity of 
translation by detecting mis-incorporated amino acids and premature terminating protein 
synthesis (Zaher and Green, 2009, 2011). 
Post-termination ribosomes are split into subunits with the help of the ribosome 
recycling factor (RRF) and EF-G, in a GTP-dependent manner (Karimi et al., 1999). RRF 
binds in the P-site of LSU in a fully rotated state of ribosome with deacylated tRNA in P/E 
position (Dunkle et al., 2011). Upon binding of EF-G, RRF promotes disruption of 
intersubunit bridges leading to subunit dissociation, which is stabilized by the interaction of 
IF3 with the SSU (Barat et al., 2007; Ito et al., 2002; Pai et al., 2008; Singh et al., 2005; 
Zavialov et al., 2005). 
1.1.3.1 Inhibitors of the small ribosomal subunit 
A number of antibiotics inhibit the delivery of tRNA to a vacant A-site and the 
process of decoding (Figure 4). 
Edeine interrupts binding of 
initiator-tRNA to the SSU (Schafer 
et al., 2002) and can stimulate 
translational misreading (Dinos et 
al., 2004). Pactamycin mimics 
mRNA (Brodersen et al., 2000), 
and aborts the first translocation 
reaction (Dinos et al., 2004). 
Tetracyclines disable stable binding 
of the ternary complex aa-
tRNA•EF-Tu•GTP to the A-site of the ribosome, thus impairing accommodation of aa-tRNA 
(Blanchard et al., 2004). Aminoglycosides have been proposed to stimulate misreading by 
inducing flipping-out of A1492 and A1493 and stabilizing them in the open conformation, 
allowing near-cognate aa-tRNA to accommodate (reviewed by (Ogle et al., 2003)). 
Streptomycin changes the GTPase rates of EF-Tu, thus stabilizes both cognate and near-
cognate aa-tRNAs, which leads to loss of selectivity and induces high rate of misreading 
(Gromadski and Rodnina, 2004). Kasugamycin mimics codon nucleotides at the P- and E-site 
(Schluenzen et al., 2006) and inhibits translation of canonical mRNAs by destabilization of 
initiator tRNA binding, however translation of leaderless mRNAs remains unaffected (Moll 
Figure 4. Inhibitors of the small ribosomal subunit. (A-B)
Superimposition of binding sites of antibiotics (from (Wilson
2009)). 
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and Blasi, 2002). Moreover, kasugamycin induces the formation of 61S ribosomal particles 
that lack several ribosomal proteins of the SSU, including protein S1, in order to translate 
leaderless mRNAs (Kaberdina et al., 2009). Spectinomycin arrests the translocation reaction 
(Fredrick and Noller, 2003) by stabilizing an intermediate state of the translocating ribosome 
(Pan et al., 2007). Viomycin binds in the interface of ribosomal subunits, namely within 
bridge B2a (Stanley et al., 2010) and inhibits translocation by locking tRNAs in hybrid state 
in PRE complex and destabilizing the POST complex (Feldman et al., 2010; Ly et al., 2010).  
1.1.3.2 Inhibitors of the large ribosomal subunit 
The translation cycle is a target for a number of antibiotics, including inhibitors of 
peptide bond formation, progression of the nascent polypeptide, and the function of 
translational factors. 
1.1.3.2.1 Inhibitors of the peptidyl-transferase center 
Most of antibiotics targeting the LSU inhibit the PTC and bind in positions 
overlapping A- and/or P-site tRNA (Figure 5). Puromycin, hygromycin A, chloramphenicol, 
linezolid and lincosamides belong to the class of A-site inhibitors. Puromycin mimics a 
terminal adenosine (A76) of the CCA-end of aa-tRNA (Nissen et al., 2000) and accepts the 
nascent polypeptide chain from the 
P-tRNA (Pestka, 1969; Traut and 
Monro, 1964). Hygromycin A 
inhibits the PTC reaction and 
competes with chloramphenicol 
(Guerrero and Modolell, 1980). 
Chloramphenicol overlaps the 
aminoacyl moiety of an aa-tRNA 
(Bulkley et al., 2010; Dunkle et al., 
2010) and inhibits peptide bond 
formation (Irvin and Julian, 1970). 
Moreover, P-tRNA enhances significantly the affinity of chloramphenicol to ribosome 
(Pestka, 1974). Although the binding site of the oxazolidinone (linezolid) is known (Leach et 
al., 2007; Wilson et al., 2008), the mechanism of inhibition remains unclear. However, it was 
proposed that oxazolidinones prevent accommodation of initiator fMet-tRNA on the ribosome 
(Wilson et al., 2008). Lincosamides (lincomycin, clindamycin) inhibit peptide bond formation 
Figure 5. Inhibitors of the peptidyl transferase center. (A-B) 
superimposition of binding sites of antibiotics (from (Wilson, 
2009)). 
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(Kallia-Raftopoulos et al., 1994) by sterically clashing with the A-site tRNA (Dunkle et al., 
2010).  
Blasticidin S, sparsomycin and pleuromutilins are P-site inhibitors. Blasticidin S 
mimics C74 and C75 of the CCA-end of P-tRNA in the interaction with P-loop (Hansen et al., 
2003) and inhibits PTC reaction of both bacterial and eukaryotic ribosomes (Petropoulos et 
al., 2004). Sparsomycin inhibits the PTC reaction by blocking A-tRNA from binding while, at 
the same time, increasing the affinity of the P-tRNA (Ottenheijm et al., 1986). Pleuromutilins 
overlap with both A- and P-tRNA (Schlunzen et al., 2004), prevent aa-tRNA binding to the 
A-site and inhibit the PTC reaction (Hodgin and Hogenauer, 1974). Streptogramins are a 
mixture of two distinct molecules, type A (SA) and type B (SB) which act synergistically 
(Cocito and Chinali, 1985). SA disrupts the binding of both A- and P-tRNA (Harms et al., 
2004), while SB acts analogous to macrolides by blocking progression of polypeptide (Tenson 
et al., 2003).   
1.1.3.2.2 Inhibitors of the progressing nascent polypeptide chain 
Recent studies underline the importance of the ribosomal exit tunnel in the regulation 
of polypeptide translation (reviewed by (Bogdanov et al., 2010; Lovett and Rogers, 1996)). 
The growing nascent polypeptide chain can interact with the exit tunnel (reviewed by (Wilson 
and Beckmann, 2011)). This interaction depends on the sequence of the emerging polypeptide 
and can modulate the rate of translation (Lu and Deutsch, 2008) as well as induce 
translational stalling of leader peptides, thus leading to an expression of downstream genes 
(Ramu et al., 2009; Tenson and Ehrenberg, 2002) or even induce antibiotic resistance 
(Lovmar et al., 2006; Ramu et al., 2009). Macrolides and ketolides bind in the upper part of 
ribosomal tunnel (Figure 5) (Hansen et al., 2002a) and induce drop-off of the peptidyl-tRNA 
(Mankin, 2008; Tenson et al., 2003). 
1.1.3.2.3 Inhibitors of the GTPase-associated center (GAC) 
Although each class of antibiotics has a distinct structure, their binding sites tend 
either to overlap or are in close proximity from each other, promoting the situation where 
resistance mutations to one class of antibiotics often leads to cross-resistance to other classes 
(Li et al., 2011; Long et al., 2006; Tu et al., 2005). The GAC is a functional site involved in 
the interaction with translational factors and stimulation of their GTPase activities. The GAC 
is located approximately ~50Å from the PTC and consists of helices 42-44 of 23S rRNA 
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(H42-44), SRL (H95) and ribosomal proteins L10, L11 and L7/L12 (Connell et al., 2007; Li 
et al., 2006). 
Thiopeptides interfere with the binding of translational factors, such as EF-G (Harms 
et al., 2008), and are effective inhibitors of the translocation reaction (Munro et al., 2010b). In 
contrast, a subgroup of thiopeptides, including GE2270A, prevent ternary complex formation 
by inhibiting the binding of aa-tRNA to EF-Tu (Parmeggiani and Nissen, 2006). 
Orthosomycins interfere with fMet-puromycin reaction in an IF2-dependent manner (Belova 
et al., 2001). Fusidic acid (FA) stabilizes EF-G binding to the ribosome in the GTP 
conformation (Gao et al., 2009) and inhibits EF-G turnover (Ticu et al., 2009), although at 
low concentrations FA allows multiple GTPase cycles (Seo et al., 2006). α-sarcin and ricin 
are toxins targeting the conserved ribosomal region called the SRL. α-sarcin cleaves rRNA 
between nucleotides G2661 and A2662 (Endo and Wool, 1982) while ricin depurinates 
nucleotide A2660 (E. coli numbering) of eukaryotic ribosomes (Endo et al., 1987). 
Ribosomes lacking the SRL or having depurinated A2660 are not able to activate GTP 
hydrolysis (Benson et al., 1975; Clementi et al., 2010; Sperti et al., 1975) and thus the 
translocation reaction is inhibited (Gessner and Irvin, 1980; Sperti et al., 1976). Kirromycin 
stalls ternary complex aa-tRNA·EF-Tu·GTP on the ribosome by arresting conformational 
changes of EF-Tu (Parmeggiani and Nissen, 2006). 
1.1.4 Mechanism of cell death induced by bactericidal antibiotics 
Antibiotic-induced cell death is linked with rifampicin-induced inhibition of mRNA 
synthesis (Floss and Yu, 2005), fluoroquinolone-associated double-stranded DNA breaks 
(Drlica et al., 2008), β-lactamase-stimulated cell wall damage (Tomasz, 1979) and protein 
mistranslation as a result of aminoglycoside action (Vakulenko and Mobashery, 2003). 
Lethal concentrations of bactericidal antibiotics induce hydroxyl radicals as a result 
of activation of the oxidative damage cellular death pathway, involving the tricarboxylic acid 
cycle, NADH deprivation, disruption of iron-sulfur clusters and induction of the Fenton 
reaction (Kohanski et al., 2007). 
Aminoglycosides, as well as edeine and streptomycin, induce translational 
misreading leading to incorporation of incorrect amino acids into the polypeptide chain. 
Mistranslated membrane proteins can increase the permeability of the membrane to antibiotics 
and activate the envelope two-component stress-response system – Cpx-Arc (Figure 6). Cpx 
induces expression of the pepriplasmic protease DegP, an element of envelope stress 
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response, and activates the redox-responsive two-component system Arc, which leads to 
modulation of the metabolic and respiratory pathways, formation of hydroxyl radicals, and 
eventually to cell death (Kohanski et al., 2008). 
 
Figure 6 Mechanism of cell death induced by bactericidal antibiotics. (a) Aminoglycosides, (b) quinolones 
and (c) β-lactams stimulate the oxidation of NADH through the electron transport chain, which is dependent on 
the tricarboxylic acid (TCA) cycle. Hyperactivation of the electron transport chain stimulates superoxide (O2-) 
formation. Superoxide damages Fe–S clusters, which results in release of ferrous iron and induction of the 
Fenton reaction. The Fenton reaction leads to the formation of hydroxyl radicals (•OH), which damage DNA, 
lipids and proteins. This accounts for antibiotic-induced cell death. Antibiotics also trigger hydroxyl radical 
formation and cell death through the envelope (Cpx) and redox-responsive (Arc) two-component systems. 
Redox-sensitive proteins, such as those containing disulphides (dashed lines) may also contribute to the cell 
death mechanism. acnb, aconitase b; mdh, malate dehydrogenase; uq, ubiquinone, according to (Kohanski et al., 
2010b; Kohanski et al., 2007; Kohanski et al., 2008). 
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1.2 Antibiotics used in these studies 
1.2.1 Hygromycin A 
Hygromycin A (HygA) was discovered in the 1950’s as a metabolite excreted by 
Streptomyces hygroscopicus NRRL 2388 (Pettinger and Wolfe, 1953) and does not share 
structural similarities with the aminoglycoside with a similar name, hygromycin B. HygA is a 
potent inhibitor of Gram-positive bacteria, while ineffective against Gram-negative strains 
due mainly to the ArcAB efflux pump mechanism (Hayashi et al., 1997). It was shown that 
HygA inhibits peptide bond formation and competes with chloramphenicols for binding to 
ribosomes (Guerrero and Modolell, 1980), suggesting that HygA is an inhibitor of the LSU. 
Footprinting experiments showed that HygA binding to the ribosome can be abolished by 
macrolides carrying two sugar moieties at the C5 position (Poulsen et al., 2000), which would 
extend towards the PTC (Hansen et al., 2002a). HygA protects nucleotides located in the 
PTC, namely U2585 (Poulsen et al., 2000), which is important for tRNA accommodation and 
peptidyltransferase reaction (Schmeing et al., 2005b), and U2506, from CMCT modification 
(Poulsen et al., 2000). 
HygA is composed of the three structurally distinct moieties: subunit A – 
dehydrofucofuranose (SubA), B – α-methyl cinnamic acid (SubB), and C – aminocyclitol 
(SubC) (Habib el et al., 2003). SubA is moderately sensitive to chemical manipulation and 
when replaced with a hydrophobic allyl group retains antimicrobial potency (Hayashi et al., 
1997; Jaynes et al., 1992). In contrast, substitution of the methyl group with propyl, allyl or 
hydrogen in SubB leads to decreased activity of the derivatives compared with HygA 
(Hayashi et al., 1997). SubC is essential for the antimicrobial activity of HygA (Hayashi et al., 
1997). 
The HygA biosynthesis operon consists of 29 open reading frames (ORFs) (Figure 
7) and includes genes responsible for providing resistance to HygA, as well as regulation and 
synthesis of each of the HygA moieties (Palaniappan et al., 2006). The biosynthetic origin of 
each HygA moiety has been established using isotope-labeled precursor studies (Habib el et 
al., 2003): SubA is derived from glucose, SubB originates from 4-hydroxybenzoic acid and 
propionic acid, and SubC is synthesized from myo-inositol and methionine (Habib el et al., 
2003). The glycoside bond formation between SubA and SubB, and the amide bond between 
SubB and SubC, follow the assembly of each of the respective moieties (Habib el et al., 
2003). 
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The function of some of the gene products within the HygA operon was analysed by 
genetic manipulations. Knock-out of hyg26 gene showed that its role plays crucial role in final 
oxidation step in biosynthesis of SubA. S. hygroscopicus Δhyg26 mutant strain was shown to 
produce 5”-dihydro-HygA, instead of HygA (Palaniappan et al., 2006). However, it was not 
possible to establish whether oxidation happened before or after moieties A and B were linked 
together.  
Methylation at position A2503 of 23S rRNA prevents HygA from binding to the 
ribosome (Toh et al., 2008). Moreover, among the genes assigned as resistance genes, hyg21 
was shown to encode a 2-O-phosphotransferase, which inactivates HygA (Dhote et al., 2008). 
Hyg6 and hyg29 genes were assigned as putative methyltranferases, and hyg19 and hyg28, as 
efflux pumps.  
From the perspective of development of new antimicrobials, elucidation of the 
biosynthetic pathway of the aminocyclitol moiety remains an interesting and open question. 
Aminocyclitol, as shown in previous studies (Hayashi et al., 1997), is essential for HygA’s 
inhibitory activity. Aminocyclitols are often found in active natural compounds, for example, 
the aminocyclitole-aminoglycosides (e.g. gentamycin, kanamycin or streptomycin), which are 
very potent antibiotics (Flatt and Mahmud, 2007). 
 
Figure 7 A HygA biosynthesis genes cluster from Streptomyces hygroscopicus NRRL 2388. Subunit A
(shown in green) originates from glucose-6-phosphate via a mannose intermediate, reaction is driven by Hyg5,
23, 29, 16. The final step, oxidation of C-5”-dihydrohygromycin A is catalyzed by NAD dependent Hyg26
Subunit B (in purple) is derived from 4-hydroxybenzoic acid and propionic acid in a polyketide-like manner. 
Subunit C (in pink) Aminocyclitol originates from glucose-6-phosphate via myo-inositol intermediate,in a series 
of reactions catalyzed by Hyg 18, 25, 17, 8. The methylenedioxy bridge formation between C4 and C5 involves 
Hyg6 and Hyg7 (Dhote et al., 2009; Habib el et al., 2003; Palaniappan et al., 2006; Palaniappan et al., 2009) 
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1.2.2 Macrolides 
The first members of the macrolide class of antibiotics, picromycin (Brockmann and 
Henkel, 1950) produced by Streptomyces venezuelae, and erythromycin (McGuire et al., 
1952) produced by Saccharopolyspora erythraea, were discovered in the 1950’s. The 
foundation of the chemical structure of macrolides is the 12-16 membered lactone ring, to 
which a range of sugar moieties is attached. The classic macrolide, erythromycin (Ery), 
belongs to the 14-membered family with C3 cladinose and C5 desosamine sugars, while 
azithromycin (Azi) has a 15-membered ring. Tylosin (Tyl) (Figure 8c) is an example of a 16-
membered macrolide with a C5 mycaminose-mycarose disaccharide as well as a C14 
mycinose (reviewed by (Mankin, 2008; Wilson, 2009)). Macrolides bind to non-translating 
ribosomes (Pestka, 1974). Chemical probing showed that macrolides universally protect 
nucleotide A2058 (Poulsen et al., 2000) located at the entrance of the exit tunnel, adjacent to 
the PTC. Macrolides with a mycarose moiety protect U2506 in the central loop of domain V 
23S rRNA, while A752 (domain II), lying deeper in the exit tunnel, is protected from 
modifications by macrolides with a mycinose moiety (Poulsen et al., 2000). Crystal structures 
of macrolides bound to ribosomes confirm that the lactone ring binds to the wall of the tunnel, 
near the tunnel constriction formed by ribosomal proteins L4 and L22, with the C5 sugar 
moiety extending towards the PTC, and interacts with A2058 and A2059 (Figure 8a, b) 
(Hansen et al., 2002a; Schlunzen et al., 2001; Tu et al., 2005; Wilson et al., 2005). However, 
the C14 mycinose faces down the nascent polypeptide exit tunnel and interacts with A748-
A752 (Hansen et al., 2002a). Tyl, carrying C6 ethyl aldehyde group, was shown to form an 
Figure 8 Binding of macrolide antibiotics within the ribosomal tunnel (A) The large subunit of the ribosome
with visualized ribosomal exit tunnel. The position of tylosin (red), P-site tRNA (green), and a polypeptide chain
(yellow) are indicated. rRNA in light blue, ribosomal proteins in dark blue. (B) Zoom in on the macrolide-binding
site within the ribosomal tunnel. Tylosin (pink) shown with lactone ring, C14-mycinose, and C5-mycaminose-
mycarose are labeled. The arrow indicates the carbinolamine bond that forms between tylosin and the N6 of 23S
rRNA nucleotide A2062. The positions of A- and P-site aminoacyl-tRNAs are shown in green and orange,
respectively. (C) Chemical structure of tylosin 
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unusual reversible covalent bond with the N6 of nucleobase A2062 (Hansen et al., 2002a). 
Macrolides bound to the ribosome prevent the progression of most nascent 
polypeptide chains through the tunnel and induce peptidyl-tRNA drop-off. However, in the 
presence of macrolides, synthesis of short oligopeptides is still possible. The length of the 
peptide synthesized before peptidyl-tRNA drop-off depends on the number of sugar 
substituents at the position C5 and the amino acid sequence of the peptide (Tenson et al., 
2003). Monosaccharides, for example as in Ery, allow synthesis of up to eight amino acid 
long oligopeptides, while macrolides with disaccharides (e.g., Tyl) allow translation of di- to 
tetrapeptides (Tenson et al., 2003). Moreover, macrolides with a mycarose moiety can directly 
inhibit peptide bond formation (Poulsen et al., 2000). A resistance mechanism to macrolides 
involving translation of pentapeptides, which leads to dissociation of the drug from the 
ribosome, suggests a direct interaction of the macrolide with the nascent polypeptide chain 
(Lovmar et al., 2006; Tenson et al., 1996; Tenson and Mankin, 2001). Furthermore, 
pentapeptide effects on distinct macrolides vary, which implies specific interactions between 
the drug and the nascent polypeptide (Vimberg et al., 2004). A number of additional 
resistance mechanisms are known, including (i) mono- and dimethylation of the N-6 position 
of A2058 by the Erm family of methyltransferases (Lai and Weisblum, 1971; Roberts et al., 
1999), (ii) single substitution of A2058 to guanosine in the 23S rRNA (Vester and 
Douthwaite, 2001), (iii) mutations in ribosomal protein L4, such as single amino acid 
substitutions K63E (Chittum and Champney, 1994) and G69C as well as insertion of two 
amino acids, SQ, between Q67K68 (Tait-Kamradt et al., 2000), (iv) deletion of three amino 
acids ΔM82R83K84 in ribosomal protein L22 (Gregory and Dahlberg, 1999), (v) MefA and 
MsrA macrolide efflux pumps (Roberts et al., 1999; Ross et al., 1990), or (vi) inactivation of 
the antibiotic by modification, for example by Mph family of macrolide phosphorylases 
(Roberts et al., 1999). 
 Many macrolide resistance genes are expressed upon induction, which is driven by 
the presence of sublethal concentrations of the antibiotic in a mechanism called translational 
stalling. One of the best-characterized examples is the regulation of expression of the 
methyltransferase, ErmC, which is controlled by an upstream leader sequence ermCL 
(Gryczan et al., 1980; Horinouchi and Weisblum, 1980; Ramu et al., 2009). In the absence of 
the macrolide, ermC translation is attenuated, whereas the presence of the drug induces 
ribosome stalling during translation of ermCL. This, in turn, leads to a rearrangement of the 
mRNA secondary structure, exposure of the Shine-Dalgarno sequence and start codon, and 
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expression of downstream ermC gene. Recent results suggest that in addition to the sequence 
of the polypeptide, the structure of the antibiotic is also important for stalling (Vazquez-
Laslop et al., 2011). The rRNA nucleotides A2062 and U1782 monitor the structure of the 
nascent polypeptide, while nucleotides C2610, A2503, and possibly A2058 and A2059 
recognize the structure of the macrolide antibiotic (Vazquez-Laslop et al., 2011) and together 
transmit the signal that induces ribosomal stalling. Moreover, it was shown that the stalled 
peptide alters the A-site function for peptide bond formation which accounts for the 
translational arrest (Ramu et al., 2011). 
1.2.3 Thiopeptides 
 Thiopeptide antibiotics are ribosomally synthesized antimicrobials. They are produced 
as oligopeptides which undergo a series of post-translational modifications resulting in 
mature, active compounds (Wieland Brown et al., 2009). Compounds belonging to the 
thiopeptide family have a characteristic trithiazolyl pyridine core, and a macrocyclic loop 
consisting of a varying number of atoms (for example, 26 in nosiheptide, thiocillin, and 
thiostrepton, 29 in GE2270A and 35 in berninamycin) (reviewed by (Bowers et al., 2010; 
Walsh et al., 2010)). Microccocin P1 (MiC), discovered in 1948 as a metabolite of 
Microccocus (Su, 1948) and Bacillus cereus (Bycroft and Gowland, 1878), was the first 
described member of the thiopeptide family, followed by the discovery of thiostrepton (ThS), 
which is produced by Streptomyces azureus and S. laurentii (Donovick et al., 1955). To date, 
more than 80 members of this class of antimicrobials are known. Thiopeptides due to their 
poor solubility, are used only in veterinary practice. However the potency of thiopeptides 
against multidrug resistant Gram-positive strains and recent advances in total synthesis of a 
number of thiopeptides (ThS (Nicolaou et al., 2005a; Nicolaou et al., 2005b), GE2270A 
(Muller et al., 2007) and MiC (Lefranc and Ciufolini, 2009), has renewed interest in this 
group of antibiotics.  
The Bacillus cereus ATCC 14579 thiocillin biosynthesis operon has been well-
characterized (Figure 9), revealing that thiopeptides are synthesized as pre-peptides with a 
leader peptide which is cleaved-off post-translationally. The C-termini derived peptide 
undergoes a series of modification steps, thirteen in the thiocillin maturation process, resulting 
in a fully active antimicrobial compound (Wieland Brown et al., 2009). In vivo genetic 
manipulations of the thiocillin structural gene has led to generation of more than 60 new 
Agata L. Starosta    Introduction 
32 
 
thiocillin variants (Acker et al., 2009), opening up new possibilities for generating more 
active compounds with improved pharmacokinetic properties. 
The crystal structures of ThS and MiC bound to the LSU showed that thiopeptides 
bind at the GAC, spanning the N-terminal domain of ribosomal protein L11 and H43 and H44 
of the 23S rRNA (Figure 10) (Harms et al., 2008). ThS and MiC overlap with binding 
positions of translation factors, such as IF2, EF-G and EF-Tu (Allen et al., 2005; Gao et al., 
2009; Myasnikov et al., 2005; Schmeing et al., 2009). Biochemical data revealed that ThS 
inhibits IF2-dependent initiation complex formation (Brandi et al., 2004), stable binding of 
ternary complex EF-Tu·aa-tRNA·GTP to A-site (Gonzalez et al., 2007) and stable binding of 
EF-G to the ribosome (Cameron et al., 2002; Seo et al., 2006). This latter finding suggests that 
ThS is an inhibitor of the translocation reaction (Munro et al., 2010b; Pan et al., 2007; Pestka, 
1970). Functionally, it was shown that ThS inhibits ribosome dependent EF-G’s turnover 
(Pestka, 1970; Weisblum and Demohn, 1970). MiC, unlike ThS, stimulates in vitro ribosome-
dependent GTPase activity of EF-G (Cundliffe and Thompson, 1981).  
Figure 9 A thiocillin biosynthesis gene cluster from Bacillus cereus ATCC 14579. The C-terminal 14
residues of a 52-residue peptide precursor undergo 13 post-translational modifications to generate a set of eight
related antibiotics (Wieland Brown et al., 2009) 
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Figure 10 Thiostrepton. (a) An 
overview of thiopeptide binding site on 
the LSU. Interface view with helix 43 
and 44 (H43/44; orange), L11 (yellow), 
and ThS (green) highlighted with 
surface representation (PDB 3CF5) 
(Harms et al., 2008). (b) The thiazole 
rings of ThS (green) interact with the 
RNA bases at the tips of H43/44 as well 
as the prolines in the N-terminal 
domain of L11 (yellow) (Starosta et al., 
2009). 
In contrast, GE2270A does not bind to the GAC, but instead binds to EF-Tu 
(Figure 11) and interferes with binding of the aa-tRNA, leading to inhibition of ternary 
complex formation (Parmeggiani and Nissen, 2006). Crystallographic data showed that 
GE2270A spans domain I and II of EF-Tu, and therefore prevents the aminoacyl moiety of 
the aa-tRNA from binding (Parmeggiani and Nissen, 2006).  
 
 
Figure 11. Binding site of GE2270A on EF-Tu. (a) Structure of the thiopeptide GE2270A (green) bound to 
EF-Tu (yellow), with domains I, II, and III indicated (PDB 2C77) (Parmeggiani et al., 2006). (b) GE2270A 
overlaps the binding position on EF-Tu of the terminal A76 and aminoacyl moiety of tRNA. Inset shows 
overview of EF-Tu•tRNA ternary complex (PDB 1TTT) (Nissen et al., 1995) with superimposition of GE2270A. 
(c) Superimposition of EF-Tu_GE2270A (yellow) and EF-Tu•tRNA (blue) aligned on basis of domain II. Note 
that GE2270A (green) clashes with domain I of EF-Tu from the ternary complex (blue) (Starosta et al., 2009). 
 
Thiopeptides that interact with the ribosome contact nucleotides A1067 (H43) and 
A1095 (H44), and interact with P22 and P26 of L11. In accordance with structural data, 
substitutions of A1067 and A1095 (Rosendahl and Douthwaite, 1994; Thompson et al., 1988), 
or within the proline-rich region of L11’s N-terminus (Cameron et al., 2004) lower the 
affinity of the drug for the ribosome and confer resistance (Baumann et al., 2010). Bacteria 
producing thiopeptides protect themselves from the inhibitory effects of drugs through efflux 
mechanisms (Wieland Brown et al., 2009). The Streptomyces azureus genome encodes a 2’-
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O-methylase that modifies nucleotide A1067 (Thompson et al., 1982), which is used in 
molecular biology as ThS selection marker. 
1.2.4 Orthosomycins 
 The evernimicin class (orthosomycins) of antibiotics were first isolated from 
Micromonospora carbonaceae in the 1960’s (Weinstein et al., 1964). Orthosomycins are 
oligosaccharide antibiotics rich in modified L- and D-deoxysugars containing unusual 
orthoester and glycosyl linkages (Figure 12c) (Hosted et al., 2001; Weitnauer et al., 2001) 
and are active against Gram-positive bacteria (Nakashio et al., 1995). Evernimicin (Evn) and 
avilamycin (Avi) bind to the LSU and are potent protein synthesis inhibitors (McNicholas et 
al., 2000). Chemical probing shows that Evn and Avi protect nucleotides A2468, A2469, 
A2476, A2478, and A2482 in H89, and A2534 in H91 from DMS modification (Belova et al., 
2001; Kofoed and Vester, 2002), which locates the orthosomycin binding site at the base of 
the L7/L12 ribosomal stalk (Figure 12a, b). Consistent with primer extension data, mutations 
conferring resistance to Evn are located in H89 and H91 (Belova et al., 2001). Also mutations 
in ribosomal protein L16 are linked to Evn resistance (Belova et al., 2001; McNicholas et al., 
2001). Moreover, the modification of U2479 by AviRB, a 2’-O-methyltransferase from 
Streptomyces viridochromogenes (Mosbacher et al., 2005), and of G2470 by EmtA, a rRNA 
methyltransferase from Enterococcus faecium (Mann et al., 2001), led to an increase in the 
resistance to Evn. Although the exact mechanism of action of Evn remains unclear, 
biochemical data showed that Evn overlaps with the IF2 binding site on the LSU (La Teana et 
al., 2001) and inhibits fMet-puromycin synthesis on ribosome reconstituted from the 30SIC 
Figure 12 Orthosomycins. (a) An overview of the binding sites of orthosomycins on the LSU relative to EF-
G. Ribosomal proteins L1, L11, and L7 are shown for reference; (b) Putative binding site of orthosomycins 
spanning from H89 and H91 of the 23S rRNA. Residues highlighted in red have been associated biochemically
with Evn (review by (Wilson, 2009); (c) Chemical structure of Evn. 
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with IF2 bound and the LSU, suggesting that Evn may inhibit IF2-dependent 70SIC formation 
(Belova et al., 2001). 
1.2.5 Fusidic acid 
Fusidic acid (FA) is a steroid antibiotic (Figure 13c) (Godtfredsen and Vangedal, 
1962), discovered in 1960’s as a metabolite of Fusidium conccineum (Godtfredsen et al., 
1962). FA inhibits protein synthesis by impairing the function of EF-G on the ribosome. 
Biochemical data showed that FA does not inhibit GTP hydrolysis. Instead, FA stabilizes the 
ribosomal intermediate hybrid state, locks EF-G on the ribosome in the GTP conformation 
even after GTP hydrolysis (Ticu et al., 2009), and does not allow EF-G’s turnover (Datta et 
al., 2005; Spiegel et al., 2007; Ticu et al., 2009). It was shown that FA action strongly 
depends on the concentration, and at lower concentrations FA allows multiple GTPase 
turnovers (Seo et al., 2006). FA does not bind to free EF-G, but to EF-G bound to the 
ribosome in a GTP state (Tanaka et al., 1968), although the low resolution cryo-electron 
microscopy (cryo-EM) structures did not reveal the binding position of the drug (Agrawal et 
al., 1999; Datta et al., 2005). Nevertheless, the studies of the resistance mutations suggest that 
the binding site of the FA is located at the interface between domain I and III of EF-G 
(Figure 13a, b) (Laurberg et al., 2000), which is in agreement with the X-ray structure of EF-
G in complex with GDP and FA bound to a pseudo-POST state 70S ribosome (Gao et al., 
2009).  
 
  
Figure 13 Fusidic acid. (a) An overview of the binding sites of the FA on the LSU relative to EF-G. Ribosomal
proteins L1, L11, and L7 are shown for reference; (B) The structure of EF-G bound to the FA and GDP in the
ribosome. The various domains of EF-G are colored as shown (Gao et al., 2009); (C) Chemical structure of FA. 
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1.3 Alternative antimicrobials targeting virulence 
Traditional antibiotics, which inhibit essential functions of bacteria, are under 
selective pressure that favors resistance mutations (Clatworthy et al., 2007). The need for 
novel antimicrobial therapies is greater than ever before. New approaches in antimicrobial 
development focus on bacterial virulence and interactions between bacterial and host cells 
(Clatworthy et al., 2007). 
1.3.1 Definition of virulence 
In the traditional meaning, virulence is understood as the ability of a microorganism 
to cause illness (Clatworthy et al., 2007). Virulence factors (toxins, cytolysines, proteases) are 
generally not necessary for a pathogen to survive under laboratory conditions, however their 
role in vivo is crucial for the microorganism to survive in the environment (Alksne and 
Projan, 2000). The analysis of genomes of many virulent bacteria has revealed diversity in 
their gene content, for example different E. coli strains, e.g. laboratory K12 strain compared 
with pathogenic E. coli 0157, differ by up to 25% of their genome, while Salmonella enterica 
differs from E.coli K12 by up to 12% (Raskin et al., 2006). The variable genes are located on 
so-called pathogenicity islands, clustering genes responsible for virulence and antibiotic 
resistance (Pallen and Wren, 2007; Raskin et al., 2006). Bacterial virulence factors are 
responsible for colonization, survival within host cells, modification of host cell response as 
well as intracellular communication (Wu et al., 2008). 
1.3.2 Colonization 
Pathogenic bacteria invading host cells adapt the expression of entire pathways of 
genes to transition from the free-living form to one that colonizes the host cell (Alksne and 
Projan, 2000). Colonization of host cells requires induction of expression and assembly of 
adhesions, fimbriae and pili, which allow bacteria to attach to the cell surface (Finlay and 
Cossart, 1997). Bacteria invading mammal cells must reprogram their metabolism to adapt to 
new living conditions. Varying pH, oxygen accessibility, osmotic pressure, nutrient 
availability and ion homeostasis are signals to rearrange gene expression of the pathogen (Ray 
et al., 2009). 
1.3.3 Biofilm 
Bacteria hardly ever exist as free-floating cells. They tend to live in organized 
colonies associated with surfaces (Jayaraman and Wood, 2008). Such colonies, called 
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biofilms, are highly organized structures of bacteria embedded within exopolysaccharide 
matrices (Lawrence et al., 1991), where nutrient and metabolite transport is regulated by 
bacterial communication using small messenger molecules (acylated homoserine lactones, 
AHLs) (Davies et al., 1998). Biofilms give bacteria a greater chance to survive in 
unfavourable environmental conditions, increasing their chances for successful colonization. 
Bacteria in biofilms show significantly decreased susceptibility to antibiotics compared to 
free-floating cells (Luppens et al., 2002). 
1.3.4 Quorum sensing 
Communication between bacteria is mostly mediated by small autoinducer 
molecules. Autoinducers, mostly AHLs that are secreted into the environment, can modulate 
transcription of genes, including virulence factors. Quorum sensing occurs when bacterial 
populations reach high densities, which leads to the accumulation of high concentrations of 
autoinducers (reviewed by (Ng and Bassler, 2009)).  
1.3.5 Motility 
Successful colonization of new niches requires bacteria to have the ability to 
migrate. Motility is a high-energy consuming process powered by rotation of flagella or 
movement of pili (Kearns, 2010; Verstraeten et al., 2008). Swarming and swimming motilities 
are flagella-dependent. While swarming is the movement of a group of bacteria over a solid 
surface, swimming, in contrast, is an act of a single cell moving though a viscous liquid 
environment (Henrichsen, 1972). Twitching motility is driven by extension and retraction of 
type IV pili and is important for biofilm formation (Mattick, 2002).  
1.3.6 Secretion systems 
Bacteria can modulate the environment or even alter the host’s physiology using 
several secretion systems (SS) (Tseng et al., 2009). However here, only three of the major SS 
in bacterial pathogenicity are mentioned. The type I SS is an ABC transporter responsible for 
efflux of antimicrobial molecules as well as toxins, proteases and lipases (Koronakis et al., 
2004). The type III SS is called the injectisome due to its ability to protrude into the host 
cell’s surface with a needle-like structure, which allows direct release of toxins into the host’s 
cytoplasm (Cornelis, 2010). The type IV SS is the only SS which can transport nucleic acids 
as well as proteins. F-plasmid based conjugation, accounts for evolution of infectious 
pathogens though propagation of antibiotic resistance and virulence genes (Cascales and 
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Christie, 2003). Moreover type IV pili have been shown to promote bacterial motility and 
stimulate biofilm formation (Mattick, 2002). 
1.3.7 Elongation factor P 
Elongation factor P (EF-P) was identified as a protein binding to the ribosome (Glick 
and Ganoza, 1975). Two-dimensional gel electrophoresis (2D) analysis of E. coli cell extract 
showed EF-P to be present in a ratio 1 per 10 ribosomes (An et al., 1980). EF-P was found to 
bind to subunits, 70S ribosomes and polysomes (Aoki et al., 2008) suggesting its role not only 
in translation initiation, but also in elongation steps. Although, EF-P function remains unclear, 
it was shown that the elongation factor stimulates formation of the first peptide bond (Ganoza 
and Aoki, 2000; Glick et al., 1979; Glick and Ganoza, 1975; Swaney et al., 2006). The 
deletion of efp gene leads to defects in the growth of E. coli (Aoki et al., 1997), virulence of 
Agrobacterium tumefaciens dependent on type IV SS (Peng et al., 2001), intestinal 
colonization of host cells by Vibrio cholerae also dependent on type IV SS (Merrell et al., 
2002) and Brucella abortus (Iannino et al., 2011), flagella driven motility of Bacillus subtilis 
and E. coli (Inoue et al., 2007; Kearns et al., 2004). Moreover, it was shown that EF-P is 
specifically expressed in porcine lymph nodes upon S. typhimurium infection (Van Parys et 
al., 2011). The EF-P crystal structures revealed a three domain architecture that resembles a 
classical tRNA L-shape, suggesting possible mimicry (Figure 14a) (Choi and Choe, 2011; 
Hanawa-Suetsugu et al., 2004; Yanagisawa et al., 2010). The crystal structure of EF-P bound 
to 70S ribosome (Blaha et al., 2009) shows that EF-P does not bind in a canonical tRNA 
binding site, but rather sits between the P- and E-sites, spanning both subunits (Blaha et al., 
2009). The conserved loop of domain I reaches the CCA-end of the initiator-tRNA, while 
domain III contacts the anticodon stem loop of tRNA (Blaha et al., 2009), supporting the 
hypothesis that EF-P stabilizes the initiator tRNA to promote first peptide bond reaction.  
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EF-P is conserved among bacteria (Bailly and de Crecy-Lagard, 2010) and is 
homologous with eukaryotic initiation factor 5A (eIF5A) (Hanawa-Suetsugu et al., 2004). 
Unlike EF-P, eIF5A has only two domains, corresponding to domain I and II of EF-P (Kim et 
al., 1998; Peat et al., 1998). However, like eIF5A, EF-P also has a highly conserved loop in 
domain I (Hanawa-Suetsugu et al., 2004). A unique feature of eIF5A is the presence of a post-
translational modification with hypusine, which is essential and characteristic only to eIF5A 
(Zanelli et al., 2006). The highly conserved lysine 50 (K50 in human eIF-5A) is modified into 
an unusual amino acid derived from spermidine. Hypusylation is a two-step reaction, 
catalyzed by two enzymes. First, the deoxyhypusine synthase (DHS) catalyzes the cleavage of 
the polyamine spermidine as well as the transfer of its 4-aminobutyl moiety to the ε-amino 
group of lysine residue of the eIF-5A precursor to form deoxyhypusine (Park, 2006). In a 
second step, deoxyhypusine hydroxylase (DOHH) mediates the addition of a hydroxyl group 
to the deoxyhypusine residue forming hypusine (Park, 2006). DHS and DOHH are not present 
in bacterial genomes, however, analyses of endogenous E. coli EF-P revealed the presence of 
an additional 144 Da mass (Aoki et al., 2008). Two unrelated to DHS and DOHH gene were 
implied to function as modification enzymes for EF-P pathway, namely, yjeA (a paralog of 
lysyl-tRNA synthetase) and yjeK (lysine 2,3-aminomutase) (Figure 14c) (Bailly and de 
Crecy-Lagard, 2010). Interactions between yjeA and yjeK were reported to be critical for 
virulence and stress resistance in S. enterica (Navarre et al., 2010). Salmonella yjeA and yjeK 
mutants share extensive phenotypic pleiotropy, including attenuated virulence in mice, a 
decreased ability of bacteria to colonize swine host, growth defects, susceptibility to a variety 
Figure 14. Elongation factor P. (a) EF-P crystal structure shows classical tRNA L-shape, in red - Lysine 34
undergoing modification (PDB 3A5Z); (b) EF-P (violet) in a complex with YjeA (yellow) (PDB 3A5Z)
(Yanagisawa et al., 2010); (c) Physical clustering of efp (violet), yjeK (pink), and yjeA (yellow), according to
(Bailly and de Crecy-Lagard, 2010). 
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of various growth inhibitors and altered expression of multiple proteins, including several 
encoded on the SPI-1 pathogenicity island (Bearson et al., 2011; Bearson et al., 2006; Kaniga 
et al., 1998; Navarre et al., 2010; Yanagisawa et al., 2010). YjeA mediates the post-
translational modification of bacterial elongation factor P resulting in an additional 128 Da 
mass on EF-P (Figure 14b) (Navarre et al., 2010). In vivo experiments show that YjeK 
enhances the activity of YjeA (Yanagisawa et al., 2010), which is consistent with observation 
that (R)-β-lysine is 100-fold better substrate for YjeA than (S)-β-lysine or α-lysine (Roy et al., 
2011).  
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2 Objectives of these studies 
 
 (I) Hygromycin A (Paper 1 and 2). Analysis of fermentation broth contents of several  
S. hygroscopiscus NRRL 2388 mutants revealed the presence of a mixture of HygA 
derivatives. Intermediates of the HygA biosynthetic pathway were investigated and 
affects of alterations of the aminocyclitol moiety on the antimicrobial activity of 
HygA were studied. Moreover how differential oxidation states of the C5” position 
of dehydrofucofuranose moiety affects the activity of HygA was also examined. 
Additionally, unpublished data is presented showing the inhibitory effect of HygA 
derivatives on peptide bond formation and the effect of phosphorylation of HygA by 
the 2-O-phosphotransferase was evaluated. 
(II) Macrolides. (Paper 3) Structural data show that D. radiodurans ribosome can bind two 
molecules of azithromycin (AZI) (Schlunzen et al., 2003). However in the crystal 
structure of AZI with Haloarcula marismortui LSU only one molecule of AZI was 
bound (Hansen et al., 2002a). Here the kinetics of AZI binding to E. coli and  
D. radiodurans ribosomes were studied to investigate in more details the 
discrepancies between antibiotic binding in different species. (Paper 4). The C6 
ethyl aldehyde group of the Tylosin (Tyl) forms a unique covalent bond with 
ribosomal RNA A2062 (Hansen et al., 2002a). The contribution of the covalent 
linkage in the binding to the ribosome and the inhibitory activity of Tyl was 
determined. Moreover, Tyl derivatives designed to establish interactions with 
ribosomal tunnel wall, and derivatives with substituents mimicking nascent 
polypeptide was also tested. 
(III) Thiopeptides. (Paper 5) The complicated structure and poor solubility of thiopeptides 
account for their limited possibilities in terms of application for bacterial infection 
therapies. Therefore, a library of thiopeptide synthetic precursors was screened for 
their potency to inhibit protein synthesis and ribosome-dependent GTPase activity of 
EF-G in order to find the minimal carbon scaffold necessary for targeting the 
ribosome and which, in the future, could provide a basis for design of more soluble 
compounds. (Paper 6) MiC binds in a cleft between ribosomal protein L11 and H43 
and H44 of the 23S rRNA (Harms et al., 2008), and stabilizes the C-terminal domain 
of protein L7/L12 (CTD-L7/L12) (Harms et al., 2008). Crystallographic data shows 
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that the G’-domain of EF-G interacts with CTD-L7/L12 (Gao et al., 2009), and was 
shown to be crucial for GTPase activity and Pi release (Nechifor et al., 2007; 
Savelsbergh et al., 2005). By comparison of different GTPases, which have reduced 
or absent G’ domain, the hypothesis was tested that the enhanced turnover of EF-G 
by MiC is a result of stabilizing effects of the drug on L11- CTD-L7/L12 interaction. 
(IV) Orthosomycins. (Paper 6). The available data suggest that Evn inhibits initiation of 
translation, however, the exact step at which Evn acts remains unclear. Therefore, the 
role of Evn in the translation cycle was dissected. 
(V) Fusidic acid. (Paper 7) Antibiotics can trap the ribosome in distinct functional states. FA 
was used to visualize intermediate translocation events and ascertain whether it is 
possible to localize the antibiotic using Cryo-EM.  
(VI) Elongation factor P. (Paper 8) Emerging resistance to antibiotics stresses the need for 
new antimicrobial targets. EF-P is linked to virulence in a number of bacterial 
strains. The modification of EF-P is crucial for pathogenicity. The differences 
between the 144 Da modifications reported for endogenous EF-P compared with the 
128 Da modification observed in vitro was investigated. Moreover, the chemical 
composition of the modification was also dissected. Additionally, initial unpublished 
data is presented showing variability in phenotypes of wild type E. coli with deletion 
strains of the efp gene and genes encoding the EF-P modification enzymes.  
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3 Cumulative thesis 
3.1 Hygromycin A 
3.1.1 Paper 1 
Palaniappan, N., Dhote, V., Ayers, S., Starosta, A.L., Wilson, D.N., and Reynolds, K.A. 
(2009). Biosynthesis of the aminocyclitol subunit of hygromycin A in Streptomyces 
hygroscopicus NRRL 2388. Chem Biol 16, 1180-1189. 
3.1.2 Paper 2 
Dhote, V., Starosta, A.L., Wilson, D.N., and Reynolds, K.A. (2009). The final step of 
hygromycin A biosynthesis, oxidation of C-5''-dihydrohygromycin A, is linked to a putative 
proton gradient-dependent efflux. Antimicrob Agents Chemother 53, 5163-5172. 
 
The aminocyclitol subunit was shown to be essential for the antimicrobial activity of 
HygA (Hayashi et al., 1997). The HygA biosynthesis operon has seven genes assigned for 
synthesis of the aminocyclitol moiety (SubC) (Figure 7). Using a radiolabeled precursor 
approach, it was shown that the SubC of HygA is derived from glucose via a myo-inositol 
(MI) intermediate and methionine (Habib el et al., 2003). In Paper 1, Professor K. Reynold’s 
group continued studies on HygA biosynthesis pathway. Gene disruption experiments and 
chemical complementation with MI and/or mature SubC enabled the series of steps leading to 
production of mature SubC to be understood. The studies demonstrated that glucose-6-
phosphate is a substrate for Hyg18, assigned as myo-inositol-1 phosphate synthase. In the 
next step, MI-phosphate is dephosphorylated by Hyg25. MI is a substrate for inositol 
dehydrogenase (Hyg17). The reaction of Hyg17 is followed by transamination of the C5-
oxydized MI to produce neo-inosamine-2 in a reaction catalyzed by Hyg8 aminotransferase. 
Hyg6 is a SAM-dependent methyltransferase that methylates neo-inosamine-2. The structure 
of HygA revealed a unique methylenedioxy bridge between the C4 and C5 carbons of the 
aminocyclitol. Therefore, it was suggested that the cyclization of the C5 methoxy group is 
catalyzes by Hyg7. Disruption of hyg8 and hyg7 genes did not lead to HygA production. 
However, interestingly, the intermediates of HygA were accumulated. – 
desmethylenehygromycin A (Des-HygA) containing a hydroxyl group at the C5 carbon, and 
methoxyhygromycin A (Met-HygA), with a C5-OCH3 group instead of the methylenedioxy 
bridge. 
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The antimicrobial potency of the intermediates of HygA with altered aminocyclitol 
ring was examined against ΔtolC E. coli. The minimal inhibitory concentration (MIC) 
experiments for HygA and intermediates showed that, the modifications of aminocyclitol 
moiety lead to a significant loss (15-fold) of an in vivo activity of Des-HygA and Met-HygA. 
Moreover, the HygA-derivative lacking the aminocyclitol moiety (AB) (Palaniappan et al., 
2006) displayed no detectable activity. I tested the intermediate compounds for their ability to 
inhibit protein synthesis in an E. coli lysate-based in vitro coupled transcription-translation 
assay (TT) using green fluorescent protein (GFP) as a reporter. HygA showed high in vitro 
activity with half-inhibitory concentration (IC50) at 0.18 µM. Surprisingly, the intermediates 
of HygA displayed significant in vitro activity, with IC50 of Met-HygA at 0.32 µM and Des-
HygA at a concentration of 0.5 µM, whereas the AB compound displayed no or minor 
inhibitory activity, even at concentrations of 75 µM. Interestingly, the order of the activity of 
the compound reflected the progression of methylenedioxy bridge synthesis. Additionally, in 
the context of a DAAD fellowship, I visited the laboratory of Professor G. Dinos (Patras, 
Greece) where I tested the HygA analogs for their ability to inhibit AcPhe-puromycin 
(AcPhe-Puro) synthesis. Interestingly, I found the same trend of the potency to inhibit peptide 
bond formation as I observed for the inhibition of GFP synthesis (Figure 15a,c vs b,d). These 
data suggest that HygA primary activity is the inhibition of the PTC. The MIC, TT and 
AcPhe-Puro data on the HygA intermediates confirmed that the aminocyclitol is necessary for 
HygA inhibitory activity in vivo and in vitro. The data showed that for the full in vivo activity, 
the aminocyclitol must be modified with an intact methylenedioxy bridge. However, 
alterations of the methylenedioxy ring did not lead to a loss in the in vitro protein synthesis 
inhibition activity, in particular on the peptide bond formation. Taken together, these data 
suggest that the aminocyclitol ring is essential for translation inhibition activity, whereas a 
methylenedioxy ring is crucial for full in vivo activity, possibly for the uptake of the drug into 
the cell. 
 Previous studies from Professor K. Reynolds’s group showed that disruption of hyg26 
gene led to the accumulation of 5”-dihydro-HygA (DH-HygA) intermediate (Palaniappan et 
al., 2006). Hyg26 was suggested to catalyze dehydrogenation of the C5”-OH of the 
fucofuranose moiety (SubA). In Paper 2, it was shown that recombinant Hyg26 is a 
NAD/NADH-dependent oxidoreductase, and that the Hyg26 reaction is reversible and favors 
DH-HygA. Surprisingly, the disruption of the hyg19 gene also led to the accumulation of DH-
HygA. Moreover, although HygA was still detected, the level of antibiotic production was 
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significantly decreased. Hyg19 was predicted to be a proton gradient-dependent efflux pump. 
It was shown that the levels of HygA production depend on the effective export of the drug 
outside the cell by the Hyg19 pump. The DH-intermediates of HygA, Des-HygA and Met-
HygA were tested for their antimicrobial activity. The MIC values against ΔtolC E. coli 
showed that the change of oxidation state of C5” do not alter in vitro activity of neither HygA 
nor Des-HygA and Met-HygA. Additionally, I tested DH-intermediates of HygA for their 
potency to inhibit protein synthesis in E. coli lysate based TT assay. Compared with the data 
for HygA the 5” oxidized analog, DH-HygA (Figure 15a) showed slightly reduced activity to 
inhibit GFP synthesis. Interestingly, DH-intermediates of Met-HygA and Des-HygA 
displayed significantly lower potency (8- to 15-fold decrease) to inhibit protein synthesis 
(Figure 15c) in comparison to their dehydrogenized analogs. Additionally, I analysed DH-
intermediates in an AcPhe-Puro synthesis assay. As seen for inhibition of GFP synthesis, 
oxidized intermediates exhibited a decrease in potency to inhibit protein synthesis (Figure 
15b, d). Although the changes in the C5” oxidation state of SubA did not have an effect in 
vivo, they significantly altered the activity of HygA and intermediates to inhibit protein 
synthesis, suggesting the importance of this group for the interactions with ribosome.  
Additionally, the effect of phosphorylation of HygA (P-HygA) was studied. Hyg21 is 
a O-phosphotransferase that modifies C2” of SubA. (Dhote et al., 2008). Inactivation of HygA 
by phosphorylation was observed in vivo for ΔtolC E. coli and Streptomyces lividans (Dhote 
et al., 2008). I found that P-HygA significantly loses activity to inhibit protein synthesis in TT 
assay (>150 fold) (Figure 15e) and potency to inhibit AcPhe-Puro synthesis (~500 fold) 
(Figure 15f), suggesting that the modification decreases the affinity of the compound to the 
ribosome. 
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Collectively, it was shown that gene disruption of the HygA biosynthesis pathway 
results in accumulation of intermediates, which enables functional studies of distinct chemical 
moieties of HygA to be performed. The intermediates are becoming progressively more active 
antimicrobials, with HygA as the most potent inhibitor. The methylene bridge was proven to 
be important for the in vivo activity of HygA, whereas it does not significantly affect 
translation inhibition in vitro. Furthermore, the C5” oxidation has no effect on in vivo activity, 
but alters the effect of HygA on the translation in vitro. I showed that HygA and intermediates 
inhibit peptide bond formation, suggesting that HygA binds in the PTC, in agreement with 
previous biochemical data (Guerrero and Modolell, 1980; Poulsen et al., 2000). Additionally, 
I demonstrated that the modification of C2” leads to the loss of inhibitory activity of HygA, 
possibly through sterical clashes with ribosomal components and altering the affinity to the 
ribosome. In conclusion, the new structurally diverse compounds may lead to design of novel 
antimicrobials. 
 
 
 
 
Figure 15. HygA and derivatives action (a, c, e) on the GFP synthesis in a TT assay and (b, d, f) on the AcPhe-
Puro synthesis 
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3.2 Macrolides 
3.2.1 Paper 3 
Petropoulos, A.D., Kouvela, E.C., Starosta, A.L., Wilson, D.N., Dinos, G.P., and Kalpaxis, 
D.L. (2009). Time-resolved binding of azithromycin to Escherichia coli ribosomes. J Mol 
Biol 385, 1179-1192. 
3.2.2 Paper 4 
Starosta, A.L., Karpenko, V.V., Shishkina, A.V., Mikolajka, A., Sumbatyan, N.V., 
Schluenzen, F., Korshunova, G.A., Bogdanov, A.A., and Wilson, D.N. (2010). Interplay 
between the ribosomal tunnel, nascent chain, and macrolides influences drug inhibition. Chem 
Biol 17, 504-514. 
 
Azithromycin (AZI) is a 15-membered semi-synthetic derivative of erythromycin, 
structurally distinguished by the absence of a keto oxygen at position C9 and the insertion of a 
methyl-substituted nitrogen at position C10. AZI shows higher stability and improved potency 
against Gram-negative bacteria. AZI displayed anti-inflammatory and modulatory effects on 
the expression of virulence factors of P. aeruginosa (Bala et al., 2011). Interestingly, crystal 
structures of AZI bound to either the bacterial (Schlunzen et al., 2003) or archaeal (Hansen et 
al., 2002a) ribosome showed a different number of molecules bound per ribosome. A single 
molecule was found in the archaeal structure, whereas two molecules of the drug were 
observed in the structure of D. radiodurans 50S subunit.  
In Paper 3, the group of Professor G. Dinos used kinetic and footprinting methods to 
characterise binding process of the AZI. It was shown that AZI binds to E. coli ribosomes in a 
two-step process. First, an initial rapid low-affinity binding state occurs where AZI inserts 
into a hydrophobic cleft formed by nucleotides G2057-A2059 and is also positioned by 
G2505. Secondly, AZI slowly accommodates into a high-affinity binding state, where 
interaction with hydrophobic cleft weakens and AZI moves towards U2609 and nucleotides of 
domain II of 23S rRNA. Moreover, U2609C substitution promotes formation of the stable 
complex. The low- and high-affinity AZI binding sites are unique and only one molecule of 
the drug binds per E. coli ribosome at a time. In order to to evaluate the species specific mode 
of AZI binding, I prepared D. radiodurans 70S ribosomes which were used. In contrast to 
previously obtained data for AZI binding to E. coli ribosomes, kinetic and binding data 
indicated that two molecules of AZI bind cooperatively to the D. radiodurans ribosome. This 
finding supported the crystallographic observations on differential binding of AZI to 
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ribosomes from varying species. In conclusions, in the future, our results may lead to design 
of compounds that preferentially target ribosomes of specific species of bacteria 
 
The crystal structure of tylosin (Tyl) bound to Haloarcula marismortui LSU showed 
a covalent bond between the C6 ethyl aldehyde group of Tyl and the N6 of nucleobase A2062 
of 23S rRNA (Hansen et al., 2002a). Nucleobase A2062 was suggested to establish 
interaction with nascent polypeptide (Bhushan et al., 2010; Seidelt et al., 2009; Vazquez-
Laslop et al., 2011) and contribute for the stalling mechanism of ErmCL (Vazquez-Laslop et 
al., 2008). In Paper 4, the importance of ethyl aldehyde group for Tyl binding was elucidated. 
A series of macrolide derivatives with oligopeptide substituents was tested in order to 
investigate tunnel-nascent polypeptide interactions.  
The group of Professor A. Bogdanov designed and synthesized several Tyl 
derivatives, which I have tested for their ability to establish interactions with either the 
ribosomal exit tunnel wall and/or the nascent polypeptide. Two sets of Tyl derivatives, with 
substitution at either the C6 or C14 positions were monitored for their ability to (i) compete 
for binding to empty D. radiodurans 70S ribosomes with [14C]-erythromycin ([14C]-Ery), or 
(ii) inhibit GFP synthesis in E. coli lysate-based TT assays.  
I demonstrated that the reduced form of Tyl (Tyl-H2), where the C6 ethyl aldehyde is 
replaced with a hydroxyl group, is unable to compete with [14C]-Ery. Moreover, in the TT 
assay, Tyl-H2, displayed significantly decreased potency to inhibit GFP synthesis, and was 
not able to inhibit protein synthesis completely. This showed that the covalent bond 
established between Tyl and ribosomal nucleotide A2062 is critical for drug binding and 
inhibitory activity. Furthermore, several C6 ethyl aldehyde oligopeptide substituents were 
tested. Tyl with C6-Ala-Ala dipeptide (Tyl-Ala) showed improved binding ability compared 
to Tyl-H2, however was still significantly worse than Tyl. The potency of Tyl-Ala to inhibit 
GFP synthesis was comparable with Tyl suggesting that the new analog may establish 
additional interactions with nascent polypeptide or ribosomal tunnel wall. The crystal 
structure of Tyl-Ala bound to D. radiodurans 50S subunits showed that Ala dipeptide stacks 
onto nucleotide A2062, which could account for the improved binding affinity. On this basis, 
a series of Tyl derivatives were designed to optimize stacking interactions with A2062. 
Additionally, I tested several Tyl derivatives with nucleotides and aromatic amino acids 
attached to C6 carbon with linkers varying in length and flexibility, including uridine, tyrosine 
and phenylalanine. Tyl-U with a uridine attached with a 4 atom linker was not sufficient to 
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significantly improve the potency of a compound in either binding to the ribosome or 
inhibition of a GFP synthesis. A tyrosine with either rigid or flexible 5 atom linker (Tyl=Tyr 
and Tyl-Tyr, respectively) showed differential effects. While Tyl=Tyr had poor properties, 
Tyl-Tyr was as effective as Tyl for inhibition of protein synthesis. Interestingly,  
a phenylalanine attached with flexible 6 atom linker showed enhanced potency to inhibit GFP 
synthesis compared with Tyl. Nevertheless, it has to be noted, that none of the new 
compounds displayed better binding properties in comparison to Tyl. This suggested that the 
potency of new derivatives originated not from the binding affinity but rather from the steric 
perturbation of growing nascent polypeptide or/and additional interactions established with 
nascent polypeptide.  
Additionally, the activity of 5-O-mycaminosyl-tylonolid (OMT), lacking both the C5 
mycarose and the C14 mycinose, was evaluated. OMT is known to be a potent antimicrobial 
with MIC values comparable with Tyl (Fu et al., 2006). However, little or no significant 
inhibitory effect of OMT on GFP synthesis was detected in our experimental set-up. 
To investigate the differential effects of OMT in more detail, our collaborators 
synthesized a series of peptide-OMT compounds, where BocAlaAlaPhe and fMetLeuPhe 
peptides are attached to the C14 position. In the TT assay, only fMLF-OMT showed 
improved potency to inhibit GFP synthesis compared to OMT, although translation was not 
inhibited by more than 60%, even at a concentration 200-fold higher than the inhibitory 
concentration (IC90) for Tyl. In contrast, the competition assay showed that OMT and OMT 
analogs bind to empty ribosomes. The discrepancy between the in vivo data, TT assay and 
binding experiments has led us hypothesis that OMT displays some template specificity. To 
address this question, the GFP reporter was substituted with firefly luciferase (Fluc). 
Interestingly, OMT displayed an excellent inhibitor effect of Fluc synthesis, with a potency 
similar to that observed for the inhibition of GFP by Tyl. The effect was remarkable for the 
macrolide class of antibiotics, since such differences for tetracycline (Tet) and 
chloramphenicol (Cam) were not observed.  
In summary, for many macrolide derivatives, a lack of correlation between the 
binding affinities and inhibitory activity was observed. In other words, despite their potency 
to inhibit protein synthesis, all of the macrolide derivatives tested here were less effective at 
binding to the ribosome than Tyl. This suggests that the binding affinity does not exclusively 
determine the effectiveness of the compound and that peptide substituents of the lactone ring 
may contribute to the inhibitory activity. This might occur due to steric blockage of the 
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passage of the nascent polypeptide chain or establishment of interactions with the nascent 
polypeptide. Moreover, the data suggest that the sequence of the nascent chain may influence 
the inhibitory ability of particular macrolide antibiotics. This finding may lead to design of 
macrolide antibiotics exclusively inhibiting particular polypeptides. 
3.3 Thiopeptides 
3.3.1 Paper 5 
Starosta, A.L., Qin, H., Mikolajka, A., Leung, G.Y., Schwinghammer, K., Nicolaou, K.C., 
Chen, D.Y., Cooperman, B.S., and Wilson, D.N. (2009). Identification of distinct thiopeptide-
antibiotic precursor lead compounds using translation machinery assays. Chem Biol 16, 1087-
1096. 
3.3.2 Paper 6 
Mikolajka, A., Liu, H., Chen, Y., Starosta, A.L., Marquez, V., Ivanova, M., Cooperman, 
B.S., and Wilson, D.N. (2011). Differential effects of thiopeptide and orthosomycin 
antibiotics on translational GTPases. Chem Biol 18, 589-600. 
 
Recent advances in thiopeptide total synthesis have identified synthetic fragments 
that can serve as lead compounds for drug development. In Paper 5, a library of precursors of 
nitrogen heterocycle core of thiopeptides synthesis provided by Professor K. C. Nicolaou was 
tested. Compounds were divided into four structurally distinct groups (PA-PD), which were 
tested for their ability to inhibit (i) 70S initiation complex formation (70SIC), monitored via 
fluorescence of IF2Cy3, which increases upon LSU binding to the 30SIC; (ii) the ribosome-
dependent GTPase activity of EF-G using Malachite Green assay, and (iii) in vitro synthesis 
of GFP in E. coli lysate based TT.  
The group of Professor B. Cooperman determined that ThS and nosiheptide (NoS) 
are potent inhibitors of the 70SIC. However, only one compound from group A – PA1 – 
showed detectable inhibition of the 70SIC, but at concentrations significantly higher (60- to 
400- fold) than for ThS and NoS. It should be noted that the stereochemical derivatives of 
PA1 showed no inhibitory activity, which emphasizes the specificity of the compound. ThS 
was a very effective inhibitor of the ribosome-stimulated multiple turnover GTPase activity of 
EF-G . However, the tested compounds showed significantly lower potency to inhibit the 
GTPase activity of EF-G, even at the concentrations 50- to 100-times higher than ThS. I 
tested ThS, NoS and GE2270A in the TT assay. All three compounds displayed high potency 
to inhibit GFP synthesis, whereas in contrast, none of the tested precursor compounds showed 
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any significant inhibitory activity, even at concentrations as high as 10-fold of ThS inhibitory 
concentration (IC90). Surprisingly, addition of 10-fold excess of representative precursor 
compounds over ThS IC90 could reverse the inhibitory effect of ThS. Moreover, different 
subsets of compounds were able to restore translation inhibited by ThS, NoS or GE2270A. 
This finding suggests that although the active compounds in the library showed no potency to 
inhibit translation, they retained the ability to bind to their targets. Additionally, the ability to 
restore translation in the presence of GAC and EF-Tu inhibitors, suggest they may lead to 
design of dual inhibitors, targeting ribosomes and ternary complex formation. 
 
Crystallographic data showed that MiC binds in a cleft spanning protein L11 and 
H43-44, and stabilizes CTD-L7/L12 (Harms et al., 2008). Stimulation of the GTPase activity 
of EF-G by MiC was suggested to be due to the stabilization of the interaction of L7-CTD 
with G’ domain of EF-G (Harms et al., 2008). In Paper 6, the mode of action of MiC was 
elucidated. A set of translational GTPases, namely, EF-G, IF2, EF4 (LepA), BipA and TetM 
was tested in (i) the ribosome-dependent GTPase activity assay using the Malachite Green 
assay, and (ii) translocation reaction stopped flow fluorescence. 
Unlike ThS that inhibited ribosome-dependent GTPase of EF-G, MiC stimulated the 
GTPase activity of EF-G. I confirmed that both ThS and MiC inhibit GFP synthesis in the TT 
assay. Therefore, the group of Professor B. Cooperman has tested the effect of ThS and MiC 
on EF-G dependent translocation. Despite the differential effects of MiC and ThS on the 
GTPase activities of EF-G, it was found that both antibiotics inhibit the translocation reaction, 
probably by reducing the binding affinity of EF-G to the ribosome. The MiC-dependent 
activation was investigated in more details. Interestingly, crystallographic data suggest that 
the G’ domain of EF-G and ribosomal protein L7/L12 play a role in GTPase stimulation by 
MiC. In these study, it was found that G-proteins naturally lacking or having reduced G’ 
domains (IF2, BipA, EF4, and TetM) were inhibited by MiC. Therefore, EF-G lacking G’ 
domain (EF-GΔG’), as well as ribosomes lacking proteins L7/L12 (ΔL7/L12) were tested. 
MiC inhibited the ribosome-dependent GTPase activity of EF-GΔG’. Moreover the ΔL7/L12-
ribosome dependent GTPase activity of EF-G was arrested. Collectively, these results suggest 
that the interaction between G’-domain of EF-G and CTD-L7/L12 is indeed necessary for Pi 
release. MiC, by stabilizing CTD-L7/L12, enhances turnover of EF-G. 
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3.4 Orthosomycins 
Evn was observed to inhibit fMet-Puro synthesis in an IF2-dependent manner 
(Belova et al., 2001). In Paper 6, the step at which Evn inhibits protein synthesis was 
investigated. Evn was tested in (i) the ribosome-dependent GTPase activity of G-proteins 
using the Malachite Green assay; (ii) 70S initiation complex formation (70SIC); (iii) EF4-
dependent back-translocation, and (iv) the translocation reaction using stop-flow fluorescence. 
Professor B. Cooperman’s group demonstrated that Evn inhibits 70SIC formation by 
preventing the binding of the LSU to 30SIC in an IF2 dependent manner. This is in 
accordance with the observation that Evn inhibits ribosome-dependent GTPase activity of 
IF2. Thus, it was concluded that Evn sterically interferes with 30SIC-IF2 binding to the LSU.  
Additionally, Evn was also tested for potency to inhibit the translocation step. Yet 
unlike thiopeptide antibiotics, Evn did not inhibit the EF-G catalyzed translocation reaction. 
This result is consistent with the observation that Evn did not affect ribosome-dependent 
GTPase activity of EF-G. In contrast, Evn was found to be a potent inhibitor of ribosome-
dependent EF4 (LepA) GTPase activity, as well as EF4-dependent back-translocation 
reaction. Since EF4 is not essential for E. coli viability (Dibb and Wolfe, 1986), IF2-
dependent initiation seems to be a major target of Evn action. Moreover, the values for 
inhibition of 70SIC were comparable with results I obtained for inhibition of GFP synthesis in 
TT assay. This observation supports the hypothesis that Evn targets predominantly the 
initiation phase. 
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3.5 Fusidic acid 
3.5.1 Paper 7 
Ratje, A.H., Loerke, J., Mikolajka, A., Brunner, M., Hildebrand, P.W., Starosta, A.L., 
Donhofer, A., Connell, S.R., Fucini, P., Mielke, T., Whitford, P. C., Onuchic, J. N., Yu, Y., 
Sanbonmatsu, K. Y., Hartmann, R. K., Penczek, P. A., Wilson, D. N., and Spahn, C. M. 
(2010). Head swivel on the ribosome facilitates translocation by means of intra-subunit tRNA 
hybrid sites. Nature 468, 713-716. 
 
Despite the availability of a number of EF-G-ribosome structures, the precise 
mechanism of tRNA movement through the ribosome remains unclear. In Paper 7, Dr. A. 
Mikolajka, A Dönhöfer and I prepared the complex of EF-G stalled with FA on the 
T. thermophilus 70S in the presence of GDP, which was investigated by the group of 
Professor C.M. Spahn using cryo-EM. Two separate ribosome populations were observed, 
which varied in the degree of ratcheting and positioning of the L1 stalk, as well as by the 
degree of head swivelling of the SSU. Population I showed ~7° ratcheting with respect to the 
LSU, while at the same time head swivelling of ~5° was observed. On contrast, population II 
exhibited a 4° ratcheting but strong swiveling of the head by 18°. Examination of these two 
ribosomal populations revealed that the movement of tRNA with respect to the SSU is 
coupled with 30S head swivelling and unratcheting of the SSU. Moreover, the P-tRNA on the 
SSU maintains contact with P-site of the body and simultaneously establishes interaction with 
the exit site (E site) of the head to form previously unseen intrasubunit pe/E hybrid states.  
In both populations, EF-G·GDP stalled with FA on T. thermophilus 70S ribosomes 
showed an open conformation compared to free EF-G·GDP GDP (A et al., 1994; 
Czworkowski et al., 1994; Laurberg et al., 2000), with domains IV and V moved relative to 
domains I and II. Domain III was rotated and an additional density, spanning domain I and III 
into which FA could be modeled, was found. The position of FA was close to the position of 
the switch I region in the GTP state. This suggests that FA stabilizes the rotated state of 
domain III, preventing the conformational change of EF-G into the GDP state and thus 
prevents EF-G recycling from the ribosome. 
In summary, using Cryo-EM, it was possible not only to characterise translocation 
events, but also identify and visualize binding of a small molecule, namely the antibiotic 
fusidic acid. 
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3.6 Elongation factor P 
3.6.1 Paper 8 
Peil L., Starosta, A.L., Virumäe, K, Aktinson, G.C., Tenson, T., Remme, J., Wilson, D.N. 
(2011). Formation of ε(R)-β-lysyl-hydroxylysine on translation elongation factor EF-P 
requires YjeK, YjeA and YfcM. Under revision in Nature Chemical Biology. 
 
Elongation factor P (EF-P) and its modification are important for growth, drug 
resistance and virulence in pathogenic bacteria. Curiously, mass spectrometry analyses 
indicated that lysinylation of K34 of EF-P by YjeA results in a ~128 Da modification, leaving 
a difference of ~16 Da when compared with the ~144 Da reported for endogenous EF-P (Aoki 
et al., 2008). In collaboration with the group of Professor J. Remme, the discrepancies 
between in vivo and in vitro data were investigated using (i) an E. coli lysate-based immuno-
precipitation approach, coupled with (ii) high-resolution mass spectrometry (MS) and (iii) 
SILAC labeling were applied in order to characterize the chemical nature of the E. coli EF-P 
modification and define the modification pathway in vivo.  
The analyses of endogenous EF-P revealed an increase of the mass of EF-P by 144.2 ± 
0.1 Da compared to expected mass of unmodified EF-P. Chymotrypsin digested EF-P showed 
that peptide containing lysine 34 (K34) had an additional mass of 144.09 Da 
(F.30VKPGK*GQAF38.A) which was in accordance with digestion of endogenous EF-P with 
LysC (K.32PGK*GQAFARVK42.L). Fragmentation of both the chymotrypsin and the LysC 
peptides confirmed K34 as the site of modification. Moreover, it was shown that modification 
of endogenous EF-P involves attachment of β-lysine to ε-amino group of K34 accounting for 
128 Da, and that the additional 16 Da modification is associated with K34 of endogenous EF-
P, rather than the added lysine. 
In order to demonstrate that YjeA and YjeK were responsible for the modification of 
K34 of EF-P in vivo, endogenous EF-P was immuno-precipitated from E. coli AT713 strains 
lacking the genes for yjeA (ΔyjeA) or yjeK (ΔyjeK). Chymotrypsin proteolysis of EF-P from 
the ΔyjeA strain produced a fragment containing K34 (F.30VKPGKGQAF38.A) with no 
detectable modification. Similarly, an unmodified chymotrypsin fragment was also detected 
upon proteolysis of EF-P isolated from the ΔyjeK strain. Additionally, a peptide with a mass 
increase of +128.09 Da was found. Quantification of modified/unmodified peptide ratios 
revealed that the modified form is present at only ~2 % of the level of the unmodified form. 
These observations indicated that while YjeA can perform the lysinylation of EF-P in vivo in 
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the absence of YjeK (and therefore in the absence of (R)-β-lysine), the reaction appears to be 
extremely inefficient.  
Given the discrepancy of 16 Da between the modification mass of the endogenous EF-
P and in vitro lysinylated EF-P (+128 Da) (Navarre et al., 2010; Yanagisawa et al., 2010), it 
was concluded that a third enzyme should exist that is also involved in the modification of 
K34 of EF-P in vivo. I used STRING (Search Tool for the Retrieval of Interacting 
Genes/Proteins) database (http://string.embl.de) to search for proteins associated with YjeA, 
YjeK and EF-P. From the output, YfcM, a protein that has no reasonable homology with any 
protein of known structure or function, was chosen. Chymotrypsin proteolysis of EF-P from 
the ΔyfcM strain produced a fragment containing K34 (F.30VKPGKGQAF38.A) with a mass 
increase of 128.09 Da. Consistently, the LysC fragment of EF-P containing K34 
(K.32PGK*GQAFARVK42.L) isolated from the ΔyfcM strain had a mass increased of 128.09 
Da. The precision of the mass difference, i.e. 15.995 Da, is indicative of one atom of 
molecular oxygen, which has a monoisotopic mass of 15.995 Da, thus revealing YfcM as a 
potential hydroxylase (mono-oxygenase) that modifies K34 of lysinylated EF-P. 
In order to determine the site of hydroxylation by YfcM on K34 of EF-P, the 
differentially deuterated lysine isoform of lysine was used. 4,4,5,5-D4-L-lysine (D4-Lys) has 
the hydrogen atoms (1.008 Da) of the C4-C5 positions of L-lysine substituted with deuterium 
(2.014 Da). LysC fragments from the wildtype were 14.993 Da larger, instead of the expected 
15.995 Da. This is consistent with 14.988 Da increase expected by the mass loss of a 
deuterium atom (-2.014 Da) and the addition of a hydroxyl OH group. The 1 Da loss indicates 
that YfcM hydroxylates either the C4 (γ) or C5 (δ) position. 
To screen for potential substrates of YfcM, I applied differential scanning fluorimetry 
(DSF), which monitors the increase in thermal stability of a protein due to the interaction with 
a ligand. The largest increases in thermal stability for YfcM were observed with nucleotide-
based chemicals, for example, the maximum shift of ~5°C was observed in the presence of 
<600 μM NADP or CoA. 
Dr. G. Atkinson checked genomic distribution and context of the yfcM gene. All 
bacterial species that contain the yfcM gene also have efp, yjeA and, with one exception 
(Haemophilus influenzae strain PittGG), yjeK. However, unlike yjeA and yjeK that often 
cluster together in the same operon as efp, yfcM is always located in a distinct region of the 
chromosome. The six-gene operon structure of the prmC-aroC-mepA-yfcA-yfcM-yfcL operon 
is highly conserved within the Enterobacteriaceae family. 
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In summary, the conserved K34 of endogenous E. coli EF-P was shown to bear a 
144.09 Da modification, which results from two distinct reactions, namely a 128.09 Da 
lysinylation performed by YjeK and YjeA, followed by an additional 16 Da YfcM-dependent 
hydroxylation. The mass spectrometry fragmentation data supports the attachment of the 
lysine to the ε-amino group of K34. Moreover, the low level of modified peptide observed in 
the absence of yjeK, suggests that the conversion of (S)-α-lysine to (R)-β-lysine by YjeK 
precedes the lysinylation of EF-P by YjeA. 
Future plans 
Subsequent experiments for this project will focus on establishing the functional state 
of EF-P, verification of the state of modification of EF-P bound to the ribosome and 
investigation of the mechanism of translation regulation by EF-P. Moreover, we will check 
how this state changes during bacterial life cycle. Initial functional data indicate that deletion 
strains of efp or modification enzymes have growth defects (smaller colonies size) (Figure 
17). Interestingly, the size of colonies correlates with the state of modification verified by MS. 
We found that ∆efp strain had the most severe phenotype, followed by ∆yjeA, which, as seen 
in MS data, had fully unmodified EF-P. ∆yjeK strain (~2% modification of EF-P) showed to 
be less affected while ∆yfcM shows only minor growth effect. Motility tests showed that the 
lack of EF-P or complete loss of the modification leads to decreased motility (Figure 17). 
Figure 16. Modification pathway of EF-P and eIF-5A. (A) The FeS protein YjeK converts (S)-α-lysine to (R)-
β-lysine using S-adenosyl-l-methionine (SAM) and pyridoxal-5′-phosphate (PLP). YjeA uses ATP to lysinylate
EF-P by the addition of β-lysine to the ε-amino group of K34. YfcM uses molecular oxygen to hydroxylate the
C4 (γ) or C5 (δ) position of K34 of EF-P. (B) Deoxyhypusine synthase (DHS) uses NAD to transfer the amino-
butyl moiety from spermidine to the ε-amino group of K50 of human eIF5A, which is then hydroxylated by
deoxyhypusine hydroxylase (DOHH). (C) Relative positions of K34 of EF-P (green) and the acceptor stem of
the P-tRNA (blue) when bound on the ribosome. The γ, δ and ε carbon atoms of K34 and the C74, C75 and A76
positions of the tRNA are indicated. The model was built by mutation of Arg to Lys (equivalent to K34 in E.
coli) in the T. thermophilus EFP·70S structure 
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However, ∆yfcM was found to swim better than wild type, suggesting that YfcM and 
hydroxylation may act as a negative regulator of EF-P function. 
 
 
.  
Figure 17. Upper panel – Colonies morphology of E. coli wild type strain and deletion strains of efp, yjeK,
yjeA and yfcM genes. Cells from late logarithmic phase were plated on LB agar plates with 2,3,5-
triphenyltetrazolium chloride (TTC) as a color indicator. Lower panel – swimming assay of E. coli
wildtype and deletion strains of efp, yjeK, yjeA and yfcM. Cells were grown in meat extract-peptone 0.35%
agar plates with TTC as color indicator 
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4 Conclusions 
(I) Hygromycin A. (i) Gene disruption of HygA biosynthesis pathway leads to 
accumulation of intermediates; (ii) the methylene bridge is important for the in vivo activity of 
HygA, probably in terms of uptake; (iii) the C5” oxidation has a negative effect on the 
translation, possibly alters binding to ribosome; (iv) HygA and intermediates inhibit peptide 
bond formation; and (v) C2”-phosphorylation leads to loss of inhibitory activity of HygA. 
(II) Macrolides. (i) Two molecules of AZI bind cooperatively to the D. radiodurans 
ribosome, while only one binds to E. coli ribosomes; (ii) the C6 ethyl aldehyde interaction 
with A2062 is crucial for binding of Tyl to ribosomes and translation inhibitory activity; (iii) 
the loss of ethyl aldehyde can be compensated by oligopeptides; (iv) macrolides display 
polypeptide chain-specific inhibition. 
(III) Thiopeptides. (i) Thiopeptide synthesis precursors, despite the loss of potency 
to inhibit translation, display dual activity to restore translation in the presence of inhibitory 
concentrations of thiopeptides targeting ribosome or EF-Tu; (ii) the activation by MiC of the 
ribosome-dependent GTPase activity of EF-G requires the presence of ribosomal proteins 
L7/L12 as well as the G’ domain of EF-G. 
 (IV) Orthosomycins. (i) Evn sterically interferes with 30SIC-IF2 binding to the 
LSU; (ii) Evn inhibits of EF4-dependent back-translocation. 
(V) Fusidic acid. (i) FA binds in cleft between domain I and III of EF-G and 
stabilizes the rotated state of domain III and prevents EF-G recycling from the ribosome. 
(VI) Elongation factor P. (i) endogenous EF-P is modified with a 144.09 Da 
modification; (ii) lysinylation of K34 is performed by YjeK and YjeA and is followed by an 
additional 16 Da hydroxylation by YfcM; (iii) lysine is attached to the ε-amino group of K34; 
(iv) conversion of (S)-α-lysine to (R)-β-lysine by YjeK precedes the lysinylation of EF-P by 
YjeA; (v) YfcM displays specificity for nucleotide compounds. 
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The antibacterial activity of hygromycin A (HA) arises
from protein synthesis inhibition and is dependent
upon a methylenedioxy bridged-aminocyclitol moiety.
Selective gene deletions and chemical complementa-
tion in Streptomyces hygroscopicus NRRL 2388
showed that the hyg18 and hyg25 gene products,
proposed to generate a myo-inositol intermediate,
are dispensable for HA biosynthesis but contribute
to antibiotic yields. Hyg8 and Hyg17, proposed to
introduce the amine functionality, are essential for
HA biosynthesis. Hyg6 is a methyltransferase acting
on the aminocyclitol, and a Dhyg6 mutant produces
desmethylenehygromycin A. Deletion of hyg7, a met-
allo-dependant hydrolase homolog gene, resulted in
methoxyhygromycin A production, demonstrating
that the corresponding gene product is responsible
for the proposed oxidative cyclization step of methyl-
enedioxy bridge formation. The methyl/methylene
group is not required for in vitro protein synthesis
inhibition but is essential for activity against Escheri-
chia coli.
INTRODUCTION
Aminocyclitols, which are characterized by the presence of
a cyclohexane moiety with hydroxyl and amino or guanidino
substituents, are found in a large class of natural products with
broad-ranging biological properties. The aminocyclitol-amino-
glycosides have long been known for their antibacterial activities
and have found applications as antibiotics in clinical use (strepto-
mycin, gentamicin, and kanamycin), veterinary medicine (specti-
nomycin), and agriculture (kasugamycin and validamycin A) (Flatt
and Mahmud, 2007; Mahmud, 2009). The C7N aminocyclitol-
containing compound, acarbose, has a-glucosidase inhibitory
activity, potentially useful in the treatment of type II insulin-inde-
pendent diabetes mellitus (Mahmud, 2003). Structure-activity
relationship studies have established the importance of the
aminocyclitol moiety for the biological activity of many of these
natural products. Genetic and biochemical studies have also
revealed the complexity and diversity of the biosynthetic path-Chemistry & Biology 16,
CHBIOLways that produce these critical aminocyclitol moieties (Flatt
and Mahmud, 2007; Mahmud, 2009).
Hygromycin A (HA, compound 1) (Figure 1) is a secondary
metabolite produced by the soil bacterium Streptomyces hygro-
scopicus NRRL 2388 (Mann et al., 1953; Pittenger et al., 1953).
HA is structurally distinguished by the presence of three distinct
moieties, 5-dehydro-a-L-fucofuranose (subunit A), (E)-3-(3,4-
dihydroxyphenyl)-2-methylacrylic acid (subunit B), and the ami-
nocyclitol, 2L-2-amino-2-deoxy-4,5-O-methylene-neo-inositol
(subunit C). The mechanism of action of HA as a bacterial
ribosomal peptidyl transferase inhibitor, and also its hemaggluti-
nation inactivation, antitreponemal, and immunosuppressant
properties have been well-elucidated (Guerrero and Modolell,
1980; Nakagawa et al., 1987; Omura et al., 1987; Uyeda et al.,
2001; Yoshida et al., 1986). Herbicidal properties have been
identified for HA and methoxyhygromycin A (2) (Figure 1), a shunt
product or pathway intermediate obtained in the course of HA
biosynthesis (Kim et al., 1990; Lee et al., 2003). Structure-activity
relationship studies have revealed that subunit C is indispens-
able for HA’s antibacterial activity (Hayashi et al., 1997).
A plausible pathway for HA biosynthesis has been proposed,
based on isotope-labeled precursor incorporation studies
(Habib et al., 2003). Analyses of labeling patterns of the resulting
HA have shown that (1) subunit A originates from glucose-6-
phosphate via a mannose intermediate, (2) the central subunit
B is derived from 4-hydroxybenzoic acid and propionic acid in
a polyketide-like manner, and (3) myo-inositol and methionine
are the precursors for subunit C. It has further been suggested
that the glycoside bond (which links subunits A and B) and the
amide bond (linking subunits B and C) are formed after each of
the subunits is assembled. The results from the biosynthetic
incorporation studies provided a strategy for identification, and
subsequent cloning and sequencing of the HA biosynthetic
gene cluster of S. hygroscopicus (GenBank DQ314862) (Pala-
niappan et al., 2006). Analysis of this 31.5 kb gene cluster led
to the identification of 29 open reading frames (ORFs).
Several of the gene products were assigned putative roles
in biosynthesis of the aminocyclitol subunit of HA. In the
proposed pathway, glucose-6-phosphate is first converted to
myo-inositol-1-phosphate (MIP) by a myo-inositol-1-phosphate
synthase encoded by hyg18. MIP is then dephosphorylated
to form myo-inositol by the hyg25 gene product, a putative
myo-inositol phosphatase. Analogous steps are also encoun-
tered in the biosynthesis of the aminocyclitol moiety of1–10, November 25, 2009 ª2009 Elsevier Ltd All rights reserved 1
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Figure 1. Relationship between Hygromycin A Analogs and the Biosynthetic Pathway Leading to the Aminocyclitol Moiety
The three structural moieties, 5-dehydro-a-L-fucofuranose (subunit A), (E)-3-(3,4-dihydroxyphenyl)-2-methylacrylic acid (subunit B), and 2L-2-amino-2-deoxy-
4,5-O-methylene-neo-inositol (subunit C) are indicated.
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D-inositol of kasugamycin (Flatt and Mahmud, 2007). The subse-
quent oxidation and transamination reactions in the above
compounds occur at the C2 hydroxyl of myo-inositol to form
scyllo-inosamine, whereas in the case of HA biosynthesis the
labeling studies are consistent with them occurring at the C5
hydroxyl, leading to the unique neo-inosamine-2 product. An
inositol dehydrogenase (encoded by hyg17) and a putative
aminotransferase (encoded by hyg8) were proposed to catalyze
these steps, respectively. A distinct structural feature of HA is the
methylenedioxy bridge between C4 and C5 of the C subunit,
shown to be derived from S-adenosylmethionine (SAM). It has
been proposed that the bridge formation involves methylation
of the C5 hydroxyl group of neo-inosamine-2 (which is equivalent
to C1 of myo-inositol) by a SAM-dependent methyltransferase,
followed by cyclization. The hyg6 and hyg29 genes in the HA
gene cluster are methyltransferase homologs, and it was not
possible to determine from sequence analysis which of the two
encodes the putative O-methyltransferase acting on neo-inos-
amine-2. No candidate gene for the subsequent cyclization
step was identified and sequence analysis gave no insight into
the timing of the various steps.CHBIOL 159
2 Chemistry & Biology 16, 1–10, November 25, 2009 ª2009 ElsevierWe report herein a verification of the proposed roles of these
hyg genes in biosynthesis of the aminocyclitol subunit through
a series of targeted gene disruption experiments and chemical
complementation studies. A biologically active new desmethy-
lene analog of HA has been purified and characterized from
a Dhyg6 mutant, demonstrating that Hyg6 is the C5 O-methyl-
transferase that introduces the methyl group on the aminocycli-
tol and that introduction of the amine group can occur without
this step. The analyses have also shown that the hyg7 gene
product is required for the cyclization step that generates the
methylenedioxy bridge. The selective production of hygromycin
analogs by the Dhyg6 and Dhyg7 mutants has provided an
opportunity to probe the importance of a methyl or methylene
group on the aminocylitol ring for both in vitro protein synthesis
inhibitory activity and antibacterial activity.
RESULTS
Hygromycin Production by Mutant Strains
The HA biosynthetic gene cluster harbors seven genes that
are predicted to be functional in the biosynthesis of the 2L-2-
amino-2-deoxy-4,5-O-methylene-neo-inositol moiety (subunit C)5
Ltd All rights reserved
Table 1. Results of Feeding Antibiotic Precursors to Different hyg Mutant Strains
Strain
Antibiotic Production
Production with myo-inositol
Supplementation
Production with
Subunit C Supplementation
HA (mg/l) 3 (mg/l) 5 (mg/l) HA (mg/l) 3 (mg/l) 5 (mg/l) HA (mg/l) 3 (mg/l) 5 (mg/l)
Wild type 1190 ± 120 1090 ± 40
Dhyg18 (myo-inositol-1-
phosphate synthase)
588 ± 21 1090 ± 15
Dhyg25 (myo-inositol-1-
phosphatase)
961 ± 84 956 ± 74
Dhyg17 (myo-inositol
dehydrogenase)
147 ± 20 204 ± 41 630 ± 12
Dhyg8 (Aminotransferase) — — N/D
Dhyg8+Dhyg7 3 ± 1
Dhyg6 (Methyltransferase) — — 530 ± 60 435 ± 30 180 ± 90 690 ± 270
Dhyg29 (Methyltransferase) 485 ± 21
Dhyg7 287 ± 19 411 ± 19 671 ± 40 386 ± 33
N/D, not detectable.
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targeted gene replacement strategy for in vivo functional
analyses of these genes was used (Gust et al., 2003) and the
fermentation broths of the corresponding mutants were exam-
ined for the presence of HA or its analogs. The mutants were
also chemically complemented with either subunit C (the putative
final product of the aminocyclitol pathway) or the putative myo-
inositol intermediate, and the effect on product ratios and yields
were determined (Table 1).
The involvement of myo-inositol-1-phosphate synthase and
myo-inositol phosphatase to generate myo-inositol from glu-
cose-6-phosphate has been reported from a host of diverse
sources such as higher plants and animals, parasites, fungi,
green algae, bacteria, and archaea (Majumder et al., 2003).
The hyg18 gene product is proposed to be a myo-inositol-1-
phosphate synthase and the Dhyg18 mutant produced HA, 3,
and their corresponding C500-reduced analogs 2 and 4 (Figure 1)
at approximately 50% of the levels observed for the wild-type
strain (Table 1). A small amount (23 mg/l) of (E)-3-(3-hydroxy-
4-O-a-fucofuranosylphenyl)-2-methylacrylic acid (7) (Figure 1)
was also observed. This shunt product is not observed in the
wild-type but has been identified previously in the SCH30
(short-chain dehydrogenase, Dhyg26) mutant (Palaniappan et al.,
2006). Chemical complementation of the Dhyg18 mutant with
myo-inositol led to almost complete restoration of HA and loss
of production of the 7 shunt product. In contrast, no increase in
HA yields was observed with addition of myo-inositol to the
wild-type strain (suggesting that myo-inositol is limiting in the
Dhyg18 mutant but not in the wild-type). The hyg25 gene product
is predicted to be a myo-inositol phosphatase, and a Dhyg25
mutant was observed to produce HA in amounts comparable
to that in the wild-type, both in the absence and presence of
myo-inositol.
Blocking the aminocyclitol pathway at steps subsequent to
the proposed myo-inositol intermediate had more pronounced
effects on antibiotic production. Disruption of hyg17, which
presumably encodes a myo-inositol dehydrogenase for C5
oxidation of myo-inositol, resulted in an 8-fold decrease in
HA production (Table 1). Consistent with predictions, chemicalCHBIOL
Chemistry & Biology 16,complementation of the Dhyg17 mutant with myo-inositol did
not lead to restoration of HA production. Chemical complemen-
tation of this mutant with subunit C led to a 4-fold increase in
HA production levels, to approximately 50% of that seen in
the wild-type. This experiment provided clear evidence that
Hyg17 operates at a step in the aminocyclitol pathway after
formation of the myo-inositol and that the final subunit C can
be incorporated intact into HA. The Dhyg17 strain was also
grown in the presence of valienamine, the C7N aminocyclitol
moiety used in biosynthesis of the antifungal antibiotic validamy-
cin A (Mahmud et al., 2007). Liquid chromatography mass spec-
trometry (LC-MS) analyses of the fermentation broth showed
the presence of an ionic species with a [M+H]+ of 496 amu, the
expected mass resulting from valienamine incorporation in
place of the normal biosynthetic aminocyclitol moiety. A limited
supply of valienamine precluded efforts to purify the proposed
new HA analog for either structural elucidation or bioactivity
assays. Further mutasynthesis experiments in Dhyg17 using
amino sugars such as glucosamine, galactosamine, and man-
nosamine did not result in production of any detectable new
HA products.
The hyg8 gene is proposed to encode a putative class III
pyridoxal-phosphate-dependent aminotransferase, catalyzing
transamination of C5-oxidized myo-inositol to produce neo-
inosamine-2 (Palaniappan et al., 2006). A complete loss of HA
production was observed in the Dhyg8 mutant and could not
be restored by chemical complementation with subunit C. An
additional mutation, where hyg7 and hyg8 were both deleted,
also abolished HA production completely. In this case, however,
very low levels of HA production were observed with subunit C
addition. As described below, a Dhyg7 mutant gives dramatically
different results, and the loss of HA production and poor chem-
ical complementation with subunit C appear to be linked to loss
of hyg8.
The hyg6 and hyg29 genes show homology to methyltrans-
ferases and analysis of their predicted amino acid sequences
did not indicate which of them was likely required for the
proposed SAM-dependant methylation of neo-inosamine-2.
A Dhyg29 mutant was generated, and high-performance liquid1595
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Figure 2. Effect of Methyltransferase gene
(hyg6, hyg29) Disruptions on Hygromycin A
Production
(A) Reverse-phase HPLC analysis of fermentation
broths of wild-type, Dhyg29, and Dhyg6 strains.
Disruption of hyg29 caused a decrease in hygro-
mycin A production. Disruption of hyg6 resulted
in the generation of new metabolites with shorter
retention times than hygromycin A.
(B) Mass spectrometric analysis (negative mode)
of Dhyg6 fermentation broth. Two new species
were identified with [M-H]- values of 498 and 500
corresponding to desmethylenehygromycin A (5)
and 500-dihydrodesmethylenehygromycin A (6),
respectively.
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broth of this strain revealed the same products (HA and 3) at
approximately 60% of those seen in the wild-type. In contrast,
the production of HA was completely abolished in a Dhyg6 strain,
and HPLC analysis of the fermentation broth of this mutant
revealed a dominant new peak and an additional minor peak
with shorter retention times than HA under the standard
reverse-phase HPLC conditions (Figure 2). The major peak
showed a mass in negative mode of m/z = 498 [M - H]- and the
minor peak showed a mass of m/z = 500 [M - H]-. An m/z of
499 is consistent with the mass of HA that is missing the methy-
lene group bridging O-4 and O-5. An m/z of 501 observed for the
smaller peak corresponds to a reduced derivative of the major
peak. The MS analyses were thus consistent with production
of desmethylene HA analogs (5, 6) (Figure 1) by the Dhyg6 strain.
The production titers of 5 were 400 mg/l. When subunit C was
provided to this strain, low levels of HA could be observed
although the levels of 5 were not significantly altered.
A unique feature of the aminocyclitol moiety of HA is the C4-C5
methylenedioxy bridge, which is essential for optimal biological
activity (Hecker et al., 1992). Sequence analyses of the 29
ORFs of the HA gene cluster did not reveal a putative candidate
gene product for the cyclization step of bridge formation. We hadCHBIOL 1595
4 Chemistry & Biology 16, 1–10, November 25, 2009 ª2009 Elsevier Ltd All rights reservedhypothesized that the hyg7 gene product,
which is homologous to D-aminoacy-
lases/amidohydrolases, mediates forma-
tion of the amide bond between subunits
B and C, and that a Dhyg7 mutant would
accumulate 7. However, as shown in
Figure 3A, the Dhyg7 strain produced 3
and trace levels of 4. Chemical comple-
mentation with subunit C, but not myo-
inositol, led to a restoration of HA produc-
tion (55% of that seen in the wild-type
strain) (Figure 3A). A series of chemical
complementation experiments of this
strain with subunit C in the presence of
either radiolabeled [2-3H] myo-inositol or
[carboxyl-14C] 4-hydroxybenzoic acid
was also carried out (Figure 3B). These
analyses demonstrated that while HA
production was restored by supplemen-
tation with subunit C, radiolabeled myo-inositol incorporation was only observed into 3. A similar study
with radiolabeled 4-hydroxybenzoic acid resulted, predictably,
in its incorporation into both HA and 3. Taken together, these
observations clearly indicate that cyclization of the C5 methoxy
group, resulting in formation of the methylenedioxy bridge, is
dependant upon the hyg7 gene product.
Structural Elucidation of Desmethylene HA Analogs
The two new compounds isolated from the Dhyg6 strain were
purified by semipreparative HPLC and their structures were
elucidated by nuclear magnetic resonance (NMR). The most
obvious change observed in the 1H-NMR spectra of 5 and 6
was the absence of either the three-proton singlet at 3.5 ppm
(for the O-5 methyl group of 3), or two one-proton singlets
at 5.18 ppm and 4.83 ppm (for the methylene group bridging
O-4 and O-5 of HA).
The differences in the 1H-NMR spectra between 5 and 6
involve the fucofuranose moiety. The H-600 signal for 5 is a singlet
at 1.99 ppm (overlapping with protons from a–CH3), whereas the
H-600 signal for 6 is a doublet at 1.20 ppm. The H-400 signal is also
shifted from 4.4 ppm in 5 to 3.74 ppm in 6 (shifts are approxi-
mate for H-400 in 5 because this signal is obscured by other
signals at the same chemical shift). There is also a new signal
3
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Figure 3. Effect of hyg7 Gene Disruption on
Hygromycin A Production
(A) Reverse-phase HPLC analysis of Dhyg7
fermentation broth. The Dhyg7 strain produced
only compound 3. Restoration of HA production
was observed upon subunit C supplementation
as seen in the HPLC chromatogram ‘‘Dhyg7-C.’’
(B) HPLC analysis of Dhyg7 fermentation supple-
mented with C subunit in the presence of [2-3H]
myo-inositol or [carboxyl-14C] 4-hydroxybenzoic
acid. Dhyg7-C-MI(UV) and Dhyg7-C-pHBA(UV) are
UV traces of fermentation broth of Dhyg7 supple-
mented with subunit C in the presence of [2-3H]
myo-inositol and [carboxyl-14C] 4-hydroxybenzoic
acid, respectively. Dhyg7-C-MI(R) and Dhyg7-
C-pHBA(R) represent the radiolabeled traces
recorded by Beta-Ram (R) radioactivity quantiza-
tion system for their respective UV traces. This
analysis clearly indicated the role of hyg7 in the
cyclization step of methylenedioxy bridge forma-
tion.
Chemistry & Biology
Biosynthesis of Aminocyclitol Subunit Hygromycin A
Please cite this article in press as: Palaniappan et al., Biosynthesis of the Aminocyclitol Subunit of Hygromycin A in Streptomyces hygroscopicus NRRL
2388, Chemistry & Biology (2009), doi:10.1016/j.chembiol.2009.10.013for H-500 of 6 that appears at approximately 3.79 ppm, which is
obscured by other signals.
Activity of Desmethylenehygromycin A
The antibacterial activity of 5 was determined using DtolC E. coli
as test organism and compared with that of HA, 3, and 7 to
determine the importance of the methyl/methylene group on
the cyclitol. The MIC90 of HA for DtolC E. coli was determined
to be 10 mg/ml (Table 2). Compounds 3 and 5 had much less
activity, with the MIC90 for both being 150 mg/ml. Compound 7
lacked inhibitory activity even at a concentration of 250 mg/ml.
The compounds were also assessed for their ability to inhibit
the synthesis of green fluorescent protein (GFP) using an
E. coli in vitro coupled transcription-translation system (Dinos
et al., 2004; Szaflarski et al., 2008). HA was shown to be highly
active in vitro, having an IC50 and IC90 of 0.18 mM and 0.25 mM,
respectively, whereas compound 7 was inactive exhibiting no
effect on translation at 75 mM. In contrast to their poor MIC
values, both 3 and 5 displayed significant activity as in vitro tran-
scription-translation inhibitors, although their IC50/90 values were
higher than those of HA (Table 2, Figure 4).
Resistance of Dhyg29 Mutant Strain to HA
In order to verify whether the hyg29 gene contributed to self-
resistance of S. hygroscopicus, spores of the wild-type and
Dhyg29 strains were grown on agar plates with different HA
concentrations. The MIC95 of HA for the wild-type was found
to be 400 mg/ml. The mutant also showed high level of self-resis-
tance, with an MIC95 value of 300 mg/ml.Table 2. Comparison of MIC90 and IC50/90 Data for Hygromycin A
and Analogs
HA 3 5 7
MIC90 (mg/ml) 10 150 150 >250
IC50 (mM) 0.18 0.5 0.32 >75
IC90 (mM) 0.25 2 1 >75
CHBIOL
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Myo-inositol represents a common intermediate in the majority
of pathways that generate aminocyclitol components of amino-
glycoside antibiotics (Flatt and Mahmud, 2007; Mahmud,
2009). Branch points from this intermediate then give rise to
the various products. In the proposed biosynthetic pathway
(Figure 1B) that generates the aminocyclitol moiety of hygromy-
cin A, this branching step is oxidation of the C5 hydroxyl of myo-
inositol to form neo-inosose (Habib et al., 2003). The steps that
precede myo-inositol are well known, reasonably widespread
in organisms, and involve the sequential action of a MIP synthase
(catalyzing formation of myo-inositol- phosphate from glucose
6-phosphate) and a MIP phosphatase. In actinomycetes these
are essential activities, required for the biosynthesis of the
essential metabolite mycothiol (the major cellular thiol and redox
co-catalyst). For this reason, actinobacterial genomes mostly
harbor more than one gene, and sometimes have several genes
with either L-myo-inositol-1-phosphate synthase or inositol
monophosphatase signatures (Wehmeier and Piepersberg,
2009). Thus for many aminocyclitol pathways, it appears that
genes encoding these two enzymes are not necessarily located
within the corresponding biosynthetic gene cluster. In the strep-
tomycin producer S. griseus, a MIP synthase has been purified
and it has been shown that the corresponding gene is not
present in the streptomycin biosynthetic gene cluster (Flatt and
Mahmud, 2007; Pittner et al., 1979; Sipos and Szabo, 1989).
The MIP synthase is also lacking in the biosynthetic gene clus-
ters of bluensomycin and spectinomycin (Flatt and Mahmud,
2007), although this enzymatic activity is presumably required
for formation of these natural products. The partial loss of HA
production with deletion of hyg18 and restoration with myo-
inositol are consistent with (1) Hyg18 encoding a putative MIP
synthase required for efficient production of MIP and (2) the
presence of an additional MIP synthase that can catalyze this
reaction in Streptomyces hygroscopicus. A MIP phosphatase
gene is present in the streptomycin (strO) and spectinomycin1595
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Figure 4. Effect of Hygromycin A and Derivatives on In Vitro Tran-
scription-Translation
(A) Detection of template-dependent synthesis of GFP using fluorescence in
the absence or presence of increasing concentrations (mM) of the antibiotic
hygromycin A (HA), methoxyhygromycin A (3), desmethylenehygromycin A
(5), or 500-dihydroAB subunit (7) (see Figure 1 for structures).
(B) Quantitation of (A). GFP fluorescence is given as a percentage where 100%
is defined as the fluorescence detected in the absence of the antibiotic.
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chemically confirmed (Ahlert et al., 1997; You-Young et al.,
2003), although it has not been determined if these genes are
essential for biosynthesis of the antibiotics. The hyg25 gene
product has conserved domains of the haloacid dehalogenase
like hydrolase superfamily, which includes phosphatases
(although there is no significant sequence similarity between
Hyg25, and either known MIP phosphatases, StrO or SpeA).
The wild-type production levels of HA by the hyg25 mutant do
not provide evidence that Hyg25 is a MIP phosphatase.
However, because this is the only putative phosphatase in the
HA biosynthetic gene cluster, the evidence indicates that an
enzyme not encoded by the hyg gene cluster can catalyze
dephosphorylation of MIP.CHBIOL 159
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introduction of the amine functionality (at the C-5 hydroxyl) and
introduction of the methyl group (at the C2 hydroxyl group).
Although the exact order of these steps in the normal biosyn-
thetic process is unclear, the production of desmethylenehygro-
mycin A by Dhyg6 demonstrates that the amine functionality
can be introduced without the methyl group. In such a pathway,
the C-5 hydroxyl group would be oxidized to form neo-inosose,
with a subsequent transamination to form neo-inosamine-2
(Figure 1B). The data with Dhyg17 strain (an almost a 90% reduc-
tion in HA yields relative to wild-type strain, and a 4-fold increase
in these yields with supplementation with subunit C, but not myo-
inositol) support the proposed role of this gene product as an
myo-inositol dehydrogenase. The continued production of low
levels of HA in this strain suggests that another enzyme or
enzymes present in S. hygroscopicus are able to catalyze C5
oxidation of myo-inositol. The data with the Dhyg8 mutant
(complete loss of HA production and modest HA production on
supplementation with the subunit) support the proposed role of
the gene product as the pyridoxal-phosphate-dependent amino-
transferase that introduces the amine functionality. The poor
yields of HA in the chemical complementation experiments
with subunit C are puzzling, given how effective this moiety is
at restoring HA production in other mutants. The HA shunt
product 7, which would be expected to form in the absence of
adequate levels of the aminocyclitol moiety, was not observed
in Dhyg8. A polar effect from replacement of hyg8 with the
apramycin resistance marker may account for these observa-
tions (the current lack of a genetic complementation system
did not permit this possibility to be tested). Another possible
explanation is that the intermediate neo-inosamine-2 may
have a key regulatory role. In principle, only Dhyg8 is unable to
generate this intermediate.
The production of desmethylene analogs 5 and 6 by the Dhyg6
strain provide conclusive evidence that the C4-C5 methylene
group in HA (and the methyl group in 3) is carried out by an
O-methylation activity of Hyg6 and not by Hyg29, the second
methyltransferase homolog in the HA gene cluster (Figure 1).
The high titers of 5 and 6 also demonstrate that introduction of
the amine functionality in myo-inositol is not dependant upon
methylation. The MIC analyses showed that the antibacterial
activity of 5 against DtolC E. coli was 15 times less than that of
HA. Interestingly, the MIC value of 5 was the same as that of 3,
which has a C5-OCH3 group instead of the methylenedioxy
bridge. The lower antibacterial activity of 3 has been reported
previously (Chida et al., 1990; Yoshida et al., 1986). HA analogs
in which the aminocyclitol is replaced by aminocyclohexadiols
and aminocyclohexatriols have also shown markedly reduced
biological activity (Hecker et al., 1992). The MIC data on the
new shunt product 5 finalize these analyses, demonstrating
that for maximal antibiotic activity subunit C must be an amino-
cyclitol and that this must be modified through formation of the
methylenedioxy bridge. An unexpected observation is that
removal of the methylenedioxy ring does not lead to a loss in
the in vitro protein synthesis inhibition activity. Compounds 3
and 5, where the methylenedioxy ring is disrupted, both retained
potent protein synthesis inhibitory activity despite showing poor
MIC values (Figure 4, Table 2). In contrast compound 7, which
lacks the aminocyclitol ring, is totally inactive. In fact, the IC505
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macrolide antibiotic tylosin (0.4 mM) in the same in vitro tran-
scription-translation assay (A.L.S. and D.N.W., unpublished
data). These data suggest that the aminocyclitol ring is indeed
essential for translation inhibition activity, whereas an intact
methylenedioxy ring is not. It appears that the loss in biological
activity due to methylenedioxy ring disruption stems from
another factor, potentially a reduced uptake of the drug into
the cell rather than abolishing the ribosome binding ability of
the compound.
Inactivation of the second methyltransferase homolog, hyg29,
resulted in a decrease in the yield of HA, although the antibiotic
production profile and self-resistance were not affected.
Because HA binds to the ribosomes, rRNA methylation by
Hyg29 may provide a self-resistance mechanism in S. hygrosco-
picus. There is as yet no evidence to support such a role for
hyg29 and, moreover, ribosomal self-resistance is not always
observed for ribosome-targeting antibiotics (e.g., oleandomycin)
(Cundliffe, 1989). If the hyg29 gene product is indeed an rRNA
methylase, the high level of HA resistance of the Dhyg29 mutant
suggests that in the absence of target-site modification by
hyg29, self-resistance is possibly being conferred by the other
resistance determinants in the HA gene cluster, namely a HA
inactivating O-phosphotransferase (Dhote et al., 2008), and
putative efflux pumps encoded by hyg19 and hyg28.
The final step in the proposed pathway for formation of the
C-subunit of HA is a oxidative cyclization to provide the methyl-
enedioxy bridge. No gene product likely responsible for cata-
lyzing this step was identified in the initial analyses of the hyg
biosynthetic gene cluster (Palaniappan et al., 2006). The role of
the hyg7 gene product was unknown. A more detailed analysis
has revealed clear homology of Hyg7 with aminoacylases, which
catalyze hydrolytic deacetylation of N-acetyl-D-amino acids.
Furthermore, Hyg7 is a member of the metallo-dependant hydro-
lase superfamily. Enzymes in this class have hydrolytic activities
and typically have two, or less commonly one, metal ion-binding
sites (Lai et al., 2004). Our analysis of Hyg7 revealed the four
highly conserved residues (a Cys, Asp, and two His) that
comprise a single metal-binding site and suggest a role in
a hydrolytic process. Nonetheless, the selective production of
methoxyhygromycin A (3) by Dhyg7 and the restoration of HA
upon supplementation with subunit C clearly demonstrate
that Hyg7 is required for the oxidative cyclization process which
forms the methylenedioxy bridge of HA. Natural products with
a methylenedioxy bridge have been identified more commonly
in plants, and involve an initial methylation with subsequent
action by a cytochrome p450 enzyme complex (Ikezawa et al.,
2003). There are a limited number of examples of secondary
metabolites from actinomycetes possessing methylenedioxy
bridge. A 1,3-dioxine ring is found in dioxapyrrolomycin
from Streptomyces fumanus, simaomicin from Actinomadura
madurae, and the streptovaricins from Streptomyces spectabilis
(Charan et al., 2006; Carter et al., 1989; Staley and Rinehart,
1991). FR-900109 from S. prunicolor, the dioxolides from
S. tendae, and pseudoverticin from S. pseudoverticillus possess
a 1,3-dioxolane ring similar to that seen in HA (Blum et al., 1996;
Cui et al., 2007; Koda et al., 1983). Deuterium labeling studies in
dioxapyrrolomycin by Charan et al. indicated an oxidative cycli-
zation mechanism for methylenedioxy bridge formation similar toCHBIOL
Chemistry & Biology 16,that reported for the plant metabolite berberine (Bjorklund et al.,
1995; Charan et al., 2006). The pyr20 gene product in the biosyn-
thetic gene cluster of pyrrolomycin has resemblance to cyto-
chrome P450 enzymes (and not to Hyg7) and has been proposed
to potentially carry out the above function (Zhang and Parry,
2007). However, to the best of our knowledge there have been
no genetic or biochemical characterization of the processes
that lead to methylenedioxy bridge formation in bacterial natural
product biosynthesis. Our results with hyg7 represent the first
example of in vivo characterization of a functional methylene-
dioxy bridge-forming gene of bacterial origin. Furthermore, the
data indicate that a member of the metallo-dependent hydrolase
superfamily, rather than a cytochrome p450 enzyme, is involved.
The role of Hyg7 in this process, and the need for other enzymes
or cofactors, remains to be biochemically determined.
The ability of subunit C to restore HA biosynthesis in most of
the mutants described herein, demonstrates that it is an effective
substrate for the enzyme that catalyzes amide bond formation. It
is thus possible that the normal HA biosynthetic process involves
formation of a complete C subunit prior to formation of the amide
bond. Formation of 3 and 5, and the apparent incorporation of
valienamine, suggest relaxed substrate specificity of the corre-
sponding coupling enzyme (Figure 1B). However, the data do
not preclude the possibility that the final steps of C-subunit
biosynthesis (methylation and formation of the methylenedioxy
bridge) occur after amide bond formation.SIGNIFICANCE
The roles of key hyg gene products in formation of the struc-
turally unusual, methylene-bridged aminocyclitol of HA
have been elucidated. Deletion of key genes in the pathway
leads in some cases to accumulation of intermediates in
the aminocyclitol biosynthetic process. As such the genetic
tools to access novel HAs in Streptomyces hygroscopicus
and to generate various aminocyclitols for combinatorial
biosynthetic processes (generating new structurally diverse
compounds) have been identified. The methylenedioxy
bridge in HA has been shown not to be required for in vivo
versus translation inhibition activity, but is required for bio-
logical uptake. These discoveries may help in the continued
evaluation of HA-based structures for development of novel
antibacterials. The discovery of the need for Hyg7 in the
oxidative cyclization that yields the methylene-bridged ami-
nocyclitol suggests a new enzymatic paradigm for formation
of these unusual structural moieties.EXPERIMENTAL PROCEDURES
Chemicals, Bacterial Strains, Growth Conditions,
and General Procedures
Hygromycin A and 2L-2-amino-2-deoxy-4,5-O-methylene-neo-inositol (sub-
unit C) were kindly supplied by Pfizer Inc. [2-3H] myo-inositol (20.0 Ci/mmol)
was purchased from Moravek Biochemicals. [carboxyl-14C]-4-hydroxyben-
zoic acid was obtained from American Radiolabeled Chemicals Inc. All other
antibiotics and chemicals were purchased from Sigma Aldrich. The E. coli
DtolC strain, deficient in the outer membrane protein TolC, was procured
from the E. coli Genetic Stock Center at Yale University. All E. coli strains
were grown following standard protocols (Sambrook and Russell, 2001).
S. hygroscopicus wild-type and mutant strains were maintained using media1595
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Table 3. PCR Primers Used for Gene Disruptions
Gene Putative Function Primer Name Primer Sequence (50-30)
hyg6 Methyltransferase hyg6_Forw CGCCCCTCGACCGCGAAGACCTTCTGGGGGCAGCGGATGATTCCGGGGATCCGTCGACC
hyg6_Rev ATGGTGGTCCGGCCTCCTCGTGTCGTCTGCGTGCCACTGTGTAGGCTGGAGCTGCTTC
hyg7 D-aminoacylase hyg7_Forw GACGACACGAGGAGGCCGGACCACCATGCATGACCTGATATTCCGGGGATCCGTCGACC
hyg7_Rev TCGCGCGCCCCGCCGGTGCGGCGGGCCGCCTCGCGGTCATGTAGGCTGGAGCTGCTTC
hyg8 Aminotransferase hyg8_Forw CTGTCCGAGAAGGACTACGTCATCGAGCGGGACCGGCTGATTCCGGGGATCCGTCGACC
hyg8_Rev GGTTTCCGCGAAGAACGCGTCCTGCATCGCCCGTGACCGTGTAGGCTGGAGCTGCTTC
hyg17 myo-inositol
dehydrogenase
hyg17_Forw TTCCGCCGTCGTGCGGGCCGCGGGGGTGAGCCGGTGAGCATTCCGGGGATCCGTCGACC
hyg17_Rev GTCATCCCCTCGCGCCGCCGGCCAGGACGCCACCGGTCATGTAGGCTGGAGCTGCTTC
hyg18 myo-inositol-1-
phosphate synthase
hyg18_Forw GGCCTGCGGCCCGGAGATTTCGCGAAGGGAAGAACCATGATTCCGGGGATCCGTCGACC
hyg18_Rev CACGGGTCGGATCTCGGTTCGGAAACGCCCGGCGGCTCATGTAGGCTGGAGCTGCTTC
hyg25 myo-inositol-1-
phosphatase
hyg25_Forw CACGCATGTCCGATACGACCGAATCGGGGTTGAGTGATGATTCCGGGGATCCGTCGACC
hyg25_Rev GCGTCAGCGAATTCTGAGCCGCGCAACCGTCCGCGGTCATGTAGGCTGGAGCTGCTTC
hyg29 Methyltransferase hyg29_Forw GCCGCCCGACCCGAGGCGCCCGGAGACGCCGCCGCGATGATTCCGGGGATCCGTCGACC
hyg29_Rev GCCGTCCGGCCTCTGTCCACCAGCTGTGCGCCGCCTCCATGTAGGCTGGAGCTGCTTC
The 39-nucleotide homologous region flanking the targeted gene is indicated in normal font. The italicized primer region is homologous to pIJ773.
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et al., 2006). For qualitative analysis of the fermentation broths, the mycelium
was removed by centrifugation and the supernatant was examined by HPLC
and LC-MS as described previously (Palaniappan et al., 2006).
Targeted Disruption of the Aminocyclitol Biosynthetic Genes
The individual hyg genes were individually replaced with apramycin resistance
cassette using the PCR-targeted Streptomyces gene replacement method
(Gust et al., 2003; Palaniappan et al., 2006). The primer sequences used to
amplify the resistance cassette from pIJ773 plasmid are listed in Table 3. All
of the genes, except hyg29, were first disrupted in cosmid 17E3. For hyg29
disruption, cosmid 15A10 was used. The recombinant cosmids were subse-
quently transferred to S. hygroscopicus wild-type by conjugation and the
exoconjugants resulting from homologous recombination were selected
based on resistance to apramycin. The genotype of the mutant strains was
confirmed by PCR amplification using an appropriate set of outer primers
(Table 3), and by sequencing the PCR product.
In the studies on hyg8, the apramycin resistance gene was removed from the
hyg8 mutant cosmid 17E3 using FLP recombinase. This cosmid with the 81 bp
scar in place of hyg8 sequence was then used to for replacement of hyg7
with the apramycin resistance gene. The resulting 17E3 cosmid derivative
was introduced into the wild-type S. hygroscopicus to provide the desired
hyg7+hyg8 deletion mutant.
Chemical Complementation Studies
The wild-type and appropriate mutant strains were grown in 5 ml production
medium and treated with an amino sugar (the HA C subunit, glucosamine,
galactosamine, or valienamine,) after 24 hr of fermentation to a final concentra-
tion of 5 mM. [2-3H] myo-inositol and [carboxyl-14C] 4-hydroxybenzoic acid
were added to a final concentration of 0.4 mCi/ml. The supernatant was
analyzed by HPLC and LC-MS after 6 days of fermentation (Palaniappan
et al., 2006). Fermentation broths from the radiolabeled precursor feeding
studies were analyzed by Beckman HPLC system linked to Beta-Ram (R)
radioactivity quantization system (IN/US Systems, Inc.).
Quantitative Analysis of Antibiotic Production
Quantitative analyses of production of HA and its analogs were determined
from triplicate cultures of the wild-type and mutant strains. Pure HA was
used to generate a standard curve of peak area versus amount in mg within
a 5 to 50 mg range. Then 50 ml filtered fermentation broth from each culture
was used for HPLC analyses. The amounts of HA and related products in
each injection sample were determined from their individual peak areas using
the standard curve as reference and used to determine total production in the
fermentations.CHBIOL 159
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and 500-Dihydrodesmethylenehygromycin A (6)
The desmethylene HA analogs (5, 6) (Figure 1) produced by the Dhyg6 strain
were extracted from culture filtrate and purified as described earlier (Palaniap-
pan et al., 2006; Habib et al., 2003). The two products were characterized by
MS and NMR techniques. 1H-NMR spectra were recorded on a Bruker AMX-
400 NMR. Two-dimensional correlated spectography correlation spectra were
recorded on a Bruker AMX-600 NMR spectrometer. Coupling constants (J)
were expressed in Hertz. Abbreviations for multiplicities are: s = singlet, d =
doublet, t = triplet, q = quartet, m = multiplet.
Hygromycin A (1)
1H-NMR (400 MHz, D2O) d 7.10 (1H, d, J = 8.0, H-9
0), 7.01 (1H, s, H-30), 6.88 –
6.91 (2H, m, H-50, H-80), 5.69 (1H, d, J = 4.4, H-100), 5.18, 4.83 (2H, -OCH2O-),
4.50 – 4.48 (1H, m, H-2), 4.40 – 4.18 (5H, m, H-200, H-400, H-4, H-5, H-6), 4.08
(1H, t, J = 2.8, H-300), 3.95 (1H, dd, J = 5.2, H-1), 3.82 (1H, dd, J = 3.6, H-3),
2.16 (3H, s, H-600), 2.02 (3H, s, a-CH3).
Desmethylenehygromycin A (5)
1H-NMR (400 MHz, D2O) d 7.14 (1H, d, J = 8.4, H-9
0), 6.99 (1H, s, H-30), 6.94
(1H, s, H-50 ), 6.93 (1H, d, J = 8.4, H-80), 5.72 (1H, d, J = 4.4, H-100), 4.74 –
4.62 (1H, m, H-2), 4.41 – 4.40 (2H, m, H-300, H-400), 4.30 – 4.22 (1H, m, H-200),
4.02 (1H, t, J = 2.8, H-5), 3.95 – 3.92 (2H, m, H-1, H-3), 3.72 (2H, dd,
J = 10.0, 2.8, H-4, H-6), 1.99 (6H, s, a-CH3, H-6
00).
500-Dihydrodesmethylenehygromycin A (6)
1H-NMR (D2O, 400 MHz) d 7.17 (1H,d, J = 8.2, H-9
0), 7.08 (1H, s, H-30), 7.01
(1H, s, H-50), 6.99 (1H, d, J = 8.2, H-80), 5.69 (1H, d, J = 4.4, H-100), 4.7 (1H,
partially obscured by solvent peak, H-2), 4.33-4.29 (2H, m, H-200, H-300), 4.11
(1H, t, J = 2.8, H-5), 4.03 (2H, dd, J = 10.0, 4.2, H-1, H-3), 3.87-3.80 (3H, m,
H-4, H-6, H-500), 3.74 (1H, t, J = 6.0, H-400) 2.08 (3H, s, a-CH3), 1.13 (3H, d,
J = 6.8, H-600).
MIC90 of HA and Analogs for DtolC E. coli
Five microliters of an overnight culture of DtolC E. coli were added to 195 ml
final volume of fresh LB supplemented with HA or its analogs (Figure 1). The
tubes were grown with shaking for 2 hr at 37C and the absorbance at
600 nm was measured. The MIC90 was defined as the lowest concentration
of the antibiotic at which 90% of growth was inhibited compared to a control
E. coli culture grown in the absence of any antibiotic.
Coupled Transcription-Translation Assay
All coupled transcription-translation experiments were performed using an
E. coli lysate-based system in the presence and absence of antibiotics as
described previously (Dinos et al., 2004; Szaflarski et al., 2008). Reactions
were transferred into 96-well microtiter plates and the GFP fluorescence
was measured with a Typhoon Scanner 9400 (Amersham Bioscience) using5
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tified using ImageQuantTL (GE Healthcare) and represented graphically using
SigmaPlot (Systat Software, Inc.).
Hygromycin Sensitivity of Dhyg29 strain
The MIC95 of HA for the Dhyg29 mutant and the wild-type strain were deter-
mined by the agar plate dilution method (Dhote et al., 2008). Briefly, spores
were plated on ISP2 agar plates containing varying amounts of HA, incubated
at 30C for 48 hr, and scored for growth. The MIC95 was defined as the lowest
concentration of HA that prevented visible growth of 95% or more of the
colony forming units on the agar plate.
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Hygromycin A (HA) is an aminocyclitol antibiotic produced and excreted by Streptomyces hygroscopicus.
Deletion of hyg26 from the hygromycin A biosynthetic gene cluster has previously been shown to result in a
mutant that produces 5-dihydrohygromycin A (DHHA). We report herein on the purification and character-
ization of Hyg26 expressed in Escherichia coli. The enzyme catalyzes an NAD(H)-dependent reversible inter-
conversion of HA and DHHA, supporting the role of the reduced HA as the penultimate biosynthetic pathway
intermediate and not a shunt product. The equilibrium for the Hyg26-catalyzed reaction heavily favors the
DHHA intermediate. The high-titer production of the HA product by S. hygroscopicus must be dependent upon
a subsequent energetically favorable enzyme-catalyzed process, such as the selective and efficient export of HA.
hyg19 encodes a putative proton gradient-dependent transporter, and a mutant lacking this gene was observed
to produce less HA and to produce the DHHA intermediate. The DHHA produced by either the hyg19 or the
hyg26 mutant had slightly reduced activity against E. coli and reduced protein synthesis-inhibitory activity in
vitro. The data indicate that Hyg26 and Hyg19 have evolved to produce and export the final potent HA product
in a coordinated fashion.
Antibiotic biosynthetic gene clusters contain genes required
for the process of assembling the natural product and for the
generation of specific biosynthetic precursors that are not
readily available from primary metabolism (16). In addition,
they often contain genes that are responsible for self-resis-
tance, thereby protecting the organism from its own natural
product, and regulatory genes that control the expression of
biosynthetic genes. Although these gene classifications are use-
ful, they are often incomplete in their descriptions. In fact, a
complex interplay between biosynthesis, resistance, and regu-
lation has been observed for many natural product biosynthetic
processes, and it is becoming increasingly evident that some of
these gene products perform multiple functions.
Hygromycin A (HA; compound 1) (Fig. 1) is an aminocycli-
tol antibiotic that acts by inhibiting the peptidyltransferase
reaction of protein synthesis in gram-positive and gram-nega-
tive bacteria (7, 15, 25). Biosynthetic studies have shown that
HA is assembled from three independently synthesized sub-
units, 5-dehydro--L-fucofuranose (subunit A), (E)-3-(3,4-di-
hydroxyphenyl)-2-methylacrylic acid (subunit B), and the ami-
nocyclitol, 2L-2-amino-2-deoxy-4,5-O-methylene-neo-inositol
(subunit C) (6). The corresponding biosynthetic gene cluster
has been cloned and sequenced from Streptomyces hygroscopi-
cus NRRL 2388, and putative functions have been assigned to
the 29 open reading frames (22). The proposed role of hyg26 as
a short-chain dehydrogenase gene has also been verified at the
genetic level (22).
Disruption of hyg26 in S. hygroscopicus abolished the
production of HA and methoxyhygromycin A (compound 3)
and, instead, yielded their reduced analogs, 5-dihydrohy-
gromycin A (DHHA; compound 2) and 5-dihydromethoxy-
hygromycin A (compound 4), respectively, and small
amounts of (E)-3-(3-hydroxy-4-O--fucofuranosylphenyl)-2-
methylacrylic acid (compound 7). Compound 7 is DHHA
without the C subunit (see Fig. 1 for the structures). While
these results showed that Hyg26 is required for the dehy-
drogenation of the C-5 OH on the fucofuranose moiety, the
timing of this reaction in the biosynthetic sequence and,
subsequently, the question as to whether DHHA is a shunt
metabolite or a precursor of the final product (HA) remain
unresolved.
Analysis of the HA biosynthetic gene cluster has also re-
vealed multiple genes likely to be involved in antibiotic resis-
tance. Of these, the function of hyg21 has been biochemically
determined (4). hyg21 encodes a phosphotransferase that in-
activates HA by phosphorylating the C-2 OH on the fuco-
furanose. A hyg21 strain has been shown to retain resistance
to HA, indicating the presence of other mechanisms of self-
resistance. Antibiotic transporters/efflux pumps are additional
mechanisms of self-resistance in antibiotic producers and likely
operate in S. hygroscopicus also, as all of the HA produced is
found outside the cell. The HA biosynthetic gene cluster con-
tains two putative HA transporter genes, hyg19 and hyg28. The
hyg19 gene shows similarity to proton gradient-dependent
transporter genes. The hyg28 gene encodes a putative type II
ATP-binding cassette transporter. The role of these gene prod-
* Corresponding author. Mailing address: Department of Chemis-
try, Portland State University, P.O. Box 751, Portland, OR 97207.
Phone: (503) 725-3886. Fax: (503) 725-9525. E-mail: reynoldsk@pdx
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ucts in exporting HA or pathway intermediates and in contrib-
uting to self-resistance has not been determined.
In the work described here, we show that a recombinant
Hyg26 catalyzes the reversible interconversion of DHHA and
HA and that the equilibrium for this reaction lies heavily
toward the biologically less active, reduced HA product. The
putative proton gradient-dependent transporter encoded by
hyg19 is observed to be required for the high-level production
of HA and is hypothesized to operate by the selective and
efficient exportation of HA. A hyg19 deletion mutant did not
show increased sensitivity to HA, but a mutant in which both
hyg19 and hyg21 were deleted had markedly increased HA
sensitivity. This work has demonstrated that DHHA is likely
the final biosynthetic pathway intermediate and that Hyg19 has
a role in both self-resistance and biosynthesis, ensuring that the
final and most biologically active HA product is generated.
MATERIALS AND METHODS
Chemicals, bacterial strains, and growth conditions. All antibiotics and chem-
icals were purchased from Sigma Aldrich unless otherwise stated. PCR primers
were obtained from Integrated DNA Technologies. The enzymes used for DNA
manipulations were obtained from New England Biolabs. HA was kindly pro-
vided by Pfizer Inc. DHHA, 5-dihydromethoxyhygromycin A (compound 4), and
(E)-3-(3-hydroxy-4-O--fucofuranosylphenyl)-2-methylacrylic acid (compound
7) were purified from the fermentation broth of mutant strain S. hygroscopicus
SCH30 by a semipreparative high-performance liquid chromatography (HPLC)
method, as described earlier (22). A hyg7 strain of S. hygroscopicus was used as
the source for methoxyhygromycin A (compound 3). A hyg6 disruption strain
was used as the source for desmethylenehygromycin A (compound 5) and 5-
dihydrodesmethylenehygromycin A (compound 6) (submitted for publication).
The S. hygroscopicus strains were propagated by using the media and culture
conditions described earlier (6, 22). The Escherichia coli strains were cultured by
standard protocols (28). E. coli tolC was procured from the E. coli Genetic
Stock Center at Yale University.
Nucleotide and protein sequence analysis. Searches for sequences with ho-
mology to the sequences of the hyg19, hyg26, and hyg28 genes were carried out
with the BLAST suite of programs at the National Center for Biotechnology
Information website (1). Protein sequence alignments were obtained by using the
CLUSTALX program at the European Bioinformatics Institute website (14).
Protein motif searches were carried out by using the PROSITE database at the
Expasy proteomics server (9). Hydropathy analysis for Hyg19 was based on the
amino acid hydropathy values of Kyte and Doolittle (13) and carried out at the
Transporter Classification Database server (26, 27). The MEMSAT3 program
was also used for prediction of the secondary structure and topology of Hyg19
(10).
Cloning, overexpression, and purification of recombinant Hyg26. The 816-bp
hyg26 gene was amplified from cosmid 17E3 (22). Primers were designed to
introduce an NdeI restriction site at the initiation codon and a BamHI restriction
site 3 to the termination codon (Table 1). Amplification was performed by using
the following temperature program: initial denaturation at 95°C for 5 min, 25
cycles of amplification (45 s of denaturation at 95°C, 45 s of primer annealing at
56°C, 1 min of extension at 72°C), and a final 7-min extension at 72°C. The gene
was subsequently cloned into the NdeI and BamHI restriction sites of the
pET15b vector (Novagen). The resulting pET15b-hyg26 construct was intro-
duced into the E. coli BL21-CodonPlus (DE3) expression host (Stratagene) by
transformation. For protein expression, cells were grown at 37°C in LB medium
containing 100 g/ml ampicillin and 50 g/ml chloramphenicol. When an A600 of
0.6 was reached, the culture flask was brought to room temperature (23°C) and
expression was induced by adding 0.5 mM isopropyl thio--D-galactoside. After
a further 6 h of incubation, cells were harvested by centrifugation and stored at
80°C.
The N-terminal His-tagged Hyg26 was purified under native conditions ac-
cording to Qiagen’s Ni-nitrilotriacetic acid protocol. The cells were resuspended
in BugBuster master mixture protein extraction reagent (Novagen) and lysed by
incubation at room temperature for 30 min. The lysate was cleared by centrifu-
gation; and the supernatant was loaded onto Ni-nitrilotriacetic acid agarose
preequilibrated with buffer containing 50 mM NaH2PO4, 300 mM NaCl, and 10
mM imidazole (pH 8.0). The column was washed with buffer containing 50 mM
NaH2PO4, 300 mM NaCl, and 20 mM imidazole (pH 8.0). The protein was
eluted with the same buffer containing a higher concentration of imidazole (250
mM). Fractions containing Hyg26 were pooled, dialyzed overnight against a
buffer (50 mM Tris-HCl, 20% glycerol, 5 mM 2-mercaptoethanol at pH 7.5), and
stored at 80°C until further use.
Determination of molecular mass of Hyg26. The molecular mass of purified
His-tagged Hyg26 was determined by size-exclusion chromatography with a Phe-
nomenex BioSep-SEC-S4000 size-exclusion column fitted to an Agilent 1100
series HPLC system. The column was equilibrated and eluted with 20 mM
sodium phosphate (pH 7.2) at a flow rate of 0.5 ml/min. Carbonic anhydrase (25
kDa), bovine serum albumin (66 kDa), -amylase (200 kDa), apoferritin (443
kDa), and thyroglobulin (669 kDa) were used as standards.
Hyg26 enzyme assays and kinetic analyses. Initial enzyme assays were per-
formed at 30°C with 4 g of purified enzyme in a 100-l reaction mixture of 50
mM Tris-HCl (pH 7.5) and 2 mM Tris(2-carboxyethyl) phosphine (TCEP). The
dehydrogenase activity was studied by incubating Hyg26 with 100 M DHHA,
FIG. 1. Structures of HA and related compounds.
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compound 4, compound 6, or compound 7 and 1,000 M NAD or NADP. For
lactate dehydrogenase-coupled assays, 1,000 M sodium pyruvate and 5 U of
lactate dehydrogenase were added. The reductase activity was detected using 100
M HA, compound 3, or compound 5 and 1,000 M NADH or NADPH. After
incubation for 2 h at 30°C, the sample was loaded onto a reverse-phase HPLC
column (Agilent Eclipse XDB-C18) to detect the oxidized products (with longer
retention times) in the dehydrogenase assay or the reduced products (with
shorter retention times) in the reductase assay. Samples were separated at a flow
rate of 1 ml/min with a methanol-water gradient, as described earlier (4). The
optimal temperature and pH for Hyg26 reductase activity were determined with
100 M HA and 1,000 M NADH in a 15-min assay by the use of HPLC analysis
and the peak area to quantitate the production of DHHA. The temperatures
studied were 23°C (room temperature), 30°C, 37°C, and 42°C. For the pH
studies, the following buffers were used: 50 mM potassium acetate, pH 4.0 and
5.0; 50 mM potassium phosphate, pH 6.0 and 7.0; and 50 mM Tris-HCl, pH 7.5,
8.0, and 9.0. The metal requirement was probed by conducting the assay in the
presence of 5 mM and 10 mM EDTA. Kinetic analyses of reductase activity were
carried out at 37°C for 15 min with 800 ng Hyg26 in 100 l assay buffer comprised
of 50 mM phosphate (pH 6) and 2 mM TCEP. The NADH concentration was
fixed at 60 mM, while the antibiotic concentration was varied from 2 mM to 60
mM. For kinetic analyses of NADH, the HA concentration was fixed at 20 mM,
while the NADH concentration was varied from 0.25 mM to 10 mM. Each assay
was performed in duplicate, and the average values of the two measurements
were plotted in the GraFit 4 program to determine the kinetic parameters.
Gene disruption experiments. The hyg19 and hyg28 genes and a segment of the
HA biosynthetic gene cluster comprised of the hyg19, hyg20, and hyg21 genes
were individually replaced by the apramycin resistance cassette by the PCR
targeted Streptomyces gene replacement method (8). The primers used to amplify
the disruption cassette from plasmid pIJ773 are listed in Table 1. The primers
used for hyg28 disruption were designed such that the 68-nucleotide overlap
between the 3 end of hyg28 and the 5 end of the downstream hyg29 gene was
unaffected. The hyg19 and the hyg19, hyg20, and hyg21 disruptions were carried
out in cosmid 17E3, while the hyg28 gene disruption was done in cosmid 15A10
(22). The recombinant cosmids were introduced into a wild-type S. hygroscopicus
strain by conjugation and selected for apramycin resistance. The genotype of the
mutant strains was confirmed by PCR amplification of the apramycin cassette
from chromosomal DNA and by verifying the sequence of the PCR product.
Automated DNA sequencing was done at the Molecular Microbiology and
Immunology Research Core Facility at Oregon Health and Science University.
The DNA sequence data were analyzed by using Accelrys DS Gene software.
Analysis of antibiotic production in S. hygroscopicus strains. Fermentation
broths of S. hygroscopicus disruption strains were analyzed for antibiotic produc-
tion by HPLC and liquid chromatography-mass spectrometry methods on a
Bruker Daltonics MicroTOF-Q instrument fitted with an Agilent 1100 series
HPLC system. Cell extracts were generated by methanol lysis of the mycelia and
were examined by HPLC (4). The production yields of HA and related metab-
olites were estimated from their corresponding peak areas in the chromatograms
by using a standard curve of HA as a reference.
Susceptibilities of S. hygroscopicus strains to HA. The HA susceptibilities of S.
hygroscopicus wild-type and mutant strains were determined by the agar plate
dilution method, as described previously (4). Briefly, spores were plated on yeast
extract malt extract agar plates containing various amounts of HA, incubated at
30°C for 48 h, and scored for growth. The MIC was defined as the lowest
concentration of HA that prevented the visible growth of 95% or more of the
CFU on the agar plate.
Bioactivity of DHHA and other dihydro analogs. The tolC E. coli strain was
used as the test organism to determine the antibiotic activities of DHHA and
compounds 4, 6, and 7. The strain was grown in 200 l LB medium at 37°C for
2 h in the presence of different concentrations of antibiotic, and the A600 was
measured. The MIC was defined as the lowest concentration of the antibiotic at
which 95% of bacterial growth was inhibited compared to the amount of growth
of a control E. coli culture grown in the absence of any antibiotic.
Coupled transcription-translation assay. All coupled transcription-translation
experiments were performed with an E. coli lysate-based system in the presence
and absence of antibiotics, as described previously (5, 30). The reaction mixtures
were transferred into 96-well microtiter plates, and the fluorescence of the green
fluorescent protein (GFP) was measured with a Typhoon 9400 scanner (Amer-
sham Bioscience) and a Typhoon blue laser module (Amersham Bioscience).
The images were then quantified with the ImageQuantTL program (GE Health-
care) and are represented graphically by using the SigmaPlot program (Systat
Software, Inc.).
RESULTS
Enzymatic characterization of a short-chain dehydrogenase
encoded by hyg26. The hyg26 gene from the HA biosynthetic
gene cluster shows homology to short-chain dehydrogenase/
reductase genes. A previous gene disruption study demon-
strated that a hyg26 mutant accumulates DHHA and that
Hyg26 is likely responsible for dehydrogenation of the C-5 OH
on the L-fucofuranose moiety (22). It was suggested that this
reaction may precede the glycosyltransferase reaction that con-
nects the A subunit of HA to its B subunit. Alternatively,
Hyg26 may act at a much later step in the biosynthetic pathway
and may be responsible for converting DHHA to HA (Fig. 1).
In such a case, DHHA could represent the penultimate path-
way intermediate and not a shunt metabolite, and Hyg26 would
be responsible for catalyzing the last step of HA biosynthesis.
To probe this possibility, we generated and purified recombi-
nant Hyg26 and determined its ability to interconvert HA and
DHHA. A pET15b-hyg26 expression vector was constructed
TABLE 1. Primers used in this study
Primer purpose and primer Sequencea
Disruption primers for hyg19 gene
Forward ..............................................................GATCCGACCCGTGCCGGGCGGAAGGGAGCACCAGTGATGATTCCGGGGATCCGTCGACC
Reverse ...............................................................GGTGATGAGCGGGGCGCTGAGCCAGAGGAACATCACGACTGTAGGCTGGAGCTGCTTC
Disruption primers for hyg28 gene
Forward ..............................................................CTGATGACTGCCACTCTCGTCGCCAAGGATCTGGCCGCCATTCCGGGGATCCGTCGACC
Reverse ...............................................................CTCGGTGACCCGGCCGTCCGCCACCTCCAGGCGGCGGGTTGTAGGCTGGAGCTGCTTC
Disruption primers for hyg19, hyg20,
and hyg21 genes
Forward ..............................................................GATCCGACCCGTGCCGGGCGGAAGGGAGCACCAGTGATGATTCCGGGGATCCGTCGACC
Reverse ...............................................................ACCGTTGACCGAGAATGGGTAAAGGAGCAGAAAACAATGTGTAGGCTGGAGCTGCTTC
Expression primers for hyg26 gene
Forward ..............................................................CATATGAGTGGACTGATGCGGGAC
Reverse ...............................................................GGATCCTCAGAATTCGCTGACGC
a The 39-nucleotide homologous region flanking the targeted gene is indicated in boldface. The italicized primer region is homologous to pIJ773. The NdeI and
BamHI sites in hyg26 expression primers are also indicated in boldface.
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and the N-terminal hexahistidine-tagged Hyg26 was purified by
Ni2	 affinity chromatography. The purified protein showed the
expected size of 30 kDa on sodium dodecyl sulfate-poly-
acrylamide gel electrophoresis and an apparent molecular
mass of 64,000 Da by size-exclusion chromatography, suggest-
ing that recombinant Hyg26 is a dimeric protein.
The dehydrogenase activity was assayed by incubation of
DHHA, compound 4, or compound 6 in the presence of
NAD	 or NADP	 as a cofactor. In assays with NAD	, re-
verse-phase HPLC analysis of each reaction mixture showed
the appearance of a new peak with a retention time longer than
that of the substrate (see Fig. 2 for the results of the assay with
DHHA). This peak was not observed in a control assay without
Hyg26 or in the assay with NADP	. The retention time of the
new peak, the results of coinjection experiments with the ap-
propriate standards, and the results of mass spectrometric
analyses were all consistent with the formation in the assays of
the corresponding C-5-oxidized analog (HA, compound 3,
and compound 5), products of an Hyg26-dependent dehydro-
genation. In each case, there was only a low level of product
formation (1.2 to 1.5 M from 100 M of substrate after 2 h at
30°C). Attempts to increase the conversion level by the use of
increased incubation times or by the performance of coupled
enzymatic assays that would regenerate NAD	 (by using pyru-
vate and lactate dehydrogenase) were unsuccessful.
The ability of Hyg26 to catalyze the reverse reaction (reduc-
tase activity) was also investigated. Assays were carried out
with HA, compound 3, or compound 5 in the presence of
NADH or NADPH, followed by HPLC analyses. Compared to
the results for a control without Hyg26, each of the NADH
assays showed a significant decrease in the amount of substrate
and the appearance of a new peak with a retention time shorter
than that of the substrate (see Fig. 3 for the results of the assay
with HA). This peak was not observed in the reaction with
NADPH. Mass spectrometric analyses of the NADH reaction
mixtures showed that the compounds under the new peaks had
an increase in mass by 2 atomic mass units with respect to the
masses of the substrates, consistent with that expected for the
C-5-reduced analogs. Coinjections of the reaction mixtures
with authentic materials provided additional support for the
characterization of the reaction products. These observations
confirm that Hyg26 is an NAD	/NADH-dependent oxi-
doreductase with broad substrate specificity. These data also
demonstrated that under the given assay conditions, the en-
zyme catalyzed the reverse reaction more efficiently than the
forward biosynthetic reaction, suggesting that the equilibrium
position favors the DHHA product.
The optimal pH for catalysis of the reduction reaction was
determined over a pH range of 4.0 to 9.0 and was found to be
6.0. Among the temperatures from 23°C to 42°C that were
tested, the optimal temperature was 37°C, although no signif-
icant difference was observed between the amounts of product
formed at 30°C and 37°C. The metal-chelating reagent EDTA
did not reduce the enzyme activity, suggesting that, like other
short-chain dehydrogenases, Hyg26 is metal ion independent
(24). Analysis of the steady-state kinetic parameters for the
reduction of HA, compound 3, and compound 5 showed that
Hyg26 has a very low affinity for them, as indicated by the high
Km values (in the millimolar range; Table 2). The catalytic
efficiency, as indicated by kcat/Km, was found to be comparable
FIG. 2. Reverse-phase HPLC analysis of DHHA (compound 2) dehydrogenation by Hyg26. (A) Control reaction of DHHA and NAD	 without
Hyg26; (B) reaction of DHHA and NAD	 after incubation with Hyg26 showing the formation of HA. mAU, milli-absorbance units.
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for all three substrates. The Km for NADH was determined to
be 400 
 34 M.
Predicted roles of hyg19 and hyg28 genes in the HA biosyn-
thetic gene cluster. The biosynthetic gene cluster of hygromy-
cin A has two genes, hyg19 and hyg28, that encode putative
transporter proteins. The predicted translation product of
hyg19 has 416 amino acids with a theoretical molecular mass of
43.8 kDa. A search of the National Center for Biotechnology
Information protein sequence database by use of the deduced
Hyg19 sequence returned several transmembrane proteins be-
longing to the major facilitator superfamily (MFS). The high-
est level of sequence similarity (66%) was observed with a
presumptive transmembrane protein, Ata9, from the biosyn-
thetic gene cluster of antibiotic A201A from Saccharothrix
mutabilis subsp. capreolus. The structure of HA resembles that
of A201A, particularly in the A and B subunits, and many
genes with similar sequences and possibly similar functions
have been identified in the biosynthetic gene clusters of these
two antibiotics (22). The N-terminal region of Hyg19 specifi-
cally shows a high degree of similarity to the MFS proteins
involved in drug efflux, such as the TetV tetracycline resistance
determinant from Mycobacterium smegmatis, the MefA mac-
rolide efflux protein from Streptococcus pneumoniae, and the
chloramphenicol resistance protein from Streptomyces lividans.
Hydropathy analysis and transmembrane topology prediction
suggest that Hyg19 has 12 transmembrane helices with cyto-
plasmic N and C termini and, therefore, is likely a member of
the proton gradient-dependent DHA12 family of MFS trans-
porters. Five sequence motifs have been identified in the
DHA12 efflux proteins (23). Hyg19 does not show full conser-
vation of all the motifs but shows a partially conserved motif C
(gxxxGPxxGGrl) in transmembrane 5 (positions 163 to 181),
and a partially conserved motif G (GxxxGPL) in transmem-
brane 11 (positions 373 to 392) can clearly be distinguished. On
the basis of these observations, Hyg19 is hypothesized to be a
proton gradient-dependent efflux protein that confers resis-
tance to S. hygroscopicus by exporting HA out of the cell.
The deduced translation product of hyg28, with 570 residues
and a theoretical molecular mass of 61.5 kDa, shows homology
to several ATP-binding cassette (ABC)-type transporter pro-
teins, including Ard1 from the A201A gene cluster that is
known to confer resistance to A201A in S. lividans (2). Two
ABC domains containing the Walker A and Walker B motifs
characteristic of ATPases are present in Hyg28. The Walker A
motif ([AG]-x4-G-K-[ST]) is a glycine-rich loop that binds to
the phosphates of ATP or GTP (32). The Walker B motif
FIG. 3. Reverse-phase HPLC analysis of hygromycin A (HA) reduction by Hyg26. (A) Control reaction of HA and NADH without Hyg26;
(B) reaction of HA and NADH after incubation with Hyg26, showing the formation of DHHA. An additional peak (11.1 min) eluting earlier than
HA is the C-4 epimer of HA and not a substrate for Hyg26. mAU, milli-absorbance units.
TABLE 2. Kinetic parameters for Hyg26 reductase activity
Substrate kcat(s1) Km (mM)
kcat/Km
(M1 s1)
HA 5.1 5.8 
 0.8 1.0  103
Methoxyhygromycin A
(compound 3)
15.5 19.8 
 1.9 0.9  103
Desmethylenehygromycin A
(compound 5)
31.7 63.6 
 24.4 0.9  103
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(hhhhDEPT, where h indicates a hydrophobic residue) coor-
dinates a magnesium ion (32). Therefore, the hyg28 gene is
predicted to encode a type II ABC transporter protein, which,
in association with an unidentified membrane component, con-
stitutes the second transporter system for HA efflux and sub-
sequent self-resistance.
Effect of hyg19 and hyg28 gene disruptions on HA biosyn-
thesis and efflux. In order to determine whether Hyg19 and
Hyg28 are involved in antibiotic biosynthesis and efflux, the
corresponding genes were individually replaced with the apra-
mycin resistance cassette in the S. hygroscopicus wild type. The
resulting mutant strains, hyg19 and hyg28, were cultured;
the mycelia were removed by centrifugation; and the filtered
supernatants were analyzed by HPLC and liquid chromatog-
raphy-mass spectrometry for antibiotic production. Analysis of
the fermentation broth of the hyg28 mutant revealed that the
antibiotic production profile was unaffected by the disruption
of hyg28. The strain produced and excreted nearly the same
amount (1.5 g/liter) of HA as the wild type (data not shown).
This clearly indicates that Hyg28 is not essential for antibiotic
biosynthesis and efflux. On the other hand, the disruption of
hyg19 caused the level of HA production to drop to 509
mg/liter, a threefold decrease compared to the HA yield from
the wild type (Fig. 4). The levels of methoxyhygromycin A
(compound 3) and 5-dihydromethoxyhygromycin A (com-
pound 4) (Fig. 1) also appeared to be similarly reduced. Inter-
estingly, the yield of DHHA in hyg19 increased 10-fold to
380 mg/liter from the 37 mg/liter seen for the wild type. A
slight increase in the amount of compound 7, detected only at
trace levels in the wild type, was also observed in hyg19. It was
speculated that the reduced amount of HA in the fermentation
broth of hyg19 could be a consequence of intracellular HA
accumulation due to impaired transmembrane transport. To
test this possibility, the mycelium of hyg19 was lysed by meth-
anol treatment and the lyaste was analyzed by HPLC. The cell
lysates of the wild type and hyg28 were also examined along-
side in the same way. However, neither HA nor any known
related compounds, including any phosphorylated forms, were
detected in the cell lysates of either the hyg19 or the hyg28
strain. The data demonstrate that all detectable HA and re-
lated products are located outside the cell even in the absence
of Hyg19. Nonetheless, the efficient and selective biosynthesis
of HA is dependent upon the hyg19 gene product.
Contribution of hyg19 and hyg28 gene products to self-re-
sistance of S. hygroscopicus. The wild-type and mutant strains
were assessed for their susceptibilities to HA by growing their
spores on agar plates with antibiotics at different concentra-
tions. The MIC of HA for the wild type was found to be 400
FIG. 4. Reverse-phase HPLC analysis of fermentation broth of the wild-type (A) and hyg19 (B) strains. Reduced HA production and
accumulation of DHHA were observed in the hyg19 strain. mAU, milli-absorbance units.
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g/ml. The mutants also showed high levels of resistance,
with MICs of 400 g/ml and 300 g/ml for hyg19 and
hyg28, respectively. These data indicate that the self-resis-
tance of S. hygroscopicus is not entirely conferred by hyg19
or hyg28. Another mutant strain was generated by disrupting
hyg19 together with the hyg20 and hyg21 genes present im-
mediately downstream of it (Fig. 5). The hyg20 gene encodes
a putative transglucosylase/mutase for the generation of the
A subunit, and its disruption has been observed to abolish
antibiotic production completely (unpublished data). hyg21
encodes an antibiotic-modifying O-phosphotransferase with
a role in self-resistance, and loss of this gene results in
reduced HA production (4). The (hyg19-hyg20-hyg21)
strain did not produce HA and showed significantly in-
creased susceptibility (MIC, 75 g/ml). A hyg20 strain had
a MIC of 300 g/ml, which was not significantly lower than
that of the wild type. The MIC of S. lividans for HA was
determined to be 20 g/ml. These data suggest that the
increased susceptibility of (hyg19-hyg20-hyg21) is due to
the loss of hyg19 and hyg21, implying a synergistic role of
these two genes in self-resistance.
Biological activity of C-5-dihydro analogs. DHHA and
compounds 4 and 6 are the C-5-dihydro analogs of HA, me-
thoxyhygromycin A (compound 3), and desmethylenehygromy-
cin A (compound 5), respectively (Fig. 1). These three C-5-
dihydro compounds and compound 7 were studied for their
ability both to inhibit the growth of tolC E. coli and to inhibit
protein synthesis in an E. coli in vitro-coupled transcription-
translation system (5, 30). The MICs of DHHA, compound 2,
and compound 4 were determined to be 20 g/ml, 150 g/ml,
and 150 g/ml, respectively (Table 3). These values are similar
to the MICs for the corresponding 5-oxidized analogs, albeit
for the most active pair, HA appeared to be slightly more
active (10 g/ml) than DHHA. The DHHA analog lacking the
C subunit (compound 7) was inactive against E. coli tolC even
at 250 g/ml. The data demonstrate that for in vivo activity, the
presence of the methylene bridge on the C subunit is of greater
importance than the C-5 oxidation state of the A subunit. HA
was also the most active compound in vitro, having a 50%
inhibitory concentration (IC50) and an IC90 of 0.18 M and
0.25 M, respectively, whereas compound 7 was inactive (con-
sistent with the MICs), exhibiting no effect on translation at 75
M (Fig. 6A and B and Table 3). On the basis of the IC50s,
compounds 3 and 5 were as effective as DHHA and their
activities were similar to the activity of HA. In contrast, the
reduced forms of these compounds, compounds 4 and 6, had
significantly lower (8 to 15 times) potency (Fig. 6C and Table
3). The data demonstrate that for in vitro activity, the presence
of the methylene bridge on the C subunit is of lesser impor-
tance than the C-5 oxidation state of the A subunit.
DISCUSSION
hyg26 in the HA biosynthetic gene cluster encodes a protein
that is a member of the short-chain dehydrogenase family. The
requirement for this gene to obtain HA and not DHHA has
FIG. 5. Schematic representation of replacement of the hyg19,
hyg20, and hyg21 genes with the apramycin resistance cassette. WT,
wild type.
TABLE 3. Comparison of MIC and IC50/IC90 data for HA and
DHHA analogs
Compound MIC(g/ml)
IC50
(M)
IC90
(M)
HA 10 0.18 0.25
DHHA 20 0.3 1.5
3 150 0.5 2
4 150 7.4 50
5 150 0.32 1
6 150 2.7 14.1
FIG. 6. Effects of HA and derivatives on in vitro transcription-
translation. (A) Detection of template-dependent synthesis of GFP by
using fluorescence and native polyacrylamide gel electrophoresis in the
presence of template with increasing concentrations (M) of the an-
tibiotic HA, DHHA, and compound 7 on GFP synthesis; (B) quanti-
tation of effects of HA, DHHA, and compound 7 on GFP synthesis;
(C) quantitation of effects of HA and compounds 3, 4, 5, and 6 on GFP
synthesis. The experiments whose results are shown in panels B and C
were performed in triplicate. GFP fluorescence is given as a percent-
age, where 100% is defined as the fluorescence detected in the absence
of the antibiotic. Rel., relative.
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previously been demonstrated by a gene disruption study (22).
Most short-chain dehydrogenase enzymes are dimers or tet-
ramers and typically do not need a divalent metal ion for
activity, unlike the classical metal-dependent medium-chain
alcohol dehydrogenases (11, 18). The results of analyses of
recombinant Hyg26 in the present study are consistent with it
being a dimeric, metal ion-independent protein. The enzyme
showed an absolute preference for NAD(H) and did not utilize
NADP(H). The coenzyme-binding site of short-chain dehydro-
genases preferring NAD(H) has an acidic residue (Asp or Glu)
that forms hydrogen bonds with the hydroxyl groups of the
adenine ribose, whereas the binding site for NADP(H) has two
basic residues (Arg or Lys) that bind to the phosphate (12, 31).
The specificity of Hyg26 for NAD(H) is consistent with the
presence of an Asp residue at position 38 in the putative
coenzyme-binding region within residues 12 to 38 (VTGAAR
GQGREHAVRMAGEGADVIAID; conserved residues are
indicated in boldface). Both the ability of Hyg26 to catalyze the
interconversion of DHHA and HA and the production of
DHHA by a hyg26 mutant are consistent with this being the
last step of HA biosynthesis. A previous proposal that Hyg26
may catalyze the conversion of L-fucofuranose to 5-dehydro-
-L-fucofuranose during the formation of just the A subunit
appears to be less likely.
Additional support for the hypothesis that DHHA is the
penultimate intermediate in the HA pathway comes from
the analyses of the hyg19 mutant. The equilibrium for the
Hyg26-catalyzed process was observed to heavily favor
DHHA, even though HA is the primary fermentation prod-
uct. Loss of the subsequent energetically favorable step,
which would shift the equilibrium toward HA, would be
predicted to result in the formation of decreased of levels of
HA and the formation of increased levels of DHHA, as seen
for the hyg19 mutant. The possibility that this accumula-
tion of DHHA arises from a polar effect on the adjacent
hyg20 is unlikely, as a hyg20 deletion mutant does not pro-
duce any detectable levels of HA. There are several exam-
ples of this, in which the final steps of antibiotic biosynthesis
are linked with efflux. In the case of nystatin biosynthesis by
S. noursei, disruption of the nysH and nysG genes for a
putative type III ABC transporter resulted in the accumu-
lation of 10-deoxynystatin, a precursor of nystatin lacking
the hydroxyl at C-10 (29). Furthermore, expression in the
mutant strains of an additional copy of nysL, which presum-
ably encodes a monooxygenase for C-10 hydroxylation, par-
tially restored nystatin production with a concomitant de-
crease in 10-deoxynystatin. NysL has been expressed and has
been shown to catalyze the hydroxylation of 10-deoxynysta-
tin (29). The reaction has not been shown to be reversible
(in contrast to the reaction observed for Hyg26), and there
does not appear to be detectable inhibition of NysL by the
product nystatin. Thus, while the observations indicate that
the final biosynthetic step is balanced with efficient efflux,
the biochemical basis seems to be less clear than that pro-
posed herein for HA. A linkage between the final proposed
step in chromomycin A3 biosynthesis, the conversion of
dideacetylated precursor by a membrane-bound acetyltrans-
ferase, and exportation by a type I ABC transporter in S.
griseus subsp. griseus have also been reported (17).
The increased level of production of DHHA by the hyg19
mutant is consistent with Hyg19 being the primary efflux pump
responsible for the selective and efficient transport of HA. In
our working hypothesis, Hyg19 is able to preferentially bind to
and export HA over the intermediate DHHA (Fig. 7). These
properties would contrast with those observed for Hyg26,
which, in the reduction reaction, exhibited poor binding for
HA (approximately 6 mM) and showed limited evidence of
binding specificity (compounds 3 and 5 were also substrates).
The poor HA binding by Hyg26 would permit facile transfer to
Hyg19 for export. Hyg19 must also export HA sufficiently fast
such that it is not phosphorylated by the resistance element,
Hyg21 (this enzyme has an observed kcat of 2.2 min
1 and a Km
for HA of 30 M), and gets trapped inside the cell (4).
The presence of HA and DHHA in the fermentation broth
of hyg19 implies the existence of an alternative system for
antibiotic efflux (Fig. 7). This system would have reduced se-
lectivity (exporting both HA and DHHA) relative to that for
the process mediated by Hyg19. The most obvious candidate
within the hyg biosynthetic gene cluster is the hyg28-encoded
ABC transporter. Hyg28 does not appear to have a significant
role in efflux in the wild type, as the hyg28 strain continues to
produce wild-type levels of HA in the fermentation broth. The
Hyg19 process may be significantly faster that that proposed to
be catalyzed by Hyg28, or hyg28 expression may increase in the
hyg19 strain. Attempts to probe these possibilities by the
generation of a mutant in which both genes have been deleted
have thus far been unsuccessful. There are numerous prece-
dents for the association of multiple efflux systems with anti-
biotic biosynthetic processes and, in particular, transporters
that can excrete pathway intermediates. The 10-deoxynystatin
intermediate, produced by deletion of the putative type III
ABC transporter in S. noursei, is found in the fermentation
broth, suggesting an additional efflux process (29). The prema-
ture efflux of landomycin D, an intermediate in landomycin A
biosynthesis in S. cyanogenus, has been reported with either the
overexpression of the proton gradient-dependent transporter
gene lanJ or the disruption of the regulatory gene, lanK, that
represses lanJ (19).
In addition to ensuring the production of the final HA prod-
uct, Hyg19 also contributes to HA resistance in the producing
organism. The loss of hyg19 alone did not lead to decreased
HA resistance. Similar observations with regard to resistance
have been made for the landomycin E producer S. globisporus
1912. Self-resistance was not affected when the proton gradi-
ent-dependent transporter gene lndJ and the ABC transporter
gene lndW, both of which occur in the landomycin E biosyn-
thetic gene cluster, were independently disrupted. Heterolo-
gous expression of these genes, however, conferred resistance
to landomycin E, proving their function as resistance genes (20,
21). The intrinsic resistance of an antibiotic producer is often
due to the synergistic action of multiple gene products (3). This
appears to be the case for HA self-resistance, as the simulta-
neous deletion of two putative HA resistance determinants,
hyg19 and hyg21 (in addition to the hyg20 biosynthetic gene),
resulted in an increase in susceptibility greater than that
achieved when either of them was individually disrupted (the
HA susceptibility of the hyg21 mutant has been described
separately [4]). In this mutant with triple mutations, both the
proposed efficient HA efflux system and an enzyme that can
modify and inactivate HA inside the cell are absent. The high
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wild-type level resistance of the hyg20 HA-nonproducing
strain [versus the reduced resistance seen for the mutant with
triple mutations, (hyg19-hyg20-hyg21)] suggests that HA is
not essential for the induction of expression of the resistance
genes. It is possible that the hyg28 gene product and a putative
methyltransferase encoded by hyg29 may also contribute to
resistance in the wild-type strain and to residual self-resistance
in the (hyg19-hyg20-hyg21) mutant with triple mutations. A
gene inactivation experiment targeting all four putative resis-
tance determinants has been pursued but has been unsuccess-
ful to date.
These analyses provide compelling evidence that Hyg26 cat-
alyzes the final step in HA biosynthesis and that Hyg19 plays a
role in ensuring the efficient production of HA (and not the
DHHA intermediate) as well as resistance to HA. The MIC
and in vitro translation data indicate that HA is the most
potent inhibitor (albeit only in tests against E. coli). The pres-
ence of the methylene bridge does not significantly affect trans-
lation inhibition in vitro but does lead to lower MICs, suggest-
ing the importance of this group for some other aspect of the
activity such as cellular uptake. In contrast, changes in the C5
oxidation state clearly affect the in vitro activity of HA and its
analogs, indicating a previously unknown role of this group in
interacting with the ribosome target. Thus, the final steps of
the HA biosynthetic process lead to a progressively more active
compound, culminating in the most active and major product,
HA, and have presumably evolved as a result of an ecological
advantage to S. hygroscopicus in its natural environment.
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0022-2836/$ - see front matter © 2008 EAzithromycin is a semisynthetic derivative of erythromycin that inhibits
bacterial protein synthesis by binding within the peptide exit tunnel of the
50S ribosomal subunit. Nevertheless, there is still debate over what
localization is primarily responsible for azithromycin binding and as to
how many molecules of the drug actually bind per ribosome. In the present
study, kinetic methods and footprinting analysis are coupled together to
provide time-resolved details of the azithromycin binding process. It is
shown that azithromycin binds to Escherichia coli ribosomes in a two-step
process: The first-step involves recognition of azithromycin by the
ribosomal machinery and places the drug in a low-affinity site located in
the upper part of the exit tunnel. The second step corresponds to the slow
formation of a final complex that is both much tighter and more potent in
hindering the progression of the nascent peptide through the exit tunnel.
Substitution of uracil by cytosine at nucleoside 2609 of 23S rRNA, a base
implicated in the high-affinity site, facilitates the shift of azithromycin to this
site. In contrast, mutation U754A hardly affects the binding process.
Binding of azithromycin to both sites is hindered by high concentrations of
Mg2+ ions. Unlike Mg2+ ions, polyamines do not significantly affect drug
binding to the low-affinity site but attenuate the formation of the final
complex. The low- and high-affinity sites of azithromycin binding are
mutually exclusive, which means that one molecule of the drug binds per E.
coli ribosome at a time. In contrast, kinetic and binding data indicate that in
Deinococcus radiodurans, two molecules of azithromycin bind cooperatively
to the ribosome. This finding confirms previous crystallographic results and
supports the notion that species-specific structural differences may
primarily account for the apparent discrepancies between the antibiotic
binding modes obtained for different organisms.© 2008 Elsevier Ltd. All rights reserved.Keywords: azithromycin; ribosome; peptide exit tunnel; peptidyl transferase;
slow binding inhibitorsEdited by D. E. Draperess:
qually to this work.
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Azithromycin is a semisynthetic derivative of
erythromycin, possessing a 15-membered lactone
ring that is structurally distinguished by the absence
of a keto oxygen at position C9 and the insertion of a
methyl-substituted nitrogen at position C10 (Fig. 1).
These structural features allow for high stability of
azithromycin in acidic aqueous media,1 better phar-
macokinetic characteristics,2 and improved potency
against Gram-negativemicroorganisms, while retain-
ing the efficacy of erythromycin against Gram-
positive microbes.3 For susceptible Escherichia colid.
Fig. 1. Chemical structures of
tylosin, erythromycin, and azithro-
mycin.
1180 Azithromycin Interaction with E. coli Ribosomesstrains, azithromycin is 8 to 15 times more active than
erythromycin.4,5 Although the superior potency of
azithromycin has been attributed to its faster penetra-
tion of the outer membranes of Gram-negative
bacteria,6,7 this drug also exhibits better ability than
erythromycin to compete for [14C]erythromycin-
binding sites in Staphylococcus aureus ribosomes and
higher affinity for E. coli ribosomes.8–11
Accumulated biochemical and genetic evidence
suggests that azithromycin exerts its inhibitory effect
on microbial growth by binding in a narrow part of
the peptide exit tunnel, at a position that is situated
between the peptidyl transferase (PTase) center and a
constriction in the tunnel formed by proteins L4
and L22.5,8,12–17 Binding of the drug at this region
occludes the lumen of the tunnel, thus aborting the
growth of the nascent peptide chain during the early
rounds of translation, eventually leading to pepti-
dyl–tRNA “drop-off”.18 An additional inhibitory
target of azithromycin in susceptible bacterial cells is
the assembly of the 50S subunit; azithromycin, like
erythromycin, stalls the normal assembly sequence,
leading to the accumulation of an incomplete
ribosomal particle that is subsequently degraded.19
Moreover, a recent microarray analysis indicated
that azithromycin at subinhibitory concentrations
can activate as well as repress different subsets of
genes in Pseudomonas aeruginosa.20
In the past few years, the structures of the
archaeal and bacterial large ribosomal subunits
and their complexes with azithromycin have been
solved by X-ray crystallography.21,22 Not only did
this structural information improve our under-
standing of how azithromycin binds to the ribo-
some, but it could also provide tools to assess
previous findings regarding macrolide resistanceconferred by base substitutions or modifications in
23S rRNA and mutations of ribosomal proteins.
Although there is an underlying similarity between
the archaeal and bacterial crystallographic models
in the localization of azithromycin-binding site, the
precise position and conformation of the lactone
ring of azithromycin seen in these structures differ
significantly (Fig. 2). An additional notable differ-
ence relates to the number of azithromycin mole-
cules bound per ribosome. In contrast to the one
molecule found in the archaeal structure, two
molecules of the drug were observed in the
structure of Deinococcus radiodurans 50S subunit
complexed with azithromycin. One of the azithro-
mycin molecules (AZI-1) is found in the conven-
tional macrolide-binding site, while the other (AZI-
2) is located directly adjacent to it, but deeper in the
tunnel, making direct contacts with proteins L4 and
L22 as well as with domain II of 23S rRNA (Fig. 2a).
It has been suggested that the mode of dual binding
is species specific.23 Consistent with this suggestion
is the finding that, although the general ribosomal
architecture between archaea and bacteria is the
same, the nature and precise orientation of the
rRNA and ribosomal protein residues in their
ribosomes differ in details. For instance, wild-type
archaeal ribosomes contain a guanosine at position
2058 (E. coli numbering is used throughout the text)
of 23S rRNA, whereas D. radiodurans, like most
eubacteria, contains an adenosine at the equivalent
position. It is known that mutation A2058G in
eubacteria confers resistance against macrolides.12
Consequently, A/G difference at position 2058 may
account for the structural discrepancies obtained.
This possibility was investigated by Tu et al., using
a Haloarcula marismortui strain containing mutation
Fig. 3. AcPhe–puromycin synthesis in the absence or
presence of antibiotics. Complex C prepared from E. coli
ribosomes reacted in buffer A for specified time intervals
at 25 °C with (○) 200 μΜ puromycin alone or with a
mixture containing both (●) 200 μΜ puromycin and
0.5 μM azithromycin or (▴) 200 μΜ puromycin and 2 μM
tylosin. The values of the percentage of the initially added
complex C, which is converted to product, x, have been
Fig. 2. The binding site(s) of azithromycin on the 50S ribosomal subunit. (a) Binding of two molecules of azithromycin
(pink) to the D. radiodurans 50S ribosomal subunit (Protein Data Bank accession no. 1NWY). Parts of domain Vand helix
H35 of 23S rRNA (light blue) aswell as parts of ribosomal proteins L4 (dark blue) and L22 (light green) are shown by ribbon
representation. Important nucleoside residues for macrolide binding are presented by their structures (E. coli numbering);
those contributing to hydrogen bonds are connectedwith the drug by dotted lines. (b) Binding position of azithromycin on
the H. marismortui 50S ribosomal subunit (Protein Data Bank accession no. 1M1K). Labeling is the same as in (a).
1181Azithromycin Interaction with E. coli RibosomesG2058A.24 It was found that azithromycin binds to
wild-type and mutant 50S subunits of H. marismor-
tui in a virtually identical way, making impossible
the hypothesis that the variability of azithromycin
binding to bacterial and archaeal 50S subunits may
be attributed to sequence differences at position
2058. However, it is worth considering the possi-
bility that the two azithromycin-bound molecules
in the 50S ribosomal subunit from D. radiodurans
may result from other idiosyncratic structural
characteristics of this bacterium23 and/or the near
in vivo ionic conditions followed during the crystal
preparation25 or reflect snapshots of azithromycin
binding at different steps of the drug binding
process. With respect to the latter postulation, it
should be mentioned that kinetic and NMR studies
have provided evidence that binding of azithromy-
cin to E. coli ribosomes occurs in a two-step process,
the first one involving the recognition and selection
of the drug by the ribosomal machinery and the
second one being the strong interaction responsible
for the protein synthesis inhibition.10,26,27
In the present study, chemical footprinting and
kinetic analysis are applied together in a dual
strategy to investigate the entire course of azithro-
mycin binding to E. coli functional ribosomes and to
monitor the effects of ionic environment on the
binding process. In the context of this work, we also
seize the chance to construct a mechanistic model
that explains our results as well as crystallographic
and other data collected so far.corrected by the extent of AcPhe–puromycin synthesis
achieved in the absence of azithromycin and tylosin. The
two upper lines were drawn by linear fitting of the x and t
values to the equation ln[100/(100−x)]=kobs∙t, where kobs
represents the observed first-order rate constant of the
puromycin reaction. The lower line was drawn from the
calculated ln[100/(100−x)] values at each time point,
using the B-Spline function of the Microcal Origin 6.1
program (Microcal Software, Inc). Puro, puromycin; Azi,
azithromycin; Tyl, tylosin.Results
Azithromycin is a slow binding ligand of E. coli
ribosomes
Sixteen-membered macrolides, such as tylosin,
possess a disaccharide branch at position C5 of thelactone ring (Fig. 1), from which extending towards
the PTase center perturbs the relative positioning of
the bound tRNA substrates. Consequently, macro-
lides of this type inhibit the PTase activity in most
reference cell-free systems.28–30 In contrast, azithro-
mycin has a single desosamine moiety at the C5
position, which is too short to reach the PTase center.
Consistently, azithromycin fails to inhibit AcPhe–
puromycin formation (Fig. 3). Nevertheless, pre-
vious studies have demonstrated that azithromycin
Scheme 1. Competition between tylosin (T) and
azithromycin (A) for common binding sites in ribosomal
complex C.
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[post state ribosomes programmed with poly(U)
and bearing AcPhe–tRNA and deacylated tRNA at
the P- and E-site, respectively].8,10 This is also shown
in Fig. 4; when complex C is added in a solution
containing 4 μM tylosin and azithromycin, a
progressive decrease in the inactivation of complex
C by tylosin occurs as the concentration of azithro-
mycin increases. At high concentrations of azithro-
mycin (N2 μM), the inactivation of complex C is
completely reversed. Another feature of the compe-
tition mechanism is that the initial slopes of the
inactivation plots vary as a function of azithromycin
concentration. The overall kinetic pattern is remi-
niscent of that observed in a recent study of
erythromycin binding performed under the same
ionic conditions (4.5 mMMg2+, 150 mMNH4
+)30 and
is in agreement with previous kinetic studies of
azithromycin carried out under conventional ionic
conditions (10 mMMg2+, 100 mMNH4
+).10 Thus, it is
reasonable to employ a similar kinetic model for the
competition of tylosin (T) binding by azithromycin
(A), as represented by Scheme 1. The values of kon,A,
koff,A, KA, and the overall dissociation constant KA⁎,
estimated by nonlinear regression fitting of the
obtained data to Eq. (7) (see Materials andMethods),
are shown in Table 1.
Previous genetic studies have indicated that
mutations in hairpin 35 of domain II and in the
central loop of domain V of the E. coli 23S rRNA
confer resistance to low concentrations of ery-
thromycin.5,31 To check if two of these mutations,
U754A and U2609C, also influence the kinetics of
azithromycin binding, the affinity of mutant ribo-
somes for azithromycin was estimated in parallel
experiments. As shown in Table 1, mutation U754AFig. 4. Inactivation of complex C by tylosin in the
absence or presence of azithromycin. Complex C prepared
from E. coli ribosomes reacted in buffer A with (×) 4 μM
tylosin alone or with a mixture containing both 4 μM
tylosin and azithromycin at (○) 25 nM, (●) 50 nM, (▵)
100 nM, (▴) 200 nM, (□) 500 nM, and (■) 2000 nM. After
removing the excess of each antibiotic, the percentage of
complex C input remaining active, x, was titrated with
2 mM puromycin. The curves were drawn by nonlinear
fitting of the x and t values to Eq. (7). The kon,T and KT
values were measured via experiments performed in the
presence of tylosin alone and set in the above computer
simulation as constant factors. The tangent at zero time of
the nonlinear plot obtained at 4 μM tylosin and 2 μM
azithromycin is indicated by a broken line.hardly affects the affinity of azithromycin, at both
the initial and final positions of its accommodation
within complex C. The small alterations in the KA⁎
and kon,A/koff,A values are not statistically signifi-
cant (Pb0.05). In contrast, U2609C mutation
increases the isomerization constant kon,A/koff,A by
55%. As a result, the value of the overall dissocia-
tion constant for azithromycin, KA⁎, undergoes a
40% reduction, reflecting an increase in affinity of
the drug for the mutant ribosome. By repeating the
kinetic analysis of azithromycin binding to wild-
type ribosomes in the presence of 100 μM spermine,
we observed that the kon,A value is decreased by
63%, resulting in a parallel reduction of the iso-
merization constant. Consistently, the KA⁎ value
undergoes a twofold enhancement. Similar altera-
tions were recorded by using 50 μM spermine and
2 mM spermidine (optimized Mg2+/NH4
+/polya-
mine system32), instead of spermine alone (Table 1).
Thus, the presence of polyamines leads to an
overall decrease in azithromycin binding.
One molecule of azithromycin binds per E. coli
ribosome
Scheme 1 assumes that only one molecule of
azithromycin binds per E. coli ribosome at the same
time. To verify this assumption, we performed two
series of experiments. In the first, C⁎A complex was
exposed to 4 μM tylosin for various time intervals,
and its activity, after removing the excess tylosin,
was titrated with puromycin. As shown in Fig. 5a,
the data of complex C regeneration from complex
C⁎A give a simple first-order time plot, which is
consistent with one molecule of azithromycin bound
per E. coli ribosome. An alternative explanation
could be that only one molecule of azithromycin
competes with tylosin for a common binding in the
ribosome. In any case, koff,A is more than two orders
Table 1. Kinetic parameters derived from analysis of azithromycin interaction with complex C
Ionic conditions
4.5 mM Mg2+,
150 mM NH4
+
4.5 mM Mg2+,
150 mM NH4
+,
100 μM spermine
4.5 mM Mg2+,
150 mM NH4
+,
50 μM spermine,
2 mM spermidine
10 mM Mg2+,
100 mM NH4
+
Constant (unit) Wild type U2609C U754A Wild type Wild type Wild typea
KA (nM) 29.6±2.6 26.6±1.5 30.5±2.3 25.0±1.8 23.4±1.9 48.0±5.0
kon,A (min
−1) 0.049±0.004 0.055±0.003 0.045±0.004 0.018±0.001 0.022±0.001 0.0086±0.011
koff,A (min
−1) 0.0051±0.0004 0.0037±0.0002 0.005±0.0004 0.0053±0.0003 0.0066±0.0005 0.015±0.001
kon,A/koff,A 9.66±1.08 15.03±1.00 9.00±0.96 3.40±0.27 3.33±0.29 5.73±0.82
KA⁎ (nM) 2.77±0.38 1.66±0.17 3.05±0.43 5.68±0.57 5.32±0.62 7.12±1.17
Data are expressed as means±standard error (duplicate analysis in three ribosomal preparations).
a Data taken from Ref. 10.
Fig. 5. Analysis of azithromycin dissociation from or
binding to complex C prepared from E. coli. (a) Dissocia-
tion of azithromycin from complex C⁎A; complex C⁎A
formed by incubating complex C with 1 μΜ azithromycin
for 80 min in buffer A was collected by filtration on a
cellulose nitrate filter, exposed to 5 ml of 4 μΜ tylosin in
buffer A for the time intervals indicated, and its percentage
remaining active, x, was titrated with 2 mM puromycin.
The line was drawn from the calculated lnx values at each
time point, using the linear fitting function of the Microcal
Origin 6.1 program. (b) Binding of [3H]azithromycin to
complex C; each 400-μl reaction mixture containing
6.5 pmol complex C and [3H]azithromycin (1786 dpm/
pmol) at various concentrations in buffer Awas incubated
for 2 h at 25 °C, and the complex formed in each case was
isolated by filtration through a nitrocellulose filter. The
concentration of free [3H]azithromycin in the reaction
mixture is given on the abscissa. The curve was drawn by
nonlinear fitting of the bound [3H]azithromycin (B) at each
concentration of the free ligand (A) to Eq. (1), using the
Hyberbola function of the Microcal Origin 6.1 program.
1183Azithromycin Interaction with E. coli Ribosomessmaller than kon,T. Therefore, the net flux from C⁎A
to C⁎T depends on this rate-limiting step. From the
slope of the plot shown in Fig. 5a, a value of
0.005 min−1 is determined, which is quite similar to
the koff,A value estimated by nonlinear regression
fitting of kinetic data to Eq. (7) (see Table 1).
In the second series of experiments, complex C or
70S ribosomes from E. coli were incubated for 2 h in
buffer A containing radiolabeled azithromycin at
increasing concentrations (equilibrium binding).
Azithromycin was present in a molar excess relative
to complex C or 70S ribosomes for all of the drug
binding assays. The value of bound [3H]azithromy-
cin was measured by nitrocellulose filtration. As
shown in Fig. 5b, the binding of azithromycin to
complex C follows a rectangular hyperbolic curve.
Therefore, the relationship between the amount of
bound ligand (B) and the concentration of free
ligand (A) can be expressed by the equation:
B =
Bmax A½ 
Kd + A½ 
ð1Þ
where Bmax is the maximum level of bound
azithromycin and Kd is the dissociation constant of
the azithromycin–ribosome complex. The number of
drug-binding sites in complex C, estimated after
dividing Bmax by the amount of complex C, is equal
to 0.75. Similar results were obtained when 70S
ribosomes from E. coliwere used, instead of complex
C (data not shown). In contrast, dissociation of the
[3H]azithromycin–ribosome complex prepared from
D. radiodurans 70S ribosomes follows a clear biphasic
curve, suggesting two molecules of azithromycin
bound per ribosome, dissociating with rate con-
stants 0.020 min−1 and 0.004 min−1, respectively
(Fig. 6a). Moreover, binding of radiolabeled azithro-
mycin toD. radiodurans ribosomes follows a sigmoid
hyperbola (Fig. 6b). Therefore, the data were fitted
to the equation
B =
Bmax  A½ n
Kd + A½ n
ð2Þ
where n represents the Hill coefficient. The value
obtained after dividing Bmax by the amount of
ribosomes (=1.61) and the value of n (=2.31) suggestthat two cooperatively interacting sites for azithro-
mycin exist in ribosomes from D. radiodurans. It
should be mentioned that the ribosomal populations
Fig. 6. Analysis of [3H]azithromycin dissociation from
or binding to 70S ribosomes from D. radiodurans. (a)
Dissociation of the azithromycin–ribosome complex; 70S
ribosomes (6.5 pmol) were incubated with 30 μl of buffer B
containing 1 μΜ [3H]azithromycin for 80 min at 25 °C,
filtered through a nitrocellulose filter, and then exposed to
5 ml of buffer B at 25 °C for the indicated time intervals.
After washing with buffer B, the trapped radioactivity on
the filters was determined by scintillation counting. The
two linear portions of the biphasic curve were drawn from
the calculated values of ln[AZI]bound at each time, using the
linear fitting function of the Microcal Origin 6.1 program.
(b) Binding of [3H]azithromycin to 70S ribosomes; binding
was carried out in buffer B (400 μl) containing 6.5 pmol 70S
ribosomes and [3H]azithromycin (1786 dpm/pmol) at
various concentrations. The mixture was incubated at
25 °C for 2 h (equilibrium binding) and the amount of
bound azithromycin was measured by nitrocellulose
filtration and radioactivity counting. The concentration of
free [3H]azithromycin in the reaction mixture is given on
the abscissa. The curve was drawn by nonlinear fitting of
the bound [3H]azithromycin (B) at each concentration of
the free ligand (A) to Eq. (2), using the Hill hyperbola
function of the Microcal Origin 6.1 program.
1184 Azithromycin Interaction with E. coli Ribosomesisolated from E. coli and D. radiodurans were 75%
and 84.3% capable of binding, respectively, as found
by titration with [14C]erythromycin. Thus, correct-
ing for the binding efficiency, the number of drug
molecules bound per E. coli and D. radiodurans
ribosomes becomes 1 and 1.9, respectively.
Footprinting of azithromycin–ribosome
complexes
To identify the individual drug–ribosome interac-
tions occurring in the encounter complex CA and
the final complex C⁎A, we followed a kinetic-
footprinting approach, recently applied in studying
the interactions of erythromycin and tylosin with E.coli ribosomes.30 Footprinting of the CA complex
was achieved by incubating complex C prepared
from E. coli ribosomes with azithromycin in buffer A
for 10 s, the latter at concentration 50×KA, thus
ensuring that most of the binding sites are occupied.
Because the equilibrium C+A⇄CA is established
rapidly, while the isomerization reaction proceeds
slowly (t1/2=13 min), the product during this time
interval mainly consists of complex CA (N95%). The
formed CA complex was then probed with chemical
reagents that attack nucleosides of 23S rRNA that
are neither occupied by the drug nor participating in
secondary or tertiary interactions. The incubation
time of complex C with azithromycin was extended
to 100 min to footprint the C⁎A complex. Because
the isomerization constant is higher than 3 (Table 1),
it is reasonable to presume that at the end of this
time interval (≈8× t1/2), most of the added complex
C should be in the form of complex C⁎A.
Representative autoradiograms obtained by pri-
mer extension analysis are shown in Figs. 7 and 8.
The final modification results are summarized in
Table 2. Azithromycin at the CA binding state and in
the absence of polyamines strongly protects A2058
and A2059 from dimethyl sulfate (DMS) and G2505
from kethoxal modification, while moderately redu-
cing the accessibility of U2609 to 1-cyclohexyl-3-(2-
morpholinoethyl) carbodiimide metho-p-toluene
(CMCT). A weak protection effect is also observed
on C2611, although this residue is not normally
accessible to DMS, due to its base pairing with
G2057.33 Interestingly, in the presence of polya-
mines, the reactivity of C2611 against DMS is lost,
both in ribosome–azithromycin complexes and in
complex C alone. Consequently, it is reasonable to
suppose that at low Mg2+ concentrations, polya-
mines reestablish the C2611/G2057 base pair. In the
C⁎A binding state, new protection effects appear on
A788, U790, and U2586. Also, protection of U2609
becomes stronger, whereas protections at A2058 and
G2505 soften and the accessibility of A752 is slightly
enhanced. The presence of spermine hardly affects
the protection pattern of complex CA. However, in
complex C⁎A, it stimulates the accessibility of all
nucleotides implicated in the binding of azithromy-
cin, in particular of U2609 and those situated in helix
35 of 23S rRNA. The increased accessibility indicates
reduced binding of the drug, in agreement with the
increased dissociation constant KA⁎ when polya-
mines are present.Discussion
High-resolution crystallographic structures of
ribosomal particles and their complexes with azi-
thromycin have elucidated basic concepts in azithro-
mycin binding mode at the molecular level.21,22,24
However, a disadvantage of crystallography is that
the structures offer only a snapshot of stably bound
azithromycin position on the ribosome, where-
as the complete picture of the drug binding pro-
cess may be significantly more complex. Kinetic
Fig. 7. Alterations in the chemical reactivity of nucleosides in domain II of 23S rRNA, caused by azithromycin binding
to complex C prepared from E. coli ribosomes. Complex C was incubated in the absence or presence of azithromycin in
buffer A (lanes 1 to 4) or in the same buffer also containing 100 μM spermine (lanes 5 to 8). The resulting complexes were
then probed with DMS or CMCT. Modification sites were detected by primer extension analysis. U, A, G, and C denote
dideoxy sequencing lanes. Lanes 1 and 5, unmodified complex Cwith no drug present; lanes 2 and 6, complex C probed in
the absence of azithromycin; lanes 3 and 7, complex C incubated with azithromycin for 10 s and then probed; lanes 4 and
8, complex C incubated with azithromycin for 100 min and then probed. Numbering of nucleotides for the sequencing
lanes is indicated at the left, while nucleotides with altered reactivity against chemical probes as well as reference bands
are indicated by arrows. AZI, azithromycin.
1185Azithromycin Interaction with E. coli Ribosomesanalysis and chemical footprinting used in the
present work provide additional tools to (i) inves-
tigate the entire course of azithromycin binding to
E. coli ribosomes and (ii) rationalize the available
crystallographic, genetic, and other data collected
so far.
According to our kinetic results, the overall
association rate constant of azithromycin binding
to complex C, (kon,A+koff,A)/KA, equals 3×10
4 M−1
s−1, a value that is two orders below the upper limit
set for the characterization of a drug as a slow
binding ligand.34 Corroborative evidence that azi-
thromycin is a slow binder is also derived from the
preincubation effect, namely, the strengthening of
the azithromycin competition potency against tylo-
sin when complex C is preincubated with azithro-
mycin before the addition of tylosin (data not
shown). Moreover, the ratio kon,A/koff,A is much
higher than 1, regardless of ionic conditions used, a
fact implying that azithromycin is a slowly rever-
sible ligand as well. Another important character-
istic of the azithromycin kinetic behavior is that the
initial slope of each inactivation plot in Fig. 4
decreases as the concentration of azithromycin
increases. This is consistent with a two-step mechan-
ism of binding, since otherwise, the initial slope
should be independent of azithromycin concentra-
tion. According to this mode, the first step equili-brates rapidly, while the second one representing
the accommodation of azithromycin at its final
position is established slowly, within the minute
timescale (t1/2=13 min). A two-step mechanism has
also been suggested by transferred nuclear Over-
hauser effect studies,26 as well as by previous kinetic
studies.10 Comparing the results presented here
with previous studies performed at 10 mM Mg2+,
we conclude that a decrease of Mg2+ concentration
from 10 to 4.5 mM enhances azithromycin affinity at
both steps of binding. Noteworthy is the threefold
reduction in the koff,A value, suggesting that rela-
tively low Mg2+ concentrations preserve complex
C⁎A from disassembly. Although polyamines do
not affect the initial step of binding, they obstruct the
accommodation of azithromycin at its final position,
primarily by lowering the kon,A value. Our results
emphasize the role that ionic conditions may have in
the ligand/ribosome binding free energy. Compar-
ing azithromycin with erythromycin binding to
ribosomes at optimal ionic conditions for efficient
and accurate protein synthesis (4.5 mM Mg2+,
150 mM NH4
+, 50 μM spermine, and 2 mM
spermidine),32 we realize that azithromycin exhibits
a higher affinity for complex C (KE⁎/KA⁎=19.9) and
forms a more stable final complex with ribosomes
(koff,E/koff,A=14.8). Although the efficacy of a drug
depends on many factors, our data at least partially
Fig. 8. Alterations in the chemical reactivity of nucleosides in domain Vof 23S rRNA, caused by azithromycin binding
to complex C prepared from E. coli ribosomes. Incubation of complex C with azithromycin was made as in Fig. 7. Samples
were modified with DMS, CMCT, or kethoxal and analyzed as in Fig. 7.
1186 Azithromycin Interaction with E. coli Ribosomesexplain the superiority of azithromycin as an anti-
microbial agent against E. coli and are also consistent
with its prolonged inhibitory activity on growth
following antibiotic removal from the medium (Post
Antibiotic Effect)35 and with its relatively lower
efficiency in inducing A2058 dimethylation in cells
carrying inducible erm(C).36
The kinetic model shown in Scheme 1 is based on
the assumption that one molecule of azithromycin
transiently binds to an initial site in the ribosome
and, subsequently, converts to a final position
exhibiting high affinity for azithromycin. Conse-
quently, the two binding sites are regarded as
mutually exclusive. As can be seen from its outcome,
this assumption seems to be right; first, our data fitEq. (7) well, and second, if two molecules of
azithromycin could bind simultaneously per ribo-
some, then KA⁎ representing the overall dissociation
constant should depend on drug concentration. As
found by calculating the KA⁎ value at different
azithromycin concentrations, KA⁎ value exhibits
very little variation (b15%). Dissociation and bind-
ing of azithromycin to complex C were analyzed in
detail to better address this issue. As shown in Fig.
5a, dissociation of azithromycin from the C⁎A
complex follows a linear first-order plot, suggesting
that one molecule of the drug binds per E. coli
ribosome. However, if a second molecule of azithro-
mycin is actually involved but does not compete
with tylosin, then it would not be discriminated by
Table 2. Footprinting of azithromycin bound at the initial and final positions in the large subunit of the E. coli ribosomes
23S rRNA
residue
Ionic conditions
4.5 mM Mg2+, 150 mM NH4
+
4.5 mM Mg2+, 150 mM NH4
+,
100 μM spermine
C CA C⁎A C CA C⁎A
A752 ++ ++ +++ ++ ++ ++
A788 ++ ++ (+) ++ ++ +
U790 ++ ++ (+) ++ ++ +
A2058 ++++ + ++ ++++ ++ ++
A2059 +++ + + +++ ++ ++
A2062 +++ +++ +++ +++ ++++ +++
G2505 + 0 (+) + 0 (+)
U2586 + + (+) + + +
U2609 +++ ++ (+) +++ ++ ++
C2611 + (+) (+) 0 0 0
Intensities of the modified residues are assigned as follows: ++++, very strong; +++, strong; ++, moderate; +, weak; (+), very weak; 0, no
modification. Quantification of the band intensities was made by phosphorimaging of the gels. The accessibility of U762 to CMCT in Fig.
7a was not affected by azithromycin binding, and therefore, this band was used as a reference one to normalize the intensity of U790.
Quantification of the band intensities at A752 and A788 in Fig. 7b was made as for Fig. 7a, normalizing against the A782 band. Similarly,
quantifications of the band intensities at A2058, A2059, and A2062 in Fig. 8a; G2505 in Fig. 8b; U2586 and U2609 in Fig. 8c; and C2611 in
Fig. 8d were made, normalizing against bands A2082, G2529, U2585, and A2602, respectively. The normalized intensity of A2058 was the
highest one and assigned as ++++.
C, poly(U)-programmed 70S ribosomes bearing tRNAPhe at the E-site and AcPhe–tRNA at the P-site; CA, encounter complex between C
and azithromycin; C⁎A, final complex resulting from CA by isomerization.
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ing of radioactive azithromycin to complex C was
employed to overcome the above limitations: Data
collected by binding of [3H]azithromycin to E. coli
ribosomes yield a rectangular hyperbolic curve (Fig.
5b), from which it is calculated that one molecule of
azithromycin binds per ribosome. In contrast, those
obtained with D. radiodurans ribosomes display a
clear sigmoidal hyperbolic curve (Fig. 6b), with a
Bmax corresponding to 1.9molecules of azithromycin
bound per ribosome. The calculated value of the Hill
coefficient equals 2.3, a fact suggesting that the
binding sites of azithromycin in D. radiodurans
ribosomes are cooperative. This is consistent with
crystallographic data indicating that AZI-1 and AZI-
2 bound to the 50S ribosomal subunit of D. radio-
durans are directly connected by a hydrogen bond
and indirectly through a Mg+2 ion (Fig. 2).22 Also,
consistent with a 2:1 stoichiometry is the finding that
the dissociation of [3H]azithromycin–D. radiodurans
ribosome complex follows a biphasic curve (Fig. 6a).
In summary, our results verify the number of
azithromycin molecules observed by crystallogra-
phy to be bound per D. radiodurans ribosome but
suggest that for E. coli ribosomes, only one binding
site is susceptible at any given time.
Structural characterization of CA and C⁎A com-
plexes was gained by footprinting analysis. As
shown in Table 2, the footprinting pattern of
complex CA resembles that previously reported
for erythromycin.30 A shift of azithromycin to the
high-affinity site (complex C⁎A) is accompanied by
drug interactions with nucleosides A752, A788, and
U790 in domain II of 23S rRNA, as well as with
U2586 and U2609 in domain V. Meanwhile, the
interactions with A2058 and G2505 become weaker.
The footprinting pattern of complex C⁎A correlates
better than the CA pattern with crystallographicdata regarding the binding of AZI-1 to D. radio-
durans 50S ribosomal subunits.22 This may be due to
the fact that co-crystallization has been carried out in
the presence of sevenfold excess of azithromycin for
prolonged time, conditions that favor the C⁎A
formation. Nevertheless, the C⁎A footprinting pat-
tern does not correlate with the binding of the
second molecule of azithromycin, AZI-2, detected
by crystallography in D. radiodurans.22
Drawing clues from the protection experiments,
one can envisage that azithromycin binds initially to a
hydrophobic crevice of E. coli ribosomes, formed by
nucleosidesG2057–A2059 at the upper part of the exit
tunnel (Fig. 9b). The pivotal role of A2058 and A2059
in the contact of azithromycin with the hydrophobic
crevice has been well documented by studies testing
the resistance against this drugof laboratory strains or
clinical isolates of bacteria carrying mutations or
methylated bases at these positions.12,15 Consistently,
A2058 has been found to form a hydrogen bond with
the 02′ of the desosamine sugar in both archaeal and
bacterial crystal structures of 50S ribosomal subunits
complexed with azithromycin.22–24 The accommoda-
tion of azithromycin at the CA binding state is also
facilitated by drug interaction with the adjacently
placed G2505. For thermodynamic reasons (ΔΔGo=
−1.4 kcal∙mol−1), azithromycin partially loses its
interaction with the hydrophobic crevice, a fact
resulting in a shift of the drug towards the other
side of the tunnel where U2609 and residues of
domain II are situated (Fig. 9c). Enhancement of DMS
reactivity at A752 upon drug binding to the final
position suggests changes in the local conformation of
23S rRNA rather than direct interaction with azithro-
mycin. It is possible that these conformational
changes are mediated through U2609, which has
been shown in D. radiodurans to interact with both
A752 and azithromycin.22,38 It should be mentioned
1188 Azithromycin Interaction with E. coli Ribosomesthat upon binding of AZI-2 to the 50S ribosomal
subunit of D. radiodurans, the loop connecting helices
73 and 93 of 23S rRNA is significantly shifted.22 In
turn, this causes the base of U2609 to adopt a
distinctly different orientation that allows hydro-phobic interactions with AZI-1.22 Because azithro-
mycin does not bind to E. coli ribosomes in a manner
analogous to that of AZI-2, a similar alteration in the
orientation of base U2609 in E. coli cannot be easily
speculated. Therefore, a direct contact of U2609 in E.
coli with azithromycin, like that observed with
erythromycin,39 seems more probable. Even so, a
mutation of U2609 to C is predicted to favor rather
than interrupt this contact.5 Consistently, we found
that mutation U2609C increases the formation and
stability of complex C⁎A. In contrast, mutation
U754A barely affects the azithromycin–ribosome
interaction. Our results obtained with mutant E.
coli ribosomes are in remarkable agreement with
resistance studies performed in E. coli by Garza-
Ramos et al.,5 but in apparent variance with earlier
results published by the same research group.31 It is
possible that the use of a heterogeneous ribosomal
population (wild-type plus mutant ribosomes) in
this earlier study is the cause of this discrepancy.
Another finding of the present work is that
interaction of azithromycin with A788 and U790
favors the formation of complex C⁎A. Both nucleo-
sides are placed on the same side of the exit tunnel,
opposite to that forming the G2057–A2059 hydro-
phobic crevice. Nevertheless, the loop in which A788
and U790 are situated is poorly conserved and
relative flexible.23 Therefore, it is not surprising that
interactions of this loop with azithromycin, not
detected in crystals ofD. radiodurans orH.marismortui
50S ribosomal subunits, are adopted in E. coli
ribosomes, probably via a swinging of A788 and
U790 towards the drug (shown in Fig. 9c by a double
arrow). Polyamines bound to this region may esta-
blish a conformational state that disfavors inter-
actions of A752, A788, and U790 with azithromycin,
a postulation that could explain their negative effect
on C⁎A formation. Spermine cross-linking to helices
73, 35, and 35a has already been detected.40
In conclusion, our results demonstrate that one
molecule of azithromycin binds per E. coli ribosome.
The binding process is characterized by an initial
step that rapidly equilibrates, followed by a slower
step when the drug accommodates into its final
position. Both interactions between azithromycin
and the ribosome are Mg2+ dependent. Polyamines
do not affect the initial binding step but instead
hinder the shift of azithromycin to the high-affinityFig. 9. Schematic representation of azithromycin bind-
ing at the low- and high-affinity sites within the ribosomal
exit tunnel. (a) Azithromycin crystal structure; the
orientation of the molecule is represented by three
connected circles reflecting the planes of the lactone ring
and the two sugar substituents. (b and c) Positional and
orientation clustering of azithromycin within the exit
tunnel, at the low- and high-affinity sites, respectively. The
broken line represents the tunnel axis, while the position
of PTase center is shown by an arrow. A putative rotation
of U790 upon binding of azithromycin to the high-affinity
site is indicated in (c) by a double arrow. Representations
are based on the results of the present study and
crystallographic data taken from Refs. 22,37.
1189Azithromycin Interaction with E. coli Ribosomessite. Nevertheless, the general characteristics of the
binding model are conserved, regardless of the ionic
conditions used. Therefore, the apparent discrepan-
cies between the antibiotic binding modes obtained
for E. coli and D. radiodurans cannot be attributed to
differences in the ionic conditions used. As pro-
posed by Schlünzen et al.,22 it seems more probable
that these discrepancies predominantly result from
species-specific differences in the ribosomal proteins
and rRNA constituting the drug-binding sites. The
present work shows that the simultaneous binding
of two azithromycin molecules to D. radiodurans
ribosomes is cooperative. This observation may be
important for the future rational design of macro-
lides that work in a synergistical fashion.Materials and Methods
Reagents and materials
Puromycin dihydrochloride, tylosin tartrate, spermine
tetrahydrochloride, spermidine trihydrochloride, tRNAPhe
from E. coli, DMS, and DMS stop solution were from
Sigma-Aldrich. Kethoxal and CMCTwere purchased from
MP Biomedicals and Fluka Biochemicals, respectively.
Radioactive materials L-[2,3,4,5,6-3H]phenylalanine and
[α-32p]ATP were from Amersham Biosciences. AMV
reverse transcriptase, dNTPs and ddNTPs were obtained
from Roche Diagnostics. Cold and radioactive azithromy-
cin (9.9 Ci/mmol) was kindly provided by Pfizer (Groton/
New London Laboratories). Cellulose nitrate filters (type
HA; 0.45 μm pore size) were from Millipore Corp.
Bacterial strains and biochemical preparations
70S ribosomes were prepared from E. coli K12 and D.
radiodurans cells as described elsewhere.41 E. coli TA531
cells lacking chromosomal rrn alleles but containing
pKK3535 plasmids expressing wild-type or mutated 23S
rRNA (U2609C or U754A) were kindly provided by Prof.
A. S. Mankin, University of Illinois. These strains were
used to prepare ribosomes in studying the effect of 23S
rRNA mutations on the mechanism of azithromycin
binding. Ac[3H]Phe–tRNA charged to 80% and posttran-
slocation complex of poly(U)-programmed ribosomes,
complex C, bearing tRNAPhe at the E-site and Ac[3H]
Phe–tRNA at the P-site were prepared and purified
according to Dinos et al.41 The percentage of ribosomes,
active in AcPhe–tRNA binding, was more than 65%. This
fraction was 90–95% reactive towards puromycin.
Inactivation of complex C by tylosin in the absence or
presence of azithromycin
Complex C in buffer A [100 mM Tris/HCl, pH7.2,
4.5 mM Mg (CH3COO)2, 150 mM NH4Cl, and 6 mM 2-
mercaptoethanol] containing 4 μM tylosin and azithro-
mycin at specified concentrations was incubated at 25 °C
for the desired time intervals. As previously proved,30 the
apparent rate constant of complex C inactivation, F, is
given by the equation
F = Fs + Fo  Fsð Þ  ek Vt ð3Þwhere Fs and Fo are the inactivation constants at the
steady state and zero time, respectively, while k′ is the
apparent equilibration rate constant for the attainment
of equilibrium between complex C and the drugs. For
the derivation of Eq. (3), we assumed that the equilibria
C+T⇄CT and C+A⇄CA in Scheme 1 are established
rapidly, while the isomerization reactions CT⇄C⁎T and
CA⇄C⁎A are established slowly. Additionally, we
assumed that the values of koff,T and koff,A might be less
than those of kon,T and kon,A, respectively, for appreciable
formation of C⁎T and C⁎A. Each of the kinetic parameters
Fs, Fo, and k′ in Eq. (3) is related to the concentrations of
azithromycin (A) and tylosin (T), through the following
equations:
Fo =
kon;T T½ 
KT 1 +
A½ 
KA
 
+ T½ 
ð4Þ
Fs =
kon;Tkoff;A T½ 
kVKT 1 + T½ KT +
A½ 
KA
  ð5Þ
kV= koff;A + kon;A
A½ 
KA
1 + T½ KT +
A½ 
KA
ð6Þ
The values of kon,A, koff,A, and KA were calculated by
nonlinear regression fitting of kinetic data obtained from
three independently performed experiments to the
equation
lnx = 4:6 Fs  t
Fo  Fsð Þ
kV
1 ek Vt
 
ð7Þ
that is derived from Eq. (3) by integration. The variable x
in Eq. (7) is the percentage of the initially added complex
C, which remains active (reactive towards puromycin)
with time. The constant factor in Eq. (7) is valid by
assuming that the extent of puromycin reaction used for
titration of complex C is 100%; otherwise, it is corrected.
The kon,T and KT constants for tylosin, measured via
experiments performed in the presence of tylosin alone,
were in good agreement with those obtained previously30
and set in the above computer simulation as constant
factors. Once kon,A, koff,A, and KA were calculated, the
overall dissociation constant KA⁎, concerning both steps of
azithromycin binding to complex C, was estimated
through the equation
K4A =KA
koff;A
koff;A + kon;A
 
ð8Þ
Details on the derivation of the above equations are
available in the Supplementary Data of Ref. 30.
Regeneration of complex C from complex C⁎A
To determine the koff,A value by an alternative way and
to check whether one or more molecules of azithromycin
bind per E. coli ribosome, complex C⁎A formed by
incubating complex C (6.5 pmol) with 1 μΜ azithromycin
in buffer A (total volume: 30 μl) for 80 min was adsorbed
on a cellulose nitrate filter, washed with buffer A, and then
immersed in 5 ml of buffer A containing 4 μM tylosin for
specified time intervals. After removing the excess of
tylosin, the percentage (x) of the complex C remaining
active was determined by titration with 2 mM puromycin.
1190 Azithromycin Interaction with E. coli RibosomesThe koff,A value was estimated from the slope of the
obtained lnx versus time plot and compared with those
calculated through Eq. (7).
Kinetic analysis of the dissociation of the azithromycin–
ribosome complexwas also performed by incubatingE. coli
70S ribosomes (6.5 pmol) with 1 μM [3H]azithromycin
(1786 dpm/pmol) in 30 μl of buffer A for 80 min at 25 °C.
The [3H]azithromycin–ribosome complex formed was
then collected by filtration through a cellulose nitrate filter,
washed with buffer A, and immersed in 5 ml of buffer A at
25 °C. The amount of azithromycin remaining bound to
ribosomes with time was monitored by washing the filter
rapidly with cold buffer A and measuring the trapped
radioactivity on the filter in a scintillation spectrometer.
Controls without ribosomes were included in each experi-
ment and the values obtained were subtracted. The same
procedure was followed when D. radiodurans 70S ribo-
somes were used. In the later case, however, buffer B
[100 mM Tris/HCl, pH7.2, 10 mM Mg (CH3COO)2,
100 mM NH4Cl, and 6 mM 2-mercaptoethanol] was
used, since 70S ribosomes from D. radiodurans were
unstable in buffer A.
Binding of azithromycin to complex C or 70S
ribosomes
Complex C or 70S ribosomes (6.5 pmol) from E. coli or
D. radiodurans were incubated with varying concentra-
tions of [3H]azithromycin (1786 dpm/pmol) in 400 μl of
buffer A or B, respectively, at 25 °C for 2 h (equilibrium
binding). The bound drug to complex C or 70S ribosomes
was then collected on a nitrocellulose filter, washed three
times (3 ml each) with cold buffer, and dissolved in 10 ml
of Bray's solution, and its radioactivity was measured in a
liquid scintillation spectrometer. Nonspecific binding was
determined by assessing the displacement of [3H]azithro-
mycin with a 100-fold excess of unlabeled azalide.
Probing of CA and C⁎A complexes
ComplexC at 100 nMwas incubated alone orwith 1.4 μΜ
azithromycin (50×KA) in 100 μl of buffer C[Hepes/KOH,
pH7.2, 4.5 mMMg(CH3COO)2, 150 mMNH4Cl, and 5 mM
dithiothreitol] in the absence or presence of 100 μΜ
spermine at 25 °C, either for 10 s (CA probing) or for
8× t1/2min (C⁎Aprobing). The term t1/2 represents the half-
life for the attainment of equilibrium between complex C
and the drug and was calculated through the equation,
t1=2 =
0:693
kq
ð9Þ
where k′′ is given by the equation
kq = koff;A + kon;A 
A½ 
KA + A½ 
ð10Þ
Complexes CA and C⁎A were then probed with DMS,
kethoxal, or CMCT, as described previously.30 Reactions
were stopped, and the rRNA was recovered from CA or
C⁎A complexes by extraction with phenol, phenol–chloro-
form, and chloroform. Finally, rRNA was precipitated by
ethanol and resuspended in Milli-Q water.
Primer extension
The modifications in 23S rRNA were monitored by
primer extension analysis using reverse transcriptase,according to Stern et al.42 The used primers were com-
plementary to the sequences 888–906, 2099–2116, 2561–
2578, and 2677–2694. The cDNA products were separated
by electrophoresis on 6% polyacrylamide/7 M urea gels.
The positions of stops in cDNA synthesis were identified
by reference to dideoxy sequencing reactions, run in
parallel on unmodified rRNA template. Three replications
were carried out for each experiment. Quantification of the
band intensities was made by phosphorimaging of the
gels (Fujifilm, FLA-3000, Berthold; Image Quant Software
AIDA, Raytest). Background values in each “control” lane
were subtracted from the corresponding bands of interest.
Each lane was searched for a reference nucleotide whose
accessibility to the chemical probe is not affected by
azithromycin binding. The intensity of this reference band
was then used to normalize the intensities of the bands of
interest in this lane (vertical comparison). The relative
intensity of the reference band between lanes was finally
used to correct for variability between lanes (horizontal
comparison).
Statistics
All data indicated in Table 2 and in the figures denote
mean values obtained from three independently per-
formed experiments. Data variability was determined by
ANOVA. Significant differences between mean values
were measured by the F Scheffé test.Acknowledgements
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Accumulating evidence suggests that, during trans-
lation, nascent chains can form specific interactions
with ribosomal exit tunnel to regulate translation and
promote initial folding events. The clinically impor-
tant macrolide antibiotics bind within the exit tunnel
and inhibit translation by preventing progression
of the nascent chain and inducing peptidyl-tRNA
drop-off. Here, we have synthesized amino acid–
and peptide-containing macrolides, which are used
to demonstrate that distinct amino acids and pep-
tides can establish interaction with components of
the ribosomal tunnel and enhance the ribosome-
binding and inhibitory properties of the macrolide
drugs, consistent with the concept that the exit
tunnel is not simply a Teflon-like channel. Surpris-
ingly, we find that macrolide antibiotics do not inhibit
translation of all nascent chains similarly, but rather
exhibit polypeptide-specific inhibitory effects, pro-
viding a change to our general mechanistic under-
standing of macrolide inhibition.
INTRODUCTION
The translational machinery represents one of the major targets
within the cell for antibiotics (reviewed by Spahn and Prescott,
1996; Wilson, 2009). The majority of antibiotics inhibit protein
synthesis by binding at the active centers on the ribosome; for
example, the tetracyclines and aminoglycosides (gentamicin)
bind within the decoding site on the small subunit, whereas the
phenylpropanoids (chloramphenicol) and oxazolidinones (line-
zolid) bind within the A-site of peptidyltransferase center (PTC)
to block peptide-bond formation. In contrast, the clinically
important class of macrolide antibiotics bind within the ribo-
somal exit tunnel, where they are thought to inhibit translation504 Chemistry & Biology 17, 504–514, May 28, 2010 ª2010 Elsevierby blocking elongation of the nascent polypeptide chain, which,
in turn, induces peptidyl-tRNA drop-off (Mankin, 2008; Poehls-
gaard and Douthwaite, 2003).
Macrolides are a diverse family of antibiotics that contain
a central 12–16-membered lactone ring to which various sugar
substituent’s are attached; for example, erythromycin has a
14-membered ring with C3 cladinose and C5 desosamine
sugars (Figure 1), whereas tylosin has a 16-membered ring with
a C5 mycaminose-mycarose disaccharide as well as a C23
mycinose (Figures 1 and 2). Crystal structures of macrolides
bound to the large ribosomal subunit reveal that the drugs bind
within the ribosomal exit tunnel adjacent to the peptidyltransfer-
ase center (Figures 2A and 2B) (Hansen et al., 2002; Schlünzen
et al., 2001). Surprisingly, 16-membered macrolides that have a
C6 ethyl aldehyde (with the aldehyde functional group at C20),
such as tylosin (Figure 1), form a reversible covalent bond with
the N6 of adenine 2062 (A2062; Escherichia coli numbering
used throughout) of the 23S ribosomal RNA (Figure 2B) (Hansen
et al., 2002). The lactone rings of different macrolides are gener-
ally positioned in the tunnel with very similar orientations, such
that the C5 sugars extend up the tunnel toward the PTC (Hansen
et al., 2002; Poulsen et al., 2000; Schlünzen et al., 2001; Wilson
et al., 2005) (Figure 2B). Consistently, macrolides such as eryth-
romycin with only a single C5 sugar allow synthesis of short
oligopeptides of six to eight amino acids before peptidyl-tRNA
drop-off occurs, whereas macrolides with C5 disaccharides,
such as tylosin, allow only two to four amino acids to be synthe-
sized (Tenson et al., 2003), and can even directly inhibit the pep-
tidyltransferase reaction (Karahalios et al., 2006).
It should be noted, however, that the length of the pep-
tide synthesized before peptidyl-tRNA drop-off appears to be
dependent on the sequence being translated (Tenson et al.,
2003). Translation of short nascent pentapeptides of defined
sequence can lead to dissociation of macrolide antibiotics from
the ribosome and thus confer macrolide resistance (Lovmar
et al., 2006; Tenson et al., 1996; Tenson and Mankin, 2001).
Moreover, different pentapeptide sequences can confer resis-
tance to distinct macrolide members, suggesting a direct and
discriminating interaction between the nascent chain and theLtd All rights reserved
Figure 1. Chemical Structures of Macrolide Antibiotics
Chemical structures of tylosin (Tyl), desmycosin (Des), OMT, erythromycin, and derivatives used in this study (1)–(12) are depicted.
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Macrolide Interaction with the Ribosomal Tunnelmacrolide (Tenson et al., 1997; Tripathi et al., 1998; Vimberg
et al., 2004). Inducible expression of some macrolide resistance
genes, such as the methyltransferase encoded by the ermC
gene, requires macrolide-dependent translational stalling during
the synthesis of an upstream leader peptide (Mayford andChemistry & Biology 17,Weisblum, 1989; Ramu et al., 2009; Vazquez-Laslop et al.,
2008). Mutations in the ErmC leader peptide as well as within
components of the ribosomal exit tunnel, namely A2062 of the
23S rRNA, have been identified that relieve the translational stall-
ing (Ramu et al., 2009; Vazquez-Laslop et al., 2008), suggestingFigure 2. Binding of Macrolide Antibiotics
Within the Ribosomal Tunnel
(A) Transverse section through the large subunit of
the ribosome to visualize the ribosomal exit tunnel.
The position of tylosin (red), P-site tRNA (orange),
and a mock polypeptide chain (yellow) are indi-
cated. CP, central protuberance; rRNA, gray and
ribosomal proteins (dark blue).
(B) Zoom in on the macrolide-binding site within
the ribosomal tunnel. Tylosin (pink) shown with
lactone ring, C23-mycinose, and C5-mycami-
nose-mycarose are labeled. The asterisk indicates
the carbinolamine bond that forms between tylo-
sin and the N6 of 23S rRNA nucleotide A2062,
whereas the arrow indicates the shift in A2062
seen upon ligand binding. The positions of
A- and P-site aminoacyl-tRNAs are shown in green
and orange, respectively.
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Macrolide Interaction with the Ribosomal Tunnela complex interplay between the antibiotic, the tunnel, and the
nascent polypeptide chain.
Although the ribosomal tunnel has for many years been
thought of as a passive conduit for the nascent chain, accumu-
lating evidence indicates the existence of many specific leader
peptides that induce translational stalling by directly interacting
with the ribosomal tunnel, and in doing so regulate translation
of a downstream gene (Tenson and Ehrenberg, 2002). Indeed,
recent cryo-EM reconstructions directly visualize interaction
between the nascent polypeptide chain and components of
the ribosomal tunnel (Becker et al., 2009; Bhushan et al., 2010;
Seidelt et al., 2009). Moreover, interaction between the nascent
chain and tunnel has been proposed to play a more general role
in modulating translation rate (Lu and Deutsch, 2008; Seidelt
et al., 2009) as well as influencing initial protein folding events
(Bhushan et al., 2010; Kosolapov and Deutsch, 2009; Lu and
Deutsch, 2005a, 2005b; Woolhead et al., 2004).
Here, we demonstrate that abolishing the potential of tylosin to
form a covalent bond with A2062 of the ribosome dramatically
reduces the binding and inhibitory properties of the drug, but
that this can be reversed by the addition of amino acid and
peptide side chains that enable interaction to be reestablished
with the ribosomal exit tunnel. A number of the macrolide-
peptide compounds are even more potent inhibitors of transla-
tion than their parent compounds. Surprisingly, we find that
macrolides exhibit nascent chain-specific effects: 5-O-mycami-
nosyl-tylonolid (OMT), a precursor of tylosin, has excellent anti-
microbial activity and is a potent inhibitor of firefly luciferase
synthesis. In contrast, OMT is a very poor inhibitor of green
fluorescent protein synthesis and can even protect the transla-
tional apparatus from the inhibitory effects of other macrolides,
such as erythromycin and tylosin. Differential effects are also
observed for other macrolide antibiotics but are not seen for non-
macrolide antibiotics, such as tetracyclines and chlorampheni-
cols. Collectively, our results demonstrate the direct and specific
interaction between peptides and the ribosomal tunnel and
suggest that the inhibitory effect of macrolides is dependent
on the sequence of the nascent polypeptide chain being
translated.
RESULTS
Peptide Interaction with the Tunnel Compensates
for Loss of the Covalent Bond
To investigate the effect of the covalent linkage between the C6
ethyl aldehyde of tylosin and the N6 of A2062 of the 23S rRNA
(Figure 2B), we synthesized a reduced form of tylosin, (1)
Tyl-H2, where the C6 ethyl aldehyde is replaced by hydroxyethyl
group (Figure 1A). Binding of (1) Tyl-H2 to the ribosome was
monitored by competition with radiolabeled [14C]-erythromycin
(apparent Kd calculations in Table S1, available online, are based
on a 2 hr incubation; see Experimental Procedures). In the con-
trol experiment, we demonstrate that tylosin is an excellent
competitor, completely abolishing the binding of erythromycin
at0.1 mM (Figure 3A). In contrast, (1) Tyl-H2 was totally inactive,
and no significant loss in erythromycin binding was observed
with 1003 higher concentrations (10 mM) of the compound
(Figure 3A). These results support the importance of the carbi-
nolamine covalent linkage for efficient ribosome binding, in506 Chemistry & Biology 17, 504–514, May 28, 2010 ª2010 Elsevieragreement with previous findings that modification of the C20
aldehyde group leads to a 100-fold increase in the MIC value
for a variety of gram-positive bacteria (Kirst et al., 1988; Narandja
et al., 1994; Omura et al., 1982; Omura and Tishler, 1972).
Next, we synthesized a series of macrolide derivatives where
amino acids and peptides were attached to the C20 aldehyde
position to investigate whether amino acids can establish
defined interactions with the ribosomal exit tunnel. We reasoned
that if this is indeed the case, then the peptide-tunnel interac-
tions should improve the binding affinity of the compounds.
As can be seen in Figure 3A, the presence of Ala-Ala at the
C20 position to generate (2) Tyl-A2 dramatically improves the
ability of the compound to compete with erythromycin for ribo-
some binding. Similar results were also obtained when Ala-Ala
was attached to the C20 position of desmycosin, a degradation
product of tylosin differing by the absence of a C5 mycarose, to
generate (3) Des-A2 (Figure 3A). This finding suggests that,
indeed, the Ala-Ala peptides establish interaction with the tunnel
to improve the binding of the compounds compared with the Tyl-
H2; however, it should be noted that the Kd of (2) Tyl-A2 and (3)
Des-A2 (18 nM for both compounds) are still significantly worse
than their C6 ethyl aldehyde–containing parent compounds tylo-
sin (0.65 nM) and desmycosin (0.3 nM) (Table S1; Figure 3A).
To test the inhibitory activity of the compounds, we utilized an
E. coli lysate–based, in vitro, coupled transcription-translation
system (Dinos et al., 2004; Starosta et al., 2009), where the syn-
thesis of green fluorescent protein (GFP) was monitored by
directly measuring fluorescence (Figure 3B). Consistent with
the ribosome binding results, tylosin was found to be an excel-
lent inhibitor, with an IC50 of 0.25 mM and abolishing translation
at 1 mM (Figures 3B and 3C), whereas (1) Tyl-H2 had an IC50 >
103 higher (4 mM) (Table S1) and did not even completely abolish
translation at 25 mM (data not shown). (2) Tyl-A2 exhibited
improved inhibitory characteristics, with an IC50 of 0.5 mM—
only slightly worse than that of tylosin (Figure 3C; Table S1).
This contrasts with the binding assay results where (2) Tyl-A2
was a significantly worse competitor of erythromycin than tylosin
for ribosome binding (Figure 3A). A similar trend was observed
when comparing desmycosin with (3) Des-A2, in that (3) Des-
A2 was a slightly more effective inhibitor than desmycosin.
However, unlike (2) Tyl-A2, both desmycosin and (3) Des-A2
could not fully abolish translation even at high concentrations
(Figure 3C; Table S1).
We have previously determined a crystal structure of (2) Tyl-A2
bound to the Deinococcus radiodurans large ribosomal subunit
(Wilson et al., 2005), which shows that the lactone ring binds in
a similar position to that seen for tylosin (Hansen et al., 2002).
The C20 Ala-Ala peptide protrudes into a small alcove or pocket
within the tunnel wall, where it stacks against the base of A2062
(Figure 3E). The presence of the C20 Ala-Ala peptide on (2) Tyl-
A2 precludes formation of the carbinolamine bond with the N6
of A2062, and as a result A2062 is in a shifted position compared
to the tylosin-50S structure (Hansen et al., 2002) (Figure 3D).
Optimized Stacking Interactions with A2062
Improves Inhibition
On the basis of the structure of the (2) Tyl-A2 bound to the large
subunit, a series of novel C6 tylosin derivatives were synthesized
that can potentially form better stacking interactions with theLtd All rights reserved
Figure 3. Inhibitory Effect of Tylosin and Desmycosin Ala2 Derivatives
(A) The ability of tylosin (pink), Tyl-H2 (gray), desmycosin (Des, blue), (2) Tyl-A2, and (3) Des-A2 to compete with radiolabeled erythromycin for binding to E. coli
70S ribosomes was determined. The binding of erythromycin in the absence of competing ligand was assigned as 100%.
(B) The amount of GFP produced in an E. coli in vitro transcription-translation assay in the presence or absence of tylosin, (1) Tyl-H2 and (2) Tyl-A2, Des, and (3)
Des-A2 was determined by monitoring fluorescence of GFP. The fluorescence of GFP in the absence of antibiotic was assigned as 100%.
(C) Quantification of (B) with symbols and colors for each compound as in (A).
(D) The binding site of tylosin on the H. marismortui 50S subunit showing the formation of a covalent carbinolamine bond between the C6 ethyl-aldehyde of tylosin
(red) and the N6 of the base of A2062 of the 23S rRNA (Hansen et al., 2002).
(E) The binding site of (2) Tyl-A2 (green) on the D. radiodurans 50S subunit showing the stacking interaction between the Ala-Ala side chain of (2) Tyl-A2 and the
base of A2062 of the 23S rRNA (Wilson et al., 2005).
Chemistry & Biology
Macrolide Interaction with the Ribosomal Tunnelbase of A2062, namely by introducing aromatic or heterocyclic
groups that replace the Ala amino acids. Because base-stacking
between RNA nucleotides is an efficient and highly ubiquitous
interaction mode within RNA particles, the first compound, (4)
Tyl-U, was designed with an uridine (U) RNA nucleobase linked
to the lactone C6 carbon by a four-atom linker (Figure 1). In the
translation assay, (4) Tyl-U was still a worse inhibitor than (2)
Tyl-A2, but was superior to (1) Tyl-H2 (Figure 4A; Table S1).
In parallel, we investigated the effect of replacing the Ala-Ala
peptide with the amino acid tyrosine (Tyr) to generate the (5)
Tyl=Tyr derivative, which also utilizes a five-atom linker.
Although this compound had improved binding and inhibitory
activity with respect to (1) Tyl-H2, it was still significantly worse
than (2) Tyl-A2 (Figures 4A and 4B; Table S1). We rationalized
that the double bond in the linker may restrict the conformational
freedom of the side chain and therefore synthesized a second
compound (6) Tyl-Tyr with a fully saturated linker. In the transla-
tion assays, (6) Tyl-Tyr was a significantly better inhibitor than (5)
Tyl=Tyr and (2) Tyl-A2 (Figure 4B; Table S1), which was consis-
tent with the improved binding properties of (6) Tyl-Tyr (Fig-
ure 4A). What was curious was (6) Tyl-Tyr had an IC50 compa-
rable to that of tylosin (Figure 4B; Table S1), despite being lessChemistry & Biology 17,effective than tylosin at competing for ribosome binding with
erythromycin (Figure 3A).
In a separate approach, we also attached carnitine to the C20
position to generate (7) Tyl-Car (Figure 1). The positively charged
side chain improves the aqueous solubility, compared with tylo-
sin, but was also intended to improve interactions with the highly
electronegative cleft in the ribosomal tunnel. Indeed, (7) Tyl-Car
displayed binding (Kd, 0.6 nM) and inhibition (IC50, 0.3) properties
very similar to those of tylosin (Figures 4A and 4B; Table S1), sug-
gesting that, like (2) Tyl-A2, the side chain of (7) Tyl-Car estab-
lishes interaction with the ribosomal tunnel that compensate
for the loss of the carbinolamine bond. (7) Tyl-Car was modeled
in the tunnel with the constraint that the lactone ring and A2062
were positioned as in (2) Tyl-A2 structure (Wilson et al., 2005).
The most energetically favorable solution indicated that the
carnitine side chain adopted a conformation that establishes
stacking interactions with A2062 (Figure 4C).
Enhanced Tylosin Antibiotics That Utilize
Peptide-Tunnel Interaction
To further explore the stacking potential of the C20 side chains
with the nucleobase of A2062, we decided to introduce504–514, May 28, 2010 ª2010 Elsevier Ltd All rights reserved 507
Figure 4. Stacking Interaction with A2062
(A) The ability of tylosin, (1) Tyl-H2, (4) Tyl-U, (5) Tyl=Tyr, (6) Tyl-Tyr, and (7) Tyl-Car to compete with radiolabeled erythromycin for binding to D. radiodurans 70S
ribosomes was determined. The binding of erythromycin in the absence of competing ligand was assigned as 100%.
(B) Quantification of the fluorescence of GFP produced in an E. coli in vitro transcription-translation assay in the presence or absence of tylosin, (1) Tyl-H2, (4)
Tyl-U, (5) Tyl=Tyr, (6) Tyl-Tyr, and (7) Tyl-Car. The fluorescence of GFP in the absence of antibiotic was assigned as 100%.
(C) Model based on Tyl-A2 for the binding site of (7) Tyl-Car (yellow) on the D. radiodurans 50S subunit showing the stacking interaction between the carinitine
sidechain of (7) Tyl-Car and the base of A2062 of the 23S rRNA.
(D) The ability of tylosin, desmycosin (Des), OMT, (8) Tyl-Phe, (9) Des-Phe, and (10) OMT-Phe to compete with radiolabeled erythromycin for binding to
D. radiodurans 70S ribosomes was determined. The binding of erythromycin in the absence of competing ligand was assigned as 100%.
(E) Quantification of the fluorescence of GFP produced in an E. coli in vitro transcription-translation assay in the presence or absence of tylosin, desmycosin (Des),
OMT, (8) Tyl-Phe, (9) Des-Phe, and (10) OMT-Phe. The fluorescence of GFP in the absence of antibiotic was assigned as 100%.
(F) Model based on (2) Tyl-A2 for the binding site of (8) Tyl-Phe (purple) on the D. radiodurans 50S subunit showing the stacking interaction between the linker of (8)
Tyl-Phe and the base of A2062, as well as a between the phenylalanine aromatic residue and the base of C2586 of the 23S rRNA.
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maintaining its overall flexibility. Binding studies indicate that
this compound, (8) Tyl-Phe, improved the ribosome bind-
ing affinity (Kd, 3.6 nM) compared to (1) Tyl-H2 (Figure 4D;
Table S1). Consistently, (8) Tyl-Phe was found to be a very
potent inhibitor of translation (Figure 4E), performing slightly
better than tylosin but significantly better than (2) Tyl-A2 and
(1) Tyl-H2 (Table S1). The Phe side chain may stabilize the bind-
ing of (8) Tyl-Phe by establishing additional stacking interac-
tions with 23S rRNA nucleotides (Figure 4F). However, the
improved ribosome binding affinity cannot be the sole explana-
tion for the increased translational inhibitory activity relative to
tylosin, because (8) Tyl-Phe was significantly less effective
compared to tylosin at competing erythromycin from the ribo-
some (Figure 4D).508 Chemistry & Biology 17, 504–514, May 28, 2010 ª2010 ElsevierWe also synthesized (9) Des-Phe and (10) OMT-Phe, where the
Phe-containing linker side chain was attached to the C20 posi-
tion of desmycosin and OMT, respectively (Figure 1). OMT is
a precursor of tylosin, which lacks both the C5 mycarose and
the C23 mycinose (Figure 1). Our erythromycin competition
studies indicate that both (9) Des-Phe and (10) OMT-Phe were
worse competitors than their respective parent compounds (Fig-
ure 4D). The order of affinities of (8) Tyl-Phe > (9) Des-Phe > (10)
OMT-Phe is the same as for tylosin > desmycosin > OMT, and
correlates with the predicted surface areas that these
compounds bury on the ribosome; that is, more surface area
buried equals higher binding affinity (Hansen et al., 2002).
However, that each derivative had a lower binding affinity than
the parent compound emphasizes again the important influence
that the C6-ethyl aldehyde and presumably the carbinolamineLtd All rights reserved
Figure 5. Protective Effects of OMT
Compounds
(A) The ability of tylosin, OMT, (11) BocAAF-OMT,
and (12) fMLF-OMT to compete with radiolabeled
erythromycin for binding to D. radiodurans 70S
ribosomes was determined. The binding of eryth-
romycin in the absence of competing ligand was
assigned as 100%.
(B) Quantification of the fluorescence of GFP
produced in an E. coli in vitro transcription-transla-
tion assay in the presence or absence of tylosin,
OMT, (11) BocAAF-OMT, and (12) fMLF-OMT.
The fluorescence of GFP in the absence of antibi-
otic was assigned as 100%.
(C) Quantification of the fluorescence of GFP
produced in an E. coli in vitro transcription-transla-
tion assay in the presence of increasing concen-
trations (upper x-axis) of erythromycin (Ery) to
5 mM, then with additional presence of increasing
concentrations (lower x-axis) of OMT (cyan), (11)
BocAAF-OMT (magenta), (12) fMLF-OMT (blue),
or (10) OMT-Phe (yellow).
(D) Quantification of the fluorescence of GFP
produced in an E. coli in vitro transcription-transla-
tion assay in the presence of increasing concen-
trations (upper x-axis) of tylosin (Ery) to 5 mM,
then with additional presence of increasing con-
centrations (lower x-axis) of OMT (cyan), (11)
BocAAF-OMT (magenta), (12) fMLF-OMT (blue),
or (10) OMT-Phe (yellow).
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rolides on the ribosome.
In the translation system, (9) Des-Phe and (10) OMT-Phe, like
(8) Tyl-Phe, were more potent inhibitors than would have been
expected on the basis of their Kd values. (9) Des-Phe and (10)
OMT-Phe had IC50 values (0.1 mM and 0.3 mM, respectively)
similar to that of tylosin (0.25 mM) (Figure 4E; Table S1), thus indi-
cating that the presence of the peptide and its interaction with
the tunnel can compensate for loss in binding affinity resulting
from disruption of the covalent linkage with the ribosome. In
contrast, we found unexpectedly that desmycosin and OMT
were very poor inhibitors of translation. Even with high concen-
trations of antibiotic (50–100 mM), desmycosin never inhibited
translation by more than 50% (Figure 3B), and OMT had little
or no significant inhibitory effect (Figure 4E). This finding was
surprising because (1) both OMT and desmycosin bound effi-
ciently to an empty ribosome (Figure 4D), with Kd values of 3 nM
and 0.3 nM, respectively (Table S1), similar to that previously
reported (Karahalios et al., 2006) and that is 5- and 50-fold better
than that of erythromycin (Kd, 15 nM) (Karahalios et al., 2006);
and (2) both OMT and desmycosin have potent antimicrobial
activity (data not shown). Indeed, OMT and desmycosin are
known to have MIC values similar to tylosin for a number of
gram-positive bacterial strains (e.g., Streptococcus pyogenes,
Staphlococcus aureus, and Enterococcus faecalis) (Fu et al.,
2006; Kirst et al., 1988; Mutak et al., 2004).
Protective Effects of Peptide-OMT Precursor
Compounds Against Translation Inhibition
To investigate the differential effects of OMT in more detail,
we synthesized a series of peptide-OMT compounds, whereChemistry & Biology 17,BocAlaAlaPhe and fMetLeuPhe peptides were attached to
C14(C23) of OMT to generate (11) BocAAF-OMT and (12) fMLF-
OMT derivatives, respectively. These compounds still retain a C5
sugar and the C6 ethyl aldehyde, and the placement of the
peptide side chain on the C14(C23) position of the lactone ring
orients it such that it would penetrate deeper into the ribosomal
tunnel. Like OMT, both (11) BocAAF-OMT and (12) fMLF-OMT
were excellent competitors of erythromycin, although the pres-
ence of the peptide did not enhance the affinity of the derivative
for the ribosome (Figure 5A). In contrast, the presence of the
peptide improved the inhibitory effect of the OMT derivatives,
particularly, (12) fMLF-OMT, which inhibited the in vitro transla-
tion reaction by 50% at 1 mM (Figure 5B).
Because OMT and some of the derivatives were shown to bind
efficiently to an empty ribosome, but were poor inhibitors in the
translation assay, we decided to test whether the compounds
could relieve the translation inhibition effect that results from
other more effective macrolide antibiotics, such as tylosin and
erythromycin. Figure 5C shows that, at 5 mM erythromycin, the
translation of GFP is totally abolished, whereas when OMT,
(11) BocAAF-OMT, or (12) fMLF-OMT are additionally titrated
into the reaction, the inhibition of translation was gradually alle-
viated. As a control, (10) OMT-Phe, which was shown itself to
be a potent inhibitor (Figure 4E), could not relieve the inhibitory
effect due to erythromycin (Figure 5C). Indeed, the extent of relief
appeared to correlate inversely with the innate inhibitory activity
of the compound; for example, OMT and (11) BocAAF-OMT,
which were the poorest inhibitors, yielded the strongest relief
(up to 40% with 5 mM—that is, equimolar concentration to eryth-
romycin), whereas (12) fMLF-OMT, which was a slightly better
inhibitor, only restored translation by up to 20% at 5 mM final504–514, May 28, 2010 ª2010 Elsevier Ltd All rights reserved 509
Figure 6. Polypeptide Chain-Dependency of Macrolide Antibiotics
(A) Comparison of the effect of desmycosin (Des) and OMT on the in vitro transcription-translation of green fluorescent protein (GFP) and firefly luciferase (Fluc).
(B) Comparison of the effect of tylosin (Tyl) and erythromycin (Ery) on the in vitro transcription-translation of GFP and Fluc.
(C) Comparison of the effect of chloramphenicol (Cam) and tetracycline (Tet) on the in vitro transcription-translation of GFP and Fluc. In (A)–(C), the fluorescence of
GFP or luminescence of Fluc in the absence of antibiotic was assigned as 100%.
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Macrolide Interaction with the Ribosomal Tunnelconcentration (Figure 5C). This latter result was slightly sur-
prising, since at 5 mM of (12) fMLF-OMT, the drug itself reduces
translation by 60% (to 40%). Similar results were observed when
5 mM tylosin was used instead of erythromycin; however, higher
excesses of OMT and the derivatives were required to obtain the
equivalent inhibitory relief that was observed with erythromycin
(Figure 5D). For example, 10 mM (23 tylosin concentration) of
OMT produced only30% relief (Figure 5D). This trend is consis-
tent with the higher affinity and IC50 of tylosin over erythromycin
(Table S1) and thus supports the idea that the relief is due to
direct competition between the OMT/OMT-derivative and the
inhibitory compound (tylosin or erythromycin). Additional evi-
dence includes the observations that (1) OMT/OMT-derivatives
could not relieve the translation inhibition resulting from nonma-
crolide antibiotics, such as tetracycline or thiostrepton (data not
shown), and (2) compounds that were very poor competitors
with erythromycin, such as (1) Tyl-H2 (Figure 3A), produced
very low inhibition relief with extremely high excesses of com-
pound—for example, 25 mM (53 excess) (1) Tyl-H2 produced
4% relief for 5 mM tylosin (data not shown).
Macrolide Antibiotics Exhibit Polypeptide-Specific
Inhibitory Effects
Because of the inconsistency between the potent antimicrobial
activity of OMT and the poor inhibitory activity in the in vitro
translation assay, we decided to test whether OMT displayed
some template-specific effects. To do this, we substituted the
GFP template with firefly luciferase (Fluc) and monitored trans-
lation of Fluc using luminescence. Figure 6A shows that OMT
is an excellent inhibitor of translation of Fluc, with an IC50 of
0.15 mM, similar to that observed for the inhibition of GFP syn-
thesis by tylosin (0.25 mM). Similarly, we found that Des, which we
had shown to be a poor inhibitor of GFP (Figure 3C), was a potent
inhibitor of Fluc synthesis (Figure 6A). Less dramatic differences
were observed when comparing the effect of tylosin and erythro-
mycin on GFP and Fluc synthesis (Figure 6B). The effect of tylo-
sin on GFP and Fluc synthesis was similar, whereas the corre-
sponding values for erythromycin were 1 mM (GFP) and 0.75 mM
(Fluc) (Table S1). We believe that this template dependency in
inhibition is specific for the macrolide class of antibiotics,510 Chemistry & Biology 17, 504–514, May 28, 2010 ª2010 Elsevierbecause we do not find such distinct inhibitory effects when
examining the inhibition of other antibiotic classes, such as the
tetracyclines or phenylpropanoids (i.e., chloramphenicol) (Fig-
ure 6C). Tetracycline inhibits GFP synthesis with an IC50 of
11 mM and Fluc with an IC50 of 7 mM, and chloramphenicol
inhibits GFP and Fluc with the same IC50 of 1 mM (Figure 6C).
DISCUSSION
The surface of the exit tunnel is largely hydrophilic and has no
patches of hydrophobic surface large enough to form a sig-
nificant binding site for hydrophobic sequences in nascent
polypeptide chains (Nissen et al., 2000). Although this general
‘‘nonstick’’ characteristic of the exit tunnel may hold for the
majority of polypeptides being synthesized by the ribosome,
growing evidence indicates that particular nascent chain
sequences interact with the ribosomal tunnel during their egres-
sion (Becker et al., 2009; Bhushan et al., 2010; Cruz-Vera et al.,
2005; Cruz-Vera and Yanofsky, 2008; Gong and Yanofsky, 2002;
Kosolapov and Deutsch, 2009; Lawrence et al., 2008; Lu and
Deutsch, 2005a, 2005b, 2008; Nakatogawa and Ito, 2002; Seid-
elt et al., 2009; Tenson and Ehrenberg, 2002; Vazquez-Laslop
et al., 2008; Woolhead et al., 2004). Here, we have utilized mac-
rolide antibiotics to direct amino acid and peptide sequences to
bind and interact with the ribosomal tunnel. Our results indicate
that specific amino acid and peptide sequences can indeed
establish distinct interactions with components of the ribosomal
tunnel, such as stacking interactions between the backbone and
aromatic moieties with nucleotide A2062 of the 23S rRNA. A2062
is a universally conserved nucleotide that appears to adopt dif-
ferent conformations within the ribosomal tunnel dependent
upon the functional state of the ribosome. In the crystal structure
of the apo Haloarcula marismortui 50S subunit, A2062 lies flat
against the tunnel wall, whereas when P-site ligands are bound
A2062 shifts position to extend into the lumen of the ribosomal
tunnel (Figure 2B). It appears that A2062 also establishes inter-
action with the nascent polypeptide chains, as observed by
cryo-EM of stalled translating ribosomes (Bhushan et al., 2010;
Seidelt et al., 2009). Mutations of A2062 relieve the translational
arrest resulting during synthesis of the ErmC leader peptide,Ltd All rights reserved
Figure 7. Factors Influencing Macrolide Inhibition
(A) Schematic view of a transverse section through the large ribosomal subunit revealing a P-site tRNA (yellow) attached to a polypeptide chain (orange) in the
tunnel exit. The nucleotide A2062 (blue) has been proposed to interact with some polypeptide chains (Ramu et al., 2009; Vazquez-Laslop et al., 2008).
(B) Tylosin (red) binds within the tunnel where it forms a covalent bond with A2062 of the 23S rRNA and allows only translation of short peptides.
(C) Reducing the C6 ethylaldehyde of tylosin to produce (1) Tyl-H2 prevents the covalent interaction with A2062, reducing the binding affinity and allowing trans-
lation in the presence of the drug.
(D) Addition of amino acids or peptides to the C20 position prevents the covalent interaction with A2062, but establishes new compensatory interaction with the
tunnel that increases the binding affinity and thus allows only translation of short peptides.
(E) OMT (cyan) binds within the tunnel where it forms a covalent bond with A2062 of the 23S rRNA and allows only translation of short peptides of the Fluc protein.
(F) Translation of short pentapeptide sequences confers resistance to macrolide antibiotics, such as erythromycin (Tenson et al., 1996). The peptide is thought to
interact with the drug and remove it from the binding site when the peptide is released from the tRNA (Tenson and Mankin, 2001).
(G) Translation of GFP is not inhibited by OMT (cyan) either because the polypeptide chain removes the drug from its binding site or can pass the drug
undisturbed.
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the nascent chain as it passes through the tunnel (Figure 7A)
(Vazquez-Laslop et al., 2008).
A2062 is also involved in the interaction of 16-membered mac-
rolides, such as tylosin, with the ribosome because it forms
a covalent bond with the drug. Here we show that reducing the
C6-ethyl aldehyde of tylosin (Tyl-H2), which abolishes the poten-
tial to form a covalent linkage with the N6 of A2062, dramatically
reduces the Kd value by >100-fold (Table S1). The corresponding
loss in effectiveness of this antibiotic in translation inhibition is
seen by a reduction in IC50 by >10-fold (Table S1), suggesting
that the nascent polypeptide chain can now expel the drug
from the ribosome (Figure 7C). It should be noted, however,
that the presence of a C6-ethyl aldehyde is not strictly necessary
for efficient binding and potent inhibitory activity because eryth-
romycin has a C6-hydroxyl and thus cannot and does not form
the carbinolamine bond (Tu et al., 2005). The differences in orien-
tation (Hansen et al., 2002; Tu et al., 2005; Wilson et al., 2005)
and kinetics (Petropoulos et al., 2009) of binding between
14-membered macrolides, such as erythromycin, and 16-
membered macrolides, such as tylosin, seems to obviate the
C6-ethyl aldehyde in the former case. It would be interesting in
the future to analyze the characteristics of C6-ethyl aldehyde
containing 14-membered macrolides, with respect to bindingChemistry & Biology 17,modes, kinetics, and formation of the carbinolamine interaction
with A2062. Nevertheless, we could show that the loss of the
covalent bond can be compensated for by addition of amino
acid or peptide side chains to the C6(C23) position of the drug
(Figure 7D). On the basis of the observation that (2) Tyl-A2 stacks
upon the nucleobase of A2062 (Figures 3E and 7D), a series of
compounds was designed to explore different modes of interac-
tions with this region of the ribosome, culminating in a series of
compounds—(6) Tyl-Tyr, (7) Tyl-Car, (8) Tyl-Phe, (9) Des-Phe,
and (10) OMT-Phe—that were similar or better inhibitors of trans-
lation compared to tylosin (Figure 4; Table S1). These results also
demonstrate the potential to use the ribosome antibiotic struc-
tures as a basis for rational design of novel derivatives of antimi-
crobial agents.
One observation with respect to many of the macrolide-
peptide derivatives is the lack of correlation between the Kd
and IC50 values, namely that all of the macrolide-peptide deriva-
tives are less effective at competing erythromycin from the ribo-
some than are tylosin, but are relatively better inhibitors of trans-
lation. This suggests that the binding affinity per se does not
solely determine the effectiveness of the compound and that
the C20-side chains contribute an additional factor, perhaps by
sterically blocking the path of the nascent polypeptide chain
(Figure 7D). The most dramatic example of this is seen for504–514, May 28, 2010 ª2010 Elsevier Ltd All rights reserved 511
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lower than that of (10) OMT-Phe (Table S1), yet (10) OMT-Phe
is a vastly superior inhibitor of GFP synthesis (Figure 4E). The
ability of OMT and the peptide-OMT derivatives, (11) BocAAF-
OMT and (12) fMLF-OMT to restore translation in the presence
of inhibitory concentrations of erythromycin or tylosin (Figures
5C and 5D) is consistent with the binding data (Figures 4D and
5A), supporting the conclusion that these compounds do bind
to the ribosome, and thus are likely to reverse the effect of eryth-
romycin and tylosin by competing the drugs from their binding
site in tunnel.
The lack of effect of OMT on GFP synthesis (Figures 5E and
6A) was surprising because OMT is known to be a potent antimi-
crobial agent that targets the translation machinery (Fu et al.,
2006; Kirst et al., 1988; Mutak et al., 2004). This finding prompted
us to test the effect of macrolides on translation of Fluc, which
we could monitor using luminescence. OMT was found to be a
potent inhibitor of Fluc synthesis (Figure 7E), as was tylosin
(Figure 6A). Similarly, we found differential effects for desmyco-
sin, which was a poor inhibitor of GFP but an excellent inhibitor of
Fluc synthesis (Figure 6A). In contrast, few significant differences
were observed between the inhibition of GFP and Fluc synthesis
by other macrolides, such as tylosin (Figure 6B), erythromycin,
(Figure 6C), nor for other classes of antibiotics, such as chloram-
phenicols and tetracyclines (Figure 6C). We also generated
chimeric Fluc-GFP templates where the first 5–15 amino acids
of Fluc were placed at the N terminus of GFP and vice versa.
Unfortunately, the efficiency of translation of these proteins ap-
peared to be dramatically affected, such that the interpretation
of the results was inconclusive (data not shown).
Collectively, the data suggest that the sequence of the
nascent chain may influence the inhibitory ability of particular
macrolide antibiotics. Precedents for this include the observa-
tion that translation of specific pentapeptides can confer resis-
tance to macrolide antibiotics by chasing the drug from the ribo-
some (Figure 7F). Distinct pentapeptides sequences are specific
for particular macrolide or ketolide members, leading to the
proposal of a direct interaction between the nascent chain and
the drug in the ribosomal tunnel (Lovmar et al., 2006; Tenson
et al., 1996; Tenson and Mankin, 2001; Tenson et al., 1997;
Tripathi et al., 1998; Vimberg et al., 2004). By analogy, we
propose that the GFP nascent polypeptide chain establishes
specific interactions with OMT, leading to its removal from the
ribosome (Figure 7G).
Because macrolide antibiotics cannot bind to and inhibit
translating ribosomes (Contreras and Vazquez, 1977; Tai et al.,
1974), we do not believe that the differential inhibitory effects
of OMT on GFP and Fluc synthesis result from the ability of the
GFP, but not Fluc, nascent polypeptide chain to pass the drug
in the exit tunnel, but we cannot totally exclude this possibility.
Macrolide antibiotics have been shown to allow synthesis of up
to six to eight amino acids before peptidyl-tRNA drop-off occurs
(Tenson et al., 2003). This may hint that the N-terminal six to eight
residues of translating nascent chains, in this case GFP, inter-
acts with drug (OMT) and removes it from the tunnel by con-
tinued translation of the nascent chain (Figure 7G) as suggested
previously (Mankin, 2008), in contrast to drug removal via pep-
tidyl-tRNA hydrolysis, as occurs in the case of the macrolide-
resistance peptides (Figure 7F) (Tenson and Ehrenberg, 2002).512 Chemistry & Biology 17, 504–514, May 28, 2010 ª2010 ElsevierThe proposed model suggests that the translation of a particular
subset of proteins in vivo may not be inhibited by macrolide anti-
biotics, which could potentially provide the cell an additional
regulatory mechanism, for example, to up-regulate relevant
resistance genes. Future works needs to address the ubiquity
of this ‘‘translating nascent chain-mediated macrolide resis-
tance’’ and to determine whether specific consensus sequences
exist for distinct macrolides.EXPERIMENTAL PROCEDURES
Synthesis of Peptide Derivatives of Macrolides
(1) Tyl-H2 was prepared by reduction of Tyl with sodium borohydride (Kirst
et al., 1988). (2) Tyl-A2 and (3) Des-A2 were synthesized as described else-
where (Sumbatyan et al., 2003). (8) Tyl-Phe, (9) Des-Phe, and (10) OMT-Phe
were prepared by analogy with (2) Tyl-A2 and (3) Des-A2 (Sumbatyan et al.,
2003) by the condensation of 2-aminooxyacetylphenylalanyl ethyl ester with
Tyl (Des or OMT) in 0.4 M Na-acetate buffer (pH 4.7) at 50C (Sumbatyan
et al., 2010). (4) Tyl-U and (5) Tyl = Tyr were prepared by coupling of Tyl with
3-(uracyl-1-yl)alanine (or tyrosine) in methanol in the presence of sodium meth-
ylate at room temperature. (5) Tyl = Tyr was reduced with sodium borohydride
to give (6) Tyl-Tyr (Sumbatyan et al., 2010). The compounds were purified by
the column chromatography on silica gel, and their homogeneity and structure
were confirmed by TLC, HPLC, NMR, and mass spectra. BocAAF-OMT and
fMLF-OMT were synthesized as described elsewhere (Korshunova et al.,
2007). (7) Tyl-Car was synthesized starting from tylosin (24 mg, 0.026 mmol,
1 eq.) and carnitine hydrazide (Oka et al., 1963) (8 mg, 0.045 mmol, 1.7 eq.),
which were dissolved in Na-acetate buffer (pH 4.7) (1.5 ml), and the mixture
was stirred for 12 hr at 50C. The crude product was extracted with chloroform
and purified by silica gel column chromatography in chloroform-methanol (3:1,
v/v) system to give (7) Tyl-Car as white crystals: the yield, 42% (11.1 mg, 0.011
mmol); TLC: Rf (CHCl3 - CH3OH, 3:1) 0;7, Rf (CHCl3 - CH3OH – CH3COOH,
6:1:0.1) 0;25, Rf (CHCl3 - CH3OH, 6:1) 0;28, HPLC: tR = 19.7 min (gradient of
CH3CN in 0,1% CF3COOH 0%–60%); MALDI MS: m/z calculated. for
C53H93N4O18 1073.7; found 1070.6; NMR
1H (600 MHz, 303K, DMSO): 0.86
(3H, t, H17), 0.94 (3H, d, H18), 1.08 (3H, d, H5’’CH3), 1.15 (3H, s, H3’’CH3),
1.23 (3H, d, H21), 1.25 (3H, d, H50CH3), 1.28 (3H, d, H5
0’’CH3), 1.58 (1H, m,
H16), 1.65 (2H, m, H4, H2’’), 1.80 (3H, s, H22), 1.82 (4H, m, H7, H16, H2,’’
Ha Car), 1.90 (3H, m, H2, H7, H16), 1.95 (1H, m, H2), 2.48 (6H, 1H, s, m,
N(CH3)3, H3
0 ), 2.77 (2H, m, H6, H19), 2.88 (1H, m, H14), 2.98 (1H, dd, H20’’),
3.13 (m, 4H, H8, H40, H50), 3.38 (1H, m, H20), 3.39 (9H, s, N+(CH3)3
Car), 3.41
(2H, m, H5,’’ H3), 3.44 (3H, s, H20’’OCH3), 3.50 (3H, s, H3
0’’OCH3), 3.52 (3H,
m, Hg Car, H23), 3.61 (3H, m, H30’’, H5, H50’’), 3.80 (1H, m, H23), 4.12 (3H, m,
H10, H4,’’ Hb Car), 4.38 (1H, m, H40’’), 4.47 (1H, d, H10’’), 4.95 (3H, m, H15,
H1,’’ NHCar), 5.82 (1H, d, H13), 6.49 (1H, d, H10), 7.10 (1H, d, H11), 8.16
(1H, s, H20).
In Vitro Transcription-Translation Assay
All coupled transcription-translation experiments were performed using an
E. coli lysate–based system in the presence and absence of antibiotics, as
described elsewhere (Dinos et al., 2004; Starosta et al., 2009; Szaflarski
et al., 2008). Two microliters of each reaction was diluted with 50 mL of buffer
A (10 mM HEPES/KOH [pH 7.8], 10 mM MgCl2, 60 mM NH4Cl, and 4 mM
b-mercaptoethanol), mixed, and then transferred into black 96-well chimney
flat bottom microtiter plates. The GFP fluorescence was either on a Tecan
Infinite M1000 with an excitation wavelength of 395 nm and emission
509 nm, or measured at 520 nm (filter cutoff) with a Typhoon Scanner 9400
(Amersham Bioscience) using a Typhoon blue laser module (excited at
488 nm). Images were then quantified using ImageQuantTL (GE Healthcare)
and were represented graphical using SigmaPlot (Systat Software, Inc.).
Synthesis of firefly luciferase (Fluc) was performed as described above for
GFP, but using pIVEX-2.3MCS with Fluc cloned into the NdeI and SacI restric-
tion sites as a template. After incubation at 30C with shaking for 4–5 hr, 2 mL of
each reaction was added directly to white 96-well chimney flat bottom micro-
titer plates, after which 50 mL of luminol substrate (Promega) was quickly
added, shaken for 3 s, and the luminescence was immediately detected usingLtd All rights reserved
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had a standard deviation of less than 10%.
Binding Assay
Binding of all compounds to empty ribosomes was examined using a compe-
tition assay with radiolabeled [14C]Erythromycin (Perkin Elmer), as described
elsewhere (Karahalios et al., 2006; Petropoulos et al., 2009). Briefly, all
reactions contained 0.25 mM D. radiodurans 70S ribosomes and 1.25 mM
[14C]erythromycin in binding buffer (10 mM HEPES/KOH [pH 7.8], 30 mM
MgCl2, 150 mM NH4Cl, and 6 mM b-mercaptoethanol), which equated with
60% binding from the saturation curve (data not shown). The saturation curve
indicated that 80% of ribosomes were active (data not shown). To measure the
apparent Kd value for each of the compound, reactions were performed in the
absence or presence of increasing concentrations of the competing com-
pounds. After incubation at room temperature for 2 hr, reactions were passed
through nitrocellulose filters, type HA, 0.45 mm pore size (Millipore). Filters were
washed three times with binding buffer and then scintillation counted in the
presence of Filtersafe (Zinsser Analytic) scintillant. All measurements were
repeated in duplicate and had a standard deviation of 5%–10%.
Modeling and Figure Preparation
All chemical structures were drawn with ChemSketch and then were modified
with Adobe Illustrator. Small molecule structures for macrolide-peptide deriv-
atives were generated using ChemSketch. The lactone rings were then
replaced with the lactone ring from D. radiodurans 50S subunit in complex
with (2) Tyl-A2 (Wilson et al., 2005), and the derivative sidechains were
modeled on the basis of the position of the Ala-Ala sidechain of (2) Tyl-A2.
The models of the macrolide-peptide compounds in complex with the large
subunit were then minimized using CNS (Brünger et al., 1998). All 3D structural
figures were produced using PyMol (http://www.pymol.org).
SUPPLEMENTAL INFORMATION
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Most thiopeptide antibiotics target the translational
machinery: thiostrepton (ThS) and nosiheptide (NoS)
target the ribosome and inhibit translation factor
function, whereas GE2270A/T binds to the elongation
factor EF-Tu and prevents ternary complex forma-
tion. We have used several in vitro translational
machinery assays to screen a library of thiopeptide
antibiotic precursor compounds and identified four
families of precursor compounds that are either
themselves inhibitory or are able to relieve the
inhibitory effects of ThS, NoS, or GE2270T. Some of
these precursors represent distinct compounds
with respect to their ability to bind to ribosomes.
The results not only provide insight into the mecha-
nism of action of thiopeptide compounds but also
demonstrate the potential of such assays for identi-
fying lead compounds that might be missed using
conventional inhibitory screening protocols.
INTRODUCTION
The translational machinery represents one of the major targets
within the cell for antibiotics (reviewed by Spahn and Prescott,
1996; Wilson, 2004). Many clinical important classes of antibi-
otics, such as the tetracyclines, phenylpropanoids (chloramphen-
icol), macrolides (erythromycin), and aminoglycosides (genta-
micin), inhibit translation by binding to the ribosome. Despite
the potency of many of these drug classes, antibiotic resistance
among clinically relevant pathogens is an increasing problem
and thus the need for new antibiotics is more urgent than ever
before. One class of antibiotics that has received renewed interest
in recent years is the thiopeptide family (reviewed by Bagley
et al., 2005; Nicolaou et al., 2009) because of their effectiveness
against Gram-positive bacteria, in particular, methicillin-resistant
Staphlococcus aureus, as well as against the malarial parasite
Plasmodium falciparum (McConkey et al., 1997). ThiopeptideChemistry & Biology 16, 1087–1antibiotics are composed of oxazoles and thiazoles, as well as
non-natural amino acids that are linked together to form complex
macrocyclic frameworks (Figures 1A–1D).
Two distinct families of thiopeptide compounds target the
translational apparatus, one that targets the ribosome, referred
to here as Class I thiopeptides, and the other, referred to as
Class II thiopeptides, which targets the elongation factor
EF-Tu. The best characterized of the Class I compounds include
thiostrepton (ThS) and nosiheptide (NoS) (Figures 1A and 1B),
both of which have been crystallized bound to the large ribo-
somal subunit (Harms et al., 2008) (see later Figures 6A, 6B,
and 6G). These structures reveal that the Class I thiopeptides
bind within a region of the ribosome that is part of the GTPase-
associated center, so-named because it is involved in translation
G protein factor binding and stimulation of GTPase activity
(Wilson and Nierhaus, 2005). Biochemically, Class I thiopeptides
have been shown to inhibit 70S initiation complex (70SIC) forma-
tion by interfering with the initiation G protein IF2 (Brandi et al.,
2004, and references therein; Grigoriadou et al., 2007) as well
as elongation by interfering with both the G proteins EF-Tu
(Gale et al., 1981; Gonzalez et al., 2007; Modolell et al., 1971),
which is necessary for rapid cognate aminoacyl-tRNA binding
to the ribosome, and EF-G, which catalyzes translocation of
the tRNA2-mRNA complex from the A and P sites to the P and
E sites (Pan et al., 2007; Pestka, 1970; Rodnina et al., 1999;
Seo et al., 2006; Weisblum and Demohn, 1970). In contrast,
the structurally similar Class II thiopeptides (Figure 1D) do not
bind to the ribosome, but instead interact directly with EF-Tu
(reviewed by Parmeggiani and Nissen, 2006). The crystal struc-
ture of the Class II thiopeptide GE2270A bound to EF-Tu reveals
that the drug binds within a cleft between domains I and II of
EF-Tu and directly overlaps with the binding site of the terminal
end of the aminoacyl-tRNA (Parmeggiani et al., 2006; Parmeg-
giani and Nissen, 2006) (see later Figures 7A–7C). GE2270A is
thought to prevent the closing of domain I and II, which is neces-
sary for the induced-fit binding of EF-Tu to the tRNA, thereby
preventing ternary complex formation (Parmeggiani and Nissen,
2006).
Although ThS is already in veterinary usage, its low water
solubility and poor bioavailability has so far precluded its use in096, October 30, 2009 ª2009 Elsevier Ltd All rights reserved 1087
Chemistry & Biology
Translation Protection AssayFigure 1. Chemical Structures of Thiopeptide Antibiotics and Precursor Families PA–PD
Chemical structures of the thiopeptide antibiotics ThS (A), NoS (B), micrococcin (MiC) (C), and GE2270A/T/C1 (D) and precursor families PA1-5 (E), PB1-3 (F),
PC1-3 (G), and PD1-2 (H).human medicine. Recent success has been reported in the
total synthesis of a number of Class I and II thiopeptides
(reviewed by Hughes and Moody, 2007; Nicolaou et al., 2009),
including among others ThS (Nicolaou et al., 2005a, 2005c)
and GE2270A (Nicolaou et al., 2006, 2008b). Such synthetic
studies pave the way to generating improved thiopeptide
derivatives by identifying synthetic fragments (or derivatives
thereof) that display biological activity or can act as new lead
compounds.
We have used a series of translation machinery assays to
screen a library of thiopeptide antibiotic precursor compounds.
Unlike the parent antibiotics ThS, NoS, and GE2270T, only
a few of the precursor compounds display any significant inhib-
itory properties, even at high concentrations. Instead, however,
four structurally distinct families of precursor compounds
(Figures 1E–1H) were discovered that relieve the inhibitory effect
imparted by the parent compounds. The different precursor
families exhibit differential effects with respect to the inhibitory
antibiotic that is counteracted as well as to the target, whether
it is the ribosome or EF-Tu. Two of the families represent
completely new compounds with respect to their ability to bind
to ribosomes and thus open the path to the development of novel
antimicrobials. The application of such screening strategies will
enable the identification of new lead compounds that are not
detected using conventional inhibitory screening protocols.1088 Chemistry & Biology 16, 1087–1096, October 30, 2009 ª2009RESULTS
Several assays were used to examine thiopeptide precursor
compounds for their abilities to bind to the ThS binding site,
either by mimicking ThS inhibition of specific ribosomal functions
or by protecting the ribosome against the inhibitory effects of
ThS via a competition effect. These assays, which are discussed
in turn below, measure (1) IF2 conformational change during
the conversion of 30S initiation complex (30SIC) to 70SIC, (2)
ribosome-dependent stimulation of the GTPase activity of
EF-G, and (3) the cell-free synthesis of green fluorescent protein
(GFP) using an Escherichia coli in vitro-coupled transcription-
translation (TT) assay.
The Thiopeptide Precursor PA1 Inhibits 70SIC
Formation
The initiation factor IF2 is essential for 70SIC formation from
30SIC and 50S subunits (Antoun et al., 2003; Grigoriadou
et al., 2007). Elsewhere we have shown that the fluorescence
of a Cy3 derivative of IF2 (IF2Cy3) increases on 70SIC formation
resulting from the binding of a 50S subunit to a 30SIC-containing
IF2Cy3 (Qin et al., 2009). This increase is inhibited by both ThS
and NoS (Figure 2A), largely as a result of the effect of these anti-
biotics in inhibiting both the rate and extent of 70SIC formation
(Grigoriadou et al., 2007; data not shown). Measuring the extentElsevier Ltd All rights reserved
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Translation Protection AssayFigure 2. The IF2 Fluorescence Change Assay
(A) Emission spectra of IF2Cy3-containing 30SIC mixed with 50S subunits in the presence of ThS or NoS. 50S was preincubated with antibiotics for 5 min at 37C
and then rapidly mixed with 30SIC at 20C, followed by 5 min incubation before measurements. Black solid trace, no antibiotics; gray dashed trace, ThS; gray
solid trace, NoS; black dashed trace, 30SIC alone. The final concentrations are IF1, IF3, and fMet-tRNAfMet, 0.45 mM; IF2Cy3, 0.15 mM; mRNA, 0.90 mM; 30S, 0.30
mM; 50S, 0.30 mM; GTP, 100 mM; ThS or NoS, 1.5 mM.
(B) Dose-response curves for the inhibition of fluorescence change on mixing IF2Cy3-containing 30SIC with 50S subunits in the presence of thiopeptide
compounds. The y axis indicates the percent DF in the presence of added compound relative to the DF in the absence of added compound relative to the fluo-
rescence of 70SIC by itself. Final concentrations are IF2Cy3, 0.15 mM; IF1, IF3, and fMet-tRNAfMet, 0.45 mM; 022AUGmRNA, 0.9 mM; 30S, 0.30 mM; 50S, 0.30 mM;
GTP, 100 mM.of fluorescence change is thus a convenient way of monitoring
thiopeptide precursor effects on 70SIC formation. A library of thi-
opeptide precursor compounds, as well three forms of the EF-Tu
inhibitor GE2270 (A, T, and C1), were screened for this activity,
along with ThS and NoS as positive controls. Only one precursor,
denoted PA1 (Figure 2B), showed any measurable activity in
inhibiting the fluorescence change, with an apparent Ki of
25 mM, some 60- to 400-fold higher than for ThS or NoS, respec-
tively. Although PA1 does not bind with very high affinity, it
apparently does so with considerable structural specificity, since
the inhibitory effect was not seen for compounds PA2 and PA3,
which have either stereochemical or minor constitutional differ-
ences from PA1 (Figure 1E). The thiopeptide precursors were
also screened for their abilities to reverse ThS inhibition of the
IF2Cy3 fluorescence increase on 70SIC formation. In no case
was such reversal observed.
Differential Effects of Precursor Compounds on Factor-
Dependent GTPase Assays
Vacant 70S ribosomes are known to stimulate the GTPase
activity of EF-G via formation of a 70SEF-GGTP complex.
Such stimulation is strongly inhibited by ThS (Pestka, 1970;
Weisblum and Demohn, 1970). We used two multiple turnover
GTPase assays to screen thiopeptide precursors for inhibitory
activity.
The first assay measured EF-G GTPase activity via formation
of a Malachite Green complex (see Experimental Procedures)
for hundreds of turnovers. Under conditions for which ThS
(1 mM) almost completely abolished such activity, we identified
three distinct classes of precursor compounds (PA–PC; Figures
1E–1G) that exhibited modest inhibitory effects when added at
50 mM (Figure 3A). However, we note that none of these
compounds added at 10 mM showed appreciable inhibition
(data not shown). As expected, the negative control, GE2270T,Chemistry & Biology 16, 1087–had no effect at a concentration of 50 mM (Figure 3A). In order
to determine whether the modest inhibitory effects seen in
Figure 3A were specific for EF-G, we next checked whether
these compounds could also inhibit the ribosome-dependent
stimulation of the Tet(M) GTPase. Tet(M) is a GTPase that binds
to the ribosome analogously to EF-G and confers resistance to
the antibiotic tetracycline by weakening its binding to the ribo-
some (reviewed by Connell et al., 2003). Similar to the results
for EF-G, representatives of the PA and PC families exhibited
modest inhibitory effects on Tet(M) GTPase at high concentra-
tion (100 mM) (Figure 3B). However, in contrast to EF-G, little or
no inhibition was observed for the PB family, suggesting that it
is specific for EF-G.
The second assay measured EF-G GTPase activity from the
fluorescence increase of released Pi binding to the fluorescent
phosphate binding protein MDCC-PBP (Brune et al., 1994;
Seo et al., 2006). This assay, which can in principle be used
for single turnover measurement, was here used to measure
several turnovers, as determined by the stoichiometric ratio
(5:1) of MDCC-PBP to ribosome. As performed, this assay
could only detect very potent inhibitors of EF-G GTPase, since
fluorescence was not measured until 1 min after initiation of
reaction, whereas in the absence of inhibition the full fluores-
cence change is complete within 5–10 s (data not shown). It is
thus no surprise, given the results presented in Figure 3A,
that although ThS inhibited this assay with an apparent Ki of
1.1 mM none of the precursors tested, nor even NoS or MiC,
showed measurable inhibition up to a concentration of 100 mM
(Figure 3C). In contrast, both NoS and MiC added at very low
concentration protected against inhibition by 1.2 mM ThS, with
half-maximal effects seen at 0.04 mM and 0.11 mM, respectively
(Figure 3D). However, none of the precursor compounds
afforded similar protective effects up to 50–100 mM of added
precursor.1096, October 30, 2009 ª2009 Elsevier Ltd All rights reserved 1089
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Translation Protection AssayFigure 3. Effect of Thiopeptides and Precursor Compounds on GTPase Activity of EF-G and Tet(M)
(A) Inhibition of uncoupled ribosome-dependent Tet(M) GTPase by ThS (1 mM) and precursors PA2, PB2, and PC2 (50 mM). Closed circles indicate GTPase activity
of Tet(M) in the absence of antibiotic.
(B) Inhibition of uncoupled ribosome-dependent TetM GTPase by ThS (1 mM) and precursors PA2, PB1, and PC2 (100 mM). Closed circles indicate GTPase activity
of TetM in the absence of antibiotic.
(C) The dose-response curves of Pi release in the presence of ThS, NoS, MiC, or precursor compounds. The y axis indicates the percent DF due to Pi release in the
presence of added compound relative to the DF in the absence of added compound relative to the fluorescence from EF-G interaction with the ribosome in the
absence of any compound. The final concentrations are 70S, 0.3 mM; EF-G, 0.75 mM; MDCC-PBP, 1.5 mM; GTP, 100 mM;7-methylguanine, 200 mM; nucleotide
phosphorylase, 0.3 U/ml.
(D) Dose-response curves for reversal of ThS inhibition of Pi release by NoS, MiC, or precursor compounds. The final concentrations for each component are 70S,
0.3 mM; EF-G, 0.75 mM; ThS, 1.2 mM; MDCC-PBP, 1.5 mM; GTP, 100 mM; 7-methylguanine, 200 mM; nucleotide phosphorylase, 0.3 U/ml.Protective Effects of Precursor Compounds on
Thiopeptide-Mediated Translation Inhibition
Although, as expected, ThS, NoS, and GE2270T were potent
inhibitors of GFP synthesis using an in vitro TT assay (Figure 4,
lanes 2–4), none of the precursor compounds tested displayed
any significant inhibitory activity in this assay (Figure 4, white
bars), even at high concentrations (50–100 mM). In contrast,
addition of 50 mM of representative precursor compounds from
four structural distinct classes PA–PD (Figures 1E–1G) could
reverse the inhibitory effect of 5 mM ThS (Figure 4, gray bars).
The most effective protection was seen with PA2, which restored
translation back to levels observed in the absence of antibiotic
(Figure 4, lane 6). In comparison, PB1, PC1, and PD1 restored
translation to 40%–60% of the original levels (Figure 4, lanes
13–28). Additionally, we find that the 5S, 6R stereoisomer of
PA2 (PA4) exhibited some protective properties (35%
compared to 100% for PA2). The structural specificity of these
effects is clear from the failure of precursors that are chemically
related to PA2 to exhibit similar protective effects against ThS
inhibition. These include PA3 (Figure 4, lanes 6 and 8), which
differs from PA2 by lacking only a double bond within the central1090 Chemistry & Biology 16, 1087–1096, October 30, 2009 ª2009dehydropiperidine ring (Figure 1E), and PD2 (Figure 4, lanes 26
and 28), which, with respect to PD1, has an altered side chain
on one of the thiazole rings (Figure 1H).
Interestingly, PA2, PB1, PC1, and PD1 displayed marked
differences in their abilities to reverse the inhibitory effects of
NoS (5 mM) and GE2270T (25 mM), as compared to the inhibitory
effects of ThS. Thus, as shown in Figure 5, PA2 was an omnipo-
tent protector of translation, restoring translation levels in the
presence of all three thiopeptide inhibitors, with the following
order of efficiency: ThS (100%) > GE2270T (80%) > NoS (60%).
PD1 rescued translation in the presence of ThS and GE2270T,
but not NoS, and PB1 and PC1 efficiently rescued translation
only against ThS. As was true for ThS, neither PA3, PB2, PC2,
nor PD2 were able to reverse inhibition by NoS or GE2270T
(data not shown).
Interaction of Thiopeptide Precursors
with the Ribosome
The specific protective effect of the precursor compounds
against ThS suggests that these compounds specifically com-
pete with ThS for binding to the ribosome. Structural (HarmsElsevier Ltd All rights reserved
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Translation Protection AssayFigure 4. Precursor Compounds Protect Translation from ThS Inhibition
In vitro TT of GFP in the absence or presence of 25 mM GE2270T, 5 mM NoS, and 5 mM ThS (black bars) or in the presence (50 mM) of precursor families PA2-5,
PB1-3, PC1-3, and PD1-2 (ThS; white bars) alone or with additional presence of 5 mM ThS (+ThS; gray bars). GFP fluorescence from microtiter plate wells shown
above each lane were quantified and represented as bars, with the fluorescence detected in the absence of antibiotic assigned as 100%.et al., 2008; Jonker et al., 2007) and biochemical data (Spahn
and Prescott, 1996; Xing and Draper, 1996) for ThS suggests
that the high affinity of this drug for the ribosome results
from cooperative interaction between nucleotides in H43/44 of
the 23S rRNA and the L11-NTD (Figures 6A and 6B). Given
the structural similarity between PA2 and ThS, it is possible to
model the position of this compound bound to the ribosome
(Figure 6C; Harms et al., 2008). The substitution of the double
bond in the piperidine ring of PA2 to generate PA3 abolishes
the protective effect of the compound (Figure 4). This is likely
to result from differences in the planarity of the piperidine ring
between PA3 and PA2, which in turn leads to differences in
the relative position (by 0.5 Å) of the attached thiazole moiety,
which, based on the model, would shift it toward Pro27 of L11-
NTD and thus encroach on the thiopeptide binding site (data
not shown). Such modest displacements within drug binding
sites have been shown to have dramatic effects on the affinity
of compounds and often lead to antibiotic resistance (Blaha
et al., 2008; Tu et al., 2005).
Although it is more difficult to model the PB and PC series of
compounds based on the available structures, it is clear that
the aromatic rings within these families suggest a potential
mode of binding that establishes simultaneous stacking interac-
tions with both H43/44 and L11-NTD (Figures 6D and 6E). Alter-
ations that disrupt these rings, as seen for PC2 (Figure 6F), could
explain a reduced binding and corresponding loss in protection
(Figure 4). The PD class of precursors is structurally most similar
to the pyridine core of NoS (Figure 1). NoS is oriented differently
on the ribosome compared to ThS, establishing stacking interac-Chemistry & Biology 16, 1087–tions with Pro22 but not Pro26 (Figure 6G; Harms et al., 2008).
Based on our modeling, PD1 can make analogous interactions
with Pro22 as NoS (Figure 6H), whereas the inactive PD2 cannot
(Figure 6I).
Figure 5. Differential Protective Effects of Precursors Against Thio-
peptide Inhibition
Protection profiles of representative precursors from all described groups
against chloramphenicol (Cam; 10 mM), NoS (5 mM), GE2270T (25 mM), and
ThS (5 mM). GFP fluorescence in the absence of antibiotic is assigned as
100%, whereas the precursor results are presented as the percentage of
protection, given as the difference between the inhibition of translation by
the active compound (Cam, NoS, GE2270T, or ThS) in the presence and
absence of the precursor compound (50 mM).1096, October 30, 2009 ª2009 Elsevier Ltd All rights reserved 1091
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Translation Protection AssayFigure 6. Binding Site of Precursor Compounds on the Ribosome
(A) Overview of thiopeptide binding site on the large ribosomal subunit. Interface view with helix 43 and 44 (H43/44; orange), L11 (yellow), and ThS (green) high-
lighted with surface representation (from PDB ID 3CF5) (Harms et al., 2008).
(B) The thiazole rings of ThS (green) interact with the RNA bases at the tips of H43/44 as well as the prolines in the N-terminal domain of L11 (yellow).
(C) Model for precursor PA2 bound to the ribosome, based on the position of ThS. PA1, but not PA3 (see text), bind similarly.
(D–F) Possible modes of binding for precursors PB1 and PC1 based on ring stacking interactions with RNA and protein components of the ribosome, whereas
PC2 lacks one phenyl ring compared to PC1.
(G) NoS (pink) interacts with the RNA bases at the tips of H43/44 as well as the N-terminal domain of L11 (yellow), but in a distinct manner compared to ThS (using
PDB ID 2ZJP) (Harms et al., 2008).
(H and I) Model for precursor PD1 and PD2 bound to the ribosome, based on the position of NoS. PD2 lacks one ring moiety, suggesting binding would be desta-
bilized.Interaction of Thiopeptide Precursors with EF-Tu
The thiopeptide GE2270A has been crystallized in complex with
EF-Tu, revealing that the drug binds within a covered groove in
domain II and spans across the active site cleft of EF-Tu, the
G domain, to interact with the domain I (Figure 7A; Parmeggiani
et al., 2006). GE2270A overlaps the binding site of the terminal
A76 and aminoacyl moiety of the tRNA (Figure 7B) and is
believed to prevent the closing of domains I and II necessary
for the induced fit binding of aa-tRNA (Figure 7C), thereby
preventing ternary complex (EF-TuGTPtRNA) formation
(reviewed by Parmeggiani and Nissen, 2006). The structural simi-
larities between PA and PD and GE2270A (Figure 1) suggest that
these compounds would also bind within the groove of domain II
of EF-Tu (Figure 7D) and overlap with the A76 of the tRNA
(Figure 7E). However, the truncated nature of these compounds
prevents them from establishing additional interactions with1092 Chemistry & Biology 16, 1087–1096, October 30, 2009 ª2009domain I, even in the closed tRNA-bound ternary complex state
of EF-Tu (Figure 7F).
DISCUSSION
Development of improved antimicrobial agents will be necessary
to combat the prevalence of multi-drug-resistant bacteria. A
number of biochemical approaches have been taken to identify
functionally important hotspots on the ribosome that do not
overlap with previously known antibiotic binding sites (Laios
et al., 2004; Llano-Sotelo et al., 2009b; Yassin et al., 2005; Yassin
and Mankin, 2007). In addition, a recent study has developed an
assay using fluorescently labeled ribosomal proteins to monitor
binding of small molecules, such as antibiotics, to the ribosome,
which is amenable to high-throughput screening (Llano-Sotelo
et al., 2009a). Here we present several translation-related assaysElsevier Ltd All rights reserved
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Translation Protection AssayFigure 7. Binding Site of Precursor Compounds on EF-Tu
(A) Structure of the thiopeptide GE2270A (green) bound to EF-Tu (yellow), with domains I, II, and III indicated (PDB ID 2C77) (Parmeggiani et al., 2006).
(B) GE2270A overlaps the binding position on EF-Tu of the terminal A76 and aminoacyl moiety of tRNA. Inset shows overview of EF-TutRNA ternary complex
(PDB ID 1TTT) (Nissen et al., 1995) with superimposition of GE2270A.
(C) Superimposition of EF-TuGE2270A (yellow) and EF-TutRNA (blue) aligned on basis of domain II. Note that GE2270A (green) clashes with domain I of EF-Tu
from the ternary complex (blue).
(D) Model for precursor PD1 bound to EF-Tu based on EF-TuGE2270A complex (PDB ID 2C77) (Parmeggiani et al., 2006).
(E) PD1 (pink) overlaps the binding position on EF-Tu of the terminal A76 and aminoacyl moiety of tRNA (blue).
(F) As (C) but with PD1 instead of GE2270A. Note that PD1 does not clash with domain I of EF-Tu from the ternary complex (blue).using high-throughput 96 or 384 microtiter plate formats that
have been used to screen a library of thiopeptide precursor
compounds for their abilities to inhibit one or more aspects of
translation and/or reverse the inhibition of known thiopeptide
antibiotics. These screens identified four distinct families of pre-
cursor compounds, termed PA–PD, which could act as potential
lead compounds for development of novel antimicrobials.
Two of the families identified, PA and PD, contain a six-
membered nitrogen heterocycle core (PA, dehydropiperidine;
PD, pyridine) analogous to the thiopeptide antibiotics ThS and
GE2270A (Figure 1). The crystal structures of thiopeptides bound
to the ribosome (Harms et al., 2008) and of GE2270A bound to
EF-Tu (Parmeggiani et al., 2006) reveal the importance of the
heterocycle core of these compounds for interaction with their
respective targets and allows modeling of how PA and PD
members are likely to interact with the ribosome and/or EF-Tu
(Figures 5 and 6). The resulting models are consistent with the
rescue of translation in the presence of ThS and GE2270T by
family members, such as PA2 and PD2, probably by direct
competition for binding between the precursor compound and
the thiopeptide antibiotic. In addition, PA1 and PA2 displayed
inhibitory activity against translational GTPases IF2 (Figure 2B)
and EF-G and Tet(M) (Figures 3A and 3B), respectively.
However, compared to the parent thiopeptide compounds,
much higher concentrations of the precursor compounds were
necessary to exhibit similar effects, most likely indicating theChemistry & Biology 16, 1087–much lower binding affinity of the precursors. The ineffective-
ness of precursor compound PA2 as a direct inhibitor was
surprising, since this compound has been previously reported
to exhibit antimicrobial activity against methicillin-resistant
Staphlococcus aureus and vancomycin-resistant Enterococcus
faecalis with a minimal inhibitory concentration (MIC) of 5 mM
(Nicolaou et al., 2005b). Our results suggest therefore that
the inhibitory effect of PA2 in vivo may in fact not be related to
translation, but verification of this point will require further
investigation.
The other two families identified in our screen, PB and PC,
have not, to our knowledge, been previously reported to target
the translational machinery. PB1 is chemically similar to the thia-
zolidine precursor compound used to generate the pyridine core
of amythiamicins (Nicolaou et al., 2008a), which target EF-Tu
analogously to GE2270A (Parmeggiani et al., 2006; Parmeggiani
and Nissen, 2006). The PC series of compounds contain a pro-
tected b-hydroxy-a-aminoacid, which is a precursor in the
synthesis of GE2270A/T/C1. Curiously, the PB and PC families
display much higher specificity for the ribosome than for
EF-Tu, as shown by the ability of PB1 and PC1 to restore trans-
lation more efficiently in the presence of ThS, as compared with
GE2270A (Figure 5). Although PB1 and PC1 are structurally
distinct (Figure 1), we believe the common aromatic/cyclic
nature of both these compounds is important for ribosome
binding. Accommodation of EF-G on the ribosome involves the1096, October 30, 2009 ª2009 Elsevier Ltd All rights reserved 1093
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Translation Protection Assayinsertion of domain V of EF-G into the crevice between H43/44
and L11-NTD. Inhibition by Class I thiopeptides has been
proposed to stem in part from their physically linking L11-NTD
to H43/44, thereby locking the cleft shut (Harms et al., 2008).
We suggest that PB1 and PC1 can also span the L11-rRNA
crevice (Figures 6D and 6E) and perform this locking function,
analogous to ThS/PA2 (Figures 6B and 6C) and NoS/PD1
(Figures 6G and 6H). Similarly to PA/D, the high concentrations
of PB/C required to inhibit the ribosome-dependent GTPase
activity of EF-G are indicative of their low binding affinities for
the ribosome. Such low affinity may allow facile displacement
of precursors from the ribosome, as a result of translation factors
(IF2 or EF-G) binding, or from EF-Tu, during ternary complex
formation, thus explaining the absence of any direct inhibitory
effect of any of the precursors on GFP synthesis. The differential
effects of the precursors on the GTPase assays compared to
the TT assay is probably related to the ribosome concentrations
in the GTPase assays being 103–1003 less (30–300 nM)
compared to the TT assay (2 mM) and to the putative higher
affinity of EF-G for translating rather than empty ribosomes
(Sergiev et al., 2005).
The majority of clinically used antibiotics targeting the ribo-
some bind either to the decoding region on the small subunit
or within either the peptidyltransferase center or the adjacent
peptide exit tunnel of the large subunit, where they interact
almost exclusively with ribosomal RNA (Spahn and Prescott,
1996; Wilson, 2004). The Class I thiopeptide compounds,
however, are distinct in that they target a different region of the
ribosome, namely the GTPase-associated region or translation
factor binding site, where they interact with both rRNA and ribo-
somal protein L11. As a consequence, no cross-resistance has
been found between thiopeptide antibiotics and other clinically
important drugs. The compounds such as PA–PD identified in
our study provide lead structures for the development of novel
antimicrobial agents that target this region of the ribosome.
Furthermore, the ability of some precursor compounds, such
as PA1 and PD1, to bind both EF-Tu and the ribosome suggests
the feasibility of developing antimicrobials that are dual inhibitors
of ribosomes and ternary complex formation.
SIGNIFICANCE
The translational machinery represents one of the major
targets within the cell for antibiotics, with many clinical
important classes of antibiotics inhibiting translation by
binding to the ribosome. Despite the potency of many of
these drug classes, antibiotic resistance among clinically
relevant pathogens is an increasing problem and there is
an urgent need for improved antibiotics. We present herein
a series of translation machinery assays that can be used
to screen for lead compounds that not only inhibit specific
steps of translation but also relieve the inhibitory effects of
other inhibitory compounds. Using these assays to screen
a library of thiopeptide precursor compounds, we have iden-
tified four distinct families of compounds that inhibit either
IF2, EF-G, and/or Tet(M), as well as confer protective effects
against thiopeptide translation inhibitors of both the ribo-
some and EF-Tu. Our findings not only elucidate the mecha-
nism of action of thiopeptide compounds but also illustrate1094 Chemistry & Biology 16, 1087–1096, October 30, 2009 ª2009the potential of such high-throughput assays to identify
distinct lead compounds that might be missed using
conventional inhibitory screening protocols. Whereas the
IF2 and EF-G GTPase assays are specifically useful for
screening antibiotics interfering with translation G factor
proteins, the TT assay is generally applicable for screening
all classes of translation inhibitors, including those targeting
the peptidyltransferase, and decoding centers of the ribo-
some and other ribosomal sites, in addition to those inter-
fering with translation G factor proteins.
EXPERIMENTAL PROCEDURES
Component Preparation
GE2270A, T, and C1 and the library of thiopeptide precursor compounds were
synthesized as described previously (Nicolaou et al., 2005b, 2006, 2008a,
2008b). ThS was purchased from Sigma, whereas NoS was a gift from
H.G. Floss and micrococcin P1 was supplied by T. Stachlhaus. The tetM
gene (Tn916) cloned into the pET24b vector was a gift from V. Burdett.
Tet(M) protein was expressed in BL21 (DE3) pRIL cells in 20C with 0.2 mM
IPTG. E. coli EF-G cloned into pQE70 vector was expressed in XL1 blue cells.
Both proteins were purified using Ni-NTA metal affinity chromatography
(QIAGEN), followed by gel filtration chromatography on a HiLoad 26/60 Super-
dex 75 prep grade column (GE Healthcare). For the experiments described in
Figures 2 and 3C and 3D, ribosomes, IF2Cy3, IF1, IF3, 30S subunits, MDCC-
labeled phosphate-binding protein (MDCC-PBP), 022AUG mRNA, and fMet-
tRNAfMet were prepared as described previously (Qin et al., 2009) as was
EF-G (Pan et al., 2007).
IF2Cy3 Fluorescence Change Assay
Reactions were carried out in a 384 well assay plate. 50S subunits were pre-
incubated (15 min at 37C) with a series of concentrations of the test
compounds in DMSO that are transferred from a premade compound plate
to the assay plate by a PerkinElmer Evolution P3 liquid handler. Reaction
was initiated by addition of 30SIC to each well of the plate. Fluorescence
(579 nm) was read with a 2103 EnVision Multilabel Plate Reader on excitation
at 550 nm. For the reversal experiment, 30SIC was preincubated with ThS
(10 min at 37C), followed by a second preincubation with test compounds
(10 min at 37C), and reaction was initiated by 50S addition.
GTPase Activity Assays
For both assays described below, reactions performed in the absence of ribo-
somes were used as a background signal to account for the intrinsic GTPase
activity of EF-G or Tet(M).
By Malachite Green
GTPase activity was measured using the Malachite Green Phosphate Kit
(BioAssay) that quantifies the green complex formed between Malachite
Green, molybdate, and free orthophosphate. All reactions contained 30 nM
E. coli 70S ribosomes, 20 mM GTP, and 60 nM protein in the presence or
absence of antibiotics as necessary. Reactions were transferred into 96 well
microtiter plates and color formation was measured on Tecan Infinite M1000
microplate reader at 650 nm.
By MDCC-Labeled PBP
GTPase activity was measured using the MDCC-labeled PBP complex, which
measures free phosphate release as an increase in fluorescence and uses
a Pi-MOP system to minimize the background due to phosphate present in
the original medium (Brune et al., 1994; Seo et al., 2006). Reactions were
carried out in a 384 well assay plate. Ribosomes were preincubated (15 min
at 37C) with a series of concentrations of the test compounds in DMSO
that are transferred from a premade compound plate to the assay plate by
a PerkinElmer Evolution P3 liquid handler. Reaction was initiated by addition
of an ice-cold solution containing EF-G, MDCC-PBP, and GTP to each
well of the plate, a process that was completed in under 30 s. Fluorescence
(450 nm) was read within 1 min using a 2103 EnVision Multilabel Plate Reader,
on excitation at 405 nm. For the reversal experiment, ribosomes were preincu-
bated with ThS (10 min at 37C), followed by a second preincubation with testElsevier Ltd All rights reserved
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Translation Protection Assaycompounds (10 min at 37C), and reaction was initiated by EF-G, MDCC-PBP,
and GTP as above.
In Vitro Transcription-Translation Assay
All coupled TT experiments were performed using an E. coli lysate-based
system in the presence and absence of antibiotics as described previously
(Dinos et al., 2004; Szaflarski et al., 2008). Reactions were transferred into
96 well microtiter plates and the GFP fluorescence was measured with
a Typhoon Scanner 9400 (GE Healthcare) using a Typhoon blue laser module
(GE Healthcare). Images were then quantified using ImageQuantTL (GE Health-
care) and represented graphically using SigmaPlot (Systat Software, Inc.).
Modeling and Figure Preparation
Chemical structures for the precursor compounds were drawn and converted
to 3D coordinates using ChemDraw (Advanced Chemistry Development, Inc.).
PA2 models used the ThS binding position on the Deinococcus radiodurans
50S (D50S) subunit (PDB ID 3CF5) (Harms et al., 2008), whereas PD1 and
PD2 were based on the D50S-NoS complex (PDB ID 2ZJP) (Harms et al.,
2008). PyMol (http://www.pymol.org) was used to model the PB1 and PC
compounds, align EF-TuGE2270A (yellow; PDB ID 2C77) (Parmeggiani
et al., 2006) and EF-TutRNA (blue; PDB ID 1TTT) (Nissen et al., 1995) on
the basis of domain II, as well as to prepare all X-ray structure figures.
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The ribosome is a major target in the bacterial cell for
antibiotics. Here, we dissect the effects that the
thiopeptide antibiotics thiostrepton (ThS) and micro-
coccin (MiC) as well as the orthosomycin antibiotic
evernimicin (Evn) have on translational GTPases.
We demonstrate that, like ThS, MiC is a translocation
inhibitor, and that the activation by MiC of the ribo-
some-dependent GTPase activity of EF-G is depen-
dent on the presence of the ribosomal proteins L7/
L12 as well as the G0 subdomain of EF-G. In contrast,
Evn does not inhibit translocation but is a potent
inhibitor of back-translocation as well as IF2-depen-
dent 70S-initiation complex formation. Collectively,
these results shed insight not only into fundamental
aspects of translation but also into the unappreci-
ated specificities of these classes of translational
inhibitors.
INTRODUCTION
Protein synthesis occurs on large macromolecular particles
called ribosomes, which are composed of RNA and protein. In
bacteria the 70S ribosome can be split into a small (30S) and
large (50S) subunit. The bacterial translational machinery repre-
sents a major target within the cell for antibiotics (reviewed by
Blanchard et al., 2010; Wilson, 2009). Many clinically important
classes of antibiotics inhibit translation by binding to the active
centers of ribosome. For example the tetracyclines and amino-
glycosides bind at the decoding site on the small subunit, and
the chloramphenicols, macrolides/ketolides, oxazolidinones,
and lincosamides bind at the peptidyltransferase center (PTC)
on the large subunit (Sohmen et al., 2009a, 2009b). Despite the
potency of many of these drug classes, antibiotic resistance
among clinically relevant pathogens is an increasing problem,
and thus, the need for new antibiotics is more urgent than ever
before. Ideally, the new antibiotics should have nonoverlapping
sites with the currently used antimicrobial agents, so that theChemistry & Biology 18,occurrence of cross-resistance is reduced or prevented. Two
such classes are the thiopeptides and orthosomycins (Figures
1A–1C), which bind to distinct sites on the large ribosomal
subunit that are located far from the PTC (Figures 1D and 1E).
The orthosomycins, such as evernimicin (Evn), are oligosac-
charide antibiotics (Figure 1A) that display excellent antimicro-
bial activity against a broad range of Gram-positive bacteria,
both in vivo and in vitro. Although attempts to introduce Evn clin-
ically as Ziracin (Schering-Plough) were unsuccessful, a related
compound, avilamycin (Avn), is used as a growth promoter in
animal feeding. A multitude of resistance mutation/modification
and chemical footprinting studies indicate that the orthosomy-
cin-binding site is located at the base of the L7/L12 stalk (Figures
1D and 1E), 50 Å from the PTC. Mutations in ribosomal protein
L16 (Aarestrup and Jensen, 2000; Adrian et al., 2000b; McNicho-
las et al., 2001; Zarazaga et al., 2002), and in helix 89 (H89) and
H91 of the 23S rRNA, as well as methylation of G2470 (E. coli
numbering used throughout) in H89 (Mann et al., 2001), confer
resistance to Evn and Avn (Adrian et al., 2000a; Belova
et al., 2001). In addition, Evn and Avn protect 23S rRNA nucleo-
tides, e.g., A2482 in H89 and A2534 in H91, from chemical modi-
fication (Belova et al., 2001; Kofoed and Vester, 2002). It is also
noteworthy that mutations in rplP (L16 gene) confer relatively
low-level resistance (MIC <12 mg ml1), whereas higher-level
resistance (MIC >256 mg ml1) is obtained by EmtA-mediated
methylation or rRNA mutations (Belova et al., 2001; Mann
et al., 2001). Taken together, these results suggest that the
orthosomycin-binding site spans from the minor groove of H89
to the loop region of H91 (Figure 1E) and that mutations in L16
confer resistance indirectly via perturbation of the 23S rRNA.
In agreement with this novel location, Evn does not inhibit
peptide-bond formation (Belova et al., 2001) or compete
with several other ribosomal antibiotics for ribosome binding
(McNicholas et al., 2000). Although some effect of Avn on
aa-tRNA binding to ribosomes has been observed (Wolf,
1973), Evn is better known as an initiation inhibitor; Evn inhibits
the formation of fMet-puromycin in an IF2-dependent manner
(Belova et al., 2001), although the exact step of inhibition remains
unclear. Moreover, to our knowledge, the effects of orthosomy-
cins on translation factors other than IF2 and EF-Tu have not yet
been addressed.589–600, May 27, 2011 ª2011 Elsevier Ltd All rights reserved 589
Figure 1. Chemical Structures and Ribosomal-Binding Sites of Thiopeptide and Orthosomycin Antibiotics
(A–C) Chemical structures of the (A) orthosomycin Evn, and the thiopeptide antibiotics (B) ThS and (C) MiC.
(D) Overview of the binding sites of orthosomycins and thiopeptides on the large subunit relative to EF-G. R-proteins L1, L11, and L7 are shown for reference.
(E) Putative binding site of orthosomycins spanning from H89 and H91 of the 23S rRNA. Residues highlighted in red have been associated biochemically with Evn
or Avn (reviewed by Wilson, 2009).
(F) Binding site of ThS (green) in the cleft between H43 and H44 of the 23S rRNA and the NTD of L11 (L11-ThS) (Harms et al., 2008). The relative positions of EF-G
(blue), C-terminal domain of L7/L12 (L7-CTD), and of a different conformation of L11 (L11-EF-G) are from Gao et al. (2009).
(G) Overview of domain arrangement of EF-G with contact between the L7-CTD and the G0 domain of EF-G as observed in the 70S-EF-G crystal structure (Gao
et al., 2009).
(H) Expansion of (G) highlighting the secondary structure elements of the G0 subdomain.
(I) Juxtaposition of the G0 subdomain of EF-G (gray transparency) with the G-domain of EF4 (orange) (Evans et al., 2008) that lacks a G0 subdomain.
See also Figure S1.
Chemistry & Biology
Thiopeptide and Orthosomycin Action on RibosomesIn contrast, thiopeptides, such as thiostrepton (ThS), have
been extensively studied (reviewed by Bagley et al., 2005;
Nicolaou et al., 2009; Wilson, 2009). Although ThS is already in
veterinary usage, its low water solubility and poor bioavailability
has so far precluded its use in human medicine. Nevertheless,
the thiopeptide class of antibiotics has received renewed
interest in the recent years because (i) of its effectiveness
against Gram-positive bacteria, in particular, methicillin-resistant
Staphylococcus aureus (MRSA), and against the malarial parasite
Plasmodium falciparum (McConkey et al., 1997), as well as (ii)590 Chemistry & Biology 18, 589–600, May 27, 2011 ª2011 Elsevierrecent successes in the total synthesis of a number of thiopepti-
des (reviewed by Hughes and Moody, 2007; Nicolaou et al.,
2009), including among others, ThS (Nicolaou et al., 2005a,
2005b) and micrococcin (MiC) (Lefranc and Ciufolini, 2009).
Thiopeptide antibiotics, such as ThS and MiC, are composed of
oxazoles and thiazoles, as well as nonnatural amino acids that
are linked together to form complex macrocyclic frameworks
(Figures 1B and 1C).
Both ThS and MiC have been crystallized in complex with the
large ribosomal subunit, revealing their binding site to be locatedLtd All rights reserved
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Thiopeptide and Orthosomycin Action on Ribosomesin a cleft formed by the N-terminal domain (NTD) of ribosomal
protein L11 and H43/H44 of the 23S rRNA (Figures 1D and 1F)
(Harms et al., 2008), consistent with a vast wealth of prior
biochemical studies (reviewed by Wilson, 2009). This region is
part of the GTPase-associated center (GAC), so named because
it is involved in binding of translation factors and stimulation of
their GTPase activities. Consistently, thiopeptide antibiotics
have been shown to inhibit IF2-dependent 70S-initiation
complex (70SIC) formation (Brandi et al., 2004; Grigoriadou
et al., 2007), EF-Tu-dependent delivery of aminoacyl-tRNAs to
the ribosome (Brandi et al., 2004; Gonzalez et al., 2007; Modolell
et al., 1971; Otaka and Kaji, 1974), translocation of the tRNA2-
mRNA complex through the ribosome (Munro et al., 2010; Pan
et al., 2007; Pestka, 1970; Pestka and Brot, 1971; Rodnina
et al., 1997), and stringent factor RelA-dependent synthesis of
ppGpp (Cundliffe and Thompson, 1981; Knutsson Jenvert and
Holmberg Schiavone, 2005). Surprisingly, however, ThS and
MiC exhibit differential effects on the uncoupled ribosome-
dependent EF-G GTPase activities: ThS strongly inhibits
multiple-turnover GTP hydrolysis of EF-G (Pestka, 1970; Weis-
blum and Demohn, 1970) by preventing inorganic phosphate
(Pi) release and, thus, trapping EF-G on the ribosome (Rodnina
et al., 1999; Seo et al., 2006). The overlap between the ThS
and EF-G binding sites on the ribosome (Figures 1D and 1F)
(Harms et al., 2008) suggests that ThS stabilizes an initial binding
state of EF-G (Rodnina et al., 1999; Seo et al., 2006), which has
weaker affinity than a subsequently formed, accommodated
state (Cameron et al., 2002; Seo et al., 2006). In contrast, MiC
does not prevent Pi release (Starosta et al., 2009) and actually
stimulates the multiple-turnover GTP hydrolysis activity of EF-
G (Cameron et al., 2002; Cundliffe and Thompson, 1981; Lentzen
et al., 2003).
The G domains of translational GTPases have a well-
conserved architecture, with the exception of a region located
between the G4 and G5 motifs, which, in EF-G, are termed the
G0 subdomain (see Figure S1 available online). In EF-G the G0
subdomain consists of 90 amino acids that form four consec-
utive b strands (2G–5G) followed by three a helices (AG–CG)
(Figures 1G and 1H; Figure S1). In contrast, translational
GTPases, such as elongation factor EF-Tu, initiation factor IF2,
the ribosome-associated stress response factor BipA (deLivron
et al., 2009; deLivron and Robinson, 2008; Owens et al., 2004),
and the back-translocation factor LepA (EF4) (Liu et al., 2010;
Qin et al., 2006), are completely lacking the G0 subdomain (Fig-
ure 1I), whereas the ribosomal protection protein TetM (Connell
et al., 2003a) has a partial G0 subdomain, lacking three b strands
(3G–5G) (Figure S1). Interaction of the G
0 subdomain of EF-G with
the C-terminal domain of ribosomal protein L7/L12 (L7-CTD) is
observed structurally (Connell et al., 2007; Datta et al., 2005;
Gao et al., 2009; Harms et al., 2008; Helgstrand et al., 2007)
(Figures 1G and 1H) and is required for efficient GTP hydrolysis
(Diaconu et al., 2005; Nechifor et al., 2007; Savelsbergh et al.,
2000, 2005) and Pi release (Diaconu et al., 2005; Savelsbergh
et al., 2005), leading to the suggestion that enhanced recycling
of EF-G by MiC results from stabilization of this interaction
(Harms et al., 2008).
Here, we show that although MiC stimulates the multiple-turn-
over ribosome-dependent EF-G GTPase, it inhibits the GTPase
activities of other translational GTPases, such as TetM, EF4,Chemistry & Biology 18,BipA, and IF2, which have reduced, or completely absent, G0
subdomains. Furthermore, deletion of the G0 subdomain from
EF-G removes the stimulatory effect of MiC, as does the
absence of L7/L12 on the ribosome. Despite the differential
effects of MiC and ThS on EF-G GTPase, we show that MiC,
like ThS, is a potent inhibitor of the EF-G catalyzed translocation
process. In contrast the orthosomycin Evn, although not inter-
fering with EF-G GTPase and translocation activities, is a potent
inhibitor of the ribosome-dependent IF2 and EF4 GTPase activ-
ities, as well as of EF4-mediated back-translocation and IF2-
dependent 70SIC formation. Collectively, our results delineate
the specific steps of interference and reveal the differential
effects that these inhibitors have on translocation factor func-
tion—an important step for the development of new, improved
antimicrobial agents.
RESULTS
Differential Effects of Thiopeptide Antibiotics
on GTPase Activities of Translational Factors
The suggestion that MiC stimulates the uncoupled ribosome-
dependent GTPase (rdGTPase) of EF-G by stabilizing the inter-
action of L7-CTD with the G0 subdomain of EF-G (Harms et al.,
2008) prompted us to investigate the effect of MiC on the un-
coupled rdGTPase activities of other translational GTPases
that have reduced or completely absent G0 subdomains (such
as TetM, EF4, and BipA), as determined using the malachite
green assay (Starosta et al., 2009). We found rdGTPase activity
of EF-G to be inhibited by ThS (Figure 2A), as expected from
previous reports (Pan et al., 2007; Pestka, 1970; Rodnina et al.,
1999; Weisblum and Demohn, 1970). The rdGTPase activities
of TetM, EF4, and BipA were also inhibited by ThS (1 mM) (Figures
2B–2D), as was the rdGTPase activity of IF2 (Figure 2E), as re-
ported previously (Grunberg-Manago et al., 1972). Similar trends
were found for all factors independent of the excess of the factor
over the ribosome (Figure S2) or the concentration of antibiotics
used (data not shown). Consistent with these results, ThS has
been shown previously to inhibit the rdGTPase activity of
a related ribosome protection protein, TetO (Connell et al.,
2003b), the formation of a stable complex between TetM and
the ribosome in the presence of GDPNP and GTP (Dantley
et al., 1998), and the IF2-dependent formation of 70SIC (Grigor-
iadou et al., 2007). However, we could not reproduce the recently
reported stimulatory effects of ThS on IF2 GTPase (Brandi et al.,
2004; Cameron et al., 2002).
Guided by a comparison of the crystal structures of T. thermo-
philus EF-G (PDB 1FNM; Laurberg et al., 2000) with E. coli EF4
(PDB 3CB4; Evans et al., 2008), we also generated an E. coli
EF-G lacking the G0 subdomain (EF-GDG0): EF-GDG0 has a
deletion of amino acids 172–265, thus truncating the G0 subdo-
main before b3G and after b61 (Figure S1). In contrast to previous
attempts to produce an EF-GDG0 protein (Nechifor et al., 2007),
soluble protein was obtained under native conditions, and
therefore, refolding or purification under denaturing conditions
was unnecessary (see Experimental Procedures). The purified
E. coli EF-GDG0 had an intrinsic GTPase activity comparable
with that of wild-type E. coli EF-G (data not shown), suggesting
that the protein was not misfolded. Moreover, although the
rdGTPase was significantly slower (>103) than wild-type589–600, May 27, 2011 ª2011 Elsevier Ltd All rights reserved 591
Figure 2. Effect of ThS and MiC on GTPase Activity of Various Translation Factors
(A–F) The rdGTPase activities of translation factors (A) E. coli EF-G, (B) TetM, (C) E. coli EF4, (D) E. coli BipA, (E) E. coli IF2, and (F) E. coli EF-GDG0, using E. coli 70S
ribosomes in the absence (black circles) and presence of 1 mM ThS (red squares) or 5 mM MiC (blue triangles).
(G–I) The rdGTPase activities of E. coli translation factors (G) EF-G, (H) EF4, and (I) BipA, using E. coli 70S ribosomes lacking L7/L12. Reactions in (G)–(I) were
incubated for 12 hr at 20C.
In all cases, background hydrolysis due to the intrinsic GTPase activity of each factor has been subtracted. See also Figure S2.
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albeit more weakly than for wild-type EF-G. As expected from
previous studies (Cameron et al., 2002; Cundliffe and Thomp-
son, 1981; Lentzen et al., 2003), we also observed that MiC
enhanced the rdGTPase activity of EF-G (Figure 2A). Conversely,
we could show that MiC inhibited the rdGTPase of all other trans-
lational GTPases that were tested, namely TetM, EF4, BipA, and
IF2 (Figures 2B–2E). Additionally, deletion of the G0 subdomain of
EF-G also produced a change in the activity of MiC because MiC
was seen to inhibit, rather than stimulate, the rdGTPase of EF-
GDG0 (Figure 2F). We note that deletion of the G0 subdomain of
EF-G greatly reduced (>10-fold) the rdGTPase activity of the
factor, similar to the previously reported introduction of muta-
tions within aAG of the G
0 subdomain (Nechifor et al., 2007).
Similarly, ThS and MiC also inhibited the rdGTPase activities of
EF-G, EF4, and BipA when E. coli 70S ribosomes were used592 Chemistry & Biology 18, 589–600, May 27, 2011 ª2011 Elsevierthat lacked L7/L12 (70SDL7/L12) (Figures 2G–2I). Defects in
rdGTPase of EF-G have also been seen when the ribosomal
proteins L7/L12 are selectively removed from the ribosome
(Diaconu et al., 2005; Kischa et al., 1971; Nechifor et al., 2007)
or mutations are made within the L7-CTD (Diaconu et al., 2005).
Inhibition of Translocation by Thiopeptide Antibiotics,
but Not by Evn
The translocation reaction occurs after peptide-bond formation
and involves the EF-G catalyzed movement of the peptidyl-
and deacylated-tRNAs in the A and P sites into the P and E sites,
respectively (Figure 3A) (reviewed by Schmeing and Rama-
krishnan, 2009). Conversion of the pretranslocational (PRE)
complex into a posttranslocational (POST) complex proceeds
through (A/P and P/E) hybrid states, where the CCA 30 ends of
the tRNAs move with respect to the large subunit while remainingLtd All rights reserved
Figure 3. Effect of the MiC and Evn on Translocation
(A) Scheme for EF-G catalyzed translocation with sites of antibiotic inhibition.
(B) Isolated PRE complex (0.1 mM) containing yeast fMetPhe-tRNAPhe(Prf16/17) in the A site and tRNAfMet in the P site, either in the absence of antibiotic (black
trace) or in the presence of ThS (10 mM; red trace) or MiC (10 mM; blue trace), was rapidly mixed in a stopped-flow spectrophotometer with 5 mM EF-G and 1 mM
GTP.
(C) Isolated PRE complex (0.1 mM) containing E. coli fMetPhe-tRNAPhe(Prf16/20) and tRNAfMet in the P site, in the absence of antibiotic (black trace) or in the
presence of Evn (10 mM; green trace) or MiC (10 mM; blue trace), was rapidly mixed in a stopped-flow spectrophotometer with 5 mM EF-G and 1 mM GTP. All
concentrations are final after mixing. The traces in the control and +Evn traces are each fit to a two-step process (Pan et al., 2007) yielding the following rate
constants: Control: 20.7 ± 0.6 s1, 1.3 ± 0.1 s1; +Evn: 28.1 ± 0.7 s1, 3.5 ± 0.2 s1.
See also Figure S3.
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2004; Moazed and Noller, 1989; Ratje et al., 2010). To monitor
translocation rates, PRE complexes were assembled containing
proflavin (prf)-labeled tRNAs, thus enabling tRNA movement to
be followed by stopped-flow monitoring of the fluorescence
change following delivery of EF-G,GTP (Pan et al., 2007;
Rodnina et al., 1997; Savelsbergh et al., 2003). In Figure 3B,
rapid addition of EF-G,GTP to PRE complexes formed with un-
labelled E. coli tRNAf
Met in the P site and yeast fMetPhe-tRNAPhe
(prf16/17) in the A site leads to an apparent monophasic increase
in fluorescence as A-site tRNA is translocated to the P site (Pan
et al., 2007; Rodnina et al., 1997; Savelsbergh et al., 2003).
Preincubation of the PRE complex with (10 mM) MiC or ThS
completely abolished fluorescence, as reported previously for
ThS (Pan et al., 2007; Rodnina et al., 1997).
By contrast, translocation clearly proceeds via a two-step
reaction for PRE complexes containing E. coli tRNAf
Met in the
P site and E. coli fMetPhe-tRNAPhe (Prf16/20) in the A site (Fig-
ure 3C) (Pan et al., 2007). In this case an initial rapid increase
in fluorescence intensity is followed by a gradual decrease,
with respective apparent rate constants of 20.7 ± 0.6 s1 and
1.3 ± 0.1 s1. The presence of MiC abolishes almost all fluores-Chemistry & Biology 18,cent change (Figure 3C), strongly inhibiting step 1 and, thus, step
2, as reported previously for ThS (Pan et al., 2007). In contrast,
Evn does not inhibit the translocation reaction. In fact the
apparent rate constants (step 1, 28.1 ± 0.7 s1; step 2, 3.5 ±
0.2 s1) suggest that the drug actually accelerates the process,
particularly the second step (Figure 3C).
Evn Inhibits IF2-Dependent 70SIC Formation
In bacteria, formation of the 70SIC involves the association of
the large 50S subunit with a 30S-initiation complex (30SIC)
comprising the 30S subunit, mRNA; initiator fMet-tRNA and
three initiation factors IF1, IF2, and IF3 (Figure 4A) (reviewed by
Laursen et al., 2005; Simonetti et al., 2009). Binding of the 50S
subunit to the 30SIC stimulates the GTPase activity of IF2,
leading to release of IF2,GDP and resulting in a puromycin-reac-
tive 70SIC (Figure 4A) (Grigoriadou et al., 2007).
Evn has previously been shown to inhibit IF2-dependent
formation of fMet-puromycin (Belova et al., 2001), leading to its
classification as a translation initiation inhibitor. However, to
our knowledge, the exact step of inhibition has not been deter-
mined. To examine this further, 70SIC formation has been moni-
tored kinetically using light scattering as described previously589–600, May 27, 2011 ª2011 Elsevier Ltd All rights reserved 593
Figure 4. Evn Inhibits IF2-Dependent 70SIC Formation
(A) Scheme for 70SIC formation with site of Evn inhibition.
(B) 30SIC (0.3 mM) was premixed with various concentrations of Evn (0–5 mM) and then rapidly mixed with 50S subunits (0.3 mM) in a KinTek stopped-flow
spectrophotometer. The sample from which IF2 was omitted demonstrates the dependence of 70SIC formation on IF2.
(C) A plot of the reciprocal of IF2-dependent light-scattering increase at 1 s versus Evn concentration, allowing calculation of an apparent Ki for Evn of 1.8 ±
0.2 mM.
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mRNA was rapidly mixed with 50S subunits, and the increase
in light scattering due to 70SIC formation (black control trace
in Figure 4B) was monitored using stopped-flow spectropho-
tometry. In the absence of IF2, no increase in light scattering
was observed (blue trace in Figure 4B), illustrating the IF2-
dependence for 70SIC reported previously (Antoun et al., 2006;
Grigoriadou et al., 2007). Pre-incubation of the 30SIC with
increasing concentrations of Evn before 50S addition led to a cor-
responding decrease in IF2-dependent light scattering (green
traces in Figure 4B). At 5 mM Evn, almost all IF2-dependent light
scattering was abolished, indicating that Evn inhibits the IF2-
dependent association of the 30SIC with the 50S subunit. A
plot of the reciprocal of the increase of IF2-dependent light
scattering at 1 s versus Evn concentration (Figure 4C) yields an
apparent Ki for Evn of 1.8 ± 0.2 mM.
Differential Effects of Evn on GTPase Activity
of Translational GTPases
Evn strongly inhibits the rdGTPase activity of IF2 (Figure 5A) but
has little or no effect on the rdGTPase activities of EF-G (Fig-
ure 5B), or EF-GDG0 (Figure 5C), or of the EF-G paralog Tet(M)
(Figure 5D), consistent with the potency of Evn in inhibiting
70SIC formation (Figure 4B) and with the lack of effect of Evn
on EF-G-dependent translocation (Figure 3C). Surprisingly, Evn594 Chemistry & Biology 18, 589–600, May 27, 2011 ª2011 Elsevierwas also found to inhibit the rdGTPase of BipA (Figure 5E) and
especially EF4 (Figure 5F). Indeed, the inhibitory activity of Evn
toward EF4 (IC50 = 3 mM) was higher than that toward IF2
(IC50 = 7 mM), and much higher than toward BipA (IC50 =
20 mM).
EF4-Dependent Back-Translocation Is Inhibited by Evn
EF4 catalyzes partial back-translocation, i.e., the movements of
mRNA and tRNAs from POST toward the PRE state (Figure 6A)
(Liu et al., 2010; Qin et al., 2006). As described previously (Liu
et al., 2010), EF4-mediated partial back-translocation was moni-
tored using prf-labeled tRNAs: POST state ribosomes containing
fMetPhe-tRNAPhe(Prf16/20) in the P site and tRNAfMet in the E
site were rapidly mixed in a stopped-flow spectrophotometer
with EF4 and GDPNP, with fluorescence change being moni-
tored over time (Figure 6B). In the absence of antibiotic, back-
translocation proceeds via a three-step process (blue trace in
Figure 6B) consistent with movement through a series of three
intermediate states as reported (Liu et al., 2010) (INT1–3 in Fig-
ure 6A). In the presence of increasing concentrations of Evn,
both the fluorescence change and rates of each step in the
partial back-translocation were inhibited by Evn, (Figure 6B),
leading to an apparent Ki for Evn binding to the POST complex
of 0.6 mM (Figure 6C). High concentrations of Evn (5 mM in Fig-
ure 6B) completely abolished the EF4-catalyzed component ofLtd All rights reserved
Figure 5. Effect of Evn on the GTPase Activity of Various Translation Factors
(A–F) Activation of uncoupled rdGTPases of translation factors (A) E. coli IF2, (B) E. coli EF-G, (C) E. coli EF-GDG0, (D) S. faecalis TetM, (E) E. coli BipA, and (F)
E. coli EF4, in the presence of increasing concentrations of Evn. The inset shows the color gradient scale from 0 (yellow) to 800 pmol (blue) of Pi produced per pmol
of 70S ribosomes, following subtraction of background intrinsic GTPase activities.
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reverse-translocation process that occurs in the absence of
EF4 was observed (Liu et al., 2010). Evn inhibition of EF4-depen-
dent partial back-translocation is similar to that reported earlier
using spectinomycin (Liu et al., 2010), a well-characterized trans-
location inhibitor (Wilson, 2009), and is consistent with the obser-
vation that Evn is a potent inhibitor of the EF4 rdGTPase activity
(Figure 5F).
DISCUSSION
Influence of Thiopeptides on Translocation
and Translation Factor GTPase Activities
Although both ThS and MiC inhibit the multiple-turnover
rdGTPase activities of IF2, TetM, EF4, and BipA (Figures 2B–
2E), MiC differs from ThS in stimulating the rdGTPase of EF-G,
an activity that is strongly inhibited by ThS (Figure 2A). Our
results suggest that ThS inhibition and MiC stimulation of EF-G
rdGTPase arise ultimately from differential effects on the interac-
tions between the G0 subdomain of EF-G and L7-CTD.
ThS allows ribosome-binding and single-turnover GTPase
activity of EF-G but prevents the stable accommodation of
EF-G on the ribosome, which is necessary for tRNA translocation
(Rodnina et al., 1999; Seo et al., 2006). Part of the accommoda-
tion of EF-G encompasses the movement of EF-G toward
L11-NTD, which is inhibited by ThS (Seo et al., 2006), consistent
with the structural overlap between the binding site of ThS and
domain V of EF-G, both locating to the cleft formed by H43/44
and L11-NTD (Figure 1F) (Harms et al., 2008). Because ThSChemistry & Biology 18,also prevents multiple-turnover GTPase activity of EF-G by
inhibiting Pi release (Savelsbergh et al., 2003; Seo et al., 2006),
EF-G remains trapped on the ribosome but in an unaccommo-
dated state. In contrast, MiC allows Pi release from EF-G
(Starosta et al., 2009) and, thus, stimulates the multiple-turnover
rdGTPase activity of EF-G, as observed here (Figure 2A) and
reported previously (Cameron et al., 2002; Cundliffe and
Thompson, 1981; Lentzen et al., 2003). In agreement with the
idea that MiC stimulates the rdGTPase of EF-G by stabilization
of the interaction between the L7-CTD and the G0 subdomain
of EF-G (Harms et al., 2008), we could show that the MiC-depen-
dent stimulation of EF-G rdGTPase activity was lost when the G0
subdomain of EF-G was removed (Figure 2F) or the ribosomes
lacked L7/L12 (Figures 2G–2I). Moreover, the rdGTPase
activities of translation factors that naturally lack or have a
reduced G0 subdomain (TetM, EF4, BipA, IF2) were also inhibited
by MiC (Figures 2B–2E).
Although many translation factors lack the complete G0
subdomain, NMR studies indicate that IF2, EF-Tu, and RF3
interact with the same conserved region of L7-CTD as EF-G
(Helgstrand et al., 2007). L7/L12 has been proposed to interact
with helix aD1 of domain I of EF-Tu. However, this interaction is
more important for initial binding of EF-Tu,GTP,aa-tRNA to
the ribosome, rather than for subsequent steps, such as A-site
binding and GTPase activation (Kothe et al., 2004). Nevertheless,
like EF-G, the rdGTPase activity of EF-Tu is dramatically reduced
when ribosomes are depleted of L7/L12 (Diaconu et al., 2005;
Mohr et al., 2002). In contrast, depletion of L7/L12 reduces the
rate of association of IF2 with the ribosome, rather than directly589–600, May 27, 2011 ª2011 Elsevier Ltd All rights reserved 595
Figure 6. Evn Inhibits EF4-Mediated Back-Translocation
(A) Scheme for EF4-catalyzed back-translocation with sites of antibiotic inhibition.
(B) Fluorescence changes over different time scales. Isolated POST complex (0.1 mM) containing fMetPhe-tRNAPhe(Prf) in the P site and tRNAfMet in the E site,
premixed with 0.15 mM tRNAfMet, to increase E-site occupancy, were rapidly mixed in a stopped-flow spectrophotometer with 3 mM EF4, 0.5 mM GDPNP, and
different concentrations of Evn as indicated on the figure. All concentrations are final after mixing. Lines through the traces are fit to a kinetic model (Liu et al., 2010)
in which back-translocation proceeds via a three-step process in the absence of Evn (the first two of which are catalyzed by EF4) and via a two-step process at
saturating Evn.
(C) A plot of the reciprocal of the apparent magnitude of the fluorescence change for the second, EF4-catalyzed step versus Evn concentration, giving an
apparent Ki for Evn binding to the POST complex of 0.6 ± 0.1 mM.
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observed that the rdGTPase of LepA and BipA with 70SDL7/L12
was significantly reduced but was also inhibited by both MiC and
ThS (Figures 2H and 2I). Further work will be needed to distin-
guish between factor binding versus GTPase activity defects.
Despite the contrasting effects of MiC and ThS on the GTPase
activities of EF-G (Figure 2A) (Cameron et al., 2002; Cundliffe and
Thompson, 1981; Lentzen et al., 2003), our kinetic analysis
demonstrates that MiC, like ThS, is a potent inhibitor of the trans-
location reaction (Figure 3B). The finding that MiC targets trans-
location is in agreement with original conclusions of Pestka and
Brot (1971), which were based upon its inhibition of poly(U)-
dependent poly(Phe) synthesis but its lack of affect on either
aa-tRNA binding or peptide-bond formation. Given the similarity
in binding site between MiC and ThS, it thus appears likely that
both MiC and ThS inhibit translocation analogously—namely,
by preventing the transition of EF-G from an initially weaker
binding state to a fully accommodated state on the ribosome,
which, we would suggest, is necessary for translocation (Seo
et al., 2006). We note that despite their diverse effects on the
rdGTPase of EF-G, the inhibitory potency of MiC and ThS with
respect to in vitro transcription-translation systems is compa-
rable (both have an IC50 of 3 mM) (Figure S3).596 Chemistry & Biology 18, 589–600, May 27, 2011 ª2011 ElsevierInfluence of the Orthosomycin Evn on Translation
Factor Activities
Unlike thiopeptides, we find that the orthosomycin Evn has no
inhibitory effect on rdGTPase activity of EF-G (Figure 5B) or on
the EF-G-mediated translocation reaction (Figure 3C). This is
consistent with the lack of overlap between the putative Evn-
binding site and the binding position of EF-G determined by
structural studies (Connell et al., 2007; Gao et al., 2009; Ratje
et al., 2010) (Figure 7A). Similarly, Evn does not inhibit the
rdGTPase of Tet(M) (Figure 5D) or of Tet(O) (data not shown),
which interacts with the ribosome in an analogous manner to
EF-G (Spahn et al., 2001). In contrast we find that Evn is a potent
inhibitor of the rdGTPase activity of IF2 (Figure 5A), BipA, and
EF4 (Figures 5E and 5F). Although little is known about the struc-
ture or function of BipA on the ribosome (deLivron et al., 2009),
structures of EF4 alone (Evans et al., 2008) and bound to the
ribosome (Connell et al., 2008) reveal an overall similarity with
EF-G. One exception is the unique CTD of EF4 (Evans et al.,
2008), which on the ribosome is oriented back toward the large
subunit (Connell et al., 2008) and encroaches upon the Evn-
binding site (Figure 7B). Such overlap is consistent with our
finding that Evn is a potent inhibitor EF4-mediated back-translo-
cation reaction (Figure 6B). Our results demonstrating potentLtd All rights reserved
Figure 7. Putative Binding Sites of Orthosomycin Antibiotics Relative to Translation Factors EF-G, EF4, and IF2
(A–C) Relative position of (A) EF-G (blue) (Connell et al., 2007; Gao et al., 2009), (B) EF4 (orange) (Connell et al., 2008), and (C) IF2 (purple) (Allen et al., 2005; Marzi
et al., 2003) to the putative Evn-binding site (encircled in red) (Belova et al., 2001; Wilson, 2009). Nucleotides associated with Evn binding in H89 and H91 are
colored red, and L16 (teal) is shown for reference. Note the overlap in positions of the CTD of EF4 and domain 4 (d4) of IF2 with the putative Evn-binding site.
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BipA and EF4, suggest that Evn can no longer be considered
exclusively as an initiation inhibitor, as it has been heretofore.
Indeed, Evn is a slightly stronger inhibitor of the rdGTPase
activity of EF4 compared with IF2, and the Ki (0.6 mM) for Evn
binding to the POST complex (Figure 6C) is a little lower than
the Ki (1.8 mM) for Evn inhibition of IF2-dependent 70SIC
formation.
Nevertheless, because the gene for EF4 is not essential for
survival in E. coli (Dibb and Wolfe, 1986), the principal antimicro-
bial target of Evn is most likely IF2. Here, we demonstrate that
Evn can inhibit the rdGTPase activity of IF2 (Figure 5A) as well
as prevent the IF2-dependent association of the 30SIC with
the large ribosomal subunit (Figure 4B). These findings support
an earlier suggestion that Evn inhibits 70SIC formation, which
was based on the ability of Evn to prevent the formation of
fMet-puromycin in an IF2-dependent manner (Belova et al.,
2001). Models for IF2 bound to the ribosome derived from
biochemical (Marzi et al., 2003) and cryo-EM data (Allen et al.,
2005; Myasnikov et al., 2005) suggest that domain 4 of IF2 and
the associated linker region encroach on the Evn-binding site
(Figure 7C). Thus, we believe that Evn sterically interferes with
IF2 binding to the large ribosomal subunit, accounting for the
Evn-dependent reduction in rdGTPase activity of IF2 with 70S
ribosomes (Figure 5A) as well as the reduction in 70SIC as
observed using light scattering (Figure 4B). The similarity
between the Ki (1.8 mM) of Evn inhibition for 70SIC formation
and the half-inhibitory concentration (IC50 = 2 mM) of Evn for
synthesis of GFP as measured in an E. coli in vitro-coupled tran-
scription-translation system (Figure S3) also supports the claim
that Evn targets predominantly the initiation phase of protein
synthesis (Belova et al., 2001).
SIGNIFICANCE
Insight into the mechanism of action of diverse classes of
antibiotics, such as the thiopeptides and orthosomycins,
to inhibit distinct steps during translation can provideChemistry & Biology 18,insight into the fundamental process of translation. Here,
we demonstrate that although the thiopeptides MiC and
ThS have contrasting effects on the rdGTPase activity of
EF-G, both antibiotics are potent inhibitors of EF-G-depen-
dent translocation reaction. Our results demonstrate that
the MiC-dependent stimulation of the rdGTPase of EF-G
requires the presence of the G0 subdomain of EF-G as well
as ribosomal proteins L7/L12. This finding supports the
idea that recycling of EF-G from the ribosome, which occurs
upon release of Pi, is mediated via the interaction of L7-CTD
with the G0 subdomain of EF-G. In contrast we can demon-
strate that Evn does not influence EF-G rdGTPase, or
EF-G dependent translocation, but is a potent inhibitor of
EF4-dependent back-translocation reaction as well as IF2-
dependent 70S-initiation complex formation. These findings
are in agreement with the predicted binding site of the ortho-
somycins relative to the binding sites of EF-G, EF4, and IF2
on the ribosome. Understanding mechanistically how antibi-
otics perturb the translational apparatus is an important
step for the future development of new improved antimicro-
bial agents to overcome the emerging resistant bacterial
pathogens.
EXPERIMENTAL PROCEDURES
Component Preparation
ThS was purchased from Sigma, MiC P1 was a kind gift of Dr. Torsten Stachel-
haus, and gDNA from S. faecalis was kindly provided by Dr. Vincent Perreten.
E. coli fusA and bipA, S. faecalis tetM as well as T. thermophilus (HB8) fusA full-
length genes were cloned into pET-46 Ek/LIC vector, and E. coli infB gene was
cloned into pET-14b, in accordance with the manufacturer’s instructions
(Novagen). EF-GDG0 mutants were prepared using QuikChange Site-Directed
Mutagenesis Kit (Stratagene). E. coli EF4 was expressed in pET14b as
described previously (Qin et al., 2006). Recombinant proteins were expressed
in BL21 (DE3) cells, at 20C with 0.2 mM IPTG, then purified with a Ni2+-NTA
affinity column (QIAGEN), followed by gel-filtration chromatography on a
HiLoad 16/60 Superdex 75 prep grade column (Amersham-Pharmacia) in
a buffer containing 10 mM Tris (pH 7.8), 100 mM NaCl, and 10 mM 2-mercap-
toethanol. E. coli 70S ribosomes lacking L7/L12 were prepared as described
by Hamel et al. (1972) and Wystup et al. (1979). Tight-coupled E. coli589–600, May 27, 2011 ª2011 Elsevier Ltd All rights reserved 597
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and E. coli [35S]fMet-tRNAfMet; E. coli [3H]Phe-tRNAPhe were prepared as
described (Liu et al., 2010). MFK-mRNA was purchased from Dharmacon
(Lafayette, CO, USA) with sequences 50-GGG AAG GAG GUA AAA AUG
UUU AAA CGU AAA UCU ACU-30 (initiator codon underlined).
IF2-Dependent 70SIC Formation Light-Scattering Assay
This assay was performed as described (Grigoriadou et al., 2007). 30SIC
was formed by mixing 0.3 mM 30S, 0.45 mM IF1, 0.45 mM IF3, 0.45 mM fMet-
tRNAf
Met, 0.15 mM IF2, 0.9 mM AUG022-mRNA (Grigoriadou et al., 2007),
and 100 mM GTP, premixed with various concentrations of Evn (0–5 mM) and
then rapidly mixed with 50S subunits (0.3 mM) in a KinTek stopped-flow spec-
trophotometer. Excitation was at 436 nm, and light scattering was determined
using a 455 nm cutoff filter. All concentrations are final after mixing.
Back-Translocation Assay
All of the following complexes were made up in buffer A (20 mM HEPES-KOH
[pH 7.5], at 0C, 150 mM NH4Ac, 4.5 mM MgAc2, 4 mM b-mercaptoethanol,
0.05 mM spermine, and 2 mM spermidine) at 37C. Initiation complex was
formed by incubating WT ribosomes (2 mM) with mRNA MFK (8 mM), IF1
(3 mM), IF2 (3 mM), IF3 (3 mM), GTP (1 mM), and [35S]fMet-tRNAfMet (3 mM) for
25 min. Ternary complex was formed by incubating EF-Tu (6 mM) with labeled
Phe-tRNAPhe (3 mM), GTP (1 mM), phosphoenolpyruvate (Roche Diagnostics)
(1.5 mM), and pyruvate kinase (Roche Diagnostics) (0.015 mg/ml) for 15 min.
POST complexes were formed by incubating ternary complex and initiation
complex at 37C briefly for 45 s and then in the presence of EF-G (molar ratio
of EF-G:ribosome was 0.2:1) and GTP (1 mM) at 37C for 10 min. Then they
were purified by ultracentrifugation through a 1.1 M Sucrose cushion in buffer
A (450,000 3 g, 40 min, 4C). POST complex concentration was calculated
from the amount of ribosome-bound fMet-[3H]Phe-tRNAPhe. Stopped-flow
fluorescence experiments were performed using an SX.18MV Stopped-Flow
Spectrofluorometer (Applied Photophysics). POST complex (0.1 mM) contain-
ing fMetPhe-tRNAPhe(Prf) in the P site and tRNAfMet in the E site was rapidly
mixed with 0.15 mM tRNAfMet, 3 mM EF4,GDPNP, and various concentrations
of Evn (0–5 mM). prf was excited at 460 nm, and fluorescence was monitored
using a 495 nm long-pass filter. Lines through the data are fit to triple-exponen-
tial equations using the program IGOR Pro (WaveMetrics).
Translocation Assay
PRE complexes were formed by incubating initiation complex and ternary
complex at 37C for 45 s. Then they were purified by ultracentrifugation
through a 1.1 M Sucrose cushion in buffer A with 20 mM Mg2+ (450,000 3 g,
40 min, 4C). PRE complex concentration was calculated from the amount
of ribosome-bound fMet-[3H]Phe-tRNAPhe. Stopped-flow fluorescence exper-
iments were performed using an SX.18MV Stopped-Flow spectrofluorometer.
prf was excited at 460 nm, and fluorescence was monitored using a 495 nm
long-pass filter. Data are fit to double-exponential equations using the
program IGOR Pro (WaveMetrics).
Malachite Green GTPase Activity Assays
GTPase activity was measured using the Malachite Green Phosphate Kit
(BioAssay) that quantifies the green complex formed between malachite
green, molybdate, and free orthophosphate. Unless otherwise mentioned, all
reactions contained 30 nM E. coli 70S ribosomes, 20 mM GTP, and 60 nM
protein in the presence or absence of antibiotics as necessary. Reactions
were transferred into 96-well microtiter plates, and color formation was
measured on Tecan Infinite M1000 microplate reader at 650 nm. Reactions
performed in the absence of ribosomes were used as a background signal
to account for the intrinsic GTPase activity of the translation factor.
In Vitro Transcription-Translation Assay
All coupled transcription-translation experiments were performed using an
E. coli lysate-based system in the presence and absence of antibiotics as
described previously (Starosta et al., 2009, 2010). Reactions were transferred
into 96-well microtiter plates, and the GFP fluorescence was measured with
a Typhoon Scanner 9400 (Amersham Bioscience) using a Typhoon blue laser
module (Amersham Bioscience). Images were then quantified using Image-598 Chemistry & Biology 18, 589–600, May 27, 2011 ª2011 ElsevierQuant TL (GE Healthcare) and represented graphically using SigmaPlot (Systat
Software, Inc.).
Figure Preparation
Chemical structures for the precursor compounds were drawn using
ChemDraw (Advanced Chemistry Development, Inc., Toronto, Canada), and
all structural figures were prepared with PyMOL (http://www.pymol.org).
SUPPLEMENTAL INFORMATION
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Head swivel on the ribosome facilitates translocation
by means of intra-subunit tRNA hybrid sites
Andreas H. Ratje1,2, Justus Loerke1, Aleksandra Mikolajka3,4, Matthias Brünner1, Peter W. Hildebrand1, Agata L. Starosta3,
Alexandra Dönhöfer3, Sean R. Connell5, Paola Fucini5, Thorsten Mielke1,6, Paul C. Whitford7, José N. Onuchic8, Yanan Yu9,
Karissa Y. Sanbonmatsu7, Roland K. Hartmann2, Pawel A. Penczek10, Daniel N. Wilson3,4 & Christian M. T. Spahn1
The elongation cycle of protein synthesis involves the delivery of
aminoacyl-transfer RNAs to the aminoacyl-tRNA-binding site
(A site) of the ribosome, followed by peptide-bond formation and
translocation of the tRNAs through the ribosome to reopen the
A site1,2. The translocation reaction is catalysed by elongation factor
G (EF-G) in a GTP-dependent manner3. Despite the availability of
structures of various EF-G–ribosome complexes, the precise mech-
anism by which tRNAs move through the ribosome still remains
unclear. Here we use multiparticle cryoelectron microscopy analysis
to resolve two previously unseen subpopulations within Thermus
thermophilus EF-G–ribosome complexes at subnanometre resolu-
tion, one of them with a partly translocated tRNA. Comparison of
these substates reveals that translocation of tRNA on the 30S sub-
unit parallels the swivelling of the 30S head and is coupled to
unratcheting of the 30S body. Because the tRNA maintains contact
with the peptidyl-tRNA-binding site (P site) on the 30S head and
simultaneously establishes interaction with the exit site (E site) on
the 30S platform, a novel intra-subunit ‘pe/E’ hybrid state is formed.
This state is stabilized by domain IV of EF-G, which interacts with
the swivelled 30S-head conformation. These findings provide direct
structural and mechanistic insight into the ‘missing link’ in terms
of tRNA intermediates involved in the universally conserved
translocation process.
After peptide-bond formation, pre-translocational (PRE) ribosomes
carry a peptidyl-tRNA at the A site and a deacylated tRNA at the
P site1,3,4. This is a highly dynamic state of the ribosome, which fluc-
tuates between classical states with A tRNA and P tRNA and hybrid
states with A/P tRNAs (A/P denotes that the tRNA is in the A site on
the 30S subunit and the P site on the 50S subunit) and P/E tRNAs5–8.
Hybrid state formation is coupled to spontaneous rotation of the 30S
subunit relative to the 50S subunit9–11 and is stabilized by the binding of
EF-G12–14. The ratchet-like subunit rearrangement induced by EF-G
and eukaryotic elongation factor 2 (eEF2) also includes a swivel move-
ment of the head that is roughly orthogonal to the inter-subunit rota-
tion of the ribosomal subunits14–16. EF-G catalyses translocation of the
hybrid-state tRNAs on the 30S subunit to form a post-translocational
(POST) state ribosome with tRNAs located at classical P and E sites.
The translocation process is accelerated by the GTPase activity of EF-G
stimulated by the ribosome17,18. However, it is still not known how
tRNAs are translocated with respect to the 30S subunit and how the
messenger RNA is advanced by one codon.
Structural snapshots of the translocation process come from cryo-
electron microscopy and X-ray analysis of EF-G bound to ribosome
complexes12–14,19. Despite considerable effort12,20–22, no direct structural
information is available for ribosomal PRE complexes simultaneously
containing EF-G and an A tRNA. It seems that this state is too dynamic
and transient to be captured, resulting in either a POST state contain-
ing EF-G or a PRE state without EF-G bound20,22. Indeed, the stable
EF-G-bound POST state determined by X-ray crystallography reveals
a non-ratcheted ribosome with tRNAs in classical P/P and E/E sites19.
Therefore, structural insights into intermediate states of transloca-
tion—that is, ratcheted ribosomal EF-G complexes—have used com-
plexes without an A-site peptidyl-tRNA12–14.
In this study we used the antibiotic fusidic acid (FA) to stall EF-G on
the 70S ribosome. FA permits the hydrolysis of GTP by EF-G but pre-
vents the associated changes in EF-G that normally accompany hydro-
lysis19. After complex formation and the collection of cryoelectron
microscopy data, we employed multiparticle refinement to resolve
the heterogeneity of the data (Supplementary Fig. 1). In the first phase
of multiparticle refinement a large population of particle images of
ribosomes containing EF-G was obtained that yielded a structure in a
ratcheted conformation. As refinement progressed to higher resolution,
the presence of intrinsic conformational heterogeneity necessitated a
second phase of multiparticle refinement, resulting in two final recon-
structions of the 70S–EF-G–GDP–FA complex (Fig. 1), at resolutions of
7.6 Å and 7.8 Å (using a 0.5 Fourier shell correlation cut-off criterion),
respectively (Supplementary Fig. 2). Both maps have density attributed
to EF-G, but they show significant conformational differences (Sup-
plementary Movies 1 and 2): specifically, the substates are distinguished
by different degrees of subunit ratcheting and positioning of the L1
protuberance, and also by the swivel movement of the head of the
30S subunit relative to the body/platform (Fig. 1e, f, Supplementary
Figs 3 and 4, and Supplementary Table 1). Unlike previous cryoelectron
microscopy and X-ray structures of ribosome–EF-G complexes, move-
ment of the head and body/platform of the 30S subunit is uncoupled: in
substate I, the 30S subunit is ratcheted by about 7u relative to the 50S
subunit, but there is only a modest (roughly 5u) swivelling of the 30S
head. In contrast, the 30S in substate II is only ratcheted by about 4u, but
there is a very large (roughly 18u) swivel of the head (Supplementary
Table 1).
The identification of two different ratcheted substates within the
70S–EF-G–GDP–FA complex prompted us to investigate whether
such intrinsic heterogeneity also exists in our previous 70S–EF-G–
GMPPNP cryoelectron microscopy data set14. Additional multiparticle
refinement did indeed reveal that the 70S–EF-G–GMPPNP complex
could be subdivided into two substates that seemed to be equivalent to
those identified in the 70S–EF-G–GDP–FA complex (Supplementary
Fig. 5 and Supplementary Table 1). Our findings here provide evidence
supporting the emerging energy-landscape model that allows the
sampling of several metastable conformations for a defined ribosomal
1Institut für Medizinische Physik und Biophysik, Charite – Universitätsmedizin Berlin, Ziegelstrasse 5–9, 10117-Berlin, Germany. 2Institut für Pharmazeutische Chemie, Philipps-Universität Marburg,
35037 Marburg, Germany. 3Gene Center and Department of Biochemistry, Ludwig-Maximilians-Universität, Feodor-Lynenstrasse 25, 81377 München, Germany. 4Center for Integrated Protein Science,
Ludwig-Maximilians-Universität München, 81377 München, Germany. 5Frankfurt Institute for Molecular Life Sciences, Institute of Organic Chemistry and Chemical Biology, Goethe University Frankfurt,
Max-von Laue-Strasse 7, D-60438 Frankfurt am Main, Germany. 6UltraStrukturNetzwerk, Max Planck Institute for Molecular Genetics, 14195 Berlin, Germany. 7Theoretical Biology and Biophysics Group,
TheoreticalDivision, Los Alamos National Laboratory, Los Alamos,New Mexico 87545, USA. 8Center for TheoreticalBiological Physics and DepartmentofPhysics, University of California, San Diego, La Jolla,
California 92093, USA. 9Florida State University, Department of Computer Science, Tallahassee, Florida 32306, USA. 10The University of Texas – Houston Medical School, 6431 Fannin, Houston, Texas
77030, USA.
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complex8. The subnanometre resolution of the 70S–EF-G–GDP–FA
subpopulations enabled the visualization of secondary structure and
thus the generation of molecular models (Fig. 1) by applying our
newly developed MDFIT algorithm (see Methods). Comparison with
available structures reveals that substate I is similar in conformation to
the ratcheted substate of the PRE complex9,10 (Supplementary Table 1)
and also that the tRNA is bound in a hybrid P/E site (Fig. 2a). We
therefore consider substate I to be related to a pre-translocational inter-
mediate (TIPRE).
In contrast, substate II of the 70S–EF-G–GDP–FA complex repre-
sents a novel conformational state of the 70S ribosome. The anticodon
stem-loop (ASL) of the tRNA has moved by 8–10 Å compared with the
P/E position of TIPRE as it maintains strong association with the P-site
components of the head and follows the large 18u swivel movement of
the head (Fig. 2b and Supplementary Movie 3). Because the tRNA
interacts simultaneously with P-site components of the head as well
as E-site components of the platform, it can be thought of as a 30S
intra-subunit hybrid site (Fig. 2b). Moreover, because the contacts of
the CCA end of the tRNA with the E site on the 50S subunit remain
unaffected, we extend the previous nomenclature of hybrid sites5 and
refer to this newly identified state as a pe/E hybrid state (P site on head
and E site on platform of the 30S subunit, and E site on the 50S subunit).
The ASL of the pe/E tRNA together with the bound mRNA codon is
very close to the position of a fully translocated E/E tRNA (Fig. 2c and
Supplementary Movie 4). Apparently, head-swivelling coupled with
partial unratcheting of the body/platform of the 30S subunit leads to
tRNA translocation, suggesting that substate II of the 70S–EF-G–
GDP–FA complex is related to a post-translocational intermediate
state (TIPOST). We note that although the intermediate states visua-
lized here contain only one tRNA, a second tRNA (ap/P) can be super-
imposed on the TIPOST state without steric interference with the
binding position of EF-G (Supplementary Fig. 6). Thus, the structures
presented here seem to be valid models for translocation intermediates
(see also Supplementary Information for further discussion), but
structures of translocation intermediates with two tRNAs will be
necessary for the validation of these predictions. The presence of the
ratchet-like subunit rearrangement in the yeast 80S–eEF2–sordarin
complex15 hints that translocation in prokaryotes and eukaryotes
may use related intermediate conformations. This structure showed
a strong head swivel comparable to that of bacterial TIPOST combined
with a strong inter-subunit rotation of bacterial TIPRE. Thus, the con-
formation of the 80S–eEF2–sordarin complex15, although obtained by
classical single-particle methods, may present a further intermediate
between TIPRE and TIPOST.
Whereas the P/E and pe/E tRNAs are in a twisted conformation
(Fig. 2d), the overall conformations of EF-G in TIPRE and TIPOST are
remarkably similar to each other (Fig. 1) and to that observed in the
cryoelectron microscopy reconstruction of the 70S–EF-G–GMPPNP14
as well as in the recent X-ray structure of EF-G–GDP–FA bound to a
POST-state ribosome19 (Fig. 3a). However, one difference between the
two EF-G–GDP–FA substates relates to the interaction patterns of
domain IV of EF-G: in the TIPRE state, domain IV does not seem to
a b
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H69
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4°7°
Figure 1 | Substates I (TIPRE) and II (TIPOST) of the 70S–EF-G–GDP–FA
complex. a–d, Cryoelectron microscopy maps of TIPRE (a, b) and TIPOST
(c, d) of the 70S–EF-G–GDP–FA complex are shown in mesh form with
docked models in ribbon representation: EF-G (red), tRNA (green), 23S/5S
rRNA (blue), 50S ribosomal proteins (orange), 16S rRNA (yellow) and the 30S
ribosomal proteins (magenta). The maps are shown from the 30S side with the
30S subunit computationally removed (a, c) and from the 50S side with the 50S
subunit computationally removed (b, d). CP, central protuberance; bk, beak; sp,
spur; pt, platform; h, head; b, back; L1 and L7, ribosomal proteins L1 and L7,
respectively; H69, helix 69 of 23S rRNA. e, f, The 30S subunit of TIPRE (e) and
TIPOST (f) (yellow) is compared with the 30S subunit of the POST state19 (grey)
by aligning the respective 50S subunits. Arrows with numbers indicate the
direction and magnitude (Supplementary Table 1) of the inter-subunit rotation
and the head-swivel from the unrotated state to TIPRE or TIPOST, respectively.
a b
c dA P
E
mRNA
P/E pe/E
P/E P A/T
P/E pe/E
Figure 2 | Localization and conformation of the tRNA of substates I (TIPRE)
and II (TIPOST). a, b, Close-up of the tRNA-binding regions of the 30S subunit
of TIPRE (a) and TIPOST (b). The 30S subunit and tRNAs are shown as yellow
and blue ribbons, respectively; ribosomal residues that contact A, P and E tRNA
(magenta, green and orange) are shown as spheres. c, In a common 50S
alignment, the P/E tRNA (green) of TIPRE and the pe/E tRNA (magenta) of
TIPOST together with their respective mRNA codons are compared with mRNA
and classical A, P and E tRNA positions (grey). d, Density for the tRNAs (wire
mesh) with molecular models for the P/E tRNA of TIPRE (left, green) and the
pe/E tRNA of TIPOST (middle, magenta). On the right, the model for P/E tRNA
(green), which is essentially the same as that for pe/E-tRNA (root mean squared
deviation 1.5 Å), is compared with a classical P tRNA (blue) and an A/T tRNA
(yellow) by alignment of the acceptor-stem, D-stem and T-stem loops.
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interact significantly with the ribosome (Fig. 3b), whereas a small shift
in the binding position of EF-G and the large swivel of the head
facilitate a more extensive interaction of domain IV of EF-G with helix
h34 of the 16S rRNA in the TIPOST state (Fig. 3c). Together, h34 and
the nucleotide 530 region of 16S rRNA form the so-called latch of the
mRNA entry channel. Because of the head-swivel in the TIPOST state,
h34 has moved about 12 Å away from the 530 region, leading to an
opening of the latch (Fig. 3c) similar to that observed previously when
eEF2 was trapped on the yeast 80S ribosome with sordarin15. This may
facilitate the movement of the mRNA–tRNA2 complex. Consistent
with this observation, transient protection of h34 by EF-G against
chemical modification during the translocation reaction has been
reported previously23. The direct interaction of domain IV of EF-G
with h34 may therefore bias the energy landscape of the ribosome
towards TIPOST.
Until now, intermediate states of inter-subunit rotation have been
considered to be intermediates on the pathway to the fully rotated
state16. The present findings implicate unratcheting (in combination
with the large swivel of the 30S head), rather than ratcheting, as being
coupled to the translocation movement of the tRNAs and the mRNA
with respect to the 30S subunit. Collectively, the insights gained from
the structures of the TIPRE and TIPOST states enable us to provide a
structural explanation for the process of translocation in a model in
which tRNA movements are facilitated by head-swivel, ratcheting and
unratcheting motions of the ribosome (Fig. 4). These motions may be
influenced by the GTPase reaction on EF-G; a network of interactions
involving domain III and the ordered switch I region of EF-G and the
c-phosphate of GTP was proposed to stabilize the rotated state of the
30S subunit14. Accordingly, fast GTP hydrolysis by EF-G17 could desta-
bilize the direct and indirect interactions of switch I of EF-G with the
maximally rotated 30S subunit14,24, therefore increasing the propensity
of the 30S subunit to rotate backwards. The unratcheting motion
produces a counter-movement of the body/platform with respect to
the head, thereby reducing the distance that the tRNAs have to travel
during translocation. Intra-subunit hybrid states allow the 30S subunit
to maintain partial contacts with the tRNAs at any time of the trans-
location reaction. In the context of the ribosome’s functioning during
translocation as a Brownian ratchet machine25, our model suggests
that EF-G acts as a dynamic pawl, decoupling the unratcheting
motions of the ribosome from the transition of hybrid-state tRNAs
back into classical states. EF-G thereby provides directionality and
accelerates translocation of the tRNAs by means of several intermediate
inter-subunit and intra-subunit hybrid states into the classical P/P and
E/E sites of the POST state.
METHODS SUMMARY
Tight-coupled 70S ribosomes from Thermus thermophilus were isolated by sucrose-
gradient centrifugation and incubated with EF-G in the presence of GTP and FA.
The resulting complexes were flash-frozen and imaged under low-dose conditions
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Figure 3 | EF-G stabilizes the swivelled head movement in the TIPOST state.
a, Comparison of the position of FA-stalled EF-G and the 30S subunit between
TIPOST and the POST-state 70S–EF-G–GDP–FA complex19. All shown
components of the POST-state 70S–EF-G–GDP–FA complex19 are depicted as
blue ribbons. The 30S, EF-G and pe/E tRNA of TIPOST are represented by yellow,
red and orange ribbons, respectively. b, c, Close-up of the decoding region and
domain IV of EF-G in the same orientation as in a. The surfaces of TIPRE (b) and
TIPOST (c) are transparent with molecular models in ribbon representation (30S
subunit, yellow; EF-G, red, P/E tRNA, green; pe/E tRNA, orange). The arrows
mark the closed latch between helix h34 and the 530 region of TIPRE (b) and the
interaction between h34 and domain IV of EF-G within TIPOST.
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Ratcheting of head/body
A/A and P/P tRNAs A/P and P/E tRNAs A/P and P/E tRNAs ap/P and pe/E tRNAs P/P and E/E tRNAs
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Figure 4 | Model for translocation. a, b, The PRE ribosome exists in a
dynamic equilibrium between base states with classical A/A and P/P tRNAs
(a) and rotated states with hybrid A/P and P/E tRNAs6,7,9–11 (b). c, Binding of
EF-G–GTP to PRE state (a) or hybrid state (b) stabilizes the ratcheted state12 as
observed in TIPRE. d, Fast GTP hydrolysis by EF-G17 accelerates translocation
by means of an unlocking step on the 30S subunit18. Domain IV of EF-G
uncouples unratcheting from the reverse movement of the A/P and P/E tRNAs
back into classical states; that is, a doorstop function. Through a head-
swivelling and unratcheting motion, the tRNAs move from aa/P and pp/E into
the 30S intra-subunit ap/P and pe/E hybrid states. e, Complete unratcheting of
the 30S subunit leads to the POST-state 70S–EF-G complex19. Back-swivelling
of the 30S head re-establishes tRNAs in the classical (pp/P) P and E (ee/E)
states. Translocation is completed by the dissociation of EF-G–GDP.
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with the use of an FEI Polara G2 electron microscope. The collected data were
digitized and processed with multiparticle refinement protocols implemented in
SPIDER26. To interpret the resulting cryoelectron microscopy maps in molecular
terms, a newly developed algorithm (MDFIT)27 that integrates molecular simu-
lation with experimental maps was employed.
Full Methods and any associated references are available in the online version of
the paper at www.nature.com/nature.
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METHODS
Formation of the EF-G–70S–GDP–FA complex. The fusA gene, encoding EF-G,
was cloned from Thermus thermophilus HB8 genomic DNA into pET-46 Ek/LIC
vector using primers (TthEFG_for, 59-GCG CGC CCG GTG GTG ATG CAG
CTC TTC CTG GGC TCC GCC CTG AAG AAC-39; TthEFG_rev, 59-GTT CTT
CAG GGC GGA GCC CAG GAA GAG CTG CAT CAC CAC CGG GCG CGC-39)
in accordance with the manufacturer’s instructions (Novagen) and expressed
in BL21 (DE3) cells. Recombinant EF-G protein was then purified with a Ni21-
nitrilotriacetate affinity column, followed by gel filtration in a buffer containing
10 mM Tris pH 7.8, 100 mM NaCl and 10 mM 2-mercaptoethanol. Tight-coupled
70S ribosomes were purified from exponential-phase T. thermophilus cells by using
sucrose-density-gradient centrifugation, as described previously for 30S subunits28.
As observed previously, the ribosomes contained a co-purified tRNA14,29. Binding of
EF-G to 70S ribosomes was done by incubating 20mM purified EF-G protein for
15 min with 5mM T. thermophilus 70S ribosomes, 500mM GTP and 500mM FA at
65 uC, in a buffer containing 10 mM HEPES-KOH pH 7.8, 30 mM MgCl2 and
75 mM NH4Cl. The occupancy of EF-G in the complexes was about 60–70%, as
judged by centrifugal binding assay28.
Cryoelectron microscopy and image processing. Ribosomal complexes were
diluted to a concentration of 30 nM and subsequently frozen onto Quantifoil grids
using a Vitrobot (FEI) device. Micrographs where collected on a Tecnai G2 Polara
(FEI) at 300 kV and a magnification of 339,000 under low-dose conditions
(19 e2 Å22) and scanned on a D8200 Primscan drum scanner (Heidelberger
Druckmaschinen) with a step size of 4.758mm, corresponding to 1.26 Å on the
specimen scale.
The Contrast Transfer Function defocus values for the micrographs were deter-
mined with CTFind30. Ribosomal projection images were automatically identified
with the program Signature31 and were subsequently screened visually or auto-
matically. From the selected projections, a reconstruction was generated by pro-
jection matching procedures and refined with the SPIDER software package32. The
complete data set comprised 586,848 projection images collected from 677 micro-
graphs at a defocus range of 1.3–4.8mm. During the later refinement rounds,
positivity of the reference volumes was enforced, the power spectrum of the
cryoelectron microscopy map was scaled to the power spectrum of a model density
derived from the atomic coordinates of the X-ray structure of the 70S ribosome33,
and the map was subsequently low-pass filtered according to the current resolu-
tion estimate.
After a first phase of multiparticle refinement20,26,34,35, performed with three-
times or two-times decimated pictures, we obtained a major subpopulation (52%;
303,665 particle images) that had strong EF-G density (Supplementary Fig. 1).
However, as refinement progressed and the resolution reached the subnanometre
range the data set was deemed heterogeneous. Parts of the 30S subunit, especially
the head domain, became partly disordered. A second phase of multiparticle
refinement was therefore employed, leading to the subdivision of the data into
two further substates having EF-G (Supplementary Fig. 1). Both data subsets were
further refined individually at full image size. The final reconstructions of
substate I (113,214 particle images) and substate II (156,332 particle images)
reached resolutions of 7.8 Å and 7.6 Å, respectively (Supplementary Fig. 2).
Using a similar strategy we revisited the previous data set (362,361 particle
images; 371 micrographs) of the 70S–EF-G–GMPPNP complex14. In a first phase
of multiparticle refinement a major population (118,991 particle images) was
further sorted by a second phase of multiparticle refinement resulting in
substate I (58,911 particle images) and substate II (38,055 particle images). The
resolutions of the maps were 9.6 Å and 10.5 Å, respectively. As the resolution for
the reconstructions of the 70S–EF-G–GMPPNP complex was significantly lower
(as a result of the smaller size data set) than the resolutions obtained for the 70S–
EF-G–GDP–FA complex, we restricted the comparison to a dissection of only the
global conformational changes, such as ratcheting and head swivelling.
Nevertheless, this analysis suggests that the 70S–EF-G–GMPPNP complex
coexists in two substates that resemble TIPRE and TIPOST of the 70S–EF-G–
GDP–FA complex (Supplementary Fig. 5 and Supplementary Table 1). The ratio
of particles within each of the two substates of the 70S–EF-G–GMPPNP complex
is inverted with respect to the 70S–EF-G–GDP–FA complex: in the 70S–EF-G–
GMPPNP complex the particle ratio of TIPRE and TIPOST is about 3:2
(58,911:38,055), whereas in the 70S–EF-G–GDP–FA complex the ratio is about
2:3 (113,214:156,332). This means that most of the ribosomes in the 70S–EF-G
complex stalled with a non-hydrolysable GTP analogue are in TIPRE (substate I),
having a fully ratcheted 30S subunit but only a modest head swivel. However, in
the 70S–EF-G complex stalled with GTP and FA, TIPOST dominates and here an
intermediate inter-subunit rotation is coupled with a large head swivel instead
(Supplementary Figs 4 and 5 and Supplementary Table 1).
Structure-based simulation fitting (MDFIT). To determine atomic models con-
sistent with the cryoelectron microscopy densities, we employed structure-based
molecular simulation27,36,37 together with an energetic term developed in ref. 38,
which incorporates the correlation between the simulated and experimental elec-
tron density throughout the simulation. Tama and co-workers38 developed a
similar method, which used a standard explicit solvent force field, as opposed to
the structure-based force field. The advantage of the structure-based force field is
that, because the potential energy function is defined by the X-ray structure,
MDFIT retains tertiary contacts present in the X-ray structure without special
constraints. Furthermore, because MDFIT explicitly includes all non-hydrogen
atoms, there are no atomic clashes and proper stereochemistry is maintained in all
fits.
We began the MDFIT procedure with a structure-based potential energy func-
tion defined by the classical unratcheted conformation. To induce hybrid-state
formation and subunit pivoting we introduced the energetic term based on the
correlation between the simulated cryoelectron microscopy map and the experi-
mentally determined cryoelectron microscopy map. Specifically, the potential
energy function is
V~VSBzVmap~VSB{W
X
ijk
rsimijk r
exp
ijk ð1Þ
where W is the energetic weight of the map and rexpijk and r
sim
ijk are the normalized
experimental and simulated electron densities at voxel (i,j,k), respectively. The
quantity VSB is the structure-based potential energy function. To calculate the
simulated map, each atom is described by a Gaussian function of width 5 Å with
the tail truncated at 1% of the peak value. Here, because the structure-based
forcefield has 1 unit (all calculations were in reduced units) of stabilizing energy
per atom (by construction), we set W to a comparable value of 150,000. The
contributions to the force due to Vmap were updated every 200 time steps.
Fitting simulations employed Langevin dynamics. All simulations were performed
with code based on Gromacs version 4.0.5 (refs 39, 40). Calculations were per-
formed on the Encanto Supercomputer. The structure-based force field is freely
available online (http://smog.ucsd.edu).
Structural models. The crystallographic structure of the 70S ribosome in complex
with EF-G19 (PDB IDs 2WRI and 2WRJ) was used as an initial structure for
MDFIT. Proteins without side chains in the X-ray structure were removed. The
carboxy-terminal domain of ribosomal protein L7 from PDB entry 1RQU41 was
inserted by hand, before fitting. The E-site tRNA was also removed from the initial
X-ray structure in accordance with the cryoelectron microscopy map. The P-site
tRNA was included in the fitting process. To facilitate fitting of the tRNA molecule
into a P/E conformation, stabilizing interactions between the tRNA and the ribo-
some were removed. Stabilizing interactions between EF-G and the ribosome (due
to their proximity in the crystal structure) were also excluded from the calcula-
tions, as were stabilizing interactions between L7 and all other components in the
system. Further, crystallographic interactions found between the 39-CCA end of
the E-site tRNA with the E site of the 50S subunit were reintroduced as short-range
(of the type 6-12; see refs 27, 36, 37) attractive interactions between the 39-CCA
end of the fitted tRNA and the E site of the 50S subunit. Introducing these inter-
actions ensured that the 39-CCA end of the P/E tRNA was in a conformation
identical to that of a classically bound E-site tRNA, although because these inter-
actions were short-range they only affected the process once the major rearrange-
ments in the tRNA had already been achieved. Codon–anti-codon interactions
were restrained by harmonic interactions with minima corresponding to the
classical configuration.
The tRNA–ribosome–EF-G crystal structure was first manually aligned in
VMD42, as a single rigid unit, to the map of TIPRE. The first round of fitting was
performed with the TIPRE map after subjecting it to a 4-Å Gaussian low-pass filter.
This filter decreased noise, effectively smoothing the energetic profile associated
with Vmap, which permitted more rapid fits. After 106 integration steps, the fit was
continued for an additional 106 steps with Vmap based on the TIPRE map filtered at
2 Å. The TIPOST map, filtered at 2 Å, was then fitted, using the TIPRE 4-Å fitted
structure as the initial structure.
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Abstract 
Elongation factor P (EF-P) is a highly conserved bacterial protein that interacts with 
the ribosome and stimulates peptide bond formation. Lysine 34 (K34) of 
Escherichia coli EF-P is lysinylated by YjeK and YjeA. Both EF-P and the 
modification are important for growth, drug resistance and virulence in pathogenic 
bacteria. Here we show that the currently accepted EF-P modification pathway is 
incomplete and that in vivo endogenous EF-P carries a unique ε(R)-β-lysyl-
hydroxylysine modification. Firstly, we demonstrate that lysinylation of EF-P by 
YjeK and YjeA results in the addition of β-lysine to the ε-amino group of K34. 
Additionally, we have discovered a hydroxylase, YfcM, which subsequently modifies 
the C4/C5 position of K34 of lysinylated EF-P. YfcM is distinct from the 
deoxyhypusine hydroxylase involved in the maturation of eIF5A, the eukaryotic 
homolog of EF-P, indicating that bacteria and eukaryotes have evolved alternative 
pathways to maintain the fully modified state of these translation factors.  
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Introduction 
Elongation factor P (EF-P) was originally identified as a soluble protein that binds to 
the ribosome and stimulates peptide bond formation1-4. Under some conditions EF-P 
has been shown to enhance the translation of natural and synthetic mRNAs in vitro3. 
EF-P is detected in the monosome and polysome fractions5 suggesting that EF-P not 
only promotes formation of the first peptide bond, but may also be involved during 
translation elongation. Deletion of the efp gene leads to defects in (i) growth of 
E. coli6 and Acinetobacter baylyi7, (ii) swarming8 and sporulation9 of Bacillus subtilis, 
and (iii) virulence of Agrobacterium tumefaciens10. EF-P has a ubiquitous 
distribution, being conserved in all bacteria11 and orthologous to archaeal and 
eukaryotic initiation factor 5A (a/eIF-5A)12. Similarly to EF-P, eIF-5A was also 
identified based on its ability to stimulate Met-puromycin formation (reviewed by 13). 
Moreover, eIF-5A is essential in yeast and higher eukaryotes, and depletion studies in 
yeast indicate that loss of eIF-5A leads to a significant reduction in protein synthesis 
in vivo13-16.  
Crystal structures of bacterial EF-P reveal a three domain (I-III) 
architecture6,17,18, whereas a/eIF-5A lack the C-terminal domain III of EF-P19,20. A 
strictly conserved lysine in domain I of eIF-5A is the site of a unique modification, 
called hypusine (reviewed by13). Co-sedimentation experiments indicate that eIF-5A 
binds to translating ribosomes in a hypusine-dependent manner13. The equivalent 
lysine 34 (K34) of endogenous E. coli EF-P has also been reported to carry a 
modification of ~144 Da5. Bound to the ribosome, K34 of EF-P, and by analogy the 
hypusine of eIF-5A, would interact with the CCA-end of the P-tRNA, suggesting that 
EF-P and eIF-5A stimulate peptide bond formation through stabilization and 
positioning of the acceptor end of the P-tRNA18. 
Hypusine is added post-translationally to eIF-5A in two enzymatic steps13; 
first, deoxyhypusine synthase (DHS) attaches the amino-butyl moiety of spermidine 
to the lysine of eIF-5A, and then the attached butyl moiety is hydroxylated by 
deoxyhypusine hydroxylase (DOHH). eIF-5A and DHS are essential in yeast, and 
while DOHH is dispensable in yeast, it is essential in higher eukaryotes13. Although 
the DHS and DOHH genes are absent from the E. coli genome, two unrelated 
enzymes, YjeK and YjeA (also termed PoxA/GenX), have been implicated in the EF-
P modification pathway6,11,21. Deletion of yjeA or yjeK in Salmonella typhimurium 
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leads to growth defects, antibiotic sensitivity and attenuation of virulence21-24, similar 
to that reported for Δefp in A. tumefaciens10. YjeK is a lysine 2,3-aminomutase that 
converts (S)-α-lysine to (R)-β-lysine25, whereas YjeA has homology to class II lysine-
tRNA synthetases but lacks the tRNA anticodon recognition domain11. In vitro 
biochemical assays indicate that YjeA cannot aminoacylate tRNALys,26 but can 
activate lysine and transfer it to K34 of EF-P6,21. Recently, (R)-β-lysine was shown to 
be 100-fold more efficient as a substrate for lysinylation of EF-P by YjeA than either 
(S)-β-lysine or α-lysine27. Curiously, mass spectrometry analyses indicate that 
lysinylation of K34 of EF-P by YjeA results in an ~128 Da modification6,21,27, leaving 
a difference of ~16 Da unexplained and unaccounted for when compared with the 
~144 Da reported for endogenous EF-P5.  
We have used an E. coli lysate-based immuno-precipitation approach, coupled 
with high-resolution mass spectrometry (MS) and SILAC labeling, to characterize the 
chemical nature of the E. coli EF-P modification and delineate the modification 
pathway in vivo. Here we demonstrate that endogenous E. coli EF-P bears a 
+144.09 Da modification, resulting from the formation of ε(R)-β-lysyl-hydroxylysine 
of K34. The sequential action of YjeK and YjeA is responsible for the addition of 
128.09 Da, with MS fragmentation data supporting the presence of β-lysine, rather 
than α-lysine, attached to the ε-amino group of K34 of EF-P. Additionally, we have 
discovered that the hypothetical protein YfcM is responsible for the discrepancy of 
16 Da between the reported in vitro and in vivo results. Indeed, we can show that 
YfcM is involved in the modification of either the C4 (γ) or C5 (δ) position of K34 of 
EF-P. YfcM is unrelated in origin and mechanism to the eukaryotic DOHH and 
although lysyl-5-hydroxylases have been reported in eukaryotes, this would be the 
first report of C4/C5-hydroxylase activity in bacteria. 
Results 
Lysine 34 of endogenous E. coli EF-P is modified by 144.09 Da 
Previous mass spectrometry (MS) analyses of tryptic fragments of in vitro 
modified EF-P reported mass increases of 127.7 Da6 and 128 Da21, compared with 
143.77 ± 0.15 Da for endogenous EF-P5. Because of limited accuracy of the MS and 
the lack of supporting MS spectra in the latter publication, we decided to re-examine 
the modification state of endogenous E. coli EF-P. To do this, endogenous EF-P was 
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isolated from the S100 fraction of E. coli strain MRE600 using multi-step 
chromatography28,29 and analyzed using high resolution and high mass accuracy nano-
LC-MS/MS approach. MS of the full-length endogenous EF-P revealed a mass 
(mono-isotopic, unless otherwise stated) of 20,591.6 Da (Fig. 1a), which is 
144.2 ± 0.1 Da larger than the expected mass of unmodified EF-P (20,477.4 Da, with 
N-terminal methionine cleaved off). To identify the site of modification, endogenous 
EF-P was immuno-precipitated from cell lysate using antibodies raised against 
recombinant E. coli EF-P and peptide fragments were generated by proteolysis using 
either chymotrypsin, which preferentially cleaves on the carboxyl side of Leu, Tyr, 
Trp and Phe, or the peptidase LysC, which preferentially cleaves on the carboxyl side 
of unmodified Lys. As expected, the chymotrypsin fragment containing K34 
(F.30VKPGK*GQAF38.A) was the only peptide observed to have an increased mass, 
namely 1074.62 Da, which is 144.09 Da larger than the theoretical mass of 930.53 Da 
(Fig. 1b), and similar to that reported previously for endogenous EF-P5. Similarly, 
digestion of endogenous EF-P with LysC produced a peptide 
(K.32PGK*GQAFARVK42.L) with a mass of 1301.76 Da - again an increase of 
exactly 144.09 Da compared with the theoretical size of 1157.67 Da (Fig. 1c). 
Although the +144.09 Da modification state appears to be the predominant form of 
EF-P in the cell, peptides with masses corresponding to the partially modified 
(+128 Da) state were also detected, but only at ~1-2% of the level of the fully 
modified form (Supplementary Fig. 1). 
Fragmentation of both the chymotrypsin peptide (F.VKPGK*GQAF.A) and 
the LysC peptide (K.PGK*GQAFARVK.L) revealed the modification site to be K34 
(Fig. 1b and 1c), as expected from previous studies5,6,11,21. In the case of the LysC 
peptide, fragmentation of the doubly charged peptide precursor gave rise to four 
intense doubly charged peaks corresponding to the modified LysC peptide 
(K.PGK*GQAFARVK.L), but with nominal mass losses of 86 Da, 104 Da, 128 Da 
and 145 Da (peaks labeled X1-X4, respectively, in Fig. 1c). Similar peaks were also 
observed when a triply charged peptide precursor was fragmented in the MS (Fig. 
3c,d, Fig. 4a,b and Supplementary Table 1). These mass peaks are consistent with 
the loss of a series of fragments from the modified K34, but not from C-terminal K42, 
as determined by [18]O-labeling (Supplementary Table 1 and Supplementary Fig. 
2): Peak X4 has a mass loss of 145 Da, which would result if the C6-N6 bond of the 
lysinylated K34 was fragmented (F4 in Fig. 1d), whereas the mass loss of 128 Da 
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(peak X3) is consistent with fragmentation at the amide bond between the ε-amino 
group of K34 and the carbonyl carbon of the added lysine (F3 in Fig. 1d). These 
fragmentation peaks therefore support the attachment of the activated lysine to the ε-
amino group of K34 during lysinylation by YjeA, as assumed previously6,11,21. In 
contrast, mass losses of 86 Da and 104 Da (peaks X1 and X2) would arise when the 
linkage between the C2 (α) and C3 (β) positions of the added lysine are fragmented, 
with the additional loss of water (18 Da) from the peptide in peak X2 (F1 and F2 in 
Fig. 1d). Importantly, the loss of the 86 Da mass is explainable only if β-lysine, rather 
than α-lysine, is attached to K34. If α-lysine were present then fragmentation at the 
same bond would generate a mass loss of only 72 Da and such fragmentation event 
would be very rare and unexpected. Collectively, the fragmentation data suggest that 
modification of endogenous EF-P comprises β-lysine attached to ε-amino group of 
K34 accounting for 128 Da, and that the additional 16 Da modification is associated 
with K34 of endogenous EF-P, rather than the added lysine. 
In vivo lysinylation of EF-P by YjeA requires YjeK  
In order to demonstrate that YjeA and YjeK are responsible for the 
modification of K34 of EF-P in vivo, endogenous EF-P was immuno-precipitated 
from E. coli AT713 strains lacking the genes for yjeA (ΔyjeA) or yjeK (ΔyjeK), as 
performed above for the parental strain. In the case of ΔyjeA, only chymotrypsin 
could be used since LysC proteolysis resulted in digestion of unmodified K34-
containing region into small peptides that were undetectable in our analysis. 
Chymotrypsin proteolysis of EF-P from the ΔyjeA strain produced a fragment 
containing K34 (F.30VKPGKGQAF38.A) that had a mass of 930.53 Da (Fig. 2a), 
corresponding exactly with the expected mass of 930.53 Da for the unmodified form. 
This is consistent with the finding that YjeA is the critical enzyme responsible for the 
in vitro modification of K34 of EF-P6,21,27. When YjeA was exogenously 
overexpressed from a plasmid (pYjeA) in the ΔyjeA strain, two LysC fragments 
containing modified K34 were detected: One fragment had a mass of 128.09 Da (data 
not shown) corresponding exactly with the predicted mass increase (+128.09 Da) 
when activated lysine is transferred to the ε-amino group of K34 of EF-P, as 
illustrated in Fig. 1d. The second fragment was 144.09 Da larger than the unmodified 
peptide (data not shown) and thus was identical to the mass detected in the 
endogenous EF-P from the parental wildtype strain, as illustrated in Fig. 1c). 
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Similarly, modified and unmodified chymotrypsin fragments were also 
detected upon proteolysis of EF-P isolated from the ΔyjeK strain (Fig. 2b, c). The 
modified form of the chymotrypsin fragment had a mass of 1058.62 Da (Fig. 2c), 
corresponding to a mass increase of +128.09 Da when compared with the expected 
mass (930.53 Da) of the unmodified form (note that the +144 Da-modified peptide 
was not detected). Quantification of the relative intensities of the peak areas for the 
modified (4.46 x 106) and unmodified fragments (2.18 x 108) reveals that the modified 
form is present at only ~2 % of the level of the unmodified form, assuming that these 
peptides ionize with similar efficiency (Fig. 2d). These observations indicate that 
while YjeA can perform the lysinylation of EF-P in vivo in the absence of YjeK (and 
therefore in the absence of (R)-β-lysine), the reaction appears to be extremely 
inefficient. Indeed, in vitro lysinylation of EF-P by YjeA performed in the absence of 
YjeK was also inefficient, requiring incubations of between 2-4 hours6,21. However, 
the reaction was 100-fold more efficient when (R)-β-lysine, rather than either (S)-β-
lysine or α-lysine, was used as a substrate27. Similarly, efficient modification of 
exogenously overexpressed EF-P was only observed when EF-P was co-expressed 
with both YjeA and YjeK6. Nevertheless, it should be re-emphasized that in the 
reported in vitro lysinylation and co-expression experiments, the modification of K34 
of EF-P was shown to be ~128 Da6,21, rather than ~144 Da of endogenous EF-P, as 
shown here (Fig. 1) and reported previously5. 
Fully modified EF-P requires the presence of YfcM 
Given the discrepancy of 16 Da between the modification mass of the 
endogenous EF-P (+144 Da; Fig. 1)5 and in vitro lysinylated EF-P (+128 Da)6,21, we 
reasoned that a third enzyme should exist that is also involved in the modification of 
K34 of EF-P in vivo. Moreover, the enzyme should be dependent on the action of 
YjeK and YjeA, since the absence of either of these genes leads to a predominance of 
completely unmodified EF-P in vivo (Fig. 2). We therefore used the STRING (Search 
Tool for the Retrieval of Interacting Genes/Proteins) database (http://string.embl.de) 
to search for proteins associated with YjeA, YjeK and EF-P. A query using E. coli 
PoxA (YjeA), for example, revealed an association (confidence value 0.6) with five 
proteins: EF-P, YjeK and three additional proteins YfcM, HflD and ECs0957. HflD is 
already reported to be involved in the λ lysis-lysogeny switch and ECs0957 has 
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homology with pyruvate dehydrogenases. In contrast, BLAST searches indicate that 
YfcM has no reasonable homology with any protein of known structure or function. 
To investigate the potential involvement of YfcM in the modification of EF-P 
in vivo, we immuno-precipitated endogenous EF-P from the E. coli AT713 strain 
lacking the yfcM gene (ΔyfcM). Chymotrypsin proteolysis of EF-P from the ΔyfcM 
strain produced a fragment containing K34 (F.30VKPGKGQAF38.A) with a mass of 
1058.62 Da (Fig. 3a) - a mass increase of 128.09 Da when compared with the 
expected mass of 930.53 Da for the unmodified fragment. When YfcM was 
exogenously overexpressed from a plasmid (pYfcM) in the ΔyfcM strain, the mass of 
the chymotrypsin fragment increased to 1074.62 Da (Fig. 3b), which is 144.09 Da 
larger than the unmodified fragment and identical to the mass increase observed for 
endogenous EF-P (see Fig. 1b,c). Similarly, the LysC fragment of EF-P containing 
K34 (K.32PGK*GQAFARVK42.L) isolated from the ΔyfcM strain had a mass of 
1285.76 Da (Fig. 3c), exactly 128.09 Da larger than the unmodified fragment 
(1157.67 Da). The mass of the LysC fragment increased to 1301.76 Da with YfcM 
overexpression (Fig. 3d), indicating the YfcM is required for the addition of exactly 
15.995 Da of the 144 Da that comprises the modification of K34 of endogenous EF-P. 
The precision of the mass difference, i.e. 15.995 Da, is indicative of one atom of 
molecular oxygen, which has a monoisotopic mass of 15.995 Da, thus revealing 
YfcM as a potential hydroxylase (mono-oxygenase) that modifies K34 of lysinylated 
EF-P.  
The C4/C5 position of lysine 34 of EF-P is hydroxylated 
Eukaryotic lysine hydroxylases modify the C5 position of lysine, which plays 
a critical role in the formation and stabilization of collagen, and loss of this activity 
leads to connective tissue disorders such as Ehlers–Danlos syndrome30. In contrast, to 
our knowledge, the only lysine hydroxylase activities reported in bacteria are the 
lysine N6-hydroxylase involved in the synthesis of siderophores, such as aerobactin31 
and the lysine-2-mono-oxygenases involved in lysine degradation32. YfcM has no 
apparent homology with any of these enzyme families. Thus, in order to determine the 
site of hydroxylation by YfcM on K34 of EF-P, we utilized differentially deuterated 
lysine isoforms, namely 3,3,4,4,5,5,6,6-D8-L-lysine (D8-Lys) and 4,4,5,5-D4-L-
lysine (D4-Lys) where the hydrogen atoms (1.008 Da) of the C3-C6 and C4-C5 
positions of L-lysine, respectively, are substituted with deuterium (2.014 Da).  
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The lysine (and arginine) auxotrophic E. coli wildtype AT713 and 
AT713ΔyfcM strains were grown in minimal media supplemented with D4- or D8-
lysine, rather than unlabelled D0-lysine. The endogenous EF-P was immuno-
precipitated from the lysates as before and then digested with LysC. The masses of 
the K34 containing LysC fragment (K.32PGK*GQAFARVK42.L) of EF-P isolated 
from the ΔyfcM strain were determined as 1297.84 Da when grown in D4- (Fig. 4a) 
and 1309.91 Da in D8-Lys (Supplementary Fig. 3a), i.e. mass increases of 
+12.07 Da or +24.15 Da, respectively when compared with the mass determined in 
D0-Lysine (1285.76 Da seen in Fig. 3c). Since the LysC fragment contains three 
lysines; K34, K42 and the lysine added to K34; the expected theoretical mass 
increases are calculated as [3 x 1.0063 Da x 4 (D4) =] +12.08 Da for D4-lysine and [3 
x 1.0063 Da x 8 (D8) =] +24.15 Da for D8-lysine, which are in very good accordance 
with the experimental masses of +12.07 Da and +24.15 Da, respectively.  
In contrast, the same LysC fragments isolated from the wildtype strain had 
masses of 1312.83 Da in D4-Lys (Fig. 4b) and 1324.90 Da in D8-Lys 
(Supplementary Fig. 3b), which are only +11.07 Da and +23.14 Da larger when 
compared with the mass determined in D0-Lys (1301.76 Da seen in Fig. 1c). When 
compared with the masses from LysC fragments isolated from the ΔyfcM strain, both 
LysC fragments from the wildtype YfcM-containing strain are 14.993 Da larger, 
instead of the expected 15.995 Da. This is consistent with 14.988 Da increase 
expected by the mass loss of a deuterium atom (-2.014 Da) and the addition of a 
hydroxyl OH group (+17.003 Da [= 15.995 Da + 1.008 Da]). Moreover, because the 
1 Da loss is observed in both the D4- and D8-labelled fragments, this indicates that 
YfcM hydroxylates either the C4 (γ) or C5 (δ) position, but not the C3 (β) or C6 (ε) of 
K34 (Fig. 4c and Supplementary Fig. 3c). 
Furthermore, data from the fragmented D8-labelled LysC peptide 
(K.32PGK*GQAFARVK42.L) from both ΔyfcM and wildtype EF-P indicate that K34 
is indeed β-lysinylated (Supplementary Table 2). It has previously been shown that 
the aminomutase YjeK transfers the α-amino group from C2 (α) to C3 (β), while one 
of the C3 (β) hydrogens is transferred back to C2 (α)25, a reaction mechanism that is 
in very good accordance with our observations. Namely, the D8-labelled F1 and F2 
fragments were ~1.006 Da smaller than anticipated (93.129 Da instead of 94.135 Da, 
and 111.140 Da instead of 112.145, respectively), which would correspond to a 
situation where one of the C3 (β) deuteriums has been transferred to the C2 (α), 
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thereby indicating that these fragments can only be derived from β-lysine 
(Supplementary Table 1 and Supplementary Fig. 2). Both F3 and F4 fragments 
have a mass identical to that of theoretical lysine fragments containing eight 
deuteriums, confirming the conclusion that one deuterium is transferred from the C3 
(β) to C2 (α) and not lost during the reaction (Supplementary Fig. 2).  
In conclusion, fragmentation data using the D4- and D8-labelled LysC 
fragments, together with [18]O-labeling, is consistent with our previous suggestion 
that the additional 16 Da mass corresponding to lysine hydroxylation is associated 
with K34 of EF-P and not with the added β-lysine (Supplementary Table 1). 
 
Substrate specificity of the YfcM hydroxylase 
The eukaryotic lysine-5-hydroxylases utilize Fe2+, O2 and α-ketoglutarate to 
carry out oxidation, and then use ascorbic acid to return the iron to its oxidized state30. 
Similarly, human DOHH activity is also dependent on Fe2+ and O2
33, but not α-
ketoglutarate or ascorbic acid34. In contrast, the substrates for the bacterial lysine-N6-
hydroxylases include NADPH, H+, O2 and the reaction requires FAD
31, whereas 
lysine-2-monoxygenases utilize O2 and FAD but do not require metals
32. To screen 
for potential substrates of YfcM, we utilized differential scanning fluorimetry (DSF), 
which monitors the increase in thermal stability of a protein due to the interaction 
with a ligand35. The thermal stability of recombinant YfcM protein was measured 
across a library of diverse ligands, including α-ketoglutarate, ascorbic acid, co-
enzyme A (CoA), FAD, NAD, NADH, NADP, NADPH, ATP, ADP, PLP, L-lysine, 
thiamine, oxaloacetate, tetrahydrofolate, succinate as well as metals, such as Fe2+ and 
Mg2+ (Supplementary Fig. 4). The largest increases in thermal stability for YfcM 
were observed with nucleotide-based chemicals, for example, the maximum shift of 
~5°C was observed in the presence of <600 µM NADP or CoA (Fig. 5a). In contrast, 
other ligands, such as Fe2+, α-ketoglutarate or ascorbic acid did not stabilize YfcM 
(Supplementary Fig. 4), even at significantly higher concentrations (<10 mM). 
These findings suggest that YfcM is more likely to use a NAD- or FAD-based co-
factor similar to other bacterial lysine hydroxylases, rather than Fe2+ or α-
ketoglutarate/ascorbic acid co-factors as used by eukaryotic lysine hydroxylases. 
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The genomic distribution and context of yfcM 
Previous bioinformatic analysis of 725 bacterial genomes revealed the 
presence of genes for efp, yjeA and yjeK in 200 genomes (28%)11. Here we have 
extended this analysis to include predicted proteomes of 1268 completely sequenced 
bacterial genomes and detect the presence of the YfcM protein in 179 species 
clustering within the γ-proteobacteria phyla (Fig. 5b, Supplementary Table 2 and 
Supplementary Fig. 5). All bacterial species that contain the yfcM gene also have 
efp, yjeA and, with one exception (Haemophilus influenzae strain PittGG), yjeK 
(Supplementary Table 2). Moreover, we find that a lysine, equivalent to position 34 
in E. coli EF-P, is strictly conserved (100%) in organisms that contain YfcM 
(Supplementary Table 2). However, unlike yjeA and yjeK that often cluster together 
in the same operon as efp11, yfcM is always located in a distinct region of the 
chromosome. The six-gene operon structure of the prmC-aroC-mepA-yfcA-yfcM-yfcL 
operon is highly conserved within the Enterobacteriaceae family (Fig. 5b). yfcA and 
yfcL are hypothetical proteins of unknown function, whereas aroC and mepA are 
annotated as chorismate synthase and Murein DD-endopeptidase, respectively. 
Curiously, the yfcM gene often neighbors other modification enzymes, such as the 
methyltransferases prmB and prmC, which modify ribosomal protein L3 and release 
factor RF1/RF2, respectively, as well as mnmC and yrdC (rimN) that are involved in 
tRNA modification36,37 (Fig. 5b). 
Discussion 
Here we have used high-resolution mass spectrometry to characterize the chemical 
composition of the lysinylation modification of EF-P as well as the enzymes of 
modification pathway. We demonstrate that the conserved K34 of endogenous E. coli 
EF-P bears a 144.09 Da modification, which results from two distinct reactions, 
namely a 128.09 Da lysinylation performed by YjeK and YjeA, followed by an 
additional 16 Da hydroxylation by YfcM (Fig. 6a). Our mass spectrometry 
fragmentation data support not only the attachment of the lysine to the ε-amino group 
of K34, but also indicate the presence of β-lysine, rather than α-lysine, as a product of 
the lysinylation reaction (Fig. 1c,d, Supplementary Table 1, and Supplementary 
Fig. 3). Moreover, the low level of modified peptide observed in the absence of yjeK 
(Fig. 2b-d), suggests that the conversion of (S)-α-lysine to (R)-β-lysine by YjeK 
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precedes the lysinylation of EF-P by YjeA (Fig. 6a). This is consistent with the 
observation that lysinylation of EF-P by YjeA is 100-fold more efficient using (R)-β-
lysine instead of α-lysine27 and that lysinylation of exogenously overexpressed EF-P 
requires co-expression of both YjeK and YjeA6. We believe that YfcM is the last 
enzyme in the EF-P modification pathway: The lack of +16 Da modified EF-P 
peptides in any of the ΔyjeK or ΔyjeA MS spectra suggests that YfcM cannot 
hydroxylate unmodified EF-P and therefore acts after YjeK and YjeA. Moreover, the 
+144 Da modified peptide was never detected in the ΔyjeK strain, which most likely 
indicates that α-lysinylated EF-P is a poor substrate for YfcM and that β-lysinylated 
EF-P is preferred. This is similar to the eukaryotic situation where 
deoxyhypusinylation of eIF-5A by DHS is a prerequisite for the subsequent 
hydroxylation by DOHH13 (Fig. 6b). In contrast to eIF-5A where the added 
spermidine moiety is hydroxylated by DOHH, our fragmentation data support the 
hydroxylation by YfcM of the C4 or C5 position of K34 of EF-P, but not 
hydroxylation of the added β-lysine (Fig. 1c,d, Supplementary Table 1, and 
Supplementary Fig. 3).  
 The crystal structure of T. thermophilus EF-P bound to the 70S ribosome 
suggests that EF-P stimulates peptide bond formation by interacting with and 
stabilizing the tRNA at the P-site18. Modeling E. coli EF-P on the ribosome using the 
T. thermophilus structure, suggests that K34 and the lysinylation moiety would extend 
towards the peptidyl-transferase center and stabilize the CCA-end of the tRNA (Fig. 
6c)18. Based on this model, hydroxylation of the C5 (δ), but not of the C4 (γ), position 
of K34 would allow additional potential stabilizing hydrogen bond interactions with 
the P-tRNA (Fig. 6c). EF-P and the lysinylation pathway are critical for attenuation of 
virulence in bacteria10,21-24. The taxonomic distribution reveals yfcM to be present 
with the yjeK and yjeA genes in most common Gram-negative pathogenic bacteria, 
such as Acinetobacter baumannii, Escherichia coli O157:H7, Haemophilus 
influenzae, Klebsiella pneumoniae, Legionella pneumophila, Salmonella 
typhimurium, Vibrio cholerae and Yesinia pestis (see Fig. 5b and Supplementary 
Table 2). Proteomics studies comparing wildtype S. typhimurium with ∆yjeA or 
∆yjeK strains reveal large changes in the expression of proteins involved in virulence 
and metabolic adaption21,24, suggesting that EF-P and the lysinylation modification 
are important for translational regulation of particular mRNAs. With a complete 
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description of the EF-P modification and pathway now in hand, this opens the way for 
future studies to address the mechanism of action of EF-P. 
Methods 
Strains. The parental strain E. coli K-12 BW25113 and the single gene deletion 
mutants Δefp (JW4147), ΔyjeK (JW4106), ΔyjeA (JW4116) and ΔyfcM (JW5381) 
were obtained from the Keio collection (National BioResource Project (NBRP) at the 
National Institute of Genetics (NIG), Japan38). Note that the ΔyjeK strain was taken 
from plate 38, since the isolate on plate 37 is not a bone fide yjeK knock-out strain39. 
The E. coli strain AT71340, which is auxotrophic for arginine and lysine, was kindly 
provided by Matthias Selbach (Max-Delbruch Zentrum, Buch-Berlin, Germany). P1 
transduction from the Keio strains was used to generate the equivalent single gene 
deletions Δefp, ΔyjeK, ΔyjeA and ΔyfcM in the AT713 background40. The deletions 
were confirmed using PCR and the strains were confirmed to be auxotrophic for 
arginine and lysine (data not shown). 
 
Plasmids and protein expression. The efp, yjeK, yjeA and yfcM genes were PCR 
amplified from gDNA of E. coli K-12 strain MC4100 using the primers listed in 
Supplemental Table 3. For protein overexpression, the efp gene was cloned into 
pET14b (Novagen) using NdeI and BamHI restriction sites, whereas yfcM was cloned 
into pET21b (Novagen) using NdeI and SacI restriction sites. Both plasmids were 
transformed into BL21 (Novagen) and the overexpressed protein was purified using 
Ni-NTA (Novagen) chromatography according to manufacturers instructions, 
followed by gel filtration on a Superdex G75 column (GE Healthcare) in a buffer 
containing 100 mM Hepes-KOH pH 8.0, 125 mM NaCl, 25 mM KCl, 5 mM β-
mercaptoethanol, 10% glycerol. Purified recombinant EF-P was used to generate 
rabbit polyclonal antibodies (Davids Biotechnologie, Regensburg, Germany). For the 
rescue experiments, the yjeK, yjeA and yfcM genes were cloned into pQE70 (Qiagen) 
and transformed into the appropriate AT713 deletion strain. Unfortunately, for 
technical reasons the rescue experiment expressing YjeA in the ΔyjeA AT713 strain 
was inconclusive. 
 
Stable isotopic labeling and sample preparation. E. coli wildtype AT713 and 
deletion strains ΔyjeA, ΔyjeK and ΔyfcM in the AT713 background were grown in 
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50 ml MOPS minimal medium41 supplemented with 0.2% glucose and 100 µg/ml of 
each amino acid42. For stable isotopic labeling, ’light’ lysine was substituted with 
’heavy’ lysine: (4,4,5,5-D4)-lysine or (3,3,4,4,5,5,6,6-D8)-lysine (Cambridge Isotope 
Laboratories Inc., USA). Collected and PBS-washed cells were resuspended in 350 µl 
cold lysis buffer: 20 mM Tris-HCl pH 7.5, 100 mM NH4Cl, 6 mM Mg-acetate, 2 mM 
PMSF). After 30 min incubation on ice, 1 mg/ml lysozyme, 20 U/ml DNase I, 0.5% 
DOC, 1% Brij were added. Cells were disrupted by sonication with multiple short 
bursts of maximum intensity, and the cell debris and aggregated proteins were 
collected by centrifugation at 13000 x g for 15 min at 4 °C. The supernatant was pre-
cleared with 5 µl protein A bead suspension (Protein A Sepharose Fast Flow, GE 
Healthcare) for at least 30 min and then centrifuged. 30 µg of polyclonal antibody 
(1 mg/ml IgG was taken equal to 1.36 A280 units) was added to the pre-cleared lysate 
and incubated at 4 °C for 1 hour, followed by 40 µl of protein A beads and an 
additional incubation for 1 hour at 4 °C on rotator. The Sepharose beads were 
collected and washed several times with lysis buffer and the beads were resuspended 
in 1x SDS sample buffer, heated and EF-P protein was separated by SDS-PAGE. 
Proteins were in-gel digested with either LysC (Wako, Japan) or chymotrypsin 
(Promega, USA), according to standard procedures43. In case of [18]O-labeling, all 
steps were as before except for digestion which was carried out in [18]O-enriched 
water (Sigma, USA). Extracted peptides were purified on C18-StageTips44 and 
analyzed via nano LC-MS/MS. 
 
Nano-LC-MS/MS and direct infusion MS. Briefly, peptides were separated by 
reversed-phase chromatography using an Agilent 1200 series nanoflow system 
(Agilent Technologies) connected to a LTQ Orbitrap classic mass-spectrometer 
(Thermo Electron, Bremen, Germany) equipped with a nanoelectrospray ion source 
(Proxeon, Odense, Denmark). C18-StageTip purified peptides were dissolved in 0.1% 
trifluoroacetic acid, loaded on a fused silica emitter (75 µm × 150 mm, Proxeon) 
packed in-house with Reprosil-Pur C18-AQ 3 µm particles (Dr. Maisch, Germany) 
using a flow rate of 700 nl/min and separated with a 30 min 3-40% B gradient (A: 
0.5% acetic acid, B: 0.5% acetic acid/80% acetonitrile) at a flow-rate of 200 nl/min. 
Eluted peptides were sprayed directly into LTQ Orbitrap mass-spectrometer operated 
at 180 °C capillary temperature and 2.0-2.2 kV spray voltage. The LTQ Orbitrap was 
operated in data-dependent mode with up to five MS/MS scans being recorded for 
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each precursor ion scan. Precursor ion spectra were recorded in profile in the Orbitrap 
(m/z 300-1900, R = 60 000); data-dependent MS/MS spectra were acquired in 
centroid either in the LTQ for low-resolution data (CID NCE 35%, wideband 
activation enabled) or in the Orbitrap for high-resolution data (CID NCE 35%, 
R = 7500). Mono-isotopic precursor selection was enabled, singly charged ions and 
ions with an unassigned charge state were rejected, each fragmented ion was 
dynamically excluded for 90 s. All measurements in the Orbitrap mass analyzer were 
performed with lock-mass option enabled (lockmasses m/z 445.12003 and 
519.13882). Fragment MS/MS spectra from raw files were extracted as MSM files 
and then merged to peak lists using Raw2MSM version 1.11, selecting the top eight 
peaks for each 100 Da45. MSM files were searched with the Mascot 2.3 search engine 
(Matrix Science) against the protein sequence database composed of E. coli strain 
MG1655 sequences from UniprotKB and common contaminant proteins, such as 
trypsin, keratins etc. Search parameters were: 5 ppm for precursor mass tolerance, 
0.6 Da for ion-trap MS/MS mass tolerance or 0.02 Da for Orbitrap MS/MS mass 
tolerance, up to three missed cleavages plus a number of variable modifications such 
as oxidation (M), lysinylation (K), and hydroxylation (K) plus their isotopically-
labeled variants. Peptide hits returned by Mascot were manually validated and 
annotated when needed.  
For full protein analysis, C8-StageTip purified sample was directly infused 
into the mass-spectrometer using borosilicate static nanospray emitters (Proxeon, 
Denmark) and positive ionization mode. Measurements were done with an ionization 
voltage of 1000 V, m/z range of 800-1500 and resolution of 60,000 @ m/z 400, 100 
micro-scans were combined into one FT transient and external calibration was used. 
 
Differential scanning fluorimetry. Thermal-dependent unfolding of YfcM was 
measured using differential scanning fluorimetry35. Purified YfcM (15 µM) was pre-
mixed with SYPROrange dye according to manufacturers instructions (Invitrogen). 
YfcM stability was measured within a temperature range of 25-95°C using iCycler5 
(Bio-Rad). Data points were measured every 0.3°C with 25s pre-incubation time. 
Concentration-dependent stability of YfcM in the presence of NADP, NADPH, NAD, 
NADH, FAD, ADP, ATP, GTP, coenzyme A, tetrahydrofolic acid, PLP, oxaloacetic 
acid and thiamine was tested at concentrations 0-600 µM, while higher concentrations 
(0-250 mM) of L-ascorbic acid and α-ketoglutarate were necessary. Stocks of each of 
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the ligands (Sigma Aldrich) were prepared in DMSO and diluted using YfcM buffer 
(100 mM Hepes-KOH pH 8.0, 125 mM NaCl, 25 mM KCl, 5 mM β-mercaptoethanol, 
10% glycerol). 
 
Phylogenetic analyses. Protein sequences were retrieved by BlastP searching against 
the NCBI RefSeq database and aligned using MAFFT version 6.626b46. Maximum 
likelihood phylogenetic analyses were carried out using RaxML version 7.0.447 run on 
the Cipres server (http://www.phylo.org/sub_sections/portal/) with the 
PROTCATWAG model and 100 bootstrap replicates. Ambiguously aligned regions of 
alignments were not included. To determine the presence and absence of yfcM, yjeK 
and yjeA genes across bacteria, hidden markov models (HMMs) were constructed 
from multiple sequence alignments of each family using HMMer 3.0b248, and 
searched against 1273 genomes across the bacterial tree of life. The genomic 
neighborhood was retrieved using Entrez Gene49. 
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Figure Legends 
Figure 1: Lysine 34 of endogenous EF-P is modified by 144.09 Da. (a) MS 
spectrum of full-length endogenous EF-P from wildtype E. coli strain MRE600. (b) 
MS/MS spectra of chymotrypsin fragment with mass of 1074.62 Da, mass increase of 
144.09 Da compared to theoretical mass. (c) MS/MS spectra of LysC fragment with 
mass of 1301.76 Da, mass increase of 144.09 Da compared to theoretical mass. 
Fragmentation of LysC peptide with y and b peptides indicated as well as peaks F1-
F4. The b and y ions correspond to N- and C-terminal charge-carrying fragments of 
peptide, respectively, where peptide backbone cleavage has taken place at CO-NH 
bonds. Under the conditions used, y ions are preferentially produced. (d) Chemical 
structures of lysinylated K34 with predicted chemical structures of mass loss 
fragments for peaks F1-F4, indicated with their respective molecular weights. 
 
Figure 2: Lysinylation of EF-P in vivo requires YjeK and YjeA. (a) MS/MS 
spectra of chymotrypsin fragment of EF-P from AT713ΔyjeA with mass of 
930.53 Da. (b,c) MS/MS spectra of chymotrypsin fragments of EF-P from 
AT713ΔyjeK with masses of (b) 930.53 Da and (c) 1058.62 Da. (d) Quantification of 
(b) and (c) reveals that modified fragment is present at 2% level of the unmodified. 
 
Figure 3: Fully modified EF-P is dependent on the presence of YfcM. (a,b) 
MS/MS spectra of chymotrypsin fragment of EF-P from (a) AT713ΔyfcM with mass 
of 1058.62 Da, and (b) AT713ΔyfcM/pYfcM with mass of 1074.62 Da. (c,d) MS/MS 
spectra of LysC fragment of EF-P from (c) AT713ΔyfcM with mass of 1285.76 Da, 
and (d) AT713ΔyfcM/pYfcM with mass of 1301.76 Da. 
 
Figure 4: YfcM hydroxylates the C4/C5 position of K34 of EF-P. (a,b) MS/MS 
spectra of LysC fragment of EF-P from (a) AT713ΔyfcM and (b) wildtype AT713 
cells grown in D4-lysine, with masses of 1297.84 Da and 1312.83 Da, respectively. 
(c) Chemical structure of lysinylated K34 with potential hydroxyl positions indicated. 
 
Figure 5: Characterization of the hydroxylase YfcM. (a) Differential scanning 
fluorimetry (DSF) of YfcM in the presence of indicated nucleotide analogues. Upper 
graph shows the relative fluorescence change as a function of temperature at 600µM 
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ligand concentration, whereas the lower panel shows the change (°C) in temperature 
stability maximum (ΔTm) as a function of ligand concentration (µM). (b) 
Phylogenetic tree (left) and genomic neighborhood (right) of representative YfcM 
proteins in bacteria (full tree in Supplementary Fig. 5). Only bootstrap support 
values >50% are shown. 
 
Figure 6: Modification pathways of EF-P and eIF-5A. (a) The FeS protein YjeK 
converts (S)-α-lysine to (R)-β-lysine using S-adenosyl-l-methionine (SAM) and 
pyridoxal-5′-phosphate (PLP)25. YjeA uses ATP to lysinylate EF-P by the addition of 
β-lysine to the ε-amino group of K3427. YfcM uses molecular oxygen to hydroxylate 
the C4 (γ) or C5 (δ) position of K34 of EF-P. (b) Deoxyhypusine synthase (DHS) 
uses NAD to transfer the amino-butyl moiety from spermidine to the ε-amino group 
of K50 of human eIF5A, which is then hydroxylated by deoxyhypusine hydroxylase 
(DOHH)13. (c) Relative positions of K34 of EF-P (green) and the acceptor stem of the 
P-tRNA (blue) when bound on the ribosome. The γ, δ and ε carbon atoms of K34 and 
the C74, C75 and A76 positions of the tRNA are indicated. The model was built by 
mutation of Arg to Lys (equivalent to K34 in E. coli) in the T. thermophilus EF-
P●70S structure18. 
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